

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 October 2001 (04.10.2001)

PCT

(10) International Publication Number
WO 01/72774 A2

- (51) International Patent Classification⁷: **C07K 14/00**
- (21) International Application Number: **PCT/GB01/01297**
- (22) International Filing Date: **23 March 2001 (23.03.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
0007268.6 **24 March 2000 (24.03.2000)** **GB**
- (71) Applicant (*for all designated States except US*): **CYCLACEL LIMITED** [GB/GB]; Dundee Technopole, James Lindsay Place, Dundee DD1 5JJ (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **DEAK, Peter** [HU/GB]; 27 George Nuttall Close, Cambridge CB4 1YE (GB). **GLOVER, David, Moore** [GB/GB]; Vincent Cottage, 20 Fox Street, Great Gransdon, Sandy, Bedfordshire SG19 3AA (GB). **MIDGLEY, Carol** [GB/GB]; Daisy Cottage, 9 Mount Pleasant, Aspley Guise, Milton Keynes MK17 8JZ (GB).
- (74) Agents: **KHOO, Chong-Yee et al.**; D Young & Co., 21 New Fetter Lane, London EC4A 1DA (GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/72774 A2

(54) Title: **CELL CYCLE PROGRESSION PROTEINS**

(57) Abstract: Polynucleotides encoding a number of *Drosophila* gene products are provided. Polynucleotide probes derived from these nucleotide sequences, polypeptides encoded by the polynucleotides and antibodies that bind to the polypeptides are also provided.

CELL CYCLE PROGRESSION PROTEINS

The present invention relates to a number of genes implicated in the processes of cell cycle progression, including mitosis and meiosis.

We have now identified a large number of genes in *Drosophila*, mutations in
5 which disrupt cell cycle progression, for example the processes of mitosis and/or meiosis. We have determined the phenotypes of these mutations and recovered nucleotide sequences associated with the corresponding genes. Many of these nucleotide sequences correspond to protein open reading frames (ORFs) present in the *Drosophila* genome.

Accordingly the present invention provides in one aspect a polynucleotide selected
10 from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 1 to 70 or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 1 to 70, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 1 to 70 or
15 a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

There is provided, according to another aspect of the present invention, a polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 1 to 14 or the complement thereof; (b) polynucleotides
20 comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 1 to 14, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 1 to 14 or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined
25 in (a), (b) or (c).

We provide, according to yet a further aspect of the present invention, a polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide

sequences set out in Examples 15 to 19 or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 15 to 19, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in
5 Examples 15 to 19 or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

As a further aspect of the present invention, there is provided a polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out
10 in Examples 20 to 30 or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 20 to 30, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 20 to 30 or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence
15 which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

We provide, according to a yet further aspect of the present invention, a polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 31 to 53 or the complement thereof; (b) polynucleotides
20 comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 31 to 53, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in 31 to 53 or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a),
25 (b) or (c).

The present invention, in a further aspect, provides a polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in 54 to 70 or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in 54 to 70, or a fragment thereof; (c)

polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in 54 to 70 or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

- 5 A polynucleotide probe which comprises a fragment of at least 15 nucleotides of a polynucleotide according to any of the above aspects of the invention.

 The present invention also provides a polypeptide which comprises any one of the amino acid sequences set out in Examples 1 to 70 or in any of Examples 1 to 14, Examples 15 to 19, Examples 20 to 30, Examples 31 to 53 and Examples 54 to 70, or a
10 homologue, variant, derivative or fragment thereof.

 Preferably the polypeptide is encoded by a cDNA sequence obtainable from a eukaryotic cDNA library, preferably a metazoan cDNA library (such as insect or mammalian) said DNA sequence comprising a DNA sequence being selectively detectable with a *Drosophila* nucleotide sequence as shown in any one of Examples 1 to 70.

- 15 The term "selectively detectable" means that the cDNA used as a probe is used under conditions where a target cDNA of the invention is found to hybridize to the probe at a level significantly above background. The background hybridization may occur because of other cDNAs present in the cDNA library. In this event background implies a level of signal generated by interaction between the probe and a non-specific cDNA
20 member of the library which is less than 10 fold, preferably less than 100 fold as intense as the specific interaction observed with the target cDNA. The intensity of interaction may be measured, for example, by radiolabelling the probe, e.g. with ³²P. Suitable conditions may be found by reference to the Examples, as well as in the detailed description below.

 A polynucleotide encoding a polypeptide of the invention is also provided.

- 25 The present invention further provides a vector comprising a polynucleotide of the invention, for example an expression vector comprising a polynucleotide of the invention

operably linked to a regulatory sequence capable of directing expression of said polynucleotide in a host cell.

Also provided is an antibody capable of binding a polypeptide of the invention.

5 In a further aspect the present invention provides a method for detecting the presence or absence of a polynucleotide of the invention in a biological sample which method comprises: (a) bringing the biological sample containing DNA or RNA into contact with a probe comprising a nucleotide of the invention under hybridising conditions; and (b) detecting any duplex formed between the probe and nucleic acid in the sample.

10 In another aspect the invention provides a method for detecting a polypeptide of the invention present in a biological sample which comprises: (a) providing an antibody of the invention; (b) incubating a biological sample with said antibody under conditions which allow for the formation of an antibody-antigen complex; and (c) determining whether antibody-antigen complex comprising said antibody is formed.

15 Knowledge of the genes involved in cell cycle progression allows the development of therapeutic agents for the treatment of medical conditions associated with aberrant cell cycle progression. Accordingly, the present invention provides a polynucleotide of the invention for use in therapy. The present invention also provides a polypeptide of the invention for use in therapy. The present invention further provides an antibody of the
20 invention for use in therapy.

In a specific embodiment, the present invention provides a method of treating a tumour or a patient suffering from a proliferative disease, comprising administering to a patient in need of treatment an effective amount of a polynucleotide, polypeptide and/or antibody of the invention.

25 The present invention also provides the use of a polypeptide of the invention in a method of identifying a substance capable of affecting the function of the corresponding

gene. For example, in one embodiment the present invention provides the use of a polypeptide of the invention in an assay for identifying a substance capable of inhibiting cell cycle progression. The substance may inhibit any of the steps or stages in the cell cycle, for example, formation of the nuclear envelope, exit from the quiescent phase of the cell cycle (G0), G1 progression, chromosome decondensation, nuclear envelope
5 breakdown, START, initiation of DNA replication, progression of DNA replication, termination of DNA replication, centrosome duplication, G2 progression, activation of mitotic or meiotic functions, chromosome condensation, centrosome separation, microtubule nucleation, spindle formation and function, interactions with microtubule
10 motor proteins, chromatid separation and segregation, inactivation of mitotic functions, formation of contractile ring, and cytokinesis functions. For example, possible functions of genes of the invention for which it may be desired to identify substances which affect such functions include chromatin binding, formation of replication complexes, replication licensing, phosphorylation or other secondary modification activity, proteolytic
15 degradation, microtubule binding, actin binding, septin binding, microtubule organising centre nucleation activity and binding to components of cell cycle signalling pathways.

In a further aspect the present invention provides a method for identifying a substance capable of binding to a polypeptide of the invention, which method comprises incubating the polypeptide with a candidate substance under suitable conditions and
20 determining whether the substance binds to the polypeptide.

In an additional aspect, the invention provides kits comprising polynucleotides, polypeptides or antibodies of the invention and methods of using such kits in diagnosing the presence of absence of polynucleotides and polypeptides of the invention including deleterious mutant forms.

25 Also provided is a substance identified by the above methods of the invention. Such substances may be used in a method of therapy, such as in a method of affecting cell cycle progression, for example mitosis and/or meiosis.

The invention also provides a process comprising the steps of: (a) performing one of the above methods; and (b) preparing a quantity of those one or more substances identified as being capable of binding to a polypeptide of the invention.

Also provided is a process comprising the steps of: (a) performing one of the above
5 methods; and (b) preparing a pharmaceutical composition comprising one or more substances identified as being capable of binding to a polypeptide of the invention.

We further provide a method for identifying a substance capable of modulating the function of a polypeptide of the invention or a polypeptide encoded by a polynucleotide of the invention, the method comprising the steps of: incubating the polypeptide with a
10 candidate substance and determining whether activity of the polypeptide is thereby modulated.

A substance identified by a method or assay according to any of the above methods or processes is also provided, as is the use of such a substance in a method of inhibiting the function of a polypeptide. Use of such a substance in a method of regulating a cell
15 division cycle function is also provided.

DETAILED DESCRIPTION OF THE INVENTION

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA and immunology, which are within the capabilities of a person of ordinary skill in
20 the art. Such techniques are explained in the literature. See, for example, J. Sambrook, E. F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual*, Second Edition, Books 1-3, Cold Spring Harbor Laboratory Press; Ausubel, F. M. et al. (1995 and periodic supplements; *Current Protocols in Molecular Biology*, ch. 9, 13, and 16, John Wiley & Sons, New York, N.Y.); B. Roe, J. Crabtree, and A. Kahn, 1996, *DNA Isolation and Sequencing: Essential Techniques*, John Wiley & Sons; J. M. Polak and James O'D.
25 McGee, 1990, *In Situ Hybridization: Principles and Practice*; Oxford University Press; M. J. Gait (Editor), 1984, *Oligonucleotide Synthesis: A Practical Approach*, Irl Press; and, D.

M. J. Lilley and J. E. Dahlberg, 1992, *Methods of Enzymology: DNA Structure Part A: Synthesis and Physical Analysis of DNA* Methods in Enzymology, Academic Press. Each of these general texts is herein incorporated by reference.

Preferably, the polypeptides and polynucleotides of the invention are such that they
 5 give rise to or are associated with defined phenotypes when mutated.

For example, mutations in the polypeptides and polynucleotides of the invention may be associated with a failure to complete cytokinesis; such polypeptides and polynucleotides are conveniently categorised as "Category 1". Phenotypes associated with Category 1 polypeptides and polynucleotides include any one or more of the following,
 10 singly or in combination: Mitotic defects in brain: cytokinesis defect (polyploidy); Male semi-sterile, Meiotic defects in testis: cytokinesis defects, segregation defects.(Seg-01/62); Meiotic defects in testis: cytokinesis defects, abnormal spindles.(Ab-02/12); Mitotic defects in brain: cytokinesis defect (no overcondensation of diploids, high polyploidy); Meiotic defects in testis: cytokinesis defects. Dark bands in eyes, dominant; Meiotic
 15 defects in testis: cytokinesis defects; Meiotic defects in testis:segregation defect, cytokinesis defect(Ck-09/32); Mitotic defects in brain: cytokinesis defect (no overcondensation of diploids, very high polyploidy); Mitotic defects in brain: cytokinesis defect(very high polyploidy); Mitotic defects in brain: cytokinesis defect. Meiotic defects in testis: cytokinesis defects (Mitotic higher level of condensation, polyploidy, Meiotic:
 20 Ck05/07); Mitotic defects in brain, Cytokinesis defect (no overcondensation of diploids, high polyploidy); Mitotic defects in brain: cytokinesis defect (very high polyploidy, chromosomes entangled?); Mitotic defects in brain: cytokinesis defect (very high polyploidy; Meiotic defects in testis: cytokinesis defects (Ck-04/06) `; Female sterile (anaphase bridges, lagging chromosomes); Mitotic defects in brain: cytokinesis defect.
 25 Meiotic defects in testis: cytokinesis defects:(mitotic: high polyploidy, no diploids, higher mitotic index, meiotic: Ck-01/05); Meiotic defects in testis: cytokinesis defects; Meiotic defects in testis: cytokinesis defects(Ck-06/09); Meiotic defects in testis: segregation defects, cytokinesis defect(Ck-07/35); Meiotic defects in testis: cytokinesis defects.

Alternatively, mutations in the polypeptides and polynucleotides of the invention may be associated with a failure to enter M-phase; such polypeptides and polynucleotides are conveniently categorised as "Category 2". Phenotypes associated with Category 2 polypeptides and polynucleotides include any one or more of the following, singly or in combination: Meiotic defects in testis: no division(no meiosis); Mitotic defects in brain: no mitosis; Meiotic defects in testis: segregation defects, meiotic failure(Mf-07/75); Meiotic defects in testis: segregation defects, meiotic failure(Mf-05/31); Meiotic defects in testis: cytokinesis defects, meiotic failure(Mf-02/15).

Mutations in the polypeptides and polynucleotides of the invention may be associated with a metaphase arrest phenotype ("Category 3"). Phenotypes associated with Category 3 polypeptides and polynucleotides include any one or more of the following, singly or in combination: Mitotic defects in brain: prometaphase arrest (overcondensation, polyploidy, scattered chromosomes with bipolar spindle); Male sterile, Female sterile, Mitotic defects in brain: prometaphase arrest (Overcondensation, polyploidy, fewer anaphases, high mitotic index, scattered chromosomes with bipolar spindle); Mitotic defects in brain: (weak overcondensation, metaphase with bipolar spindle); Mitotic defects in brain: prometaphase arrest; Mitotic defects in brain: metaphase arrest; Mitotic defects in brain: metaphase arrest. (overcondensation, polyploidy, aneuploidy, few anaphases, high mitotic index, metaphase with bent bipolar spindle); Mitotic defects in brain: metaphase arrest.(overcondensation, polyploidy, few anaphases, high mitotic index, metaphase with bent bipolar spindle); Mitotic defects in brain: Metaphase arrest (overcondensation, polyploidy, aneuploidy, no anaphases, high mitotic index, metaphase with bipolar spindle); Mitotic defects in brain: metaphase arrest (overcondensation, metaphase with bipolar spindle; Meiotic defects in testis: segregation defects, multipolar spindles (Mul-02/29); Meiotic defects in testis: cytokinesis defects, abnormal spindles.(Ab-01/03); Mitotic defects in brain: metaphase arrest; Mitotic defects in brain: metaphase arrest (overcondensation, polyploidy, metaphase with bipolar spindle); Mitotic defects in brain: metaphase arrest. Meiotic defects in testis: segregation defects. Abnormal spindles (mitotic: High mitotic index, meiotic: Ab-08/24); Mitotic defects in brain: metaphase arrest(overcondensation, few anaphases, some polyploids); Mitotic defects in brain: prometaphase arrest (overcondensation, fewer anaphases, metaphase with bipolar spindle);

Mitotic defects in brain: metaphase arrest(condensation, no polyploidy, no anaphases, metaphase with bipolar spindle).

Mutations in Category 4 polypeptides and polynucleotides of the invention may be associated with an anaphase defect phenotype; phenotypes associated with Category 4

5 polypeptides and polynucleotides include any one or more of the following, singly or in combination: Mitotic defects in brain: anaphase defects (overcondensation, high polyploidy, some lagging chromosomes); Meiotic defects in testis: segregation defects; Male and female sterile, small wings, meiotic defects in testis: segregation defects, elongation defect; Mitotic defects in brain: anaphase defects(overcondensation, anaphase

10 bridge, metaphase with swollen chromosomes and bipolar spindle); Mitotic defects in brain: Anaphase defects. (overcondensation, aneuploidy, some lagging chromosomes and breaks); Meiotic defects in testis: segregation defects; Meiotic defects in testis: segregation defects, multi-stage defects (Pl-02/17); Meiotic defects in testis: segregation defects, multi-stage defects (Pl-02/18); Meiotic defects in testis: cytokinesis defects,

15 segregation defects (seg-01/01); Mitotic defects in brain: cytokinesis defect. Meiotic defects in testis: cytokinesis defect. Multi-stage defects Polyploidy, no overcondensation Pl-01/10; Meiotic defects in testis: segregation defects, abnormal spindles. (Ab-03/30); Mitotic defects in brain: anaphase defects (weak, higher condensation, some polyploidy, fewer anaphases, polyploids with monopolar spindles); Mitotic defects in brain: anaphase

20 defects (overcondensation, polyploidy (with overcondensation), few anaphases, metaphase with bipolar spindle); Meiotic defects in testis: cytokinesis defects; Meiotic defects in testis: segregation defects,multipolar spindles(Mul-02/22); Meiotic defects in testis: segregation defects, abnormal spindles (Ab-04/26); Meiotic defects in testis: cytokinesis defects,abnormal spindles (Ab-16/13); Mitotic defects in brain: anaphase defects. Meiotic

25 defects in testis: segregation defects, abnormal spindles (mitotic : Overcondensation, lagging chromosomes/less aligned metaphase with bipolar spindles, Meiotic: Ab-06/20); Meiotic defects in testis: segregation defects; Meiotic defects in testis: no division (no meiosis); Meiotic defects in testis: segregation defects, abnormal spindles (Ab-12/48); Meiotic defects in testis: segregation defects, multipolar spindles(mitotic: High polyploids,

30 no diploids, higher mitotic index Meiotic: Mul-02/59); Meiotic defects in testis: segregation defect; Meiotic defects in testis: segregation defects,abnormal spindles

- (meiotic: Ab-08/42); Female sterile. Meiotic defects in testis: cytokinesis defects, segregation defects (Mitotic: Less condensed chromosomes, nuclear bridges, Meiotic: Seg-01/02; Mitotic defects in brain: anaphase defects; Meiotic defects in testis: cytokinesis defects, abnormal spindles (Ab-01/04); Meiotic defects in testis: segregation defects (overcondensation, fewer anaphases); Mitotic defects in brain: (some overcondensation, anaphase bridge, metaphase with swollen chromosome and bipolar spindle).

- A fifth category ("Category 5") of polypeptides and polynucleotides of the invention are associated with the presence of small imaginal discs (block to proliferation).
- 10 Phenotypes associated with Category 5 polypeptides and polynucleotides include any one or more of the following, singly or in combination: 2nd chromosome, small imaginal discs.

The polypeptides and polynucleotides of the invention may also be categorised according to their function, or their putative function.

- 15 For example, the polypeptides described here preferably comprise, and the polynucleotides described here are ones which preferably encode polypeptides comprising, any one or more of the following: a CBP activator protein; a CCR4-associated regulator of polymerase II transcription; a CTP synthase (CTPS); a Cyclin specific ubiquitin conjugating enzyme; a DNA packaging protein; a DNA repair protein; a DNA-
- 20 binding protein involved in chromosomal organisation; a DNase IV; a EIF4G2 translation initiation factor; a eukaryotic translation initiation factor 6; a Ecdysone-induced protein 78C; a Egf2 translation factor; a G protein-coupled receptor kinase 7; a GTPase exchange factor; a phosphatidylinositol transfer protein beta isoform; a His-rich protein; a Lk6 kinase; a MAP kinase; a MAP kinase interacting kinase 1; a N-arginine dibasic
- 25 convertase; a Phosphatidylinositol transfer protein; a RIP protein kinase; a RNA binding motif, single stranded interacting protein; a RNA binding protein; a RYK receptor tyrosine kinase; a Ribosomal protein L1; a selenide, water dikinase 1; a selenium donor protein 1; a selenophosphate synthetase 1; a Sqv-7-like protein; a sugar modification protein; a protein involved in cytokinesis and signalling; a TEK tyrosine kinase; a Translation elongation

factor; a UDP-galactose transporter; a v-erba related protein; a WD40 protein; a brahma protein; a calcium binding protein; a cell adhesion protein; a chaperone; a chromodomain helicase DNA binding protein; a chromodomain-helicase-DNA-binding protein; a coiled coil protein with ubiquitin like domain; a component of the 19S proteasome regulatory particle; a couch potato RNA binding protein; a cytidine 5-prime triphosphate synthetase; a cytoskeletal structural protein; a death domain containing protein; a developmentally expressed in axons of the CNS; a diacylglycerol-activated/phospholipid dependent protein kinase C inhibitor; a diazepam binding inhibitor; a diphosphate kinase; a dodecasatellite DNA binding protein; a doughnut protein tyrosine kinase; an elongation factor 2; a endoplasmic reticulum ATPase; a eukaryotic translation initiation factor 4E binding protein 2; a factor involved in axon guidance; a fatty-acid-Coenzyme A ligase; a flap structure-specific endonuclease 1; a protein involved in the formation of the contractile ring and the initiation of cytokinesis; a glucose-6-phosphate transporter; a glycoprotein glucosyltransferase; a growth factor; a transmembrane receptor protein tyrosine kinase involved in cell growth and maintenance; a guanyl-nucleotide exchange factor involved in signal transduction; a heat shock protein; a helicase; a high density lipoprotein binding protein; a histone acetyl transferase transcriptional activator; a histone acetyltransferase; a histone acetyltransferase GCN5; a protein involved in development of the abdomen (embryos); a protein involved in the development of the imaginal discs (larvae or pupae); a kinesin like protein 67a; a ligand-dependent nuclear receptor; a ligand-dependent nuclear receptor; a lola-like specific RNA polymerase II transcription factor; a matrix associated protein; a membrane glycoprotein; a mitotic heterochromatin fragment clone CH(2)6; a motor protein; a motor protein involved in cytoskeleton organization; a mushroom body RNA binding protein; a myosin like proteins; a nemo-like kinase; a non-ATPase protein; a nuclear receptor NR1E1; a nucleic acid binding protein; a nucleoside diphosphate kinase (NBR-A); a oly(rC)-binding protein 2 (hnRNP-E1); a peroxisome biogenesis factor 1; a phospholipid transporter involved in lipid metabolism; a phosphatase or enhancer of Pi uptake protein; a protease; a proteasome regulatory particle; a protein involved in cytoskeleton organization and/or biogenesis; a protein kinase associated with microtubules; a protein kinase mitogen-activated 7; a protein serine/threonine kinase involved in cell cycle, possibly targeted to cytoskeleton; a protein serine/threonine kinase involved in eye morphogenesis; a protein which associates with cdc25 phosphatase; a

protein which induces apoptosis; a ribonuclease P; a ribonuclease P protein subunit p29; a ser/thr phosphatase; a signal transduction protein; a signal transport protein; a sin3-associated polypeptide; a single stranded DNA/RNA binding protein; a sodium-dependent dicarboxylate transporters; a ssDNA/RNA binding proteins; a striatin, calmodulin-binding protein (STRN); a structural protein of ribosome involved in protein biosynthesis; a
 5 subtelomeric heterochromatin repeats; a sugar acetylase; a sugar modification protein; a suppressor of ras; a tRNA processing enzyme Ribonuclease P protein subunit; a thyroid hormone responsive gene; a tie receptor protein tyrosine kinase; a transacylase; a transcription factor; a transcription factor involved in chromatin remodelling; a
 10 transcriptional regulation of c-myc expression; a transcriptional regulator; a transcriptional regulators/telomeric silencing; a translation initiation factor; a tumor metastasis inhibitor; a tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein; a ubiquitin carrier protein; a ubiquitin-conjugating enzyme; a ugtUDP-glucose-glycoprotein glucosyltransferase; a zinc finger protein; an RNA polymerase II transcription factor; an
 15 acetylcholinesterase (YT blood group) precursor; an actin binding protein; an actin dependent regulator of chromatin; an acyl-CoA-binding protein; an alanine:glyoxylate aminotransferase; an alpha esterase; an ankyrin protein; an imitation-SWI protein; and an integrin beta 4 binding protein.

POLYPEPTIDES

20 It will be understood that polypeptides of the invention are not limited to polypeptides having the amino acid sequence set out in Examples 1 to 70 or fragments thereof but also include homologous sequences obtained from any source, for example related viral/bacterial proteins, cellular homologues and synthetic peptides, as well as variants or derivatives thereof.

25 Thus polypeptides of the invention also include those encoding homologues from other species including animals such as mammals (e.g. mice, rats or rabbits), especially primates, more especially humans. More specifically, homologues included within the scope of the invention include human homologues.

Thus, the present invention covers variants, homologues or derivatives of the amino acid sequence set out in Examples 1 to 70, as well as variants, homologues or derivatives of the nucleotide sequence coding for the amino acid sequences of the present invention.

5 In the context of the present invention, a homologous sequence is taken to include an amino acid sequence which is at least 15, 20, 25, 30, 40, 50, 60, 70, 80 or 90% identical, preferably at least 95 or 98% identical at the amino acid level over at least 50 or 100, preferably 200, 300, 400 or 500 amino acids with any one of the polypeptide sequences shown in the Examples. In particular, homology should typically be considered
10 with respect to those regions of the sequence known to be essential for protein function rather than non-essential neighbouring sequences. This is especially important when considering homologous sequences from distantly related organisms.

 Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present
15 invention it is preferred to express homology in terms of sequence identity.

 Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These publicly and commercially available computer programs can calculate % homology between two or more sequences.

 % homology may be calculated over contiguous sequences, i.e. one sequence is
20 aligned with the other sequence and each amino acid in one sequence directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues (for example less than 50 contiguous amino acids).

25 Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus

potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without penalising unduly the overall homology score. This is achieved by inserting "gaps" in the sequence alignment to try to maximise local homology.

However, these more complex methods assign "gap penalties" to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible - reflecting higher relatedness between the two compared sequences - will achieve a higher score than one with many gaps. "Affine gap costs" are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons. For example when using the GCG Wisconsin Bestfit package (see below) the default gap penalty for amino acid sequences is -12 for a gap and -4 for each extension.

Calculation of maximum % homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of Wisconsin, U.S.A; Devereux *et al.*, 1984, Nucleic Acids Research 12:387). Examples of other software that can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel *et al.*, 1999 *ibid* – Chapter 18), FASTA (Atschul *et al.*, 1990, J. Mol. Biol., 403-410) and the GENWORKS suite of comparison tools. Both BLAST and FASTA are available for offline and online searching (see Ausubel *et al.*, 1999 *ibid*, pages 7-58 to 7-60). However it is preferred to use the GCG Bestfit program.

Although the final % homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each

pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs. GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for
5 further details). It is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as BLOSUM62.

Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.

10 The terms "variant" or "derivative" in relation to the amino acid sequences of the present invention includes any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acids from or to the sequence providing the resultant amino acid sequence retains substantially the same activity as the unmodified sequence, preferably having at least the same activity as the polypeptides presented in the
15 sequence listings in the Examples.

Polypeptides having the amino acid sequence shown in the Examples, or fragments or homologues thereof may be modified for use in the present invention. Typically, modifications are made that maintain the biological activity of the sequence. Amino acid substitutions may be made, for example from 1, 2 or 3 to 10, 20 or 30 substitutions
20 provided that the modified sequence retains the biological activity of the unmodified sequence. Alternatively, modifications may be made to deliberately inactivate one or more functional domains of the polypeptides of the invention. Amino acid substitutions may include the use of non-naturally occurring analogues, for example to increase blood plasma half-life of a therapeutically administered polypeptide.

25 Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

ALIPHATIC	Non-polar	G A P
		I L V
	Polar - uncharged	C S T M
		N Q
	Polar - charged	D E
		K R
AROMATIC		H F W Y

Polypeptides of the invention also include fragments of the full length sequences mentioned above. Preferably said fragments comprise at least one epitope. Methods of identifying epitopes are well known in the art. Fragments will typically comprise at least 6 amino acids, more preferably at least 10, 20, 30, 50 or 100 amino acids.

- 5 Proteins of the invention are typically made by recombinant means, for example as described below. However they may also be made by synthetic means using techniques well known to skilled persons such as solid phase synthesis. Proteins of the invention may also be produced as fusion proteins, for example to aid in extraction and purification. Examples of fusion protein partners include glutathione-S-transferase (GST), 6xHis,
- 10 GAL4 (DNA binding and/or transcriptional activation domains) and β -galactosidase. It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences. Preferably the fusion protein will not hinder the function of the protein of interest sequence. Proteins of the invention may also be obtained by purification of cell extracts
- 15 from animal cells.

- Proteins of the invention may be in a substantially isolated form. It will be understood that the protein may be mixed with carriers or diluents which will not interfere with the intended purpose of the protein and still be regarded as substantially isolated. A protein of the invention may also be in a substantially purified form, in which case it will
- 20 generally comprise the protein in a preparation in which more than 90%, e.g. 95%, 98% or 99% of the protein in the preparation is a protein of the invention.

A polypeptide of the invention may be labeled with a revealing label. The revealing label may be any suitable label which allows the polypeptide to be detected. Suitable labels include radioisotopes, e.g. ^{125}I , enzymes, antibodies, polynucleotides and linkers such as biotin. Labeled polypeptides of the invention may be used in diagnostic procedures such as
5 immunoassays to determine the amount of a polypeptide of the invention in a sample. Polypeptides or labeled polypeptides of the invention may also be used in serological or cell-mediated immune assays for the detection of immune reactivity to said polypeptides in animals and humans using standard protocols.

A polypeptide or labeled polypeptide of the invention or fragment thereof may also
10 be fixed to a solid phase, for example the surface of an immunoassay well or dipstick. Such labeled and/or immobilised polypeptides may be packaged into kits in a suitable container along with suitable reagents, controls, instructions and the like. Such polypeptides and kits may be used in methods of detection of antibodies to the polypeptides or their allelic or species variants by immunoassay.

15 Immunoassay methods are well known in the art and will generally comprise: (a) providing a polypeptide comprising an epitope bindable by an antibody against said protein; (b) incubating a biological sample with said polypeptide under conditions which allow for the formation of an antibody-antigen complex; and (c) determining whether antibody-antigen complex comprising said polypeptide is formed.

20 Polypeptides of the invention may be used in *in vitro* or *in vivo* cell culture systems to study the role of their corresponding genes and homologues thereof in cell function, including their function in disease. For example, truncated or modified polypeptides may be introduced into a cell to disrupt the normal functions which occur in the cell. The polypeptides of the invention may be introduced into the cell by *in situ* expression of the
25 polypeptide from a recombinant expression vector (see below). The expression vector optionally carries an inducible promoter to control the expression of the polypeptide.

The use of appropriate host cells, such as insect cells or mammalian cells, is expected to provide for such post-translational modifications (e.g. myristolation,

glycosylation, truncation, lipidation and tyrosine, serine or threonine phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the invention. Such cell culture systems in which polypeptides of the invention are expressed may be used in assay systems to identify candidate substances which interfere
5 with or enhance the functions of the polypeptides of the invention in the cell.

POLYNUCLEOTIDES

Polynucleotides of the invention include polynucleotides that comprise any one or more of the nucleic acid sequences set out in Examples 1 to 70 and fragments thereof. Polynucleotides of the invention also include polynucleotides encoding the polypeptides
10 of the invention. It will be understood by a skilled person that numerous different polynucleotides can encode the same polypeptide as a result of the degeneracy of the genetic code. In addition, it is to be understood that skilled persons may, using routine techniques, make nucleotide substitutions that do not affect the polypeptide sequence encoded by the polynucleotides of the invention to reflect the codon usage of any
15 particular host organism in which the polypeptides of the invention are to be expressed.

Polynucleotides of the invention may comprise DNA or RNA. They may be single-stranded or double-stranded. They may also be polynucleotides which include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate
20 and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the polynucleotides described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the *in vivo* activity or life span of polynucleotides of the invention.

25 The terms "variant", "homologue" or "derivative" in relation to the nucleotide sequence of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the

sequence. Preferably said variant, homologues or derivatives code for a polypeptide having biological activity.

As indicated above, with respect to sequence homology, preferably there is at least 50 or 75%, more preferably at least 85%, more preferably at least 90% homology to the sequences shown in the sequence listing herein. More preferably there is at least 95%,
5 more preferably at least 98%, homology. Nucleotide homology comparisons may be conducted as described above. A preferred sequence comparison program is the GCG Wisconsin Bestfit program described above. The default scoring matrix has a match value of 10 for each identical nucleotide and -9 for each mismatch. The default gap creation
10 penalty is -50 and the default gap extension penalty is -3 for each nucleotide.

The present invention also encompasses nucleotide sequences that are capable of hybridising selectively to the sequences presented herein, or any variant, fragment or derivative thereof, or to the complement of any of the above. Nucleotide sequences are preferably at least 15 nucleotides in length, more preferably at least 20, 30, 40 or 50
15 nucleotides in length.

The term "hybridization" as used herein shall include "the process by which a strand of nucleic acid joins with a complementary strand through base pairing" as well as the process of amplification as carried out in polymerase chain reaction technologies.

Polynucleotides of the invention capable of selectively hybridising to the
20 nucleotide sequences presented herein, or to their complement, will be generally at least 70%, preferably at least 80 or 90% and more preferably at least 95% or 98% homologous to the corresponding nucleotide sequences presented herein over a region of at least 20, preferably at least 25 or 30, for instance at least 40, 60 or 100 or more contiguous nucleotides.

25 The term "selectively hybridizable" means that the polynucleotide used as a probe is used under conditions where a target polynucleotide of the invention is found to hybridize to the probe at a level significantly above background. The background

hybridization may occur because of other polynucleotides present, for example, in the cDNA or genomic DNA library being screening. In this event, background implies a level of signal generated by interaction between the probe and a non-specific DNA member of the library which is less than 10 fold, preferably less than 100 fold as intense as the
5 specific interaction observed with the target DNA. The intensity of interaction may be measured, for example, by radiolabelling the probe, e.g. with ^{32}P .

Hybridization conditions are based on the melting temperature (T_m) of the nucleic acid binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol 152, Academic Press, San Diego CA), and
10 confer a defined "stringency" as explained below.

Maximum stringency typically occurs at about $T_m - 5^\circ\text{C}$ (5°C below the T_m of the probe); high stringency at about 5°C to 10°C below T_m ; intermediate stringency at about 10°C to 20°C below T_m ; and low stringency at about 20°C to 25°C below T_m . As will be understood by those of skill in the art, a maximum stringency hybridization can be used to
15 identify or detect identical polynucleotide sequences while an intermediate (or low) stringency hybridization can be used to identify or detect similar or related polynucleotide sequences.

In a preferred aspect, the present invention covers nucleotide sequences that can hybridise to the nucleotide sequence of the present invention under stringent conditions
20 (e.g. 65°C and $0.1\times\text{SSC}$ { $1\times\text{SSC} = 0.15\text{ M NaCl}$, $0.015\text{ M Na}_3\text{ Citrate pH } 7.0$ }).

Where the polynucleotide of the invention is double-stranded, both strands of the duplex, either individually or in combination, are encompassed by the present invention. Where the polynucleotide is single-stranded, it is to be understood that the complementary sequence of that polynucleotide is also included within the scope of the present invention.

25 Polynucleotides which are not 100% homologous to the sequences of the present invention but fall within the scope of the invention can be obtained in a number of ways. Other variants of the sequences described herein may be obtained for example by probing

DNA libraries made from a range of individuals, for example individuals from different populations. In addition, other viral/bacterial, or cellular homologues particularly cellular homologues found in mammalian cells (e.g. rat, mouse, bovine and primate cells), may be obtained and such homologues and fragments thereof in general will be capable of

5 selectively hybridising to the sequences shown in the Examples. Such sequences may be obtained by probing cDNA libraries made from or genomic DNA libraries from other animal species, and probing such libraries with probes comprising all or part of any one of the sequences shown in the Examples under conditions of medium to high stringency. The nucleotide sequences of the human homologues described in the Examples, may

10 preferably be used to identify other primate/mammalian homologues since nucleotide homology between human sequences and mammalian sequences is likely to be higher than is the case for the *Drosophila* sequences identified herein.

Similar considerations apply to obtaining species homologues and allelic variants of the polypeptide or nucleotide sequences of the invention.

15 Variants and strain/species homologues may also be obtained using degenerate PCR which will use primers designed to target sequences within the variants and homologues encoding conserved amino acid sequences within the sequences of the present invention. Conserved sequences can be predicted, for example, by aligning the amino acid sequences from several variants/homologues. Sequence alignments can be performed

20 using computer software known in the art. For example the GCG Wisconsin PileUp program is widely used.

The primers used in degenerate PCR will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences. It will be appreciated by the skilled

25 person that overall nucleotide homology between sequences from distantly related organisms is likely to be very low and thus in these situations degenerate PCR may be the method of choice rather than screening libraries with labeled fragments the sequences disclosed in the Examples.

In addition, homologous sequences may be identified by searching nucleotide and/or protein databases using search algorithms such as the BLAST suite of programs. This approach is described in the Examples.

Alternatively, such polynucleotides may be obtained by site directed mutagenesis of characterised sequences, such as the sequences disclosed in the Examples. This may be useful where for example silent codon changes are required to sequences to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be desired in order to introduce restriction enzyme recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides. For example, further changes may be desirable to represent particular coding changes found in the sequences disclosed in the Examples which give rise to mutant genes which have lost their regulatory function. Probes based on such changes can be used as diagnostic probes to detect such mutants.

Polynucleotides of the invention may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labeled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors. Such primers, probes and other fragments will be at least 8, 9, 10, or 15, preferably at least 20, for example at least 25, 30 or 40 nucleotides in length, and are also encompassed by the term polynucleotides of the invention as used herein.

Polynucleotides such as a DNA polynucleotides and probes according to the invention may be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques.

In general, primers will be produced by synthetic means, involving a step wise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art.

Longer polynucleotides will generally be produced using recombinant means, for example using a PCR (polymerase chain reaction) cloning techniques. This will involve making a pair of primers (e.g. of about 15 to 30 nucleotides) flanking a region of the lipid targeting sequence which it is desired to clone, bringing the primers into contact with
5 mRNA or cDNA obtained from an animal or human cell, performing a polymerase chain reaction under conditions which bring about amplification of the desired region, isolating the amplified fragment (e.g. by purifying the reaction mixture on an agarose gel) and recovering the amplified DNA. The primers may be designed to contain suitable restriction enzyme recognition sites so that the amplified DNA can be cloned into a
10 suitable cloning vector

Polynucleotides or primers of the invention may carry a revealing label. Suitable labels include radioisotopes such as ^{32}P or ^{35}S , enzyme labels, or other protein labels such as biotin. Such labels may be added to polynucleotides or primers of the invention and may be detected using by techniques known *per se*.

15 Polynucleotides or primers of the invention or fragments thereof labeled or unlabeled may be used by a person skilled in the art in nucleic acid-based tests for detecting or sequencing polynucleotides of the invention in the human or animal body.

Such tests for detecting generally comprise bringing a biological sample containing DNA or RNA into contact with a probe comprising a polynucleotide or primer of the
20 invention under hybridising conditions and detecting any duplex formed between the probe and nucleic acid in the sample. Such detection may be achieved using techniques such as PCR or by immobilising the probe on a solid support, removing nucleic acid in the sample which is not hybridised to the probe, and then detecting nucleic acid which has hybridised to the probe. Alternatively, the sample nucleic acid may be immobilised on a
25 solid support, and the amount of probe bound to such a support can be detected. Suitable assay methods of this and other formats can be found in for example WO89/03891 and WO90/13667.

Tests for sequencing nucleotides of the invention include bringing a biological sample containing target DNA or RNA into contact with a probe comprising a polynucleotide or primer of the invention under hybridising conditions and determining the sequence by, for example the Sanger dideoxy chain termination method (see
5 Sambrook *et al.*).

Such a method generally comprises elongating, in the presence of suitable reagents, the primer by synthesis of a strand complementary to the target DNA or RNA and selectively terminating the elongation reaction at one or more of an A, C, G or T/U residue; allowing strand elongation and termination reaction to occur; separating out
10 according to size the elongated products to determine the sequence of the nucleotides at which selective termination has occurred. Suitable reagents include a DNA polymerase enzyme, the deoxynucleotides dATP, dCTP, dGTP and dTTP, a buffer and ATP. Dideoxynucleotides are used for selective termination.

Tests for detecting or sequencing nucleotides of the invention in a biological
15 sample may be used to determine particular sequences within cells in individuals who have, or are suspected to have, an altered gene sequence, for example within cancer cells including leukaemia cells and solid tumours such as breast, ovary, lung, colon, pancreas, testes, liver, brain, muscle and bone tumours. Cells from patients suffering from a proliferative disease may also be tested in the same way.

20 In addition, the identification of the genes described in the Examples will allow the role of these genes in hereditary diseases to be investigated. In general, this will involve establishing the status of the gene (e.g. using PCR sequence analysis), in cells derived from animals or humans with, for example, neurological disorders or neoplasms.

The probes of the invention may conveniently be packaged in the form of a test kit
25 in a suitable container. In such kits the probe may be bound to a solid support where the assay format for which the kit is designed requires such binding. The kit may also contain suitable reagents for treating the sample to be probed, hybridising the probe to nucleic acid in the sample, control reagents, instructions, and the like.

NUCLEIC ACID VECTORS

Polynucleotides of the invention can be incorporated into a recombinant replicable vector. The vector may be used to replicate the nucleic acid in a compatible host cell. Thus in a further embodiment, the invention provides a method of making polynucleotides of the invention by introducing a polynucleotide of the invention into a replicable vector,
5 introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector. The vector may be recovered from the host cell. Suitable host cells include bacteria such as *E. coli*, yeast, mammalian cell lines and other eukaryotic cell lines, for example insect Sf9 cells.

10 Preferably, a polynucleotide of the invention in a vector is operably linked to a control sequence that is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector. The term "operably linked" means that the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence "operably linked" to a coding sequence is ligated
15 in such a way that expression of the coding sequence is achieved under condition compatible with the control sequences.

The control sequences may be modified, for example by the addition of further transcriptional regulatory elements to make the level of transcription directed by the control sequences more responsive to transcriptional modulators.

20 Vectors of the invention may be transformed or transfected into a suitable host cell as described below to provide for expression of a protein of the invention. This process may comprise culturing a host cell transformed with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the protein, and optionally recovering the expressed protein. Vectors will be
25 chosen that are compatible with the host cell used.

The vectors may be for example, plasmid or virus vectors provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide and

optionally a regulator of the promoter. The vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid or a neomycin resistance gene for a mammalian vector. Vectors may be used, for example, to transfect or transform a host cell.

- 5 Control sequences operably linked to sequences encoding the polypeptide of the invention include promoters/enhancers and other expression regulation signals. These control sequences may be selected to be compatible with the host cell for which the expression vector is designed to be used in. The term promoter is well-known in the art and encompasses nucleic acid regions ranging in size and complexity from minimal
10 promoters to promoters including upstream elements and enhancers.

- The promoter is typically selected from promoters which are functional in mammalian cells, although prokaryotic promoters and promoters functional in other eukaryotic cells, such as insect cells, may be used. The promoter is typically derived from promoter sequences of viral or eukaryotic genes. For example, it may be a promoter
15 derived from the genome of a cell in which expression is to occur. With respect to eukaryotic promoters, they may be promoters that function in a ubiquitous manner (such as promoters of α -actin, β -actin, tubulin) or, alternatively, a tissue-specific manner (such as promoters of the genes for pyruvate kinase). They may also be promoters that respond to specific stimuli, for example promoters that bind steroid hormone receptors. Viral
20 promoters may also be used, for example the Moloney murine leukaemia virus long terminal repeat (MMLV LTR) promoter, the rous sarcoma virus (RSV) LTR promoter or the human cytomegalovirus (CMV) IE promoter.

- It may also be advantageous for the promoters to be inducible so that the levels of expression of the heterologous gene can be regulated during the life-time of the cell.
25 Inducible means that the levels of expression obtained using the promoter can be regulated.

In addition, any of these promoters may be modified by the addition of further regulatory sequences, for example enhancer sequences. Chimeric promoters may also be

used comprising sequence elements from two or more different promoters described above.

Polynucleotides according to the invention may also be inserted into the vectors described above in an antisense orientation to provide for the production of antisense
5 RNA. Antisense RNA or other antisense polynucleotides may also be produced by synthetic means. Such antisense polynucleotides may be used in a method of controlling the levels of RNAs transcribed from genes comprising any one of the polynucleotides of the invention.

HOST CELLS

10 Vectors and polynucleotides of the invention may be introduced into host cells for the purpose of replicating the vectors/polynucleotides and/or expressing the polypeptides of the invention encoded by the polynucleotides of the invention. Although the polypeptides of the invention may be produced using prokaryotic cells as host cells, it is preferred to use eukaryotic cells, for example yeast, insect or mammalian cells, in
15 particular mammalian cells.

Vectors/polynucleotides of the invention may be introduced into suitable host cells using a variety of techniques known in the art, such as transfection, transformation and electroporation. Where vectors/polynucleotides of the invention are to be administered to animals, several techniques are known in the art, for example infection with recombinant
20 viral vectors such as retroviruses, herpes simplex viruses and adenoviruses, direct injection of nucleic acids and biolistic transformation.

PROTEIN EXPRESSION AND PURIFICATION

Host cells comprising polynucleotides of the invention may be used to express polypeptides of the invention. Host cells may be cultured under suitable conditions which
25 allow expression of the proteins of the invention. Expression of the polypeptides of the invention may be constitutive such that they are continually produced, or inducible, requiring a stimulus to initiate expression. In the case of inducible expression, protein

production can be initiated when required by, for example, addition of an inducer substance to the culture medium, for example dexamethasone or IPTG.

Polypeptides of the invention can be extracted from host cells by a variety of techniques known in the art, including enzymatic, chemical and/or osmotic lysis and
5 physical disruption.

Polypeptides of the invention may also be produced recombinantly in an *in vitro* cell-free system, such as the TnTTM (Promega) rabbit reticulocyte system.

ANTIBODIES

The invention also provides monoclonal or polyclonal antibodies to polypeptides of
10 the invention or fragments thereof. Thus, the present invention further provides a process for the production of monoclonal or polyclonal antibodies to polypeptides of the invention.

If polyclonal antibodies are desired, a selected mammal (e.g., mouse, rabbit, goat, horse, etc.) is immunised with an immunogenic polypeptide bearing an epitope(s) from a polypeptide of the invention. Serum from the immunised animal is collected and treated
15 according to known procedures. If serum containing polyclonal antibodies to an epitope from a polypeptide of the invention contains antibodies to other antigens, the polyclonal antibodies can be purified by immunoaffinity chromatography. Techniques for producing and processing polyclonal antisera are known in the art. In order that such antibodies may be made, the invention also provides polypeptides of the invention or fragments thereof
20 haptenised to another polypeptide for use as immunogens in animals or humans.

Monoclonal antibodies directed against epitopes in the polypeptides of the invention can also be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies by hybridomas is well known. Immortal antibody-producing cell lines can be created by cell fusion, and also by other techniques such as
25 direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. Panels of monoclonal antibodies produced against epitopes in the

polypeptides of the invention can be screened for various properties; i.e., for isotype and epitope affinity.

An alternative technique involves screening phage display libraries where, for example the phage express scFv fragments on the surface of their coat with a large variety
5 of complementarity determining regions (CDRs). This technique is well known in the art.

Antibodies, both monoclonal and polyclonal, which are directed against epitopes from polypeptides of the invention are particularly useful in diagnosis, and those which are neutralising are useful in passive immunotherapy. Monoclonal antibodies, in particular, may be used to raise anti-idiotypic antibodies. Anti-idiotypic antibodies are
10 immunoglobulins which carry an "internal image" of the antigen of the agent against which protection is desired.

Techniques for raising anti-idiotypic antibodies are known in the art. These anti-idiotypic antibodies may also be useful in therapy.

For the purposes of this invention, the term "antibody", unless specified to the
15 contrary, includes fragments of whole antibodies which retain their binding activity for a target antigen. Such fragments include Fv, F(ab') and F(ab')₂ fragments, as well as single chain antibodies (scFv). Furthermore, the antibodies and fragments thereof may be humanised antibodies, for example as described in EP-A-239400.

Antibodies may be used in method of detecting polypeptides of the invention
20 present in biological samples by a method which comprises: (a) providing an antibody of the invention; (b) incubating a biological sample with said antibody under conditions which allow for the formation of an antibody-antigen complex; and (c) determining whether antibody-antigen complex comprising said antibody is formed.

Suitable samples include extracts tissues such as brain, breast, ovary, lung, colon,
25 pancreas, testes, liver, muscle and bone tissues or from neoplastic growths derived from such tissues.

Antibodies of the invention may be bound to a solid support and/or packaged into kits in a suitable container along with suitable reagents, controls, instructions and the like.

ASSAYS

The present invention provides assays that are suitable for identifying substances
5 which bind to polypeptides of the invention and which affect, for example, formation of
the nuclear envelope, exit from the quiescent phase of the cell cycle (G0), G1 progression,
chromosome decondensation, nuclear envelope breakdown, START, initiation of DNA
replication, progression of DNA replication, termination of DNA replication, centrosome
duplication, G2 progression, activation of mitotic or meiotic functions, chromosome
10 condensation, centrosome separation, microtubule nucleation, spindle formation and
function, interactions with microtubule motor proteins, chromatid separation and
segregation, inactivation of mitotic functions, formation of contractile ring, cytokinesis
functions, chromatin binding, formation of replication complexes, replication licensing,
phosphorylation or other secondary modification activity, proteolytic degradation,
15 microtubule binding, actin binding, septin binding, microtubule organising centre
nucleation activity and binding to components of cell cycle signalling pathways.

In addition, assays suitable for identifying substances that interfere with binding of
polypeptides of the invention, where appropriate, to components of cell division cycle
machinery. This includes not only components such as microtubules but also signalling
20 components and regulatory components as indicated above. Such assays are typically *in vitro*. Assays are also provided that test the effects of candidate substances identified in
preliminary *in vitro* assays on intact cells in whole cell assays. The assays described below,
or any suitable assay as known in the art, may be used to identify these substances.

According to one aspect of the invention, therefore, we provide one or more
25 substances identified by any of the assays described below, viz, mitosis assays, meiotic
assays, polypeptide binding assays, microtubule binding/polymerisation assays,
microtubule purification and binding assays, microtubule organising centre (MTOC)
nucleation activity assays, motor protein assay, assay for spindle assembly and function,

assays for dna replication, chromosome condensation assays, kinase assays, kinase inhibitor assays, and whole cell assays, each as described in further detail below.

CANDIDATE SUBSTANCES

A substance that inhibits cell cycle progression as a result of an interaction with a polypeptide of the invention may do so in several ways. For example, if the substance inhibits cell division, mitosis and/or meiosis, it may directly disrupt the binding of a polypeptide of the invention to a component of the spindle apparatus by, for example, binding to the polypeptide and masking or altering the site of interaction with the other component. A substance which inhibits DNA replication may do so by inhibiting the phosphorylation or de-phosphorylation of proteins involved in replication. For example, it is known that the kinase inhibitor 6-DMAP (6-dimethylaminopurine) prevents the initiation of replication (Blow, JJ, 1993, *J Cell Biol* 122,993-1002). Candidate substances of this type may conveniently be preliminarily screened by *in vitro* binding assays as, for example, described below and then tested, for example in a whole cell assay as described below. Examples of candidate substances include antibodies which recognise a polypeptide of the invention.

A substance which can bind directly to a polypeptide of the invention may also inhibit its function in cell cycle progression by altering its subcellular localisation and hence its ability to interact with its normal substrate. The substance may alter the subcellular localisation of the polypeptide by directly binding to it, or by indirectly disrupting the interaction of the polypeptide with another component. For example, it is known that interaction between the p68 and p180 subunits of DNA polymerase alpha-primase enzyme is necessary in order for p180 to translocate into the nucleus (Mizuno et al (1998) *Mol Cell Biol* 18,3552-62), and accordingly, a substance which disrupts the interaction between p68 and p180 will affect nuclear translocation and hence activity of the primase. A substance which affects mitosis may do so by preventing the polypeptide and components of the mitotic apparatus from coming into contact within the cell. These substances may be tested using, for example the whole cells assays described below. Non-functional homologues of a polypeptide of the invention may also be tested

for inhibition of cell cycle progression since they may compete with the wild type protein for binding to components of the cell division cycle machinery whilst being incapable of the normal functions of the protein or block the function of the protein bound to the cell division cycle machinery. Such non-functional homologues may include naturally occurring mutants and modified sequences or fragments thereof.

Alternatively, instead of preventing the association of the components directly, the substance may suppress the biologically available amount of a polypeptide of the invention. This may be by inhibiting expression of the component, for example at the level of transcription, transcript stability, translation or post-translational stability. An example of such a substance would be antisense RNA or double-stranded interfering RNA sequences which suppresses the amount of mRNA biosynthesis.

Suitable candidate substances include peptides, especially of from about 5 to 30 or 10 to 25 amino acids in size, based on the sequence of the polypeptides described in the Examples, or variants of such peptides in which one or more residues have been substituted. Peptides from panels of peptides comprising random sequences or sequences which have been varied consistently to provide a maximally diverse panel of peptides may be used.

Suitable candidate substances also include antibody products (for example, monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies and CDR-grafted antibodies) which are specific for a polypeptide of the invention. Furthermore, combinatorial libraries, peptide and peptide mimetics, defined chemical entities, oligonucleotides, and natural product libraries may be screened for activity as inhibitors of binding of a polypeptide of the invention to the cell division cycle machinery, for example mitotic/meiotic apparatus (such as microtubules). The candidate substances may be used in an initial screen in batches of, for example 10 substances per reaction, and the substances of those batches which show inhibition tested individually. Candidate substances which show activity in *in vitro* screens such as those described below can then be tested in whole cell systems, such as mammalian cells which will be exposed to the inhibitor and tested for inhibition of any of the stages of the cell cycle.

Polypeptide Binding Assays

One type of assay for identifying substances that bind to a polypeptide of the invention involves contacting a polypeptide of the invention, which is immobilised on a solid support, with a non-immobilised candidate substance determining whether and/or to what extent the polypeptide of the invention and candidate substance bind to each other. Alternatively, the candidate substance may be immobilised and the polypeptide of the invention non-immobilised.

In a preferred assay method, the polypeptide of the invention is immobilised on beads such as agarose beads. Typically this is achieved by expressing the component as a GST-fusion protein in bacteria, yeast or higher eukaryotic cell lines and purifying the GST-fusion protein from crude cell extracts using glutathione-agarose beads (Smith and Johnson, 1988). As a control, binding of the candidate substance, which is not a GST-fusion protein, to the immobilised polypeptide of the invention is determined in the absence of the polypeptide of the invention. The binding of the candidate substance to the immobilised polypeptide of the invention is then determined. This type of assay is known in the art as a GST pulldown assay. Again, the candidate substance may be immobilised and the polypeptide of the invention non-immobilised.

It is also possible to perform this type of assay using different affinity purification systems for immobilising one of the components, for example Ni-NTA agarose and histidine-tagged components.

Binding of the polypeptide of the invention to the candidate substance may be determined by a variety of methods well-known in the art. For example, the non-immobilised component may be labeled (with for example, a radioactive label, an epitope tag or an enzyme-antibody conjugate). Alternatively, binding may be determined by immunological detection techniques. For example, the reaction mixture can be Western blotted and the blot probed with an antibody that detects the non-immobilised component. ELISA techniques may also be used.

Candidate substances are typically added to a final concentration of from 1 to 1000 nmol/ml, more preferably from 1 to 100 nmol/ml. In the case of antibodies, the final concentration used is typically from 100 to 500 µg/ml, more preferably from 200 to 300 µg/ml.

5 ***Microtubule Binding/Polymerisation Assays***

In the case of polypeptides of the invention that bind to microtubules, another type of *in vitro* assay involves determining whether a candidate substance modulates binding of a polypeptide of the invention to microtubules. Such an assay typically comprises contacting a polypeptide of the invention with microtubules in the presence or absence of
10 the candidate substance and determining if the candidate substance has an effect on the binding of the polypeptide of the invention to the microtubules. This assay can also be used in the absence of candidate substances to confirm that a polypeptide of the invention does indeed bind to microtubules. Microtubules may be prepared and assays conducted as follows:

15 ***Microtubule Purification and Binding Assays***

Microtubules are purified from 0-3h-old *Drosophila* embryos essentially as described previously (Saunders, *et al.*, 1997). About 3 ml of embryos are homogenized with a Dounce homogenizer in 2 volumes of ice-cold lysis buffer (0.1 M Pipes/NaOH, pH6.6, 5 mM EGTA, 1 mM MgSO₄, 0.9 M glycerol, 1 mM DTT, 1 mM PMSF, 1 µg/ml
20 aprotinin, 1 µg/ml leupeptin and 1 µg/ml pepstatin). The microtubules are depolymerized by incubation on ice for 15 min, and the extract is then centrifuged at 16,000 g for 30 min at 4°C. The supernatant is recentrifuged at 135,000 g for 90 min at 4°C. Microtubules in this later supernatant are polymerized by addition of GTP to 1 mM and taxol to 20 µM and incubation at room temperature for 30 min. A 3 ml aliquot of the extract is layered on top
25 of 3 ml 15% sucrose cushion prepared in lysis buffer. After centrifuging at 54,000g for 30 min at 20°C using a swing out rotor, the microtubule pellet is resuspended in lysis buffer.

Microtubule overlay assays are performed as previously described (Saunders *et al.*, 1997). 500 ng per lane of recombinant Asp, recombinant polypeptide, and bovine serum albumin (BSA, Sigma) are fractionated by 10% SDS-PAGE and blotted onto PVDF

membranes (Millipore). The membranes are preincubated in TBST (50mM Tris pH 7.5, 150 mM NaCl, 0.05% Tween 20) containing 5% low fat powdered milk (LFPM) for 1 h and then washed 3 times for 15 min in lysis buffer. The filters are then incubated for 30 minutes in lysis buffer containing either 1 mM GDP, 1 mM GTP, or 1 mM GTP- γ -S.

5 MAP-free bovine brain tubulin (Molecular Probes) is polymerised at a concentration of 2 μ g/ml in lysis buffer by addition of GTP to a final concentration of 1 mM and incubated at 37°C for 30 min. The nucleotide solutions are removed and the buffer containing polymerised microtubules added to the membranes for incubation for 1h at 37°C with addition of taxol at a final concentration of 10 μ M for the final 30 min. The blots are then

10 washed 3 times with TBST and the bound tubulin detected using standard Western blot procedures using anti- β -tubulin antibodies (Boehringer Mannheim) at 2.5 μ g/ml and the Super Signal detection system (Pierce).

It may be desirable in one embodiment of this type of assay to deplete the polypeptide of the invention from cell extracts used to produce polymerise microtubules.

15 This may, for example, be achieved by the use of suitable antibodies.

A simple extension to this type of assay would be to test the effects of purified polypeptide of the invention upon the ability of tubulin to polymerise *in vitro* (for example, as used by Andersen and Karsenti, 1997) in the presence or absence of a candidate substance (typically added at the concentrations described above). *Xenopus* cell-

20 free extracts may conveniently be used, for example as a source of tubulin.

Microtubule Organising Centre (MTOC) Nucleation Activity Assays

Candidate substances, for example those identified using the binding assays described above, may be screening using a microtubule organising centre nucleation activity assay to determine if they are capable of disrupting MTOCs as measured by, for

25 example, aster formation. This assay in its simplest form comprises adding the candidate substance to a cellular extract which in the absence of the candidate substance has microtubule organising centre nucleation activity resulting in formation of asters.

In a preferred embodiment, the assay system comprises (i) a polypeptide of the invention and (ii) components required for microtubule organising centre nucleation activity except for functional polypeptide of the invention, which is typically removed by immunodepletion (or by the use of extracts from mutant cells). The components
5 themselves are typically in two parts such that microtubule nucleation does not occur until the two parts are mixed. The polypeptide of the invention may be present in one of the two parts initially or added subsequently prior to mixing of the two parts.

Subsequently, the polypeptide of the invention and candidate substance are added to the component mix and microtubule nucleation from centrosomes measured, for
10 example by immunostaining for the polypeptide of the invention and visualising aster formation by immuno-fluorescence microscopy. The polypeptide of the invention may be preincubated with the candidate substance before addition to the component mix. Alternatively, both the polypeptide of the invention and the candidate substance may be added directly to the component mix, simultaneously or sequentially in either order.

15 The components required for microtubule organising centre formation typically include salt-stripped centrosomes prepared as described in Moritz *et al.*, 1998. Stripping centrosome preparations with 2 M KI removes the centrosome proteins CP60, CP190, CNN and γ -tubulin. Of these, neither CP60 nor CP190 appear to be required for microtubule nucleation. The other minimal components are typically provided as a
20 depleted cellular extract, or conveniently, as a cellular extract from cells with a non-functional variant of a polypeptide of the invention. Typically, labeled tubulin (usually β -tubulin) is also added to assist in visualising aster formation.

Alternatively, partially purified centrosomes that have not been salt-stripped may be used as part of the components. In this case, only tubulin, preferably labeled tubulin is
25 required to complete the component mix.

Candidate substances are typically added to a final concentration of from 1 to 1000 nmol/ml, more preferably from 1 to 100 nmol/ml. In the case of antibodies, the final

concentration used is typically from 100 to 500 µg/ml, more preferably from 200 to 300 µg/ml.

The degree of inhibition of aster formation by the candidate substance may be determined by measuring the number of normal asters per unit area for control untreated
5 cell preparation and measuring the number of normal asters per unit area for cells treated with the candidate substance and comparing the result. Typically, a candidate substance is considered to be capable of disrupting MTOC integrity if the treated cell preparations have less than 50%, preferably less than 40, 30, 20 or 10% of the number of asters found in
10 untreated cells preparations. It may also be desirable to stain cells for γ-tubulin to determine the maximum number of possible MTOCs present to allow normalisation between samples.

Motor Protein Assay

Polypeptides of the invention may interact with motor proteins such as the Eg5-like motor protein *in vitro*. The effects of candidate substances on such a process may
15 be determined using assays wherein the motor protein is immobilised on coverslips. Rhodamine labeled microtubules are then added and their translocation can be followed by fluorescent microscopy. The effect of candidate substances may thus be determined by comparing the extent and/or rate of translocation in the presence and absence of the candidate substance. Generally, candidate substances known to bind to a polypeptide of
20 the invention, would be tested in this assay. Alternatively, a high throughput assay may be used to identify modulators of motor proteins and the resulting identified substances tested for affects on a polypeptide of the invention as described above.

Typically this assay uses microtubules stabilised by taxol (e.g. Howard and Hyman 1993; Chandra and Endow, 1993 – both chapters in “Motility Assays for Motor Proteins”
25 Ed Jon Scholey, pub Academic Press). If however, a polypeptide of the invention were to promote stable polymerisation of microtubules (see above) then these microtubules could be used directly in motility assays.

Simple protein-protein binding assays as described above, using a motor protein and a polypeptide of the invention may also be used to confirm that the polypeptide of the invention binds to the motor protein, typically prior to testing the effect of candidate substances on that interaction.

5 ***Assay for Spindle Assembly and Function***

A further assay to investigate the function of polypeptide of the invention and the effect of candidate substances on those functions is an assay which measures spindle assembly and function. Typically, such assays are performed using *Xenopus* cell free systems, where two types of spindle assembly are possible. In the "half spindle" assembly
10 pathway, a cytoplasmic extract of CSF arrested oocytes is mixed with sperm chromatin. The half spindles that form subsequently fuse together. A more physiological method is to induce CSF arrested extracts to enter interphase by addition of calcium, whereupon the DNA replicates and kinetochores form. Addition of fresh CSF arrested extract then induces mitosis with centrosome duplication and spindle formation (for discussion of
15 these systems see Tournebize and Heald, 1996).

Again, generally, candidate substances known to bind to a polypeptide of the invention, or non-functional polypeptide variants of the invention, would be tested in this assay. Alternatively, a high throughput assay may be used to identify modulators of spindle formation and function and the resulting identified substances tested for affects
20 binding of the polypeptide of the invention as described above.

Assays for DNA Replication

Another assay to investigate the function of polypeptide of the invention and the effect of candidate substances on those functions is as assay for replication of DNA. A number of cell free systems have been developed to assay DNA replication. These can be
25 used to assay the ability of a substance to prevent or inhibit DNA replication, by conducting the assay in the presence of the substance. Suitable cell-free assay systems include, for example the SV-40 assay (Li and Kelly, 1984, *Proc. Natl. Acad. Sci USA* 81, 6973-6977; Waga and Stillman, 1994, *Nature* 369, 207-212.). A *Drosophila* cell free replication system, for example as described by Crevel and Cotteril (1991), *EMBO J.* 10,

4361-4369, may also be used. A preferred assay is a cell free assay derived from *Xenopus* egg low speed supernatant extracts described in Blow and Laskey (1986, *Cell* 47,577-587) and Sheehan et al. (1988, *J. Cell Biol.* 106, 1-12), which measures the incorporation of nucleotides into a substrate consisting of *Xenopus* sperm DNA or HeLa nuclei. The
5 nucleotides may be radiolabelled and incorporation assayed by scintillation counting. Alternatively and preferably, bromo-deoxy-uridine (BrdU) is used as a nucleotide substitute and replication activity measured by density substitution. The latter assay is able to distinguish genuine replication initiation events from incorporation as a result of DNA repair. The human cell-free replication assay reported by Krude, et al (1997), *Cell* 88, 109-
10 19 may also be used to assay the effects of substances on the polypeptides of the invention.

Other In Vitro Assays

Other assays for identifying substances that bind to a polypeptide of the invention are also provided. For example, substances which affect chromosome condensation may
15 be assayed using the *in vitro* cell free system derived from *Xenopus* eggs, as known in the art.

Substances which affect kinase activity or proteolysis activity are of interest. It is known, for example, that temporal control of ubiquitin-proteasome mediated protein degradation is critical for normal G1 and S phase progression (reviewed in Krek 1998,
20 *Curr Opin Genet Dev* 8, 36-42). A number of E3 ubiquitin protein ligases, designated SCFs (Skp1-cullin-F-box protein ligase complexes), confer substrate specificity on ubiquitination reactions, while protein kinases phosphorylate substrates destined for destruction and convert them into preferred targets for ubiquitin modification catalyzed by SCFs. Furthermore, ubiquitin-mediated proteolysis due to the anaphase-promoting
25 complex/cyclosome (APC/C) is essential for separation of sister chromatids during mitosis, and exit from mitosis (Listovsky et al., 2000, *Exp Cell Res* 255, 184-191).

Substances which inhibit or affect kinase activity may be identified by means of a kinase assay as known in the art, for example, by measuring incorporation of ³²P into a suitable peptide or other substrate in the presence of the candidate substance. Similarly,

substances which inhibit or affect proteolytic activity may be assayed by detecting increased or decreased cleavage of suitable polypeptide substrates.

Assays for these and other protein or polypeptide activities are known to those skilled in the art, and may suitably be used to identify substances which bind to a polypeptide of the invention and affect its activity.

Whole Cell Assays

Candidate substances may also be tested on whole cells for their effect on cell cycle progression, including mitosis and/or meiosis. Preferably the candidate substances have been identified by the above-described *in vitro* methods. Alternatively, rapid throughput screens for substances capable of inhibiting cell division, typically mitosis, may be used as a preliminary screen and then used in the *in vitro* assay described above to confirm that the affect is on a particular polypeptide of the invention.

The candidate substance, i.e. the test compound, may be administered to the cell in several ways. For example, it may be added directly to the cell culture medium or injected into the cell. Alternatively, in the case of polypeptide candidate substances, the cell may be transfected with a nucleic acid construct which directs expression of the polypeptide in the cell. Preferably, the expression of the polypeptide is under the control of a regulatable promoter.

Typically, an assay to determine the effect of a candidate substance identified by the method of the invention on a particular stage of the cell division cycle comprises administering the candidate substance to a cell and determining whether the substance inhibits that stage of the cell division cycle. Techniques for measuring progress through the cell cycle in a cell population are well known in the art. The extent of progress through the cell cycle in treated cells is compared with the extent of progress through the cell cycle in an untreated control cell population to determine the degree of inhibition, if any. For example, an inhibitor of mitosis or meiosis may be assayed by measuring the proportion of cells in a population which are unable to undergo mitosis/meiosis and comparing this to the proportion of cells in an untreated population.

The concentration of candidate substances used will typically be such that the final concentration in the cells is similar to that described above for the *in vitro* assays.

A candidate substance is typically considered to be an inhibitor of a particular stage in the cell division cycle (for example, mitosis) if the proportion of cells undergoing that particular stage (i.e., mitosis) is reduced to below 50%, preferably below 40, 30, 20 or 10% of that observed in untreated control cell populations.

THERAPEUTIC USES

Many tumours are associated with defects in cell cycle progression, for example loss of normal cell cycle control. Tumour cells may therefore exhibit rapid and often aberrant mitosis. One therapeutic approach to treating cancer may therefore be to inhibit mitosis in rapidly dividing cells. Such an approach may also be used for therapy of any proliferative disease in general. Thus, since the polypeptides of the invention appear to be required for normal cell cycle progression, they represent targets for inhibition of their functions, particularly in tumour cells and other proliferative cells.

The term proliferative disorder is used herein in a broad sense to include any disorder that requires control of the cell cycle, for example, cardiovascular disorders such as restenosis and cardiomyopathy, auto-immune disorders such as glomerulonephritis and rheumatoid arthritis, dermatological disorders such as psoriasis, anti-inflammatory, anti-fungal, antiparasitic disorders such as malaria, emphysema and alopecia.

One possible approach is to express anti-sense constructs directed against polynucleotides of the invention, preferably selectively in tumour cells, to inhibit gene function and prevent the tumour cell from progressing through the cell cycle. Anti-sense constructs may also be used to inhibit gene function to prevent cell cycle progression in a proliferative cell. Another approach is to use non-functional variants of polypeptides of the invention that compete with the endogenous gene product for cellular components of cell cycle machinery, resulting in inhibition of function. Alternatively, compounds identified by the assays described above as binding to a polypeptide of the invention may

be administered to tumour or proliferative cells to prevent the function of that polypeptide. This may be performed, for example, by means of gene therapy or by direct administration of the compounds. Suitable antibodies of the invention may also be used as therapeutic agents.

- 5 Alternatively, double-stranded (ds) RNA is a powerful way of interfering with gene expression in a range of organisms that has recently been shown to be successful in mammals (Wianny and Zernicka-Goetz, 2000, Nat Cell Biol 2000, 2, 70-75). Double stranded RNA corresponding to the sequence of a polynucleotide according to the invention can be introduced into or expressed in oocytes and cells of a candidate organism
10 to interfere with cell division cycle progression.

- In addition, a number of the mutations described herein exhibit aberrant meiotic phenotypes. Aberrant meiosis is an important factor in infertility since mutations that affect only meiosis and not mitosis will lead to a viable organism but one that is unable to produce viable gametes and hence reproduce. Consequently, the elucidation of genes
15 involved in meiosis is an important step in diagnosing and preventing/treating fertility problems. Thus the polypeptides of the invention identified in mutant *Drosophila* having meiotic defects (as is clearly indicated in the Examples) may be used in methods of identifying substances that affect meiosis. In addition, these polypeptides, and corresponding polynucleotides, may be used to study meiosis and identify possible
20 mutations that are indicative of infertility. This will be of use in diagnosing infertility problems.

ADMINISTRATION

- Substances identified or identifiable by the assay methods of the invention may preferably be combined with various components to produce compositions of the
25 invention. Preferably the compositions are combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition (which may be for human or animal use). Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The composition of the invention may be administered by

direct injection. The composition may be formulated for parenteral, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration. Typically, each protein may be administered at a dose of from 0.01 to 30 mg/kg body weight, preferably from 0.1 to 10 mg/kg, more preferably from 0.1 to 1 mg/kg body weight.

- 5 Polynucleotides/vectors encoding polypeptide components (or antisense constructs) for use in inhibiting cell cycle progression, for example, inhibiting mitosis or meiosis, may be administered directly as a naked nucleic acid construct. They may further comprise flanking sequences homologous to the host cell genome. When the polynucleotides/vectors are administered as a naked nucleic acid, the amount of nucleic
10 acid administered may typically be in the range of from 1 µg to 10 mg, preferably from 100 µg to 1 mg. It is particularly preferred to use polynucleotides/ vectors that target specifically tumour or proliferative cells, for example by virtue of suitable regulatory constructs or by the use of targeted viral vectors.

- Uptake of naked nucleic acid constructs by mammalian cells is enhanced by
15 several known transfection techniques for example those including the use of transfection agents. Example of these agents include cationic agents (for example calcium phosphate and DEAE-dextran) and lipofectants (for example lipofectamTM and transfectamTM). Typically, nucleic acid constructs are mixed with the transfection agent to produce a composition.

- 20 Preferably the polynucleotide, polypeptide, compound or vector described here may be conjugated, joined, linked, fused, or otherwise associated with a membrane translocation sequence.

- Preferably, the polynucleotide, polypeptide, compound or vector, etc described here may be delivered into cells by being conjugated with, joined to, linked to, fused to, or
25 otherwise associated with a protein capable of crossing the plasma membrane and/or the nuclear membrane (i.e., a membrane translocation sequence). Preferably, the substance of interest is fused or conjugated to a domain or sequence from such a protein responsible for the translocational activity. Translocation domains and sequences for example include

domains and sequences from the HIV-1-trans-activating protein (Tat), *Drosophila* Antennapedia homeodomain protein and the herpes simplex-1 virus VP22 protein. In a highly preferred embodiment, the substance of interest is conjugated with penetratin protein or a fragment of this. Penetratin comprises the sequence

- 5 RQIKIWFQNRRMKWKK and is described in Derossi, *et al.*, (1994), *J. Biol. Chem.* 269, 10444-50; use of penetratin-drug conjugates for intracellular delivery is described in WO/00/01417. Truncated and modified forms of penetratin may also be used, as described in WO/00/29427.

- 10 Preferably the polynucleotide, polypeptide, compound or vector according to the invention is combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The composition may be formulated for parenteral, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration.

- 15 The routes of administration and dosages described are intended only as a guide since a skilled practitioner will be able to determine readily the optimum route of administration and dosage for any particular patient and condition.

- 20 The invention will now be further described by way of Examples, which are meant to serve to assist one of ordinary skill in the art in carrying out the invention and are not intended in any way to limit the scope of the invention.

EXAMPLESGeneration and Identification of Lethal, Semi-Lethal and Sterile Third Chromosome Mutants Having Defects in Mitosis and/Or Meiosis, and Second Chromosome Mutants Having Defects in Imaginal Disc Development By P-Element5 Insertion Mutagenesis*P-element mutagenesis*

Transposable elements are widely used for mutagenesis in *Drosophila melanogaster* as they couple the advantages of providing effective genetic lesions with ease of detecting disrupted genes for the purpose of molecular cloning. To achieve near

10 saturation of the genome with mutations resulting from mobilisation of the P-lacW transposon (a P-element marked with a mini-white gene, bearing the *E.coli lacZ* gene as an enhancer trap, and an *E.coli* replicon and ampicillin resistance gene to facilitate 'plasmid rescue' of sequences at the site of the P-insertion), *Drosophila* females that are homozygous for *P-lacW* (inserted on the X chromosome) are crossed with males carrying

15 the transposase source P($\Delta 2-3$) (Deak et al., 1997). Random transpositions of the mutator element are then 'captured' in lines lacking transposase activity. Stable, or balanced, stocks bearing single lethal *P-lacW* insertions are made.

More than 41,000 lines are derived, of which approximately one-half are on the third chromosome. Originally some 3100 lethal or strong semi-lethal lines (in homozygous

20 conditions) are identified. During preliminary characterisation unstable lines and clusters of the same mutation event are eliminated leaving 2460 lines to be characterised.

Screening for Mitotic and Meiotic Defects

About half of the mutants in the collection are embryonic lethals. We have carried out cytological screens of the 1155 lines that comprise late larval lethals, pupal lethals,

25 pharate and adult semi-lethals for defective mitosis in the developing larval CNS. This has identified 69 mutations falling into 43 complementation groups that affect all stages of the mitotic cycle. The cytological screens involve examining orcein-stained squashed preparations of the larval CNS to detect abnormal mitotic cells. In lines where defects are

identified, the larval CNS is subjected to immunostaining to identify centromeres, spindle microtubules and DNA for further examination. This leads to clarification of the mitotic defect.

As a set of common functions are essential to both mitosis and meiosis, we then
5 identify mutations resulting in sterility and failed progression through male meiosis. This involves examining squashed preparations larval, pupal or adult testes by phase contrast microscopy. We examine "onion stage" spermatids in the 519 pupal and pharate lethal lines and 463 adult "semi-lethal" and viable lines for variations in size and number of nuclei which provides an indication of whether there have been defects in either
10 chromosome segregation or cytokinesis, respectively. A total of 54 lines of the 519 pupal and pharate lethal lines and 22 of the adult lines show such defects. However, another 67 lines show male sterility without having onion-stage defects. 12 lines showing onion stage defects have been scored as having mitotic defects in the independent cytological screen of squashed preparations of the larval CNS. Twelve further lines with onion stage defects
15 show female sterility and of these, 10 show maternal effect mitotic defects in syncytial embryos. Thus greater than one half of the meiotic mutants scored appear to represent cell division functions specific to male meiosis or have targeted male germ-line specific enhancer elements, thus revealing their meiotic function but in this test not their mitotic function.

20 Further characterisation of testis preparations of each line by phase-contrast microscopy with and without staining with Hoechst to reveal DNA defined 6 broad categories of meiotic mutants:

8 mutants from the collection show defects in meiotic entry or at early stages in the first meiotic division (MF1-8).

25 18 mutants (15 complementation groups) show abnormal meiotic spindles (AB1-16). Mutants in this group almost invariably show an associated weak defect in cytokinesis, and 7 show a strong defect in spermatid differentiation. 3 of these mutants

also show mitotic defects in larval brains or in embryos derived from homozygous mutant mothers.

18 mutants (16 complementation groups) also show abnormal meiotic spindles that are strongly multipolar (MUL1-15). Three of these also show maternal effect mitotic abnormalities of multipolar spindles in syncytial embryos.

4 mutants (3 complementation groups) show strong defects at all stages of spermatogenesis from the pre-meiotic stages to spermatid elongation stages (PL1-3). In this respect they resemble the *polo*¹ mutation.

4 mutants show segregation defects as indicated by spermatid nuclei of heterogeneous sizes (SEG1-4). The spindles appear normal but all have what are either chromosome bridges or lagging chromosomes. One of these also shows a maternal effect.

9 mutants (7 complementation groups) show predominant cytokinesis defects. Two complementation groups also have cytokinesis defects in mitotic cells in the larval brain.

In the Examples below, the designations MF, AB, MUL, PL, SEG or CK are included in the category description where available. Further phenotype information for each mutant described in the results section is provided in the "Phenotype" field. There is considerable overlap between these categories, and it will be of much interest to distinguish between mutants in which the primary defect results in secondary consequences, and mutants that affect more than one aspect of spermatogenesis, as for example appears to be the case with *polo* mutants (Sunkel and Glover, 1988; Carmena et al, 1998).

In the Examples, lines exhibiting mitotic and meiotic phenotypes are categorised generally into four categories:

Category 1 : Failure to complete cytokinesis

Category 2 : Failure to enter M-phase

Category 3: Metaphase arrest

Category 4: Anaphase defect

Category 5: Small Imaginal Discs (Block to Proliferation; see below)

5 Category 1 phenotypes are exhibited by mutations in Examples 1 to 14; while Category 2 phenotypes are exhibited by mutations in Examples 15 to 19. Category 3 phenotypes are exhibited by mutations in Examples 20 to 30, Category 4 phenotypes are exhibited by mutations in Examples 31 to 53. Mutations in Examples 54 to 74 exhibit a Category 5 phenotype.

10 ***Generation and identification of second chromosome mutants having small or no imaginal discs.***

 In the case of the second chromosome the flies used were from a second chromosome P-element collection established in Szeged, Hungary (Torok et al., 1993). The process of P-element insertion mutagenesis is essentially as described above. 15475
15 insertions were recovered, of which 2711 were lethal or semi-lethal. After elimination of clusters of identical mutants, 2399 lines representing 1748 independent lethal insertions were recovered. Lines were chosen from the second chromosome collection on the basis of having small or no imaginal discs, to indicate a disruption in cell cycle progression that leads to underdevelopment of the discs. All the second chromosome mutants referred to in
20 the results section are noted under the "Phenotype" field as "second chromosome, small imaginal discs" and comprise Category 5.

Cytological Mapping of the P-Element Insertion Sites

 The site of insertion of the P-element in each mutant line was determined by *in situ* hybridisation of P-element DNA to salivary gland polytene chromosomes as described in
25 Saunders et al., 1989. Wandering third stage larvae were dissected and fixed as described and incubated with biotin-labeled DNA made from the *P-lacW* plasmid. After signal

detection chromosomes were stained with Giemsa and examined by microscopy and signals indicating the presence of P elements were assigned to polytene chromosome bands referring to the Bridges map (Lefevre, 1976). In the majority of cases a single P element was detected, only 10% of lines having multiple (two or three) insertions. The site of insertion is given as the "Map Position" field in the results section (for example 77B)

Plasmid Rescue of P-Elements from Mutant Drosophila Lines

Genomic DNA was isolated from adult flies by the method of Jowett et al., 1986, and plasmid rescue from the genomic DNA was performed according to Pirrotta et al., 1986. This allows the recovery of genomic DNA adjacent to the P-element which facilitates the identification of the site of P-element insertion and of genes which may be disrupted by the insertion. Essentially, genomic DNA derived from about 200 flies was digested with a restriction enzyme known to have a site within the P-element (EcoR1 or SacII for cloning sequences to the left of the element, or XbaI, BglII, PstI or BamHI for sequences to the right of the element). The digested DNA was ligated overnight, and plasmids recovered by electroporation of the ligated DNA into *E.coli* XL1-blue competent cells. Appropriate primers from within the P-lacW sequence were used to determine the sequence of the genomic DNA flanking the element (on average, 400 bp of sequence were obtained). The rescue sequences are provided in the results section under the heading "Rescue sequence". Where more than one sequence was recovered, the orientation of each sequence is also given.

Sequence Analysis of P Element Insertion Lines

Sequences flanking the insertion site of the P-element were derived by P element rescue as described above. In some cases sequence was obtained from only one side of the insertion, while in other cases sequences were obtained from both sides of the insertion.

As a first step, each P element rescue sequence was used to search a total database of *Drosophila melanogaster* sequences (database of the Berkley *Drosophila* Genome project) using the BLASTN program (which compares a nucleic acid sequence with a nucleic acid database, (Altschul and Lipman 1990)) with default parameters.

The search may identify a number of different types of match including *Drosophila* ESTs, known *Drosophila* genes and cloned genomic regions.

The ability to identify genes already known to be essential for cell cycle progression using this approach was confirmed, in this example, by the rescue sequence
5 obtained from line 1324/8 which mapped to the 77B locus which was used to search the database. A BLASTN search identified a number of matching *Drosophila* ESTs, a match with the known cell cycle regulatory gene *polo* and a cloned genomic region designated CSC: AC018188. These matches are recorded in the results sections under the field headings "*Drosophila* ESTs", "*Drosophila* gene hit" and "Genomic hit, Accession No.",
10 respectively. Any entries under "*Drosophila* gene hit" are further annotated with "(BLASTN with Rescue sequence)" to show that the match was obtained using the rescue sequence rather than a *Drosophila* EST or genomic clone ORF (see below). Accession numbers of ESTs, genes and genomic clones are provided where known. Genomic clones designations often include the Genbank designation as part of a longer designation.
15 However the Genbank designation is always the code beginning with "AC" and followed by six digits.

Where an EST was identified, this was subsequently used to search using the BLASTX program (default parameters) against databases of sequences from *Drosophila* and Homo sapiens (databases of the National centre for Biotechnology Information
20 (NCBI), National Library of Medicine, National Institute of Health, USA). In the case of line 1104/16, the search identified a known human gene, phosphatidylinositol transfer protein (accession no. P48739) implying a novel function for this protein in cytokinesis. Human Homologues identified as a result of a BLASTX search using a *Drosophila* EST are shown in the results section under the heading "Human homologues" and annotated
25 with "(BLASTX with EST)". *Drosophila* genes identified as a result of a BLASTX search using a *Drosophila* EST are shown in the results section under the heading "*Drosophila* gene hit" and annotated with "(BLASTX with EST)".

Where no *Drosophila* gene was identified using the initial BLASTN search but a matching genomic clone was found (a Bac or P1 clone often in excess of 100 kilobases), a

20 kilobase segment of this genomic sequence (10 kilobases either side flanking the site of the P-element insertion) was subjected to a number of analyses.

If the rescue sequence matched sequences that lie within a known gene present within the genomic clone then these are presented under the heading "*Drosophila* gene hit
5 (BLASTN with Rescue sequence". The known gene sequence was then used in a BLASTX search of a human database (NCBI – see above) to identify any human homologues. These are shown in the "Human homologue" field and annotated with "(BLASTX with *Drosophila* gene)".

If the rescue sequence does not match any sequences that lie with a known gene
10 within the genomic clone then the occurrence of ORFs within the 20 kilobase genomic segment was predicted using the Genscan programme (Burge and Karlin, 1997). Where the P-element was observed to be inserted into the coding region or within the 5' untranslated region (which we defined as within 2 kilobases of the predicted start of the coding region) we assume the P element to be capable of disrupting the expression of the
15 predicted gene. Each predicted open reading frame (or predicted coding sequence) was then used to search *Drosophila* and human databases using the TBLASTN program (compares a protein query sequence against a nucleotide sequence database dynamically translated in all reading frames) and/or the TBLASTX program (compares a nucleotide query sequence dynamically translated in all reading frames against a nucleotide sequence
20 database dynamically translated in all reading frames) to determine whether the predicted open reading frame corresponded to a known gene. Typically, TBLASTX is only used when no matches are found using TBLASTN.

Where the TBLASTN search found a known *Drosophila* gene, then this is indicated in the results in the "*Drosophila* gene hit" field, annotated with "(TBLASTN
25 with predicted ORF)". The *Drosophila* gene sequence was then typically used to search a human database (NCBI – see above) to identify any human homologues using BLASTX. These are shown in the "Human homologue" field and annotated with "(BLASTX with *Drosophila* gene)".

Where the TBLASTN and/or TBLASTX search found a known human gene, then this is indicated in the results in the "Human homologue" field, annotated with "(TBLASTN (or TBLASTX) with predicted ORF)".

5 If the TBLASTN and/or TBLASTX search found no *Drosophila* or human genes, then it was assumed that the original ORF corresponds to a novel gene. If the TBLASTN search found no *Drosophila* genes but identified a human homologue, then it was assumed that the original ORF corresponds to a novel *Drosophila* homologue of a known human gene.

10 ***Additional Sequence Analysis using the Annotated D. melanogaster Sequence (GadFly).***

Rescue sequences were also used to search the fully annotated version of the *Drosophila* genome (GadFly; Adams, et al., 2000, Science 287, 2185-2195), using GlyBLAST at the Berkeley *Drosophila* Genome Projects web site to identify the genome segment (usually approximately 200-250 kb) containing the P-element insertion site. The
15 graphic representation of the genomic fragment available at GadFly allows the identification of all real and theoretical genes which flank the site of insertion. Candidate genes where the P-element is either inserted within the gene or close to the 5' end of the gene were identified. In GadFly, the *Drosophila* genes are given the designation CG (Complete gene) and usually details of human homologues are also given. In most cases,
20 this data confirms the data derived from the sequence analysis procedure described above, and in some cases new data is obtained. Where available both sets of data are included in the individual Examples described below. To identify further candidate human homologues, BLASTP (amino acid query sequence against amino acid database) searches with *Drosophila* sequences are used against the human genome project database and also
25 the Ensembl dataset. The Ensembl dataset comprises GeneWise gene predictions using a protein template where possible or Genscan followed by BLAST confirmation via protein, cDNA or EST hits. These are matched using WUBLASTP with default parameters (Altschul et al., 1990, *J Mol Biol* 215, 403-10). The results are filtered to contain only potential homologues. Only matches with the identity of more than 50% and length of
30 more than 50 amino acids are included.

Confirmation of Cell Cycle Involvement of Candidate Genes Using Double Stranded RNA Interference (RNAi)

P-elements usually insert into the region 5' to a *Drosophila* gene. This means that there is sometimes more than one candidate gene affected, as the P-element can insert into the 5' regions of two diverging genes (one on each DNA strand). In order to confirm which of the candidate genes is responsible for the cell cycle phenotype observed in the fly line, we use the technique of double stranded RNA interference to specifically knock out gene expression in *Drosophila* cells in tissue culture (Clemens, et al., 2000, *Proc. Natl. Acad. Sci. USA*, 6499-6503). The overall strategy is to prepare double stranded RNA (dsRNA) specific to each gene of interest and to transfect this into Schneider's *Drosophila* line 2 to inhibit the expression of the particular gene. The dsRNA is prepared from a double stranded, gene specific PCR product with a T7 RNA polymerase binding site at each end. The PCR primers consist of 25-30 bases of gene specific sequence fused to a T7 polymerase binding site (TAATACGACTCACTATAGGGACA), and are designed to amplify a DNA fragment of around 500bp. Although this is the optimal size, the sequences in fact range from 450 bp to 650 bp. Where possible, PCR amplification is performed using genomic DNA purified from Schneider's *Drosophila* line 2 as a template. This is only feasible where the gene has an exon of 450 bp or more. In instances where the gene possesses only short exons of less than 450 bp, primers are designed in different exons and PCR amplification is performed using cDNA derived from Schneider's *Drosophila* line 2 as a template.

A sample of PCR product is analysed by horizontal gel electrophoresis and the DNA purified using a Qiagen QiaQuick PCR purification kit. 1µg of DNA is used as the template in the preparation of gene specific single stranded RNA using the Ambion T7 Megascript kit. Single stranded RNA is produced from both strands of the template and is purified and immediately annealed by heating to 90 degrees C for 15 mins followed by gradual cooling to room temperature overnight. A sample of the dsRNA is analysed by horizontal gel electrophoresis.

3µg of dsRNA is transfected into Schneider's *Drosophila* line 2 using the transfection agent, Transfect (Gibco) and the cells incubated for 72 hours prior to fixation.

The DNA content of the cells is analysed by staining with propidium iodide and standard FACS analysis for DNA content. The cells in G1 and G2/S phases of the cell cycle are visualised as two separate population peaks in normal cycling S2 cells. In each experiment, Red Fluorescent Protein dsRNA is used as a negative control. In some cases
 5 the phenotype is confirmed by fixing cells on poly-lysine covered slides which are then stained for DNA using DAPI and for tubulin using an anti-tubulin antibody YL1/2 and appropriate fluorescent secondary antibody to visualise aberrant mitoses.

It should be noted that RNAi could not confirm phenotype in all cases. This is to be expected as the method relies on the ability of dsRNA to prevent new protein
 10 expression. Consequently, it is necessary that S2 cells express the specific cDNA of the gene in question, and also that the protein is turned over rapidly. It would therefore probably be difficult to sufficiently reduce levels of very stable proteins using this approach.

The layout of a typical entry in the results section is shown below. Not all fields
 15 present in the actual results section contain information for each individual *Drosophila* line described.

TYPICAL RESULTS LAYOUT

20	Line ID	- <i>Drosophila</i> line designation
	Category	- Description of phenotype
	Reversion	- R = revertant, NR = non revertant, ? = not determined
	Map Position	- according to the Bridges map (Lefevre, 1976).

25	Rescue ID
	Rescue Sequence [nucleotide sequence]

Genomic hit, Accession No.

30	Associated ORF
	GENSCAN_predicted_peptide [results of Genscan - amino acid sequence]
	GENSCAN_predicted_CDS [results of Genscan nucleotide sequence]

35	<i>Drosophila</i> Gene Hit (BLASTN with rescue sequence)
----	--

(TBLASTN (or TBLASTX) with predicted ORF)
(BLASTX with EST)

Human Homologue

- 5 (BLASTX with *Drosophila* gene)
(TBLASTN (or TBLASTX) with predicted ORF)
(BLASTX with EST)
***Drosophila* EST**

- 10 **Annotated *Drosophila* genome genomic segment**
Annotated *Drosophila* genome Complete gene candidate
Human homologue of Complete gene candidate

Putative function Derived from homologies or *Drosophila* experimental data

- 15 **Confirmation by RNAi** Description of Facs analysis DNA content profile

A specific example is as follows:

- 20 **Line ID** 1324/8
Category Mitotic defects in brain: metaphase arrest
 (overcondensation, some circular chromosomes, no anaphases,
 very high mitotic index, metaphase (or less aligned) with bipolar
25 **Reversion** R
Map Position 77B
- Rescue ID** B1E
- 30 **Rescue Sequence**
GTTTTGCCCATCGATTGCACGAAAACCAAGCACAAAGCGGAGAACGCGCCGA
AACCGTTCGATTTTTTAAATGCCAAAATGAATTGGACGTGAAGCGTCAGCTGA
ATTGGTGTGCCCGTTTCGGTGGCTATCGCACACTTCTGGTATTTATCGCGGTA
TTTTGTTGAGTGTGAACAACAAATTCTATGGCCGTTACCCTTTGAATTTACT
35 TACTGGCGTTTACTCTGTTTCAATTGAGCGCAATATTTTTTCTATTGCTCTGC
GCAACACTGTGTTTTAACCGCTATTTATTTGAAAATCTACAAAACTAACCGTT
TACATTTTTGAAATTTCCAAAAGGGTTTTCCATAAATTGAGTTTTACTAAAACC
AGTCCAACGGTCCAACCTTATATTGTTAGAAGCCCCTTTTCTAATTTGAATTG
GCTTGCAAACGTTTTCTGAATTTAAAAATACTGCCACCCTTGTTAATTGCAGG
40 TTTTCCGAATCCCTGATTTGTTGTTTTAAAAAGAAAATTTATTAGAAACAGCTA
TCTCAACC

Genomic hit, Accession No. CSC:AC018188

***Drosophila* Gene Hit** Polo (X63361)

- 45 **Human Homologue** BLASTX PLK-1 (P53350)

***Drosophila* EST** several including LD11851 (AA392613) which match polo

Annotated *Drosophila* genome genomic segment AE003514

Annotated *Drosophila* genome Complete gene candidate CG12306

Human homolog of Complete gene candidate 1e-169 1709658 P53350
PLK1_HUMAN
SERINE/THREONINE-
PROTEIN KINASE PLK
(PLK-1)

5

Putative function Serine/threonine kinase known to be required for mitosis

- 10 **Confirmation by RNAi** Reduced G1 and G2/M peaks indicating fewer cycling cells, microscopy analysis of DNA and tubulin staining identified monopolar spindles characteristic of polo mutation in *Drosophila*.

CATEGORY 1: FAILURE TO COMPLETE CYTOKINESIS**Example 1 (Category 1)**

- Line ID** 1031/14
Category Mitotic defects in brain: cytokinesis defect (polyploidy)
Reversion R
Map Position 74B
- 10 **Rescue ID** 2A3B
Rescue Sequence 1
CCCCGGAACATATGTTTCAGTGTGGCCGCAGCAGAGTTGTCAAAACACGCTCCC
CAATGAAATAACCTAAATGTGCCATCACTGTTACTTAACAGTTTCTGTTACTTT
TCTAGCGGCATGTCAAAAAAACAAAAATATAGAAAATGCTAAATATATATTG
15 GACTAATGTGTTTAAATGTAACCTTACACTAGTAACAGATCCCCATTAATAAAA
GCCAAACTCTAAAATTCTGCCACAAGTACTATTTCTCACGTAACACCTTACTA
ACGGATTTACATGATATCTACGACAAGAACTGTTTGCTGATATAAAATTGC
TATCACCGCTTTCCGTAAACACTTTTACACTGATGGATTACAAGTTCAATTAAT
ACATCAACTTACCTTAACAATTTTAAGACAATAACACTCCCACAATTTAATT
20 CAACCTACACCGCTTGATAATCAGCTGTTCTGTACAAAAACAATAACACTGT
TAACAACAGCGCACAGTGGATAATACAGTCCTAAAGGCAATATACCCATTG
GCATTTTT
- Rescue ID** 2A3S
25 **Rescue Sequence 2**
TTCCGGGGAGAATGGCTGCGATTTTCGCGTCGGTAAAAATAGCAAATACTCGTTA
ATGTGCTGTGGGAACGCTTCTCCCCGGCCCCAAAGTGGCCCCGAAGAAAGTGA
GCAATGTGCGCGCCGCAAGATAGTCGCCGCCGAACAAACGATAGTGACGAAA
GTGATTTAATTCAACTACCAGCACTCCCGCAAATACGATGAGTATGTCGCGCGG
30 CGGCAACACAACCTCTGGACTTGCAGCCGCTCCTGGCGGAGAGCGATGTCGGAA
ACAGGGAGCTGGAGGAGAAGATGGGCGGATCGGCGGATCGGTCATCGCTGCTC
GATGGATCCGGTTCGAAGGAGCTGAGTCACCGGGAACGCGAGGACTCGGCGTT
GTTTCGTCAAGAAGATCGGGAGCGCCTTGTTCATGGCTTGTCTCCTTCATGATT
ACGGTGGTAAACAAGACGGTGCTTACCTCCTACCACTTCCCCTCGTTCCTGTTCC
35 TCAGCCTCGGGCAACTTACTGCTAGCATTGTGGTCCTGGGCATGGGCAAAGCGC
CTGAAAATGGTGAACCTTTTCCCCCTTTTGAGAGGAATACCTTCGCCAAGATCTTT
CCGCTGCCACTGATATTTCTGGGAAACATGATGTTTGGACTGGGTGGCACAAAA
ACCTTGAGTCTGCCCATGTTTCGCAGCCCTACGAC
- 40 **Genomic hit, Accession No.** AC019515

Associated ORF

Genscan ORF1 predicted sequences:>15:31:57|GENSCAN_predicted_peptide_4|373_aa

MSMSRGGNTTLDLQPLLAESDVGNRELEEKMGGSADRSSLDDGSGSKELSHRER
 EDSALFVKKIGSALFYGLSSFMITVVNKTVLTSYHFPSFLFLSLGQLTASIVVLGMG
 KRLKLVNFPPLQRNTFAKIFPLPLIFLGNMMFGLGGTKTSLPMFAALRRFSILMT
 MLELKILGLRPSNAVQVSVMYAMIGGALLAASDDLFSNMRGYTYVMITNALTASN
 5 GVVYVKKKLDLTSEIGKYGLMYNSLFMFLPALALNYVTGNLDQALNFEQWNDVS
 FVVQFLLSCVMGFILSYSTILCTQFNSALTTTIVGCLKNICVTYLGMFIGGDYVFSW
 LNCIGINISVLASLLYTYVTFRRKRAPDKQDHL PSTRGENV

>15:31:57|GENSCAN_predicted_CDS_4|1122_bp

10 atgagtatgtcgcggcggaacacaactctggacttgagccgctcctggcggagagcgatgtcggaacaggagctgga
 ggagaagatggcgcgatcgcgatcggtcatcgctcgtgatccggctcgaaggagctgagtcaccgggaacgcgag
 gactcggcggtgttcgcaagaagatcgggagcgcttgttctatggctgtcctcctcatgattacgggtgtaaacagacgggtc
 ttacctctaccacttcccctgttctgttctcagcctcgggcaacttactgctagcattgtgtcctggcgatgggcaagcgct
 gaaattggtgaacttccccctctgcagaggaataccttcgccaagatcttccgctgccactgatattctgggaaacatgatgttg
 15 gactgggtggcacaacaccttgagctgcccattgtcgcagccctacgacgcttctctatcctgatgacatgctgctggagctca
 agatcctgggactgcgaccttcgaatcggttcaggtcagcgatatacgcaatgacgggtggagcgctgctggcgccctctgatga
 tctgtccttcaacatgaggggtacatctatgtgatgactaactgacgcttgaccgctcgaatggcgatatgtgaagaaaaaactc
 gacacctcggagatcggaagtaggcctaattgtactacaactcgtgtttatgtttctgcctgccctggccctcaactatgttacag
 ggaatctagatcaggcgctgaacttgaacaatggaatgactcagtggttggtgcagttcctgctcagttgcgttatgggttcac
 20 ctatcgtacagcaccatcctgtgcacgaattcaactcggcgctgaccaccaccattgtgggatgcctgaaaaacatctgcgtaac
 atatctgggcatgttcattggaggcgactacgtctctcgtggctcaactgtattgggatcaacatcagcgctgctgtagtctgctc
 acacgtacgtcacttttcggcggaagcgggctcccataagcaggaccacttcccagcaccggcggaatgtctag

25 **Human Homologue** (TBLASTN with ORF1): KIAA0260 gene (D87449) and putative
 Sqv-7-like protein (AJ005866)
Drosophila EST CK00510 (AA140776)

Annotated Drosophila genome genomic segment AE003524

30 **Annotated Drosophila genome Complete gene candidate** CG3874 – novel glucose-6-
 phosphate transporter

Human homologue of Complete gene candidate

35 EMBL:D87449 protein
 KIAA0260_id:BAA13390
 gi:166578 Similar to a
 C.elegans protein encoded in
 cosmid C52E12 (U50135) and
 Ensembl predicted gene
 ENSG00000024527
 Clone:AL133320
 40 Contig:AL133320.00001
 8.10E-95

Putative function Sugar modification protein similar to proteins involved in
 Drosophila cytokinesis and signalling

45 **Confirmation by RNAi** Marked increased G1 and S peak indicating mainly arrest in
 G1

Example 2 (Category 1)

Line ID 1066/5
Category Male semi-sterile, Meiotic defects in testis: cytokinesis defects, segregation defects.
 5 (Seg-01/62)
Reversion ?
Map Position 89B
 10 **Rescue ID** F9E
Rescue Sequence
 GTATACCATTAGAGAATATGATGAAGAAGGACTGTAAGAAGATCCTTCAGTG
 AATTTGACTGCTGACGTCGATCGGAACCTTGCTGCGCTGACGTACAAAATCGCG
 AAGTGAATAAATAATATGGATGAGACCCTGTTTCGCCGACATATACAATAGTG
 15 CTCAAGACCTAATGGAATTATACGTTAATAACCAGCCACATTTCTTAGATATTT
 CTAATATGAGCCATCTGCTGCAGGTTCTTTCCAATATCTAATTCTAGATCTTCT
 TCGAATACGACCTTTTTGGCCATGAAACGATGATTTGCCACTTCATTACACAAG
 CATTAATTTGTCATGATTCTCTTAAGCGTGCACCTTATCTGAAAGTCTGAACAG
 CTGGCTGCGAAATGGATCCCCGGGATTGGAGATGGCAAGTAAATCTGTCCTCG
 20 CTACAAACAAGTGGGCACCACTGGGCATTCGGGGAATAGGGATATGGGTTGG
 GAATGGGGATATATTGTGGCATTGGCGAAAGGTCGCTATGC

Genomic hit, Accession No. CSC:AC019750

25 **Associated ORF**
 >16:04:57|GENSCAN_predicted_peptide_4|418_aa
 MKPIPNESKGTAAVGDATVVHDVCTLFAVELDPYLRSSMGMRTTRRAQSGALLL
 QLLAVADGGFAAHICACKCRLRLPHVTCCNRPNPKATAKAKGQAVSSTKPNQL
 CFHGCCGWITTKGETFTENSPSMSGFAWERHSLGECVVVAGTEQILLIGRTLIGR
 30 MSHTQTDSTSPFVVDCHSQLCGSKCKCICVSVGFCVRPSCQRFDMKIVWANLAM
 QKRFLGAAIADMCCRNSVIWCKLQLDPVKPIDERADGSGLALVTKVCDNNNIV
 HYVVVAGVTGSQSRSLQPLRSGQNESTEQWPRTKGEGGGFNNNSRNNKHSAPT
 QEQQELWQKQLLQDQRDDCHASGSFQSASFAETRSFTFDDTTAHSEFCFRTRAEK
 RRILVLLETSIKLKPDKYATSGHTRRCAIGLLHSII
 35 >16:04:57|GENSCAN_predicted_CDS_4|1257_bp
 atgaaaccattcccaacgaatccaaggaacccttgccgcagtggagatgctactgttgatgacgtgtactttgttgccg
 tagagcttgatccctatctcaggagcagcatgggaatgaggacgctagagctcaaagcggcgtctgtattacagctccttgccg
 gttgcgatggaggttttctgctcatattgtgctgcaagtgtcggttcgttgccacatgtcacatgttgctgcaaccggaatcct
 40 ttcaaggcaactgcaaaagcaaaaggtcaggcggcagctccactaaacaaaccagctttgctttcacggctgctgtggctggat
 aattactacaaaggtgaaacgttcaccgaaactcgccagcatcatgagcggtttgcgtgggagcggcatagccttggtgagt
 gcgtggttggtggtggaacggaacaaatcctgctgattggcaggacattgattggccgatgagccatactaaactgattcgacc
 agcccccttggtgctgactgtcactcgcaactgtgcggctccaagtgaatgtatctgtgtatctgtaggtttctgtgtgcgccgtct
 tgtcagcgctttgacatgaaatagtttgggccaactggctatgcaaaagcgatttctattaggagccgcatcgccgacatgtgct
 45 gccgaaattcgggtgatttggtgcaaaactgcagctagatccagtcgaagccaattgacgaaagagccgacggcagcggttgcact
 ggttaccaaagtatgcgataacaataacatcgctccactatgtggtcgttgctgggggttacgggcagtcagtcacgggtcacggctgc

aacccctccgctccggccaaaacgagtcacagaacaatggccaaggacgaagggggggaggggggattcaataacaaca
 gcaggaacaacaacattctgctccacgcaagagcagcaggaactgtggcaaaaacagctgctgcaggatcaacgagacgat
 tgtcatgccagtggagcttcagctcgtcattcgcggagacgcgtagttcacgttcgacgacacaaccgctcacagcgaattt
 tgtttcggactagagctgagaaacggcgaattttggtgcttctggaaacatcgattaaactaaaacccgataagtatgcgacaagc
 5 ggtcacactcggcgatgtgcgataggattgctgcattcgattatag

- Drosophila* Gene Hit** rescue sequence: mitotic heterochromatin fragment clone CH(2)6
 (L36595) and subtelomeric heterochromatin repeats (L03284).
 TBLASTN with ORF1: nebula (nla) (AF147700)
 10 **Human Homologue** BLASTX with nebula: Down Syndrome candidate region 1-like
 protein 2 (AF176117)

***Drosophila* EST** rescue sequence: CK01138 (AA141069)

- 15 **Annotated *Drosophila* genome genomic segment** AE003712
Annotated *Drosophila* genome Complete gene candidate CG6072 - nebula
 CG6046 - sap18

- 20 **Human homologue of Complete gene candidate** CG6072- 8e-36 'ZAKI4 a thyroid
 hormone responsive gene in human
 skin fibroblasts' also known as
 DOWN SYNDROME CANDIDATE
 REGION 1-LIKE 1; DSCR1L1
 EMBL:D83407
 25 protein_id:BAA11911 gi:143504

- 30 CG6046- 3e-45 2108210 (U96915)
 sin3 associated polypeptide p18
 [Homo sapiens] and gi5032067
 C7E479FFE9CA5774
 [ref]NP_005861.1| sin3-associated
 polypeptide, 18kD [Homo sapiens]
 (1.90E-43)

- 35 **Putative function** Nebula unknown function, Sap18 transcription factor

Confirmation by RNAi Both show reduction in G1 and G2/S peaks indicating fewer
 cycling cells

Line ID 234/50
Category Meiotic defects in testis: cytokinesis defects, abnormal spindles.
(Ab-02/12)
Reversion R
5 **Map Position** 89B

Rescue ID 2C5E
Rescue Sequence
10 GTTTGACTGCTGACGTCGATCGGAACTTGCTGCGCTGACGTACAAAATCGCGA
AGTGAATAAATAATATGGATGAGACTCCTGTTTCGCCGACATATACAATAGTG
CTCAAGACCCTAATGGAATTATACGTTAATAACCAGCCACATTTCTTAGATAT
TTCTAATATGAGCCATCTGCTGCAGGTTCTTTCCAATATCTAATTCTAGATCTT
CTTCGAATACGACCTTTTTGGCCATGAAACGATGATTTGCCACTTCATTCACAA
GCATTAATTTGTCATGATTCTCTTAAGCGTGCACTTTATCTGAAAGTCTGAACA
15 GCTGGCTGCGAAATGGATTCCCCGGATTGGAGATGGCAAGTAAATCTGTCCTC
GCTACAAACAAGTGGGCACCACTGGGCATTTCGGGGAATAGGGATATGGGTTG
GAAA

20 **Drosophila EST** rescue sequence: CK01138 (AA141069)
All other entries as for 1066/5.

Example 3 (Category 1)

Line ID 1104/16
Category Mitotic defects in brain: cytokinesis defect
 5 (no overcondensation of diploids, high polyploidy)
Reversion R
Map Position 92A

Rescue ID B5P
 10 **Rescue Sequence 1**
 CTCCGGACACGCAGTAGCTAAATAACAACTCATTACTAGTATATTACTGCCG
 CCGATTTGCAAGCGCGTACCGATCCCGATACCAGGCCAATCGCACTCCCCAGT
 TGTACGTCATCACTTAAGTAATAAATCAGCGGCAAATCGCATAAATTGCTATT
 GATATTCCGCCCGCTGTGTGTGCGTGTGTATTTGCAAGAGAGTGTGTGTGTGT
 15 GTGTGCATATGACTCGTGCCTTTAGCCGACAATTGGAGAAAAAGCATTACCAA
 TCCCAATTGGCTAACTAACTAAAGTTGGCTTGGCCAAACATAAACAAAAAGT
 GCGGGCGCAGCGATTTGGCAGCGAAACATATACACCAAAGCGCTATTGGCAG
 ATATATATGTAGATTAAATATAGAAAGTGCGTGCGAAGGTTAAGAGTCGAGT
 GCAAGTGCATTTATATTTGGAAATAATAAATGCTACAAT

20 **Rescue ID** B5E
Rescue Sequence 2
 GTCCGGAGCGGAGCTAAAGTTCGATGTTTCGTGCAAAACACTTCGATTCCGATA
 GGCGGATGCTATCGATTTTCGGCGATGCCCGTTGGTCACACTTGGTGGTGGGCG
 25 CTGCCCGTCGCCGACTATCGATAGCACAAAGCGGGTTATTTAGGTGTGCGCAGC
 TTGTAAGGGTGACTCATGCTGTTAAAATTATTATAAAAAGTTAATGAATATAA
 TATAGTTATAATAAAATTATATATAAATCTATAAGATCAAAGATCATCAGTTA
 TCATTTATCATTTGATTATATGAAAAACAAGAACAGAAACAAGATTTAATAGG
 TTTTGTAAATGTGAAAATGTGGGTTACCCCAATTCTTATTGAAATTAAATAA
 30 CCTAAAGAACAGTTATACACAGATAGGTAATTTGCACATAAGCCAAATTTGT
 CTAGAATTCGCGGAATTAATTCCTGAAGACGAAAGGGCCTCCGTGATACGCC
 TATTTTATAGGTTAATGTCATGATAATAATGTTTCTTA

Genomic hit, Accession No. AC006589
 35 **Associated ORF**
 Genscan: ORF1 predicted sequences
 >/tmp/aaaaainga|GENSCAN_predicted_peptide_2|850_aa
 MATRGANVIWFRHGLRLHDNPALLAALADKDQGIALIPVFIFDGESAGTKNVGY
 NMRMFLDLSLQDIDDQLQAATDGRGRLLVFEGEPAYIFRRLHEQVRLHRICIEQDC
 40 EPIWNERDESIRSLCRELNIDFVEKVSHTLWDPQLVIETNGGIPPLTYQMFLIRCTH
 HNGDVNGDEDTGEGETGGRIDWAKEGACWRAGNSDEQEQACQSVSSVIMM
 VLQYSNPAHHCQLECLMTLKHNVVKDILCVVAYGTAVSRTSAAKLLFYYP
 AFNANLFDRKVLKLTNDLVPFTCQREHCPNSGNAEAAKVCYDHSISLAYAPDC
 PPPLYLCIECANIEHREHGSLEFGDILHPMQQVSMVCENKNCRSNEKSAFSICFSTE
 45 CASFNGNHPIRYCSQCHSNRHSRRGGDHVVHRS LQPAWQMDPEMQMHMVESV
 VSLLREAKPLNFEPGKESSSESCKNGSGITADNISLEERQRLGRYGIWLLVGRCTP

TADTPVEVLGRILSMLFHWFHVTAYSYDGFISCLVPHPEYARVGGHWETLASRT
 SHLKEGLQRLICLVPEVITSEIWDYVMPHWMEAITNDVAEKELNELKIVLSKILD
 PEMSPLGFDATMYNFVAIRFEKTTAKVQQALHWLQILTKLEILPLVQLFAMF
 GDGVRIMKYGIQHELMREKDAQSLSLAKAPKTPCKESKETKADMANPPRPPVVE
 5 DDSGNTSAISDDEAPTNRHTEFSTDAEHNLTCCILMLDILLKQMELODVEQHMGI
 HTSVCENVSRLLKCMVTAARVGLSSHVCALKVPIDIIIEEEKSSRKSPESDKEKTR
 DRDVLSMAPLPIPLGLGPFADP

>/tmp/aaaainga|GENSCAN_predicted_CDS_2|2553_bp

10 atggccacgcgagggcgcaatgtgattgtttcgccatgattgcgcctccatgataat
 cccgctctattggccgcccgcgataaggatcagggatagccctaattcccgtttcatattcgatggagagagtgagggtacc
 aagaatgtgggttacaatcgatgcgtttctcctgagctcgttcaggacatcgatgatcagctacaggcggaactgatggacg
 tggacgctcctgtgttcgagggcgaaccggcttatcttcggcggtacatgagcaagtgcgtctgcacaggatttgcatag
 agcaggactgcgagccaattggaatgagcgcgatgaaagcatccgttctctatgtcgggagctgaatcgcactttgtcgaag
 15 gtatcacacacgctttggatcccaattggtgattgagaccaatgttggcattccaccgctgacctaccaaatgttctgatacgt
 gcacgcaccacaatggagatgtgaatggggatgaggatacgggagaaggagaaggaaaccggcggaaggatcgactgggcta
 aggaaggggcctgttggaggcggaactccgacgaacagggaatgtcaggcctgccaatcagtgctcctggatcatcatgatg
 gtgctccagctaccaacaatccagcgcatcattgccagctcctggagtgctgatgactcttaagcacaatgtcgaaggacatc
 ctctgcgttggcagacggaaccgctgttcccgacctcggtgccaagctgctcttactactgcccagccttaacgccaatc
 20 tgttcgatcgcaagtcctactctccaaactaaccatgacctagtgccttcacctgccaacgggagcactgtccgaactccggg
 aatggcgaggcgcaaaagggtgtgtctacgaccacagcattagcatcgatacgcgccgattgtccaccgcccctttacctgtgca
 tcgagtgcgcaacgagattcatcgggagcaggaagcctggaggttcggcgacattctgcatccatgacgaggtatcgatgg
 tgtgcgaaaacaagaactgtcgtccaacgagaagtcgcttctccatctgcttctccacggagtgtccagcttcaatggcaac
 catccgatccgctactgcagccagtgccacagtaataggcacaattccggcgaggtggcgatcacgtgtgtccatcgagctctgc
 25 agcccgctcgagatggatccagagatgcagatgcacatggtggagtcgggtgtaagccttctgcgagagcggaaggcacta
 aactttgagcccgcaaggagtcctcgtcgtcgagtcgcaaaaagaacggctccggcatcacagctgacaatatttctctggagg
 aacgccagagactgggacgctatggtatctggtactgtgtggtcgtgtacaccactgcagatactccgtagaagttctggg
 caggattctgagcatgctcttcacttggttcatgtaaccgcttactatcagatggtttatatcctgcctggtgccacatccccgga
 gtatgcccggtgtggagggcactgggagaccttgccgtcgcgaacaaggcacttgaagagggtcttcagcggttatatgcctg
 30 gtccatgatgaggttatcacttccgaaattgggactatgtgatgccgactggatggaggccatcaccaacgacgtggccgaga
 aggaactgaacgagctgaagattgtgctcagcaagatcctgatccggaatgtcgcctctgggcttggatgccaaaacctgtac
 aactttgtggcattcgatttgagaagacaacggcaaaagggtgcagcagcaggcactccactggctgcagatcctcaccaagctgg
 agattctcattccactgggtcagttgttcgcatgttcggcgatgtgttcgcataatgaaatacggcatccagcagcagctgatcg
 cgagaaggatgccaatctcagtccttgccaaaggctcccaagaccccgtgtaagagagcaaggagaccaaagcgatgatg
 35 gccaatccgcccaggcctcctgtgtcaggatgactctgtaatacgtctgccatttcggatgacgagggcgccacgaatcgta
 cacggaattctccacggatgctgagcacaatctacactgttgcacatcctcatgctggacatacttctgaagcaaatggaactacagga
 cgtggagcagcacatgggcatccatacagtgctcgcgagaacgtctccaggctgatcaagtgcagtggtcactgcagctcaggt
 ggtctcagtagtcatgtcgccttaagggttccatcgaggacatcattgaggaagaaaagtcctcgcgcaaatctccaccg
 aatccgacaagggaagaccggtgatcgagatgttccctctcagtggtccactaccattccgctgggacctttaggaggtttg
 40 cagacccttaa

Human Homologue BLASTX with EST: Phosphatidylinositol transfer protein
 (P48739)

45 **Drosophila** EST SD01527 (AI530804), GH18602 (AI387906)

Annotated Drosophila genome genomic segment AE003725

Annotated *Drosophila* genome Complete gene candidate CG5269 – vib PIP transfer protein

- 5 **Human homologue of Complete gene candidate** 1e-90 1346772 P48739
PPI2_HUMAN
PHOSPHATIDYLINOSITOL
TRANSFER PROTEIN BETA
ISOFORM
- 10 **Putative function** phosopholipid transporter involved in lipid metabolism
- Confirmation by RNAi** Slight reduction of G1 and increase in G2/M peaks
 indicating arrest in G2/M

Line ID 418/32
Category Meiotic defects in testis: cytokinesis defects. Dark bands in eyes, dominant.
Reversion ?
5 **Map Position** 69C

Rescue ID G2E
Rescue Sequence
10 AGCTAAATAACAAACTCATTACTAGTATATTACTGCCGCCGATTTGCAAGCGC
GTACCGATCCCGATACCAGGCCAATCGCACTCCCCAGTTGTACGTCATCACTT
AAGTAATAAATCAGCGGCAAATCGCATAAATTGCTATTGATATTCGCCCCGCT
GTGTGTGCGTGTGTATTTGCAAAAGAGTGTGTGTGTGTATGTGCATATGACTC
GTGCGTTTAGCCGACAATTGGAGAAAAAGCATTAGAATCCCAATTGGCTAACT
15 TGGCAGCGAAACAAAAACACCAAAGTGTTATTGGCAGATATATATGTTAATTA
AATATNAAAAAGTGCGTGCGAA

Genomic hit, Accession No. AC006589

20 **Drosophila EST** SD01527 (AI530804), GH18602 (AI387906)

Rest of results same as line 1104/16

Example 4 (Category 1)

Line ID 1285/1
Category Meiotic defects in testis: cytokinesis defects
Reversion ?
Map Position 85D1-5

Rescue ID D8E
Rescue Sequence
10 GTTCGCAAAAAATATATCTCACCGTGAGTGCAGAAAGAGAAAAAGAGAAGCGG
AGAGGTGGAGAGCAAGTGGACATGAATCGTCGAGAGTCAGAGAGAGAGAGG
TGGAGAGGGTGAGCAGCTGTTGTCTGACAATAACATAATCAGCAACAATTTAT
GCTGTTTAAAAAGAGCAAGAGAAACGCTAATGAAGGGGAACACGGGCAGGGT
15 CAGGGGTTGGTGGATCCCCTACATATCTCTCTTTTACCGCCCCCGCTCTGGC
ACCCTCTCTGTCGCTCTCCATTAGCCGCACACGTGCAAGCTTAGCATTCTATC
TGTCTGTCTCTGTTTGTGTTTGTGTTGCTAAGCCGAATTCT

Genomic hit, Accession No. CSC:AC014256

20 **Associated ORF**
Genscan ORF1 predicted sequences
>/tmp/aaaaakfaa|GENSCAN_predicted_peptide_1|702_aa
MIQRCVLLWVCFCDLFLGLLFLKRKRNAHTPPPPQFTTYRHLLCYCFRNGEIM
ANICLSRLSVLEEIVLLLRVPCAFYFVDYYYVPCLLSVLSSEFLYHDQLKVFNRK
25 QQHQQQQQQQQQQLYQQHQQQQQQHYGPPPPYFQQLHQQHQQQQQQQQQQ
HQQHMKFLGGNDDRNGRGGVGVGTDAIVGSRGGVSQDAADAAGAAAAAAGV
YVFQQRSPGGVGVGVGGVGGVPGVGAVGSTLHEAAAAEYAAHFAQKQQQT
RWACGDDGHGIDNPDWKYNPPMNPANAAPGGPPGNGSNGGPGAIGTIGMSG
LGGGGGGGAGGGNNGSGTNGGLHHQSMAAAAANMAAMQQAALAKHNHMI
30 SQAAAAVAAQQHQHPHQHPQQQQQQQAQNQGHPHLMGGGNGLGNGNG
LGIQHPGQQQQQQQQQQHQPQYNNANLLNHAAALGHMSSYAQSGGSMYDH
HGGAMHPGMNGGMPKQQLGPPGAGGPQDYVYMGGQTTVPMGAAMMPQNQ
YMNSSAVAAANRNAAITTSTAKKLWEKSDGKGVSSSTPGGPLHPLQIPGIGDPSS
VWKDHTWSTQGENILVPPPSRAYAHGGASDTSNSGNAGILSPRDSTCAKVVEYVF
35 SGSPTNKDSSLSGLEPHLRNLKFDDNDKSRDDKEKANSPFDTNGLKKDDQVTNSN
GVVNGIDDDKGFK

>/tmp/aaaaakfaa|GENSCAN_predicted_CDS_1|2109_bp
atgattcagcgctgctgttctctatggatgtctgtctgcgactgtcttgggctcctgttctcaaacgtaaacgcaacgca
40 cactcctccccccccccgaattcaccactatcgcatcttctgttattgtttcgtaagggaatcagctaatattgc
cttagctgtctttagaagaattgtttgtttacgctgctgtcttattgttgattattattgtgcccgtgtctgt
ctgtgtatcggaattttttaccatgaccagctcaaggttttaatcgcaaaaacagcaacaccaacagcagcagcagca
gcagcagcaactatcagcaacatcaacagcagcagcagcaacattacggtccaccaccgaccttcaacagctacacca
gcaacaccaacagcagcagcaacaacagcagcagcagcaacaccagcaacacatgaagttttgggtgtaacgatgacgca
45 atggccgaggcgctgctgctgttgacggatgcatgtaggatctcaggtggcgtctcaggtgcccggatgagcagctg
gtgcccgcgagccgcccgcgtgctgctccagcagcgtccatgcctggtggggttggtgctggcggtggcggtggtg

ggtggcggtgtgccaggggtcggagccgtaggctcgacctgcacgaggccgcccgcgagtagccgcccactttgcc
 agaagcaacagcagacccgatggcggtgcggcgacgacggccatgggatcgaacccggacaaatggaagtacaatccgc
 cgatgaatccggccaatgccgctcctggcggtccaccgggaaatggcagtaatggtgggcccggcgccattggaaccattggc
 atgggcagcggattgggtggtggtggcgggcgaggctggcggggaaataatggcggtctgtgtacgaatggcggtctgc
 5 atcatcaatcgatggcggtgcagctgcgaatatggcagccatgcaacaggcggcggttgccaagcacatcacatgat
 cacaggcagcagccgagttgcagctcagcaacaacatcagcatccacaccagcagcatcccagcagcagcagcaacagca
 gcaggcgagcaaccaggggcatccacatcacctatggcggtggcaatggactgggcaacggcaatggattgggcatacaa
 catccggccagcaacagcagcagcagcaacaacagcagcagcaacatccggccagtacaacgcgaatctgcttaacc
 atcggtgctccttgggtcacatgtcatcttatgccaatcggtggcagcatgtacgaccatcatggtggagccatgcaccggg
 10 aatgaacggcgcatgcccaagcaacagccattgggtccaccggagccggaggacccaggactatgtctacatgggtggc
 cagaccactgtgccatgggagccgaatgatccgccagaaatcaatatgaacagctctgtgttgacgtgccaatcggga
 atgcagcgattaccacatccactgccaaagattgtgggagaaatccgatggcaaggcgatcctcgagcactcccggtggac
 cgttgcaccccctgcagatccccggcatcggggatccctcctcgtgtggaaggatcacacctggtccacacagggcgagaatat
 attggtgccccccctcgcgagcctacgccatggaggcgctcgcgatactcaaacagcggaatgcgggcatactgagtc
 15 ccgcgattcgactgcgcaaaagtgttgaatatgtttcagtggtcgcgccaccaaaagatagctcgtttccggattggaacc
 gcatttgcggaatctaaagtgtgacgacaacgataagtcacgcgacgataaggagaaagcaaacctcctggttgacacaaacggt
 tgaagaaagacgatcaggtcacaaactcaatggtgtgtcaacggcattgacgatgacaagggttcaagtga

***Drosophila* Gene Hit** TBLASTN of ORF1: pumilio protein (L07943)
 20 **Human Homologue** TBLASTX with pumilio: Soares fetal heart NbHH19W Homo
 sapiens cDNA clone (W77820)

Annotated *Drosophila* genome genomic segment AE003681
Annotated *Drosophila* genome Complete gene candidate CG9755 – pumilio RNA

25 **Human homologue of Complete gene candidate** 1e-154 1944416
 dbj|BAA19665| (D87078)
 similar to *D.melanogaster*
 pumilio protein (S22026)

30

Putative function Putative RNA binding protein which is localised to the cytoplasm.
 Wild-type allele of pum involved in development of the abdomen
 (embryos) and of the imaginal discs (larvae or pupae), perhaps
 35 having a function in signal transport.

Confirmation by RNAi Only wild type profiles observed

Example 5 (Category 1)

	Line ID	1389/1
	Category	Meiotic defects in testis:segregation defect, cytokinesis defect
5		(Ck-09/32)
	Reversion	NR
	Map Position	93B4-8
	Rescue ID	2C9P
10	Rescue Sequence 1	G TTCGGGGTGTGTGCGTGCTTGCAGTGTGCCTGTGTGTGTGTAGGAAAGGAG CAAGAAGCAGCAGCAGCGGCAGCAGTAGAAATAGCAAAAGGAGGCAGCAAC AACAAATAAGCTAGAGAAACCGCCAGCAGCAGCCCCCTAATAAAGAGCAGAGA AAAAAATGAGTTCAAGTTGTGAAAGGTGTGTGCCGTTACACTACAACTACAA 15 CACCACCATCAGCGGCAGCAAAGAAATACAACAACAAATACGGCAATCTCCA GACAACGCGAATGTCGAAATTGTGTATACAATTTATTAAGAAAGCAAGAGCA GCAACAACAATGACCAGCTGCAGTTCATCAGCGGTGTCCTCCTGAATGCCGCT GTCGTCGTTGGTGTCTGCCACCGGCGGTTCCCTCAATAATAAGGGCAGGAGGAG CTGCTTAGGTGCACACAATGTAGTTTGGCTTGGTGAATGCTTCTCTTTTGTG 20 CTGCTGGCGCATACGTTCTCTTCTCCCCTCATGATCTCAGTTGTCTGCATCGA TGAGCCGCCACCAACGGTGGCTTCTTCTGCTCCTCTTTGGCAACGGACTGCTG CAGTCTTGCCAGAAATTTTCTAAAATACTGAGCTTCAACTTGGTCTGCTTGGT AATGGTATACCATAAGCCATGGACTTGATGCCCCTACAAAGCTCTGTGATTG AAATGGGATGCA
25	Rescue ID	2C9E
	Rescue Sequence 2	CCCCGAACGCACTTTATATATATAAATATATATATTATTTCTTTCACTTATTTT CGTTTCGGCCGCGACAGCGAATATGCAATTTTCCTCTCAATTGATTTTTTACA 30 CACTCGCACTCCTTTTCACATGCGTGCAGTTTATGTTGCTATTGCTGCTACTGC TGCTGTTGTTGTTATTGTTGTTCTGGCTGCCGCTGCAGTGCAACTTGTAACACT TTCACATTTATGACATAATGCACTGGCCATAATTTTGGCTTGGCTCTCCGTTTGT GCAACTGCATGTTCCCAGTGCTTTTTTAATTTTATGCTGCAGTGCGTGCAAAT TCGAACGCGAGACGATCCGCTTTTCGCTGCATCTATGCGCTGAAGATGTGCTG 35 CAGTCGATGGGCTCGTCGATAGTGGGAAGGCTCGGTGCCGGCACTATCGATTTC CCAACACCATACGATAATATCGGCTAAAGTTATCAATATCGAAGTTTACTATA TTTCGGGTTTTTACGTTTTAAATCTACCTTATCAACATTTTTGNAAGAAGTAAA AAGTAGTTCTCTTATGGATGCATC
40	<i>Drosophila</i> EST	several including LD10379 (AA816796)
	Annotated <i>Drosophila</i> genome genomic segment	AE003733
	Annotated <i>Drosophila</i> genome Complete gene candidate	CG3421 - novel protein with
		weak homology to myosin

	Human homologue of Complete gene candidate	Ensembl predicted Gene:ENSG00000071333 Clone:AC022505 Contig:AC022505.00011 5.60E-37 (predicted protein with Core domain in kinesin and myosin motors ENSG00000087179)
5		
10	Putative function Possible novel motor protein involved in cytoskeleton organization	
	Confirmation by RNAi Marked reduction of G1 and G2/M peaks indicating fewer cycling cells	

Example 6 (Category 1)

Line ID 293/9
Category Mitotic defects in brain: cytokinesis defect
 5 (no overcondensation of diploids, very high polyploidy)
Reversion NR
Map Position 66B

Rescue ID 2G5E
 10 **Rescue Sequence**
 GTACAAACGAATTATTTGTCTCCTTGTGCGTTCGTTTTATTGTGTTTCGAGTTCT
 GTTGGTGTGTGTTTTTGTGTATGTTCCACGAGTTGTTTCGCATTAAAAAATTAAC
 TGCAGAAGATCCATGGAAATGGAGACCATTGAAGAGCAATCGAAGTGCGGTG
 AGTACTGAAAGAGGGCGCGGGGCGTGGCAGCTCCAAATGGCCGGCGAATTTA
 15 TCATTTTTCAATGTCGTCCAAAGGGGTTGGGTACGGGGTAAAACCACATTCGG
 GGCCAAAAGATCCTCATAAAAAATGTCGTGCCAGCAAATGCAAAAAATAAA
 ATAAAAAAGAACGACTATAAGTACATCTTTGTGTGTATTTGTGTGACTAAAA
 AAGCAACGGCATCGTGTGCANATATTTAATCTTTNTTTCTGAATTTATTTTCG
 GTGTACAAAATATTTATCGCATAAATGCGAAATGCCTCCCTCTCTTCATCATCG
 20 T

Genomic hit, Accession No. AC008303

Associated ORF

25 Genscan ORF1 predicted sequences >20:53:38|GENSCAN_predicted_peptide_3|261_aa
 MMDNDDALLNNGPQSGAETVYGTEDNNMVMSEKCRIFPATQRTGFVGATFSG
 VLLDLGALQHCDVIRIDVNIATLEQIKRERQEELAAERIRAQIAADRAEQARF
 NTPDISSTNSVAATAASNVTITDASVSSVDETRLQIRLPGGIQRKTSFPAGEVLAT
 VRVYVRNEMLAASDVRFDTLATSYPREFQTEDEVKTLNELNLVPAVVLVLT
 30 EQVNPADDQTAKRSASTKRTKTHRHKRQLMADEPQSDHYKN

>20:53:38|GENSCAN_predicted_CDS_3|786_bp

atgatggacaacgatgatgcactgctcaaatggaggaccacagtccggagctgaaactgtctacggtaccgaggacaacaac
 atggtcatgtcggagaagtgccgatattccggcgactcagcgtactggattgtggcgcgacgtttcgggagtgctgcttct
 35 gatcttggtgcctccagcattgtgatgtgatccggattgatgtaacattgcaacgctggaacagattaagcgtgagcgtcaggag
 gagctggcgccaggagcgcattcgtgccaaattgcagccgatcgggcagagcaggcacaacgttttaatacggcgacat
 tagcagcacgaccaattcgggtggcgccaccgctgcctccaacgtgacacaacagacgcctcggtagttcgggtggacgaga
 cgaggctgcagatccgactaccgggtggcattcagcgcaccaaattccttcagccggcgagggtgctggctaccgttcgtgcta
 cgtgcgaacgagatgctggcgggcagcgtatgacgcgactttaccctggctaccagttaccacgaagggagttccaacgg
 40 aggacgaggtcaagaccctgaacgagctaaatctagtgccaatcgggtggttctggtgctgaccaaggagcaagtgaatccag
 ctgatgaccagacagcaaacgatcagcaagcaccacacacacagacacaagcggaattgatggcagacga
 gccacaatctgaccattataaaaactga

Drosophila Gene Hit rescue sequence: pebble (rho1 GTPase exchange factor)

45 (AF136492)

Human Homologue BLASTX with pebble: KIAA0337 (AB002335)

	<i>Drosophila</i> EST	SD09146 (AI542703), SD01796 (AI530981)
	Annotated <i>Drosophila</i> genome genomic segment	AE003557
5	Annotated <i>Drosophila</i> genome Complete gene candidate	CG8114 - pbl pebble rho1 GTPase exchange factor
10	Human homologue of Complete gene candidate	2224615 dbj BAA20795 (AB002335) KIAA0337 [Homo sapiens (3e-21) also mouse homologue 3e-95 42359 transforming protein (ect2) - mouse >gj 293332 (L11316) ect2 [Mus musculus]
15	Putative function	A guanyl-nucleotide exchange factor involved in signal transduction which is localised to the mitotic anaphase. pbl is required for the formation of the contractile ring and the initiation of cytokinesis in <i>Drosophila</i>
20	Confirmation by RNAi	Slightly reduced G1 and G2/M peaks indicating fewer cycling cells

Line ID 542/3
Category Mitotic defects in brain: cytokinesis defect
(very high polyploidy)
Reversion NR
5 **Map Position** 66A
Rescue ID 2A1E
Rescue Sequence
GTCCAGTTAATGAAAGTAAACGAATCGAGTACAAACGAATTATTTGTCTCCTT
GTGCGTTCGTTTTATTGTGTTTCGAGTTCTGTTGGTGTGTGTTTTTGTGTATGTT
10 CCACGAGTTGTTTCGCATTAAAAAATTAAGTGCAGAAGATCCATGGAAATGGA
GACCATTTGAAGAGCAATCGAAGTGCGGTGAGTACTGAAAGAGGGCGCGGGGC
GTGGCAGCTCCAAATGGCCGGCGAATTTATCATTTTTCAATGTCGCCCAAAGG
GGTTGGGTACGGGGTAAAACCAATTCGGGGCCAAAAGATCCTCATAAAAAA
TGTCGCTGCCAGCAAATGCAAAAAATAAAATGAAATAAGAACGACTATAAGT
15 ACATCTTAGTGTGTATTTGTGTGACTAAAAAAGCAACGGCATCGTGTTCGCANA
TATTTTAATCTTTTTTCTGAATTTATTTTCGGNGTANAAAAATATTTATCGCATA
AATGCGAAATGCCTCCCTCTTTCATCATCGNTTCCCCTNACTCTCCCTCTCTT
CGCCCGACACTGTACCGACGCAAGAAGAAC
20 **Genomic hit, Accession No.** CSC:AC018042
Drosophila EST SD09146 (AI542703), SD01796 (AI530981)

rest of results same as line 293/9

Example 7 (Category 1)

5	Line ID Category	229/30 Mitotic defects in brain: cytokinesis defect. Meiotic defects in testis: cytokinesis defects (Mitotic higher level of condensation, polyploidy, Meiotic:
	Ck05/07)	
	Reversion	?
	Map Position	91F
10		
	Rescue ID	A7E
	Rescue Sequence	TCTTGGCCAAACAACGCGAGCAGCTGATGTCGCATGGTGGGAAAATGAGGGT GGCGCGAGTGGAAGTTGCCATATCGCTGCGATCACAAGCAGCAAATATGGAA 15 GATTAAGCGGAAAACGAAAGACAAAATAATTACAATCAAACAACCGAATTAT AAAAAGAAAATGGTTTGTCTCCGAGTTCGTTTAAATATGCTTATCTACGTATC AATTAAAAAAACCGTAGAAAGAAATTCACGATTCACCCTAATCTAGCTAAGA CACCAACCAAAAATTTCCGATTTACTTTCAGTTGAAGTTGTTGTTACACACTTT TCTTGTCGATGTTTTGAAGCGCCCATTGAAATTGATCATTTGAATGTTTTTCCA 20 AATTACCCACATCCATTACAATAAAATTTAAATTGCTTATTATTTGATTTTACT TGGGAAAATCCCGTTGCCAAATTGGAATTACAATTCCAGCTTGGAATCCGTCA AACTTTACAACATAAACTTATTGTTCTTTTCCGGACAATGCTTCCA
25	Annotated <i>Drosophila</i> genome genomic segment	AE003686
	Annotated <i>Drosophila</i> genome Complete gene candidate	CG6284 - novel protein possible sir2 family of transcriptional regulators/telomeric silencing
30	Human homologue of Complete gene candidate	gi7706710 0268A424791DE5BF [ref]NP_057623.1 sir2-related protein type 6 [Homo sapiens] (1.10E-74)
35		
	Putative function	Putative transcriptional regulator
40	Confirmation by RNAi	Complete loss of G1 and G2/M peaks indicating fewer cycling cells

Line ID 1104/16
Category Mitotic defects in brain, Cytokinesis defect (no overcondensation of diploids, high polyploidy)
Reversion R
Map Position 92A

Rescue ID B5E
Rescue Sequence
 GTCCGGAGCGGAGCTAAAGTTCGATGTTTCGTGCAAAACACTTCGATTCCGATA
 10 GGCGGATGCTATCGATTTCGGCGATGCCCGTTGGTCACACTTGGTGGTGGGCG
 CTGCCCCGTCGCCGACTATCGATAGCACAAGCGGGTTATTTAGGTGTGCGCAGC
 TTGTAAGGGTGACTCATGCTGTTAAAATTATTATAAAAAGTTAATGAATATAA
 TATAGTTATAATAAAATTATATATAAATCTATAAGATCAAAGATCATCAGTTA
 TCATTTATCATTTGATTATATGAAAAACAAGAACAGAAACAAGATTTAATAGG
 15 TTTTGTAAATGTGAAAATGTGGGTTACCCCAATTCTTATTCGAAATTAAATAA
 CCTAAAGAACAGTTATACACAGATAGGTAATTTGCACATAAGCCAAATTTTGT
 CTAGAATTCGCGGAATTAATTCTTGAAGACGAAAGGGCCTCCGTGATACGCC
 TATTTTATAGGTTAATGTCATGATAATAATGGTTTCTTA

20 **Rescue ID** B5P
Rescue Sequence
 CTCCGGACACGCAGTAGCTAAATAACAAACTCATTACTAGTATATTACTGCCG
 CCGATTTGCAAGCGCGTACCGATCCCGATACCAGGCCAATCGCACTCCCCAGT
 TGTACGTCATCACTTAAGTAATAAATCAGCGGCAAATCGCATAAATTGCTATT
 25 GATATTCCGCCCCGCTGTGTGTGCGTGTGTATTTGCAAGAGAGTGTGTGTGTGT
 GTGTGCATATGACTCGTGCGTTTAGCCGACAATTGGAGAAAAAGCATTACCAA
 TCCCAATTGGCTAACTAACTAAAGTTGGCTTGGCCAAACATAAAACAAAAGT
 GCGGGCGCAGCGATTTGGCAGCGAAACATATACACCAAAGCGCTATTGGCAG
 ATATATATGTAGATTAAATATAGAAAGTTCGTGCGAAGGTTAAGAGTCGAGT
 30 GCAAGTGCATTTATATTTGGAAATAATAAATGCTACAAT

other results same as 229/30

Example 8 (Category 1)

Line ID 343/5
Category Mitotic defects in brain: cytokinesis defect
 5 **Reversion** NR
Map Position 75B

Rescue ID C6E
 10 **Rescue Sequence**
 GGTTTCGAGTTCGTTTCGGTTCGGCCTCTCCGTTTCGGCTCTCTCTCGCCATCCC
 GCTGCCGCACACATTGGCCTCTCTCTCGCAGCTCCACATTCTGAAGGTGGCTGA
 CCGAAATGTGGGTCACGACAATGGCGGGGTTTCGTTGAACTGAACCACCGCCG
 CAGTCGCTGCCGTGCTCGCTGCTCTGCCTCTGCTGACGTCGTTAACGTTTGGG
 15 GCTTTCGGTTACGTAGCTCGTGTGCGAGCGAGAGGGGCTACTAGAGGGACTGC
 GACACACAAGTTGTGTGCATTTTTTGGCCCCAAAAAATCACAATGGGCACAAA
 ATATTATTTAATACATCACATAATTGTTTAATCATCTGGCTGGAAAGTGTCTGAG
 TTCATCGAACTGCCAGCGATTGACAAATTGCGATTTTCAATGCGGCAAAAAATA
 TTTACTCAAGCAAATTGTTTGCATTCTGTTAATTAGGCGGGGAGTGCCGCCAA
 20 ATTGGGTCATATTGCAGAAGTATCCAAGAAGTTGGAGAAACAAGCTGCTTAA
 ACATTAATTAACACACACCTAAATGGATACATTTGCTACAAACAATTATAAAT
 GTTACCCTTATATTAATTTTCAAATTTCTAAATAATCAA

Genomic hit, Accession No. CSC:AC015427
 25

Associated ORF
 Genscan ORF1 predicted sequences
 MVCAMQEVA AVQHQQQQQLQLPQQQQQQQT TQQQHATTIVLLTGNGGGNL
 HIVATPQQHQPMHQLHHQHQQHQQHQQQAQSKQLKQQHSALVKLLESAPIKQQ
 30 QQTPKQIVYLQQQQQQPQRKRLKNEAAIVQQQQQTPATLVKTTTTSNSNSNNTQT
 TNSISQQQQQHQIVLQHQQPAAAAATPKPCADLSAKNDSSESGIDEDSPNSDEDCPN
 ANPAGTSLEDSSYEQYQCPWKKIRYARELKQRELEQQQT TGGSNAAQQQVEAKPA
 AIPTSNIKQLHCDSPFSAQTHKEIANLLRQQSQQQQVVATQQQQQQQQHQQHQQ
 QRRDSSDSNCSLMSNSSNSSAGNCCTCNAGDDQQL EEMDEAHDSGCDDELCEQH
 35 HQRLDSSQLNYLCQKFDEKLD TALSNSSANTGRNTPAVTANEDADGFFRRSIQQK
 IQYRPCTKNQQCSILRINRNCQYCRLKKCIAVGMSRDVLRLEQPKAGAKNKSCE
 PSKNSTVNQINSKLELGNSNEMK

>21:55:09|GENSCAN_predicted_CDS_1|1533_bp
 40 atggtttgtgaatgaagaggttgctgcccgtgcagcatcagcagcagcaacagcaactccagttgccccagcagcaacagcag
 cagcagcagacaacagcagcaacatgaacaactatagtgctgacgggcaatggcggcggaatctgcacattgtgcc
 acaccgcaacagcatcagccgatcagctccaccatcagcatcagcatcagcaccagcagcaggccaagagcc
 aacagctgaagcaacaactcgcgctgtgaagttgctggagtcggcgcccatcaagcagcaacagcagacgccaagca
 aattgtttacctgcagcagcagcagcagcaaccgcaacgcaaaagactgaaaacgaagcagcaatcgtacaacagcaaac
 45 aaacacctgaacactagtaagacaacaaccaccagcaacagcaacagcaacaacaccagacaacaatatgtattagtcag
 cagcaacagcagcatcagattgtgtgcagcaccagcagccagccgcgagcaacaccaagccatgtgccgatctgagcg

ccaaaaatgacagcggagtcgggcatcgacgaggactccccaacagcgcgatgaggattgcccgaatgccaacccggcggggcac
 atcgctcgaggacagcagctacgagcagtatcagtgcccctggaagaagatagctatgcgcgtgagctcaagcagcgcgagt
 tggagcagcagcagaccaccggaggcagcaacgcgcagcagcaagtcgaggcgaagccagctgcaatacccaccagcaac
 atcaagcagctgcactgtgatagtccttttcggcgagaccacaaggaaatcgcaatctcctgcgccaacagctccagcaac
 5 aacagggtgtggccacgcagcagcagcagcaacagcagcagcagcaccagcaccagcaacaacgaagggatagctccgaca
 gcaactgctcgtgatgagcaactcagcaactccagtcgggcaattgtgcacctgcaacgctggcgacgaccagcagctgg
 aggagatggacgaggcccacgattcgggctgcgacgatgaactttgcgagcagcatcaccagcgactggactcctccaactg
 aattacctgtgccagaagttcgatgagaaactggacacggcgctgagcaacagcagcgccaacacggggagggaacacgccag
 ctgtaacagctaacgaagatgccgatggattctccgcctccatccagcaaaagatccagtatcgccgtgcaccaagaatca
 10 gcagtgcagcattctgcgcataatcgcaatcgttgcaatattgccgcctgaaaaagtcattgccgtgggcatgagtcgcgatgt
 tctgcgcctagagcaacctaaagctggtgccccaaaataagtcattgtaaccgagcaaaaattcgaccgtcaaccaaataaacagc
 aaactcgaactcggcaacgaatgaatgaaatga

15 **Drosophila Gene Hit** TBLASTN with ORF1: ecdysone-inducible gene E75B (X51549)
 and nuclear receptor superfamily protein (U01087) BLASTN with
 genomic sequence matches ecdysone inducible gene

20 **Annotated Drosophila genome genomic segment** AE003522
Annotated Drosophila genome Complete gene candidate CG8127 Eip75B ecdysone-
 inducible gene E75B nuclear
 receptor NR1D3

25 **Human homologue of Complete gene candidate** ORPHAN NUCLEAR
 RECEPTOR NR1D1 (V-
 ERBA RELATED PROTEIN
 EAR-1) (REV-ERBA-
 ALPHA) Q15304 (9.40E-74)

30 **Putative function** Ligand-dependent nuclear receptor, putative transcription factor

35 **Confirmation by RNAi** Slightly reduced G1 and G2/M indicating fewer cycling
 cells

Line ID 448/23
Category Mitotic defects in brain: cytokinesis defect
(very high polyploidy)
Reversion NR
5 **Map Position** 75B

Rescue ID 2G4E
Rescue Sequence
GCTGGTGGACGCTGCTTTTCATTCGCAAATTGCTCGTCGTTGGCAGCGGTTGTGC
10 AGAGCAAGAAAAGCGCGCGAAAAACCAAGCAAAAAATTAATACAGCTGGAT
CAAGCGAAAGAGATAGAGAGCAGAGTCAACAGCAACAAATGTTCAATAGCA
AATGATATCGCATATTTTTGTTGGTGCCAGTGAAGTGAGATCAAAGTGAAGTG
TGCAATGTTTCCTTATTAGCAAATCGTAGAGCAACCAACAATCGAGAGTTCAAG
15 TGCAAGAGGTTGCTGCTGTGCAGCATCAGCAGCAGCAACAGCAACTCCAGTT
GCCCCAGCAGCAACAGCAGCAGCAGCAGACAACACAGCAGCAACATGCAAC
AACGATAGTGCTGCTGACGGGCAATGGCGGCGGTAATCTGCACATTGTCGCCA
CACCGCAACAGCATCAGCCGATGCATCAGCTCCACCATCAGCATCAGCATCAG
CATCAGCACCAGCAGCAGGCCAAGAGCCAACAGCTGAAGCAACAACACTCGG
20 CGCTGGTCAAGTTGCTGGAGTCGGCGCCCATCAAGCAGCAACAGCAGACGCC
CAAGCAAATTGGTTACCTGCAGCAGCAGCAGCAGCAACCGCAACGCAAAAAGA
CTGAAAAACGAAGCACAATCGTACAACAGCAACAACAACACCTGCAACAC

Genomic hit, Accession No. CSC:AC015427
25 **Drosophila EST** GM03519 (A801874)

Other results same as line 343/5

Example 9 (Category 1)

	Line ID	36/1
	Category	Meiotic defects in testis: cytokinesis defects
5		(Ck-04/06) `
	Reversion	R
	Map Position	79C
	Rescue ID	A8B
10	Rescue Sequence	GAGTAAAGTAACTACAGAGAAAAAACGCTTTACGGCGAGAGAACGCTTTAA TTATACTTAATTTGTTGTTAATCAAACGCACAGAGCACACAACACAGAAACAC AAAACACCGCTTGGGAAAAATCTGTAGGTAGANGAAAGGAGCTCACGTTTTT CTGGTGCAGATCGAAATCGGTATCGGGTTTATTCGCTTTGCCGGATTGTTACTT 15 CACGTTTGTTAATTGCGTTTCTTTGTTTCTTATTCTCCTGCGCACACTTTGATT GCGTTTGCAACTCGCAATTCGCAATTGGCATTGCTATGCGACAACGCGCTT ATTTCCGGTCCGTTTACTTTTCCAATGGCTTGCCTACACACCGCCAAACTTTGG CTTGAACCTGGGATATTGGTTGCCCGAATTCCTGANAAATTTTCCTT
20	Genomic hit, Accession No.	CSC:AC013886
	Associated ORF	Genscan partial ORF1: >18:33:59 GENSCAN_predicted_peptide_1 99_aa CICFALLGLLIRRKLMVVFSGTSRKAQSLESRRAKNTSQKIGNQYPKFSQVCGKPS 25 KSNDRNNGSCRIANANCELRVANANQSVRRRIRNKETQLTNVK
	>18:33:59 GENSCAN_predicted_CDS_1 300_bp tgtatctgcttcgcctgcttgggtactcattcggcgaaaattaatgggtggtgctggtctacgtcgcgcaaggcacagtctctaga gtctcgcgagagctaagaatacatctcagaaaatcggaaccaatatcccaagttcagccaagttgaggcaagccatcgaaaagt 30 aacgaccgaataaacgagtggtcgcatagcaaatgccaattgcgaattgcgagtgcaaacgcaaatcaaagtggtcgcagg agaataagaaacaaagaacgcaattaacaacgtgaagtaa	Drosophila Gene Hit rescue sequence and TBLASTN with ORF1: nucleic acid binding protein (mub) (X99340) 35 Human Homologue BLASTX with nucleic acid binding protein: poly(rC)-binding protein 2 (hnRNP-E1) (S42471) Drosophila EST several including LD32520 (AA951799 BLASTN matches nucleic acid binding protein (X99340)
40	Annotated Drosophila genome genomic segment	AE003596
	Annotated Drosophila genome Complete gene candidate	CG7437 - mub mushroom bodies RNA binding protein
45	Human homologue of Complete gene candidate	4826886 ref NP_005007.1 pPCBP2 poly(rC)-binding protein 2

>gi|542853|pir||S42471 (4e-75)

5 **Putative function** A putative RNA-binding protein specifically expressed in the CNS of *Drosophila melanogaster*

10 **Confirmation by RNAi** Only wild type profiles observed

	Line ID	472/22
	Category	Female sterile (anaphase bridges, lagging chromosomes)
	Reversion	?
5	Map Position	nd
	Rescue ID	sau 5'spl
	Rescue Sequence	
10	GCACGATCNCTAAAGTCTNGCANAGCTAAAAATACATCTNAGAAAATCGGCA ACCAATATCCCAAGTTCAGCCAAGTTTGCGGTGTGTAGGCAAGCCATCGAAAA GTAACGACCGAAATAACGGCAGTTGTCGCATAGCAAATGCCAATTGCGAATT GCGAGTTGCAAACGCAAATCAAAGTGTGCGCAGGAGAATAAGAAACAAAGA AACGCAATTAACAAACGTGAAGTAACAATCCGGCAAAGCGAATAAACCCGAT 15 ACCGATTTTCGATCGGTGCGGGCCTCTTCGNTATTACGCCAGNTGGCGAAAGGG GGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACG ACGTTGTAAAACGACGGCC ANTGCCAAGCTCTGCTGCTCTAAACGACGCATTTTCGTA CTCCAAAGTACGAAT TTTTCCCTCAAGCTCTTATTTTCATTAAACAATGAACAGGACCTAACGCCNGT 20 AAC	
	Rescue ID	Sau 5'splac
	Rescue sequence	
25	GTTGTGATCNTCTTGGTNAATC NNNTTGGAAATTC C C C T A A N G C T T C C G A C A A TGACCCNGNCNTACNNAGCAAANAATNGNAGNACNNGCNGNTGGNCGTANT ANCAANAACAGGCCCGCACCGATCGAAATNGGNATCGGNTTTATTCGCTTTGC CGGATTGTTACTTCACGTTNGTTAATTGCGTTTCTTTGTTTCTTATTCTCCTGCG CACACTTTGATTGCGTTTGCAACTCGCAATTCGCAATTGGCATTGCTATGCGA 30 CAACTGCCGTTATTTGCGTCTTACTTTTCGATGGCTTGCCTACACACCGCAAA CTTGGCTGAACTTGGGATATTGGTTGCCGATTTTCTGAGATGTATTCTTAGCTC TGCGAGACTCTAGAGACTGTGC	
35	Other results same as line 36/1	

Example 10 (Category 1)

	Line ID	459/2
5	Category	Mitotic defects in brain: cytokinesis defect. Meiotic defects in testis: cytokinesis defects: (mitotic: high polyploidy, no diploids, higher mitotic index, meiotic: Ck-01/05)
	Reversion	NR
10	Map Position	66B1-6
	Rescue ID	2D5P
	Rescue Sequence	GCTCCGTTTCGAAAGTTGAGAGAGACTTGAAACATATGTTTCGGCGTTGCTAGAG CTGGTCGGCTACCGATAGAAACATCGATAGGTCCGATGTTTTTACTCGTATAT 15 TGATTCANAGTTTGGCTATCGATGTTTTTAGAGTGCCCGCACATTATCTATTT CATCTCTATTTGTTGGTATTTTTTTGTATTTTATGACATTTGACTGCAAAAGC AGGATGGCAACGCCAGATTGCCGCGAAAGTACGTTATTTTTAAATTGGCGCAT TGAATATGAAAAATTGCAGGCACATACAGTTTCTAATAAATAATAGCAATAAT TATTATTTAGCTTGTATCATAACGAAGTGCACATTACAGCTACGCATCTGAAAT 20 AATAATTTTAATATATCGTCTTTTCTCCCATCGATAGAGTTCCGCGCCTATCGA TATATCGTTGATCACCAAATAAAATAAACTAAATAACGCCGCAATGGAACAC GCGACGAGTGAATTGAGGGAATTTATCTCAGATCTTGTAATTCCGCACCACGT TGCAATGGTAACATCAATCCGGATCACATCACAATGCTGGAAGGCACCCAGA TCCAGAACAG 25
	Annotated <i>Drosophila</i> genome genomic segment	AE003557
	Annotated <i>Drosophila</i> genome Complete gene candidate	CG8038 - novel gene ribonuclease P homology 30 CG7892 nmo - protein serine/threonine kinase involved in eye morphogenesis
35	Human homologue of Complete gene candidate	CG8038- 5e-24 4309676 gb AAD00893 (AF001176) ribonuclease P protein subunit p29 [Homo sapiens/]
40		CG7892- protein kinase mitogen-activated 7 (MAP kinase)' gi:4506093 and gi7706445 D919050533B3C33A 45 [ref NP_057315.1 nemo-like

kinase [Homo sapiens]
(3.30E-174)

- 5 **Putative function** CG8038: tRNA processing enzyme Ribonuclease P protein subunit
 CG7892: a protein serine/threonine kinase involved in cell cycle,
 possibly targeted to cytoskeleton
- 10 **Confirmation by RNAi** Both showed a marked increase in G1 peak indicating arrest in
 G1

Example 11 (Category 1)

	Line ID	623/8
5	Category	Meiotic defects in testis: cytokinesis defects
	Reversion	?
	Map Position	37E1-3
	Rescue ID	2E2E
10	Rescue Sequence	CTACGGGCATTTCGCATGTTCTGAACATCTGGTGTAACAAGTTCTGAGCAGTGT TGCCAACTCTTCAGTTAAACAGTTAAAAATAGCTAAAAAATGTTGACGGTAGC TAAATTATAAAGCTAGAAAAGAAATGATATATGATAAAATAAGTATTTGACT CACAGCATTATTATTTAAGACGGTCAGATGAAGTTACAAAAATCCTAAATTG 15 GCCCGCTGTATCTAAGAATTAATACCAAGAAGTTGTCATCAAAGGTCGAACTC GACGGAAATTCTACTTTGAGTTTTTAAATTTAATAAATATGTATTTAAATTAT GTAAATTTGTTTGTAACAACAAAAATAGTATATAGTATAGTAATAGTAGTTAAG TAGTTTTTAAAAATGGCCAGATCAAAGACTTTTGAGATATGATACTAATCAAAA GTCGAATTCGCGGAATTAATTCTTGAAGACGAAAGGCCTCGTGATCGCCTATT 20 TTTATAGGTAATGTCATGATAATAATGGTTTCTTAGACGCAGGTGGACTTTTCG GGGAAATGTGCGCGGAACCCCTATTTGTTATTTTCTAAATACATTCAAATATGT ATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGG AAGAGTATGAGTATTCAACATTTCCGGGCGCCTTATTCCTTTTTTGGGCGGCAT TTGCCTTCCTGTTTTTGTACCCAGAACGCTGGTGAAAGAAAAGATCTGAAGA 25 CAGT
	Annotated <i>Drosophila</i> genome genomic segment	AE003662
	Annotated <i>Drosophila</i> genome Complete gene candidate	CG17559 dnt - doughnut protein tyrosine kinase
30	Human homologue of Complete gene candidate	Homo sapiens RYKreceptor tyrosine kinase GDB:21773
	Putative function	growth factor transmembrane receptor protein tyrosine kinase involved in cell growth and maintenance
35	Confirmation by RNAi	Only wild type profiles observed

Example 12 (Category 1)

	Line ID	629/14
	Category	Meiotic defects in testis: cytokinesis defects
5		(Ck-06/09)
	Reversion	NR
	Map Position	64D
	Rescue ID	2A9X
10	Rescue Sequence 1	GACGGGAGGAAGTAAGTGGGAGGAGAGAGTAGTGCCTCTTTTTTACTGGAGA AATGGACAAACTCTGGGAACTGCGAACTGCGAACTAACCAGGGCAAAAATTG AGAAGCGAGCTGAAAGCGGAATTCAAACAACGCAGCGCTGACGGCGACGCCG GCAGAAGCAGCGCCGCACAAGGCATGCGCACAGAGAGTAAGAAAGAGCGCG 15 GCTAATGAATGAATGAACGAGGCGGAATGCGGGAAGAGCGCAGAGAGGCGC AATGACAAAATAGTTGTAGAAAAGCGCCGGCAAGCGGAACTCCACACTCTTT CTCACTCTCTCTTTCCACCCACACCCCTAGTTCACCGGAAAAAGAAAATTCGTT TGCGGCGGGGGTGTATTTTTCACCAAAAAGAGAGTGTGTGCAAAACGCTAGA GAGAGAGAGAGAGAGAAAGAACTGACGTCAGTTCTGCCTCCGTCGACGCC 20 GCTGCCGCGTCCCAAAGCGCCACCACCCAAAAAACGCGAGAAGAAGCAGA ACAAACACACACAAAAATTTCGCACAGTGGAGCAGAAATCAAGC
	Rescue ID	2A9E
	Rescue Sequence 2	CTCCCGTCGTTTTGAGATCAGCTGCTCTCGCAACAACAACAACTATAACTGTA 25 GTTACCGTCTCTTTTGCATCGTTCGTTTTTCGTTTGTGTGCGCAAGTGATTGTGT GTGTGCGTAAGCTTAAAGCTGACTAACAACGAAACAAGAAAAAATATAAA TTATAGGAAAATTGTTAAATTATAACCAGAAAAGAGAGCGGCACTTACGTGTGT TATTGTGTGCGTGTGCTTTAAAAAGATATAAAAAATAGCAATAGAAAGTTATTA 30 AAGCGTTGGCAAAAAAGTCCAACGAACAGCGAGAGGAAGCGGAGAACGAAA TAGTTAAAGCCAAAGTCGCTGCCGACGTGCGCACTTGAAAACGTGCAAAAGTT TGTAACACACCAGTGTGTGTTCGTGTGTGTTTTTGCCGGCGTGCCAGTGTGCG TGCGCCTAGAAAAGAGTAAAGAAGCAGAAGAAAAGGAAGAAGCCGAAGAAG CAGCAAAAGAAGCCGACAGCAAAAAGTAAATAAAATCAAATGCCCCCTGGCA 35 GAATAATATTAAATTAAGACACATACTCAAATTAATAAC
	Genomic hit, Accession No. CSC:AC015076	
	Drosophila EST	LP08767 (AI295205)
40	Annotated <i>Drosophila</i> genome genomic segment	
	Annotated <i>Drosophila</i> genome Complete gene candidate	
45	Human homologue of Complete gene candidate	

AE003567

CG10668 - novel with
homology to ssDNA/RNA
binding proteins

CG10668 - 3e-12 4506449

85

ref|NP_002889.1|pRBMS2|
RNA binding motif, single
stranded interacting protein 2
>gi|1082

5

Putative function Possible single stranded DNA/RNA binding protein

10 **Confirmation by RNAi** Slightly increased G1 and reduced G2/M indicating G1
arrest

Example 13 (Category 1)

Line ID	653/12
Category	Meiotic defects in testis: segregation defects, cytokinesis defect (Ck-07/35)
Reversion	NR
Map Position	75B
Rescue ID	I5E
Rescue Sequence	GTAAAAGCTTAGCCCATGGCGTCGACGTCGACTGCGACAGCGACGCTAGCCG AGGCAGTGACTGCGACGTTGGCCACTTTTCGCCTTCGTTTCGCTGTCGTTTTCA GTTGTCTCTCGTTGCTCAAAGCGCGCGGCACGCGAACGCTCTGAAATCCCAAG TTACAACAGCAACATCAAGCAGCAGCAACAACAGTGATTCGCTGGCAAACAA ACAAACAAACCAACATATTTTTGTGTATCAATTGTCGGCCTAAAACCTTCACAT AAAAGTGCGTTCAATACGAAACAAATATATTTGTATATATAGAGAGCGAAGC AATCGGTTGCATAAATTGAATTCGTTTCATATACTTCAATATAAATATTATTAA GTACTACAATTTGAAAACATCTTTAAATATACAACATATTTTGAATTAAGTTTA TTTTTTTTTTTAGCCACATAGAGACATCTTTGTGGCATGCTAAATTCTGTAGTA AAACTTTCTTGGGGAAAGTGAAAGCCACGTATCAGACCAAAATCCACCCAAC CCTGCACACACGCATCCCCATAAAGAACGACCTTGAGCT

Genomic hit, Accession No. CSC:AC014071

25 **Associated ORF**
Genscan ORF1 predicted sequences >16:36:33|GENSCAN_predicted_peptide_2|477_aa
MLILMRPSIKLAANQNAIKAPNGPKNFLDKVLVVRCSLSVCLLENGHIAVTASGS
NNNNNSNNINLNLKANYQMSATSIRDSFATILLDAQNRVQNATVAAKNFMLPLR
LRSDTSGDTSNNNENNSRRARQAYNCGVNWLTTHRPKRRRQVHPPLGSTPSCNN
30 NSSKISRNSSSSSNNIASATATRIFLGTSAILAIDFDNTRVPGYYQPTGEWIWVSKS
MIKQLFAVAATADDVAAAAASRGNALTFPGKEKGPRKKAEGCGMEWSGVES
GGDVMCVLSSVATVDDDDHHGGGHFDGLLGTPSALIRLNCLINPKKMRMDFEVE
VAWQIARAADLRLISMHLNVPIYEMKTMKTMSVIDGGSLYQPTALFGSLFCLVY
SSAADVLLLLANCKSLAHGVDVDCDSASRGSDCDVGHFSPSFRCRFQLSLVAQS
35 ARHANALKSQVTTATSSSSNNSDSLANKQTNQHFVYQLSA

>16:36:33|GENSCAN_predicted_CDS_2|1434_bp

atgttgatcctaatacgccgctcaatcaaattggccgcaaatcaaaatgcaattaaagcgccaaacgggcccgaagaactttttgga
caaagtcttggtgtccgctgttggtgtctgtctgtctgttgagaatgggcacatgtctgtcactgccagcggcagcaacaacaa
40 caacaacgcaacaacatcaacctcaattgaaagccaactatcaaatgtcagctacaagcatccgagattcgttcgccacgattct
tctagacgccccaaatcgagtgcaaaacgcaactgttgctgccaaaaactctatgttgccgtcgcgctgcgagtgacaccagc
ggtgacaccagcaacaacaacgaaaacaacagccggagagcaaggcaggctataattgtgcggttaactggttgacaacgcatt
cgcccgaagcggcggcggaagtgcaccgcctttgggttcaacgccagctgcaacaacaacagcagtaaaatcagcagaa
acagcagcagcagcagcaacaacatcgatcagcaacagcaacacgcattttcttggcacttccgcgattctggccatcgacttc
45 gacaatacacgagtaccgggtattatcagccaactggggagtggattgggtatccaagtccatgattaagcagctgtttgctgtt
gctgccactgcgatgatgttgctgtctgtcgcagcttcacgcggaatgcgttgaccttttgcgggaaaggaaaaggggccaa

[illegible]

10 ***Drosophila* Gene Hit** rescue sequence, ORF1 and genomic sequence: Canton S E78B
nuclear receptor superfamily protein (U01088)
***Drosophila* EST** LP11082 (AI296953 similar by BLASTN to U01088)

Annotated *Drosophila* genome genomic segment AE003593
Annotated *Drosophila* genome Complete gene candidate CG18023 - Eip78C
Ecdysone-induced protein 78C
nuclear receptor NR1E1

20	Human homologue of Complete gene candidate	CG18023- 4e-32 119100 P20393 EAR1_HUMAN V- ERBA RELATED PROTEIN EAR-1 >gi 1082832 pir A32608
----	---	---

25

Putative function	ligand-dependent nuclear receptor , putative transcription factor
--------------------------	---

Confirmation by RNAi	Not done due to failure of PCR procedure
-----------------------------	--

Example 14 (Category 1)

	Line ID	876/2
	Category	Meiotic defects in testis: cytokinesis defects
5	Reversion	?
	Map Position	73A
	Rescue ID	2H1E
	Rescue Sequence	
10	GATCAAACAGAAAATCCAAAAACGAACAGCGCGCGGCCGAACGAGAGCCGTT	
	GAAGCCGGCAGAGAAGTGCGCTGCTCGCGTCGCTGCCGGTATGTGCGTGTCTG	
	TGCACTGAGAGAAAATGCTCGATTAAACAGAGAAAATTAATAGTAATATAAAA	
	AAAAAAAAAAATTTGTTTATTATTCTCAATTCAATAAAATGTAATTATTATTAT	
	ATTGGTTGTATAAGAATTTTATAAAGTAGTATAAAATTTTCAATCAAATAAAT	
15	ATGTACATCTAACAAAAAATGTTATTATCTTATAACAAAGAGGTAAAATCATA	
	AGTAGTACGAAATCTTTAAAAGAGAAAGTGTGTTACGCAAAAAGTATTCAAA	
	GCAGTCTTTTATTTAATTTAATTAATTTATTTGTGCTTTATCCCTTATATATATA	
	TGTACATTTTCATTAAAGCTAATGGTATAATTAGGTATTTACAGTGTTTAGCTAA	
	GGCTTTCATCTGAAATATTTATTAATTATGTCTAGTTGACCTGTTTTTAGTTTTT	
20	TTGNATAACAATATTTATTATTTATTAAGGAAAACAAGGGGAGAAGAAAAAC	
	CTTAATTGAAGCAAAGCAGTCTTTTGAACCCACTGGTG	
	Genomic hit, Accession No. AC005633	
	Drosophila Gene Hit rescue sequence: argos (M91381)	
25		
	Annotated <i>Drosophila</i> genome genomic segment	AE003527
	Annotated <i>Drosophila</i> genome Complete gene candidate	CG10162 – Egf2 translation facto
30	Human homologue of Complete gene candidate	CG10162 - 4e-11 181969 (M19997) elongation factor 2 [Homo sapiens]
	Putative function	Translation elongation factor
35		
	Confirmation by RNAi	Not done due to failure of PCR procedure

CATEGORY 2: FAILURE TO ENTER M-PHASE**Example 15 (Category 2)**

Line ID 1216/12
 5 **Category** Meiotic defects in testis: no division
 (no meiosis)
Reversion NR
Map Position 82F1-2

10 **Rescue ID** 2I5X-1
Rescue Sequence 1
 AAACCAAGCAACAGAAATATCTCCAGTAGAGAGCGCCACTGGAAGATCGGAA
 TTTTATAGTGCTCTGCTCTGACTAACAGGTTTTAGTAGTAGTGCTTACTTTCTAC
 TACGATTTTTGTGCGGGCTAACAATTCTGTTTTCCCACTCCCTCTCTCAGTTTTT
 15 GCATGGTAACTTTTCGGTCATTGTACTGTTGTTGTTGTTGCTTGCACACCGCAAGA
 GAACAACAACAATCGGAGAAACACTGATAGCGCGGTACAGTGGGGCAGGCCA
 AACTAGAACCCTATACATTTAAGATGTCTCCAATTTGTGATTTTGCCTTTCAAGC
 ATACTAGTTCATAGTTGATTGTTTTGTTATGTTTTGTCTTGAATGCGATGTTTCA
 AGAAATCTTATTTTCGAATTACGATATTATTCTTATTCCTTTGACTTATTAATA
 20 TAAATGAAAACGGCGAGTAGAGCAAAAGAGCGACCACTGTGGCTCCACAAGC
 TCGTTTCTCTGTTTCTCATTGCGGCCAGCTCCAATTTGCGCTTATTCACACACA
 CACCTCACTGCTTGCGACTGCAAATTTGTGCAGCTGAACTTTG

Rescue ID 2I5E-1
 25 **Rescue Sequence 2**
 CTTGGTTTATCACCCCTCTCTCTCTCTATCGCGCGCGCGCGCTCTTTGTGGAA
 ACAGGTATAACTGTTTGGCGTGAGGGAGCACGAAACTCCAGTGGAGACTTCTC
 CGCATCGCCAGCGAAACAAACGATCAAAATGAATACTCTGATAACGTGTGAA
 GGTGAGCAACAAAATAAAGTATAAGAAAATACCGCCACGAAAACAACAACA
 30 ATAGAAATGTGACGACCCCTTTCTTTTTCTCGCAAAGAACGAGGAAATGGA
 GAAGCGCAAAACCACATCCCGCTTAAAGAGTCCCTTTCCCCCGCTGGAAGTGG
 AAGGAAAGGCAGCTTAAAGAGGAGCGGGTGGCTTCCAGTATGTGGAAAACAA
 AGCAGACGCCATTGGAATGCCGTCGTTTTTGTGTTGCTAAGCCGACATGG
 CAATTGTTGCTTTTGTTCGAGAGGGGGTGGTGAAACTCATAAATATCAGCT
 35 ATGGCGAGGGGGTGGGGGCAGTCTTTGTCTGACGTACCGTACTTTTAATTCTT
 GTCGCCCCGTTTAATCCAATTTATCCAGCTTTGAATTTTCGCGG

Genomic hit, Accession No. AC007532

40 **Annotated *Drosophila* genome genomic segment** AE003603
Annotated *Drosophila* genome Complete gene candidate CG1116 - novel
Human homologue of Complete gene candidate 2495728 HYPOTHETICAL
 PROTEIN KIAA0258(aa)

Putative function No homologies which indicate function

Confirmation by RNAi Slight loss of G1 peak

Example 16 (Category 2)

	Line ID	1344/15
	Category	Mitotic defects in brain: no mitosis
5	Reversion	NR
	Map Position	83C
	Rescue ID	2F6E
	Rescue Sequence	
10	AGCGGGAGTGAGCCGAAAGAGAGTAATTTTGGCCGTCACCAAAAAAGTGGCT	
	GCATAGTGCCAAACCAATGTATGGCCGTTACGCATCTTGTTATTCTAGTGTCTT	
	TGGCTGTAATCAGTTTGCAGTGACAGAGGAGTTCAGTTTCAGTTGACTCGGCT	
	TGGTTCAAGGTTTCTGATTGCCGTCTCTTCTCCCTCTTCGCCTACAAGTCCGC	
	TGTTCCGCACCGTGACGTACCTAGACTTACACCCCTAATCAAAGATCCACTA	
15	GTTTAGATTTCTCTGCATCAACGCCATATTAACCTTTATAAGCAGTCGTTATATCT	
	CAAGTAGGCAAAAAAGTGTAATAGATATGTATCTAAATTGTCGTACATTCTAT	
	TTATTAATAATTTCGTTTTTACATCCAACAGGTGTTATTTTTGAAGTCTTAGATAA	
	CAAACAATATTCGAATTATGTGGTAGAATACTTAGCAATATACGCACATACAT	
	ATACATATGAACATTATATCCAATGCTTTAAAACCGGAATATCAAGACAACAT	
20	AATGCAACATCTGGTCCGAGCTATCCAGGCAATCACATTTTTGAAGTTCCTCCC	
	GGTTATCACACATATATCGATCATACCCCGAAATGTGTAACACAGATACAGCT	
	CACCATCCCTCTGATAAGATCTTATCAAGTTCGGGCTTGCTCGCTATCGTGAAT	
	TGGGTTGAAGGGTCCGCGATAATTGCATTGGGCATGCCATTGGTAATCACAAT	
	TGGCTGATAATGCTGCTGCTGCAATTCCACGGGTATGAA	
25	TTCATCAATTGGTTA	
	Annotated <i>Drosophila</i> genome genomic segment	AE003602
	Annotated <i>Drosophila</i> genome Complete gene candidate	CG1347 - novel protein with myosin homology
30	Human homologue of Complete gene candidate	1503990 [dbj BAA13194 (D86958) KIAA0203 similar to mouse CC1.(aa)
35	Putative function similar to coiled coil protein with ubiquitin like domain	
	Confirmation by RNAi	Marked reduction of G1 and G2/M indicating fewer cycling cells
40		

Example 17 (Category 2)

	Line ID	703/16
	Category	Meiotic defects in testis: segregation defects, meiotic failure (Mf-07/75)
5	Reversion	R
	Map Position	83B
	Rescue ID	2E7E
	Rescue Sequence	
10	AAGCAGCCCAACAGCTACGCAAAAAGTTACTTATATTCGCAGCAAAACAGAT	
	TTTTTTGTTTAAATCGTAAGTATAGGAGTGAAAAATAGCGCTAGAGTAGACCT	
	AAGTACACAGAAAGACAAATAGGGCGAGTAAAATCGCGGTCCTGGTCATTTT	
	TCTGGCCTTGACCAATCCTTTGTCTGCGCTTTCGTTGGAAAAGGGGTTATGTAC	
	GAACTGCGTGCGTACCTAAGGCCAGATTAGTCATCGGGCAGTCATATATTCAT	
15	GCAAAAAATCATTTGGTGGCCGTCGGCCTTTGTTGCGACTGTACCTTGCTCATTA	
	TTTAATAAGCGCGACAGCAATATACACACTTTGAACCCCATCCCACATTTTTT	
	CTCACCGTTTCCCCCTAATTTTCGTTTTCCCTGTGCCCATCATTCGCTTTCGCC	
	ATGTCAGTGTATCGCTTCAAATGGCGCCGAACCACATGTCTTCGTTCTCGGC	
	TCGTCCGCTTCGTTTCGTGCGCTCGTGTGTCGTCTCATTGCTCTCCGAATTTTCG	
20	TTTAACAAAGTGGTGCGAGCAGAGGGGCCGCTGGATTTCGAGGCAAACAACAC	
	ATATACCTA	
	Genomic hit, Accession No. CSC:AC013960	
25	<i>Drosophila</i> EST	several including LD15903 (AA440858), GH20091 (AI389018).
	Annotated <i>Drosophila</i> genome genomic segment	AE003602
	Annotated <i>Drosophila</i> genome Complete gene candidate	CG2922 – novel
30	Human homologue of Complete gene candidate	286001 dbj BAA02795 (D13630)
		KIAA0005 [Homo sapiens] also
		NP_054757.1 HSPC028 protein
		[Homo sapiens] e-179
35	Putative function	Weakly similar to a region of human and murine
		EIF4G2 translation initiation factors; may act as a
		translation initiation factor
	Confirmation by RNAi	Only wild type profiles observed

Example 18 (Category 2)

	Line ID	741/3
	Category	Meiotic defects in testis: segregation defects, meiotic failure (Mf-05/31)
5	Reversion	NR
	Map Position	88D
	Rescue ID	H6E
10	Rescue Sequence	GCCTGGAGCCACCTCTAGAGCCACGGCCAAAAAATTGTGTGCCAAAAAATCG TATGGCGTTACGCATCTTGTTATTCTAGTGTCTTTGGTTCTACAAATCTGGCCA ATGGGATGGACGGATTTTGGGGCTTTTGCGCCCCACATATGTNTCTTACAACC CACTCGGCCCGGCAAGTGGGTGTCAATTACGGACATCGGCAATCCGAAGACC 15 GGAGACCCAGAGACCCTCAGACCCCAGGGCCCCATTCGATTTCGATTTTCGAGTT GCGTGGGCCGATCTCACATTAGTCACATCGAAGGAATGAAATAAAAAGAAAA AACATGACGGCCGAAAAGAACTTATCCATCTTCAAAGCTCTCAGAAAATACA AAAAACTAAAAAACTTTTGACTCTTCGTCTTTCACATTTTCGAAATCACAAAAT GTCTGCCATAAATTCCAAAGTGAACAATTGAAATAAATTTTTCGCCCATGAAC 20 ACGCCGACTG
	Annotated <i>Drosophila</i> genome genomic segment	AE003705
	Annotated <i>Drosophila</i> genome Complete gene candidate	CG12600 - novel protein
25	Human homologue of Complete gene candidate	CG12600- 5e-27 4240227 dbj BAA74892.1 (AB020676) KIAA0869 protein [Homo sapiens]
30	Putative function	putative cytoskeletal structural protein
	Confirmation by RNAi cells	Reduction of G1 and G2/M peaks indicating fewer cycling cells

Example 19 (Category 2)

	Line ID	773/1
5	Category	Meiotic defects in testis: cytokinesis defects, meiotic failure (Mf-02/15)
	Reversion	R?
	Map Position	83F
	Rescue ID	2D9P
10	Rescue Sequence	CCACCGCCCATGCCGCCATTTATTGAAAGGCCTGTACGCAGTTTGTGTTTGTGTTT TTCTCTTTTTTGTAGCTCAAACACAAAATTACTTTTTGTGGCTTGACTGGTGA GGTCTCTCTATCTCGCTTTTTCGTCTTTACCTCGCTCTCATTCCCTCTCTATCTG CCCTGCTTCCTCTCACTATCTATCTACAACGAGGTCAACAAAATAAGTGCGT 15 AGTCAAAAATGTAATTGAATTGATTGACAAACACAGCGAACGTAAATTTCCGT AATGTTTAACCTTGAATTCAAATGAACAACGTATAAATATAATACACGGGTT AAACTCCATTTCAAAGCAAGCTAAAACATTTTAAATACATTTTAGGGAAACGG CCAATTAAGAATAATATTGTGGGGATCAATCTGGGGAAAAATGCAGTATC 20 AGTAATGCTGAATATTTATTTTACTAAATTACAATGAAATGTCTCAAACAAAT GGGTTAATCATTTTCTTGCTCCATCTGCTTTTCCCAACTGTATCCAAGTACAAC TACAGCATTATCCTCAACTG
	Annotated <i>Drosophila</i> genome genomic segment	AE003675
25	Annotated <i>Drosophila</i> genome Complete gene candidate	CG10272 - novel protein
	Human homologue of Complete gene candidate	CG10272 - 2995577 AC004490 (AC004490) R29381_1(aa) protein includes HMG-I and HMG-Y DNA- 30 binding domain (A+T-hook) found in HMG non-histone components in chromatin
	Putative function	Chromosomal protein
35	Confirmation by RNAi	Loss of G1 peak indicating arrest in G2/M

CATEGORY 3: METAPHASE ARREST**Example 20 (Category 3)**

5
Line ID 1067/13
Category Mitotic defects in brain: prometaphase arrest
 (overcondensation, polyploidy, scattered chromosomes with
 bipolar spindle)
 10 **Reversion** NR
Map Position 69C4-10
Rescue ID 2F8E
Rescue Sequence
 15 GTTTGGGCACAGGGTTGTATTTTCAATTTATTTTGGGGGGAGTCGATACGCTCTC
 TTGGCGTGGTCGAACGGTCACACTGGCCGAGAGATAACGGAAAATGTTTCAA
 AGGTAAGTAAAGATTATAAACGTATTAAGCTTAATACTATAATTAGCTTACTA
 TTCCAAGTATGTATAATTATTACACGTTTAAAAGGCATAACGTTAAGTGTAAC
 CAAATTATATCAATGGATTTTGAATACCAATATTATTTATTTTATTTTGGAGC
 20 TTAATATATTAATCACATATATTTAAGCCTCTTTATATATGTAAATATTTTAA
 TTTTATTAATAAATTATATATTGTTTTGTAAATATGATCGAGGGCTGCCACCT
 TGTGATAAATGCTTACCAACACTTTTAGGTACGCCGTTTAGTGACGTAAGTTG
 CGTACCTAGATATCCAGCGAAATCAAAACATTGAGTAAATCGTGGAATG
 ATGAAAATAGCTTAATCTACGGACTCGAACTGCAGGCGCGGGCTTTAACACCT
 25 CAGTACGGAGAGAGCAACGATGTGTGCTTCTTCATAGCCACCACTCCTTGAA
 GCCACCAATCAGGTTCACTTAATCCAGTACGAAGA

Genomic hit, Accession No. CSC:AC020333

30 **Associated ORF**
 Genscan: ORF1 predicted sequences: >16:51:11|GENSCAN_predicted_peptide_2|178_aa
 MAQNISPEQSGGAGGGGSKHSDDSMVVDNHAVSKRLHKELMNLMMANERGIS
 AFPDGENIFKWVGTIAGPRNTVYSGQTYRLSLDFPNSYPYAAPVVKFLTSCFHPNV
 DLQGAICLDILKDKWSALYDVRTILLSIQSLLGEPNNESPLNAQAAMMWNDQKEY
 35 KKYLDAFYEKHKDT

>16:51:11|GENSCAN_predicted_CDS_2|537_bp
 atggcgagcaatcagccccgagcaaatgggtggagcaggcggcgaggcagcaagcacagcgatgactccatgcccggtg
 aaagacaatcacgccgtgagcaaaagactgcacaaggaactgatgaacctgatgatggccaacgagaggggcatctcagcggtt
 40 tccggcaggcgagaaacatctcaagtggtgggcaccatagcgggtccacggaacacgggtgtattcggggcaaacgtatcggtt
 gtcactggattttcccaatctatccgtatgcagcacccgtggtgaagttcctgacgtcctgctccatcccaatggtgatctgcagg
 gcgccatctgtttggacatactgaaggacaaatggtcggccctgtacgatgtgcgaccattctgctgtccatacaatccctgctgg
 gcgaaccgaacaacgagagtcactgaatgcgcaggccgcatgatgtggaatgac

- Drosophila* Gene Hit** TBLASTX with ORF1: poor homology to several sequences including homolog of RAD6 (DHR6) (M63792), bendless (L20126) and Ubc D1 mRNA for ubiquitin-conjugating enzyme (X62575).
- 5 **Human Homologue** TBLASTX with ORF1: ubiquitin carrier protein E2-C (UBCH10) (NM_007019.1) and ubiquitin-conjugating enzyme E2B (RAD6 homolog) (NM_003337.1).
- 10 **Annotated *Drosophila* genome genomic segment** AE003541
Annotated *Drosophila* genome Complete gene candidate CG10682 – vihar ubiquitin-conjugating enzyme
- 15 **Human homologue of Complete gene candidate** gi5902146
0B6F58A1F0665D9A
[ref]NP_008950.1| ubiquitin carrier protein E2-C [Homo sapiens] (2.50E-50)
- 20 **Putative function** Cyclin specific ubiquitin conjugating enzyme
- Confirmation by RNAi** Complete loss of G1 and G2/M peaks indicating fewer cycling cells. Immunostaining shows metaphase arrest with condensed chromosomes
- 25

Line ID 1105/1
Category Male sterile, Female sterile, Mitotic defects in brain: prometaphase arrest
 (Overcondensation, polyploidy, fewer anaphases, high mitotic index, scattered chromosomes with bipolar spindle)
Reversion R
Map Position 69C

Rescue ID A5B
Rescue Sequence
 GTACATATAATCACAATTGAGAATCGAAAACCCGACCGCCACGAAGCGCGCT
 AAATTACACGCACATACTGAAAGCCAAACAGCGGATAGCACTAGCATCCTAC
 ATATATAGACGTAGATATATAGTCATGGCGCAGAATATCAGCCCCGAGCAAA
 GTGGTGGAGCAGGCGGCGGCGGCAGCAAGCACAGCGATGACTCCATGCCCGT
 GAAAGACAATCACGCCGTGGAGCAAAAGGTGAGTATCACATGGTGCAGCCTA
 AGATAATCCGCCAATATACACACACTCACACTCACCCACAGACTGCACAA
 GGGAACTGATGAACCTGAATGAATGGGCCACCGAAAAAAGGGG

Rescue ID A5E
Rescue Sequence 2
 ATATGTACTGTATAGTGGAATTTAGTTTGATCGGTGCGAATACGCGTCTGTT
 GCTTTTTCAGATATTTTTTTTTCACTTTTGTGTGAAAACAAAATGGAAGGAGA
 ACGAGAAGAACTGTGTTTGGGCACAGGGTTGTATTTTCAATTTATTTTTGGGGG
 GAGTCGATACGCTCTCTTGGCGTGGTCAACGGTCACACTGGCCGAGAGATAA
 CGGAAAATGTTTCAAAGGTAAGTAAAGATTATAAACGTATTAAGCTTAATACT
 ATAATTAGCTTACTATTCCAAGTATGTTATAATTATTACACGTTTTAAAGGCA
 TAACCGTTAAGTTGTTAACCCAAATTATATCAATGGATTTTGAATACCAATATT
 ATTTATTTTATATTTTGAGCTTAATATATTAATCCACATATATTTAACCCCT
 TTATATATGTTAAATATTTTAATTTTATTAATAAATTATATATTGTTTGGTTA
 AAA

Genomic hit, Accession No. AC007328 69B-69C

Associated ORF
 Genscan: ORF1 predicted sequences
 >/tmp/aaaaanjda|GENSCAN_predicted_peptide_1|357_aa
 MGKKAKHKKKGKPEKTAMKADKKQAAARQKKMLEKLGEANIADIQLLEAKEG
 KIEAISESVCPPPTPRSNFTLVCHPEKEELIMFGGELYTGKTTVYNDLFFYNTKTV
 EWRQLKSPSGPTPRSGHQMVAVASNGGELWFPNFACISRNQSWFVFHNCRLKAA
 SREKVLLNFNGTVLHPANNIIVHVKLFFKANGFKPWLLDVKLDACRFVRTNFHPF
 VRIIFDLFKDFSTINHTCPYVVLRSMTYVRRSPRLVHPIVDVPAIGHTRPRRKA
 RVGIGCAHRCPLIRMATPCRTNVMMTMLMRGVSRSRVMAICCYRRPAIAIARRRHP
 TAIHSQEVAERLGGLLYPDIQRTNP

>/tmp/aaaaanjda|GENSCAN_predicted_CDS_1|1074_bp
 atggggcaaaaaggccaacacagaagaagggaaggccgagaaaaagccatgaaagcggacaaaagcaggcgg
 cgcggaagaaagaaatgctggaaaaactgggagaagcaaatatagctgatatcatcaattgctggaggccaaggagggaag
 attgaagccatcagtgaatccgtttgcccgccaccaactccacgatccaatttcaccttagttgccatccggaagaggagagctc

atcatgtttggcggcgaaactgtactggcacaaaaaccacagtgataacgattgttctttacaacacaaaaaccgtcgagtgg
aggcagctgaaatcgccatcgggacccacgcccagaagtgacaccaaattgggtgctgtggccagcaatggaggagaactct
ggtttccgaacttcgctgtataagtcgcaatcaatcctggttggttccacaattgtcgtctgaaggcggccagtcgtgagaagg
cttactcaactttaatggaacggttctacatccggccaataacataatagttcacgtcaagctgtttaaaaaggccaacggtttaagc
5 cttggtattagacgtaaaactgatgctgtcgtttgtcggaccaacttccatccgtttgtacgcattatattcgatcttcaaagat
ttctccaccataaaccacacgtgcccatatgtgtcctccgatcgatcggtatattgtccgccgatccccacgacttgtgcacccc
atcgtagatgttccggctattgggcacactcgccctcgacggaaggccgcccgttcgtggcatagggtgtgtcatcgctgccctct
gattcggatggcgactccgtgtgtaccaacgtggtgatgatgacgctgatgaggggctcgggtgagatcaggggtgatggcgatt
tgctgtaccgccgacccgccattgccatagcccgtcggcgccaccccactgccattgccactccaagaagtgtgtaacgc
10 ctcggtggtcttctttacccggacattcagagaaccaatccgtag

Drosophila EST several ESTs including LD04777 (AA201675)

All other entries as for 1067/13.

Example 21 (Category 3)

	Line ID	1407/13
	Category	Mitotic defects in brain:
5		(weak overcondensation, metaphase with bipolar spindle)
	Reversion	NR
	Map Position	92B1-3
	Rescue ID	2D3P
10	Rescue Sequence 1	
		ATCACGAATTTGACATTGCTACCACATTCGGTGCGTGGACTCTGAAAGCTCTG
		AGTGTTTTGTATTATGCAAAGCTTTTTTGGACTATCGCGTGGTAAGTAGCCGAAA
		GAGAAAGCTCTCTTATACGGAAGATGAAGAGTGTGATTCATGAAAATGTATA
		AGAACGCGGGTCCAAAAAGTCAAGGGAGTTCTAGTGAAATGAAAAGTTCCAA
15		AGGTTTTGAAATCGTTTTATTTTCTCGTTCGTATAATTATTGGGTGTCGATCTTT
		GTTGGGCAGTGTAAGCACAACTTTGAGCTTCATCATAATATCATATGTAA
		AGCCGGGACGAAAGCTTATGATTCTGTAAAGTGTCCGCCCAAGATAACATTTT
		TCCAGCCCTTCAAATCTTCAAATAAATACGGCTTAAGGCGAGCAAATTTGTAA
		ATCAAATGATTTGTAAATAAACATTATATGTATTTTATCATGCCAGGTTAGAA
20		CACATTGTGCTGATGCAAATAAAATTCCAATTAACGCCCTGAATGGGAAGA
		TGACGCATCTTTAATGGGAATATTATGGTAAATTTAATA
	Rescue ID	2D3E
	Rescue Sequence 2	
25		TNCGTGATTATCAGCGTTAATTGTACAATATTATGATTTATTCGAGCTGTAAAT
		CTTCACAGCAAGCACAACTGTAATTATACCACTTAGAATTCGCGGAATTAA
		TTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCAT
		GATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCG
		GAACCCCTATTTGTTTATTTTCTAAATACATTCAAATATGTATCCGCTCATGA
30		GACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAG
		TATTCAACATTTCCGTGTCGCCCTTATCCCTTTTTGCGGCATTTTGCCTTCCT
		GTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTG
		GGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAG
35	Drosophila EST	LD05707 (AA246767)
	Annotated Drosophila genome genomic segment	AE003727
40	Annotated Drosophila genome Complete gene candidate	CG7444 - very short ORF with EF hand homology
	Human homologue of Complete gene candidate	none
45	Putative function	Possible calcium binding protein

Confirmation by RNAi Slight loss of G1 peak

Example 22 (Category 3)

	Line ID	1439/7
	Category	Mitotic defects in brain: prometaphase arrest. (overcondensation, polyploid, no anaphases, scattered chromosomes with bipolar spindles)
5	Reversion	?
	Map Position	96F10-14
10	Rescue ID	G3X
	Rescue Sequence	GTCGGATGTAGAAGACGTGCCCCGAAACCCAGTTAGAAATCGATGTCAGCGAT GGCGCCGGACTGGAGGATGAGGATGATGACGATATGGAACAGATTACAGCTC AGAAGGTAAGGTAAATCGTAACAGAGCTTTTTAATACGCAAGTAATCACATTC 15 TGATATCCCTAGGTTCTGGAAATCATAGAAACCGCGTGGATAAAATGAAATGTG TGCGCCGGAGATCCTGCCAGCCAGACGGACATGCTGGAGCTGATGGTCTCCC AGGTGGCCCATATGGAGGAGCAGATGCGCGATCTGGACAAGAACGATTTCCG AGCGGTGGTGCACCTCCATGGAAGTGGAGAGGGTGCGCTACATAATGGCCAGT TATCTGCGTTGCCGCCTGCAGAAGATCGAAACCTTCACGCAGCACATCCTCAA 20 CCAGGAGGAGAGCCGTGAGCCGGATGACAAACGTCTGTCTCCCGAGGAGACT AAGTTCGCCCAGGAGTTTGCCAGTAAT

Genomic hit, Accession No. AC007825

25	Annotated <i>Drosophila</i> genome genomic segment	AE003754
	Annotated <i>Drosophila</i> genome Complete gene candidate	CG14549 – novel
	Human homologue of Complete gene candidate	none
30	Putative function	no homologies which indicate function
	Confirmation by RNAi	Only wild type profile observed

Example 23 (Category 3)

Line ID 1466/4
Category Mitotic defects in brain: metaphase arrest.
 (overcondensation, no polyploidy, fewer anaphases, metaphase
 with bipolar spindle)
Reversion NR
Map Position 72F

Rescue ID ESE
Rescue Sequence 1
 GGCTGGATGCGATTTCGCTTTCGGATTTCGGATGGATTTCAGCCGCTGTCTCGACA
 CCGCCGCAACCGCTCTCGGGAGTTTGAAAATTTGAAATGAGCGGATTTCGCGTT
 GCGAAGGCGAGCTAGCGTTGCAGGCAGTGTGGCCAGATGCCGCGTGCGAACG
 TATTCTCGAATGCAATCGGCCGAGTGCAGATGCACTAAAAATAACCCACTTCC
 AGTGACTGGAAATTAAGATCAAGGNAATAGATTTTATAAAAACTTATATGAGT
 AAAAATTTTAAAATTGTGGAGTCAACCTAAATTATAAGCAACTAATTTATAAC
 ACAAGTAAAGAATGATATTAAGTAACTTTTAAATAATATTCCATTATGCTTA
 CGCTCAATTTATGAACAAATGTTTTCTCGATCCTTAGGTAAAGTTTCGAGTTTC
 GCGACTANATTTATTAAATTAAGAACATCTCCATTTATGTACACATTTAAAG
 ATTTATGAGCGGTAATATTAGCTGGTTGAC

Rescue ID E5P
Rescue Sequence 2
 ATCCAGCCAAGATATCCTATCGTGCAGCTGAAACCCGAAACCCGAATCCGAGT
 TCGAAACGAAACGAATCGCAGTGGTGGTTTCTCTCTCGCTCTCTAGCTCTCCCT
 CTCTCTCGCGTGTGTGTATGTGTGCGAGTGGCAGGAAAAGTGCGAAGCCGAAA
 TCTTTTCTAGCTGAAAGAAAGCGCAACTTCAATTAGCGAAAAGCAAGAGTAGCT
 AACAAAAAGAAAAGCGGATCGAAAAGTAAAGAAAAACAAAAAACA
 AAAGCAACAAATCGAAATGGCAAGCGAAGTGGCCCAAATACCCGCCGAGGG
 AAACGCCCGCAGTGGCGGCGGCGGAAAAATCAGAGGAGCCGGAAAAGTCAG
 CGGCCCCGCCAGCGGACTCAGCGGCCGCTCCAGCTGCCGCCCCCGCAGTGGA
 GAAGGCTGAGGATGCCGATGGCGAAAAAAGGACGGCGAGGCCGGAAAGCA
 GGACAAGCAGCAGGATGGC

Genomic hit, Accession No. CSC:AC020154

Associated ORF
 Genscan ORF: ORF2 predicted sequences
 >21:06:03|GENSCAN_predicted_peptide_5|415_aa
 MASEVAQIPAEETPAVAAAEKSEEPEKSAAPPADSAAAPAAAPAVEKAEDADGE
 KKDGEAGKQDKQDGEPPKKDEAVAAPVATKSEAPPAQKFNVHKTNFEKDIIYL
 YQFSRTPLPSLSPYCLKVETWLRLVGLKYENVVDHKMRFRSKKGQLPFIELNGEEI
 ADSAIIKELSSKYEKYLDISGLTAEQRNVSYATIAMLENHLIWIIFYWRAKYPDNV
 LKGYKVNQLQHALGLRLPNSILNFFFKITFGRKGTKKLKAHGIGVHSAEEIEEFKGD
 DLKVLSEMLDCKPFFFGDEPTLTDVVAFAVLSQLHYLSKDIA YPLRDYMTTEKCPN
 LIGHVSRMKDKCFPDWDEICTKLDLNAHIPKPEPETKEGKEGGEQEKSNEQEGTE

GDKIEKELEKDKSNEKESTEENKEKEETK

>21:06:03|GENSCAN_predicted_CDS_5|1248_bp

atggcaagcgaagtggcccaataccccgccgaggaaacgccgcagtgccggcggggaaaaatcagaggagccggaaaa
 5 gtcagcggcccccgcagcggactcagcggccgtccagctgccgccccgcagtgaggaaaggctgaggatgccgatggcga
 gaagaaggacggcgaggccggaaagcaggacaagcagcaggatggcgaggagccaaaaaggacgagcggtggcagc
 acccggtggcgacaaaatcggaagccccgccgcccagaaattcaatgtgcacaagaccaacttcgagaaggacatcatctatct
 gtaccagttctcgcgcacccactgtctccctcctgtcgcctactgcctgaagggtggagacctggctgctcttgggcctga
 aatacagaatgtcgatcataagatgcgttccgctccaagaagggtcagctgccgttcacgagctgaatggggaggaaatcg
 10 cgattcggccatcatcaaggaactgtcgtccaatacagaaaggtacctggactcgggactaccgcccagcgaaggaatgt
 ctctacgccacgattgccatgctggagaacctatctatctggatcatcttactggcgcccaagtatccggacaatgtgctcaa
 gggctacaaggtcaacttcagcacgcccctcgccctgcggctgcccaactcattctgaacttctcttaagatcaccttggctgc
 aaggcacgaagaagctgaaggcgacggcatcggtgtccacagcgccgaggagatcgaggagttcggaaggacgacctg
 aagggtgctcagcgagatgctcactgcaagccttcttcttcggcgacgagccaccacctggatgtggtggccttcgctgtcct
 15 ctgcagctccactatctgtccaaggacattgcgtatccgctgcgcactacatgaccgagaagtgcccaactgattggccacg
 tatctcgatgaaggacaagtgttcccactgggacgagatctgcacgaagctggacctcaatgcgcacattccaagccag
 agcccagaccaaggaggggcaaggagggtggcgagcaggagaaatcaaacgaacaggagggcactgaggcgacaagat
 cgagaaggagttggagaaggacaagtcaaacgagaaggagtcgaccgaggagaacaaagagaaggaggaaacaaagtaa

20 **Drosophila Gene Hit** rescue sequence and TBLASTN with ORF2: failed axon
 connections (U21685)

Human Homologue BLASTX with fax: Metaxin 1 and 2 (Q13505 and AF053551)
Drosophila EST several including LD31362 (AA951078 similar by BLASTN to
 U21685 failed axon connections)

25

Annotated Drosophila genome genomic segment AE003527

Annotated Drosophila genome Complete gene candidate CG4609 – fax failed axon
 connectionsconnections

30

Human homologue of Complete gene candidate 4505281
 ref|NP_002446.1|pMTX|
 metaxin>gi|3024205|sp|Q135
 05|MTXN_HUMAN
 METAXIN (4e-06)

35

Putative function Drosophila fax is a dominant genetic enhancer of the Abl mutant,
 developmentally expressed in axons of the CNS

40

Confirmation by RNAi Weak reduction of G1 and G2/M peaks indicating fewer
 cycling cells

45

Line ID 262/20
Category Mitotic defects in brain: metaphase arrest.
(overcondensation, polyploidy, aneuploidy, few anaphases, high mitotic index, metaphase with bent bipolar spindle)

5 **Reversion** NR
Map Position 72F

Rescue ID G6E
Rescue Sequence

10 AGCTGCACGATAGGATATCTTGGCTGGATGCGATTTCGCTTTCGGATTTCGGATG
GATTCAGGAGCCGCTGTCTCGACACCGCCGCAACCGCTCTCGGGAGTTTGAAA
ATTTGAAATGAGCGGATTTCGCGTTGCGAAGGCGAGCTAGCGTTGCAGGCAGT
GTGGCCAGATGCCGCGTGCGAACGTATTCTCGAATGCAATCGGCCGAGTGCA
GATGCACTAAAAATAACCCACTTCCAGTGACTGGAAATTAAGATCAAGGAAT

15 AGATTTTATAAAAACTTATATGAGTAAAAATTTTAAAATTGTGGAGTCAACCT
AAATTATAAGCAACTAATTTATAACACAAGTAAAGAATGATATTAAGTAACTT
TTTAAATAATATTCCATTATGCTTACGCTCAATTTATGAACAAATGTTTTCTCG
ATCCTTAGGTAAAGTTTCGAGTTTCGCGACTAGATTTATTAAAATTAAGAACA
TCTCCATTTATGTTCCC

20

Drosophila EST several including LD28084 (AA949260)

All other results as for line 1466/4

25

Line ID	262/22
Category	Mitotic defects in brain: metaphase arrest. (overcondensation, polyploidy, few anaphases, high mitotic index, metaphase with bent bipolar spindle)
5	Reversion
Map Position	NR 72F
Rescue ID	F1E
Rescue Sequence 1	
10	AGCTGCACGATAGGATATCTTGGCTGGATGCGATTTCGCTTTCGGATTTCGGATG GATTTCAGGAGCCGCTGTCTCGACACCGCCGCAACCGCTCTCGGGAGTTTGAAA ATTTGAAATGAGCGGATTTCGCGTTGCGAAGGCNAGCTAGCGTTGCAGGCAGT GTGGCCAGATGCCGCGTGCGAACGTATTCTCGAATGCAATCGGCCGAGTGCA GATGCACTAAAAATAACCCACTTCCAGTGACTGGAAATTAAGATCAAGGAAT 15 AGATTTTATAAAAACTTATATGAGTAAAAATTTTAAAATTGTGGAGTCAACCT AAATTATAAGCAACTAATTTATAACACAAGTAAAGAATGATATTAAGTAACTT TTTAAATAATATTCCATTATGCTTACGCTCAATTTATGAACAAATGTTTTCTCG ATCCTTAGGTAAAGTTTCGAGTTTCGCGACTAGATTTATTAAAATTAAGAACA TCTCCATTTATG 20
Rescue ID	F1P
Rescue Sequence 2	
25	GTGCAGCTGAAACCCGAAACCCGAATCCGAGTTCGAAACGAAACGAATCGCA GTGGTGGTTTCTCTCTCGCTCTCTAGCTCTCCCTCTCTCTCGCGTGTGTGTATGT GTGCGAGTGGCAGGAAAAGTGCGAAGCCGAAATCTTTTAGCTGAAAGAAAG CGCAACTTCAATTAGCGAAAAGCAAGAGTAGCTAACAAAAAGAAAAGCGGAT CGAAAAGTAGAGAAAAACGAAAAAAAAAAAAACCAAAGCAACAAATCGAAATG GCAAGCGAAGTGGCCCAAATACCCGCCGATGAAACGCCCGCAGTGGCGGCCG CGGGAAAAATCAGAAGAGCCGGAATCAGCGGGCCCGCCAGCGGGACTCTG 30 CGGGCGCTCCAGCTGCCGCCCGCCGAGTGGAGAAGGCTGAGGATGCCGATGG CGAA
Drosophila EST	several including LD28084 (AA949260), LD38479 (AI518768)
35	Other results as for line 1466/4

Line ID		262/3
Category		Mitotic defects in brain: Metaphase arrest (overcondensation, polyploidy, aneuploidy, no anaphases, high mitotic index, metaphase with bipolar spindle)
5	Reversion	NR
	Map Position	72F
Rescue ID		H3E
Rescue Sequence		
10	AGCTGCACGATAGGATATCTTGGCTGGATGCGATTTCGCTTTCGGATTCGGATG GATTCAGGAGCCGCTGTCTCGACACCGCCGCAACCGCTCTCGGGAGTTTGAAA ATTTGAAATGAGCGGATTCGCGTTGCGAAGGCGAGCTATCGTTGCAGGCAGTG TGGCCAGATGCCGCGTGCGAACGTATTCTCGAATGCAATCGGCCGAGTGCAG ATGCACTAAAAATAACCCACTTCCAGTGACTGGAAATTAAGATCAAGGAATA	
15	GATTTTATAAAAACTTATATGAGTAAAAATTTTAAAATTGTGGAGTCAACCTA AATTATAAGCAACTAATTTATAACACAAGTAAAGAATGATATTAAGTAACTTT TTAAATAATATTCCATTATGCTTACGCTCAATTTATGAACAAATGTTTTCTCGA TCCTTAGGTAAAGTTTCGAGTTTCGCGACTAGATTTATTAAAATTAAGAACATC TCCCTTTATGTTC	
20	Other results as for line 1466/4	

Example 24 (Category 3)

Line ID	238/20
Category	Mitotic defects in brain: metaphase arrest (overcondensation, metaphase with bipolar spindle)
Reversion	NR
Map Position	75E1-3
Rescue ID	D7E
Rescue Sequence	<p>TTCAGTCGCGCATTTTCACCGTTTCCGAATCGGACGAACCGGGCGTGATTGCTC</p> <p>TCCTGCTGCTTTTCGAGATCGGAGTCCCGATAAGGATATAACTACAACCTAAAG</p> <p>AGGAATCCAAGCCTCCTCCTGCCGCTAGTTTCGAAAAGTAAATAGAGTACTTG</p> <p>TTATCAACTGGGGAAGCGGAGATACATAGCTCCGATATTCTGTGAAAGCCAG</p> <p>ACAAACGGATACCAACGAACAATCGCCATGTGCGTCGTCCCTTCTCGTTT</p> <p>CACACATCGTGCGATAAAAATACCGCTTTGCTTTTTGTGTTTATTTAAAAATTT</p> <p>TGGTTAGGAAGTGAACCTCGAACTCGTGACGTTTGCATTTTCACAACAACAAAA</p> <p>AGAGCAAAACATAGCAGAAGAACCCAGAAGAAACAGGAACAGAAACCGTT</p> <p>GACCGAGTGCCAGTGTGAAGGTCTAGGCACAAAGAACGCTACCAAGAACTCT</p> <p>TGGGAGTTAGGGAGGCTCTTTACAATGACAACATTGCACCAAAGATGGACTCT</p> <p>CTCTCTAAAATGCATTTTCATACCAATATTTACTTT</p>
<i>Drosophila</i> EST several including LP04802 (AI260815)	
Annotated <i>Drosophila</i> genome genomic segment	AE003519
Annotated <i>Drosophila</i> genome Complete gene candidate	CG3979 - novel gene with homology to sodium- dependent dicarboxylate transporters
Human homologue of Complete gene candidate	3e-87 4506979 ref[NP_003975.1]pSLC13A2[UNKNOWN >gi 2499523 sp Q13183 NDC1 _HUMAN RENAL SODIUM/DICARBOXY
Putative function	sodium/dicarboxylate transporter
Confirmation by RNAi	Only WT profiles observed

Line ID 490/9
Category Meiotic defects in testis: segregation defects, multipolar spindles (Mul-02/29)
Reversion NR
5 **Map Position** 95C1-8

Rescue ID I4E
Rescue Sequence
10 GCTCTGCCGCTTCAACCGCCCGCGTTCTGTGTGTTGGTGTGCCGCGACGTAGG
TGTAGGGTCCGCTGCACACGTGTGTGTGGGAGCGCGCGAGAGCGGGAGAAGA
GCAGAACGTTTTTGGGCGGCTAGTGGTGGCACCGTGAGCATGCCGGTCGTCGT
AAGATAGGCTTAGGAACACTCAGAGAAAATTTGTTTAGCTCAGCATTTTCCTA
TTATTGAAATCATTTATTTGATGGTCTATGGGGGTTTCTTTCGTAGTTATTCAT
AGATCGGCGATTTAAGCTACGCTTAAAGGGTAATTTGTCTGAGATATCTTTGT
15 CATTTAAAGTTAAGTCTCAGCTTATCCAAAAGTCAGTTATTGGAAAAAAGGAG
CCAGCTTTTCAGCAGAGTTCGGCTTAAGCGCTTATTATCATATTAACCAGCTTA
ATTAATGTATCTTTTAAATTGTTATATGCATTAAATCACTAATTAAGGTGATTA
CCATTTGTACGTTTTTAAATTAAAGTATTTTGATTTTCACTAATACAGGCTCTAA
GCTGATCCAAATCTACAAGCTTAGTTTTTGAATAGTCTTCACATGTTGACTTTT
20 ATTCTCT

Genomic hit, Accession No. CSC:AC015160

Other results same as 238/20

25

Line ID 660/3
Category Meiotic defects in testis: cytokinesis defects, abnormal spindles.
(Ab-01/03)
Reversion R?
5 **Map Position** 75E

Rescue ID H8E
Rescue Sequence
GCTCTGCCGCTTCAACCGCCCGCGTTCTGTGTGTTGGTGTGCCGCGACGTAGG
10 TGTAGGGTCCGCTGCACACGTGTGTGTGGGAGCGCGCGAGAGCGGGAGAAGA
GCAGAACGTTTTTGGGCGGCTAGTGGTGGCACCGTGAGCATGCCGGTCGTCGT
AAGATAGGCTTAGGAACACTCAGAGAAAATTTGTTTAGCTCAGCATTTTCCTA
TTATTGAAATCATTTATTTGATGGTCTATGGGGGTTTCTTTCGTAGTTATTCAT
AGATCGGCGATTTAAGCTACGCTTAAAGGGTAATTTGTCTGAAATATCTTTGT
15 CATTTAAAGTTAAGTCTCAGCTTATCCAAAAGTCAGTTATTGGAAAAAAGGAG
CCAGCTTTTCAGCAGAGTTCGGCTTAAGCGCTTATTATCATATTAACCAGCTTA
ATTAATGTATCTTTTAAATTGTTATATGCATTAAATCACTAATTAAGGTGATTA
CCATTTGTTTCGTTTTAAATTAAAGTATTTGAATTC

20 **Genomic hit, Accession No.** CSC:AC015160

Other results same as 238/20

Example 25 (Category 3)

	Line ID	273/18
	Category	Mitotic defects in brain: metaphase arrest (overcondensation, very high mitotic index, few polyploids, metaphase with bipolar spindle)
5		
	Reversion	NR
	Map Position	75E
10	Rescue ID	D1E
	Rescue Sequence	AACTGGGCTAAAACCAGCTGAAAAGTAAATATTTGGAGAAG GAAAGCCTTAAGTTCCTCTCTACGCTTCGTACACGTAATGTGCGTGGTTTAATC TACGTTAAAACAAGTGGAAACCATGTTACGTGCCGTGGCTTTGTGTGTGTGAG 15 TGGTGCTCATAGCACTATATACGCCAATTCTGGGGAATCCAGTCAGAGCTAT CCCATTACCACGCTAATCAACGCGAAATGGACGCAGACGCCCCTATATCTGGA AATCGCCGAGTATCTGGCCGATGAGCAGGCGGGCCTCTTCTGGGATTACGTTT CGGGGGTGACAAAGTTGGACACGGTTCTCAACGAATATGGTTTGTGTTTATAA GTCATGGAGAACCCGCATTAAAGAGCTTTTATATTCTCCTCAATGTGAATCC 20 GAATCCATATAAAATC
	Genomic hit, Accession No. AC015160	
	Associated ORF	
	Genscan: >ORF2 predicted sequences	
25	>16:57:34 GENSCAN_predicted_peptide_5 1548_aa	
	MLRAVALCVSVVLIALLYTPTSGESSQSYPIITLINAKWTQTPLYLEIAEYLADEQA GLFWDYVSGVTKLDTVLNEYDTESQQYNALELVKSHVSSPQLPLLRLVSMHS LTPRIQTHFQLAEELRSSGSCQSFTFAQVGSELACSFNELQKKLEVPLAKDSLDA VVTYSFDHIFPGSENNRTRTVVLYGDLGSSQFRTYHKLLEKEANAGRIRYILRHQLA 30 KKDKRPVRLSGYGVELHLKSTEYKSQDDAPKPEAGSTSDEDLANESDVQGFDFK VLKQKHPTLKRALDQLRQRLQGNDEIAQLKAWFQDLGLQAAAAIAEIQGDET LQILQYTAHNFPMLARTLLAHKVTDGLRAEVKHNTAFGRSLNVAPPDGALFING LFFDADTMDLYSLIETLRSEMRVLESLHSNNVRGSLASSLLALDLTASSKKEFAIDI RDTAVQWVNDIENDVQYRRWPSSVMDLLRPTFPGMLRNIRKNVFNLVLVVDAL 35 QPTARSVIKLSESFVIHQAPIRLGLVFDARDANEDNLADYVAITCA YNYVSQKKD ARAALSFLTDIYAAVGETKVVTKKDIVKQLTKEFTSLSFAKAEFLEEDSTYDYGR ELAAEFIQRLGFGDKGQPQALLNGVPMPSNVVTADSDFEEAIFTEIMTHTSNLQKA VYKGELTDNDVAIDYLMNQPHVMPRLNQRILSQEDVKYLDINGVAYKNLGNVG VLNRLSNRDMTATLMDNLKYFGGKKSTELIGRASLQFLTIVVFADLETQGRDLL 40 THALDYVQSGESVRVAFIPNTESSASSRRNLNRLVWAAMQSLPPTQATEQVLK WLKKPKKEIEIPTQLEDILGSTELHLKMLRVYSQRVLGLNKSQRLVIGNGRLYGPL SSDESFD SADFALLARFSSLQYSQDKVRQVLKESAQDVNEEFNSDTLLKLYASLLPR QTKTRFKLPTDLKTDHSVVKLPPKQENLPHFDVAAVLDPASRAAQKLTPILILLRQ VLNCQLNLYLIPVPQHSDMPVKNFYRYVVEPEVQFEANGGRSDGPLAKFSGLPAN 45 PLLTQQLQVPENWLVEAVRAVYDLNLIKLTDIGGPVHSEFDLEYLLLEGHCFDAA SGAPPRGLQLVLGTQSQPTLVDTIVMANLG YFQLKANPGAWSLRLREGKSADIYA	

ISHIEGNTNTHSAGSSEVQVLITSLRSHVVKLRVSKKPGMQQAELLSDDNEQAQSP
GMWNSIASSFGGGSANQAATDEDTEINFSVASGHL YERLLRIMMVSLKHTKSP
VKFWFLKNYLS PQFTDFLPHMASEYNFQYELVQYKWPRWLHQQTEKQRTIWGY
KILFLDVLFLPLNVRKIIFVDADAIVRTDIKEL YDMDLGGAPYAYTPFCDSRKEMEG
5 FRFWKQGYWRSHLMGRRYHISAL YVVDLKRFRKIAAGDRLRGQYQALSQDPNS
LSNLDQDL PNNMIHQVAIKSLPDDWLWCQTWCSDSNFKTAKVIDLCNNPQTKEA
KLTA AQRIVPEWKDYDAELKTLMSRIEDHENS SRDSA VDDSVDDSV E VTTVTPS
HEPKHGEL

10 >16:57:34|GENSCAN_predicted_CDS_5|4647_bpatgttacctgcccgtggccttgtgtgtctgtgtgtgctca
tagcactatatac gccaactctggggaatccagtcagagctatcccatcaccacgctaataacgcgaaatggacgcagacgcc
cctatatctggaaatcgccgagtatctggccgatgagcagcgccctcttctgggattacgttccgggggtgaccaagtggaca
cggttctcaacgaatatgataccgagtcgcaacagtaacaatccgccttggagctggtcaagagccatgtgagttcctcccaattg
ccccctgcttagctgggtgatccatgcatagcttgacgccccggatccagaccacttccagttggccggaggaaactgaggagca
15 gtggctcttgcagagctttacttttggccaggtgggttccgaactggcctgcagcttaacgagctgcagaagaagctggaagtgc
cgctcgccaaggatagcttggatgcttctgtgtcacctacagcttggatcacatttccctggcagtgagaacaataccgcactgt
ggtactatacggcgatttgggaagctctcaattccgcacctatcacaactattggaaaaaggaagccaatgctggccgattcgtta
catcttgcgtcatcaattggccaagaaggacaagcgacgcgtacgacttccggctatggagtggaaactccatctgaagtcaacg
gaatacaagagtcagatgatgtctcaaagcccgaagctggttccacttctgatgaggttggctaataatcgacgtccagg
20 gctttgatttcaaggtgctgaagcagaagcatcctacacttaagagagcgttggatcaactgcgtcagaggcttctcagggaac
gatgagatcgcccaattgaaagcatgggagttccaggatttgggtctccaggcgccgctgctattgcagaaatacagggtgatg
aaacctacaaattctcaatatactgcccataatttccccatgttggccagaacctgctggcccaaggttacggatggcctaag
ggcggagggtaaagcataatac ggaagcatttgaagaagcttgatgtagcgctccagatgggtgcccttttcatcaatggactctt
cttcgatgctgacacaatggatctgtattccctgattgagacgctgcgctcggagatgcgtgtctcagagatctgcacagtaataat
25 gtgagggggaagccttgcagctccttgcctgccttggatctgacggctccagcaaaaaagaattcgccatcgacatccgtgaca
ctgcagtagcagtggtgaacgatattgaaaacgatgtgcagtaccgcaggtggccctatcgggtgatggatcttttgcgtccaacct
ttcttggcatgttaaggaaatccgaaagaatgtgtcaatttggctcctagtgtgtagacgcgctgcagcccacagctagaagtgttat
taaactgtcagagtcgtttgtcatccatcaagctcccattcgccttgggttggtttgcgatcgaggggacccaacgaggataatcttg
cagattacgtagccatcacgtgcgcctataactatgtgagtcagaaaaaggatgcccgagctgcttaagtttcctcaccgacatct
30 acgcagcagttggtagaccaaagtggtcacgaaaaaagacatagtcaagcaactaacgaaggaattacatcattaagctttgc
caaagcggaggagttccttgagggaagattccacgtacgactatggcaggggagctcgacgcagagttcattcagcggctgggatt
cggagacaagggaacaacctcaggccttgttgaaatgtgttccaatgccagcaacgttgcaccgccgatagcacttcgaggga
ggctattttcaccgagattatgaccacaccagcaatctccaaaaggctgtgtcaaaaggtgaactgcagacacaacgatgtagcca
ttgattatctgatgaatcaacctcacgtgatgccagattgaatcagcgaatcctaagccaggaggatgtgaaatatcttgatattaac
35 ggcgtggcctacaaaaatcttggcaatgttggagttttaaactgctctgtctaaccgggatatgaccgctacgtaagtgaataatcttaa
atacttttggtaggaagaagtctacggagcttattggccgagcatccctacagttcctaaccgatttgggtgttgcgtatttggaaactg
accagggtcgagatctgtcaccatggccctggactatgtccaaagtggagagagtgctgcgagtcgattcatttccaaactga
aagctcttccgctcaagccggagggaatcttaactgattgtttgggtgctccatgcagagcttctccacaaactcaagccacggagc
aggttctcaagtggctaaagaaccaaaggagaaaaattgagataccactcagctcgaggatattcctgggatctacagagctgca
40 cctgaagatgttgagagtttattcccagcgagtggttgggtctaaataaatcccagcgtttgtcatcgtgaatggcggttattggg
cccccttctcgggatgaaagcttggatagcgccgatttgcgttgcagcaggttcagttcctacagtatagcgataaggtgcgtca
ggtcctgaaggaaatctgtcaagatgtcaatgaggaattcaacagcgatacatgtcttaagttgtatgccagcctgcttccaggca
aaccaaaactcgtttaagctaccaacggacttaaaaaccgatcactggtgtgtaaaactaccgccaacaggagaatcttcccc
attttgatgttggccggttttggatccgctcccgagcagctcaaaaactaacgccaactatttttcttctcaagtgctgaact
45 gccaatgaactatactgatccctgccccagcacagcgatagcccgtaagaacttctacagatagttgttgaaccggag
gtccaattcgaggcgaatggaggccgatctgatgtccttggccaaattcagtgattgccagccaatcctctgtgaccagca
gctgcaggttcccgagaactggttggtcgaagctgtgagagcagtttacatctggacaacattaaagttgaccgatattgttgac
ctgtgcacagcgaattcgatctggagtaatctgtgttggagggtcactgcttggatgctgtagcggcgctccgcccagaggacttc

agttggtgtgggtaccagagtcaacctaccttgtagatactattgtgatggcgaatttgggtatttccaactaaagccaatcca
 ggagcttggtccctacgcttgcgtgaaggcaaatcggcggatattatgcaatcagccacattgaaggaaacaaatcccatcattc
 ggctggctcttctgaaggtcaggttctataacctccttgcgatcccatgttgcataaagggtgtctaagaagccaggcatgcag
 caggcgggaactcctgtcagatgacaacgaacaggcagcgcaatcaggcatgtggaacagcatgccagcagtttggcggcgg
 5 cagtgccaaaccaagcagccactgatgaggatacggaaaccatcaacattttctgtggcatcgggacactgtacgaacgtcttct
 aaggatcatgatggttctgctgaagcacacaaaatcacctgtgaagttctgttctgaagaactatcttccgcaatttacgg
 atttcttctcatatggccagtgaagtacaacttcagtagcaattgggtccagtacaaatggccccgctggctcatcagcaaacgg
 aaaaacagaggaccatttggggctacaagatcctttctggacgtgctctcccgtgaatgtgaggaaaatcatttctggtgatgc
 cgatgccatcgtaagaacggatataaaggagttgatgacatggacctcggaggagcaccctatgcctacacgccattctcgatt
 10 cccgcaagagatggagggttccgattctggaagcagggtactggcgaagccatctgatggcaggcgttaccacatttccg
 cctgtacgtggtggactgaagagattccgcaagattgcggcaggagataggctaagaggccaataaccaggcacttagccagg
 atccgaacagcttatccaatttggatcaggacttgcacaaacatgatccaccaggctgccatcaaatccctgcccagcagctgg
 ctatggtgcaaacgtggtgcagcgacagcaactcaagactgctaaagtattgattgtgcaacaacccgagaccaaggagg
 ccaaaactcacggcccccagaggattgtcccgaatggaaggactacgatgccgagctgaagaccctgatgtctgcacgcag
 15 gatcatgagaattcgcatagcagggactcggcagttgatgattcgggtgacgattcgggtggaggtcaccactgtgacgccttctcat
 gagccaagcacggcgagctgtga

Drosophila Gene Hit rescue sequence and BLASTX with EST and TBLASTN with
 ORF2: UDP-glucose:glycoprotein glucosyltransferase (U20554)
 20 **Human Homologue** BLASTX with UDP-GGT: hypothetical protein (AL133051)
Drosophila EST several including GH16576 (AI293351)

25 **Annotated Drosophila genome genomic segment** AE003519
Annotated Drosophila genome Complete gene candidate ugtUDP-glucose-glycoprotein
 glucosyltransferase

30 **Human homologue of Complete gene candidate** CG6850-
 IGI_M1_ctg14521_41
 D65BCE6EEC187AE3
 TRANS:SEPT20T.ctg14521.2
 2 FPC_ctg:ctg14521
 FPC_start:1284609
 FPC_end:1284696
 35 FPC_strand:+ (1.20E-215)

Putative function ugtUDP-glucose-glycoprotein glucosyltransferase

40 **Confirmation by RNAi** Only wild type profiles observed

Example 26 (Category 3)

	Line ID	430/5
	Category	Mitotic defects in brain: metaphase arrest (overcondensation, polyploidy, metaphase with bipolar spindle)
5	Reversion	NR
	Map Position	98B5-8
	Rescue ID	2C2E
10	Rescue Sequence	GTGCGGCCCATGGATGTGCGAACGTGTACGAAGACCAAGATCGGCATCGCCA TCGGCGGCAGCACGACGGACGATAACGAAAAAGCTACAGCCGCCGCCACAGA TACAGATGCAGATGCCATGCCGCTGTTATCAGCGCGAGCGGGAGAATGATAA GGGATGGGATCGCTCAGCGCGGCAGGCAAGACGACCAAAAAGAGAGCCAAC TAAATGATGTGCCTAAGACTAAGAGTTTAAATGAGCATTACTGTCGCGCACTCT ATGTATTATGAATAAAATTCATACAACTTTTGTGGTTTATTATAATATAAAAGT GTGTCAGCTCTACTCGGGGGAAAGTAAGTTTACTTCTTGGCCGCTGGCTTCTTG GCGGCGACCTTCTTCTTGGGGCGGCCAGCAACTTGGCGCGATTGGCGCAGCC TTGGTGGCCACATTGGCGAAGTGCGACTTGGCCAGCTCGACGTTCTGCTTCTT GGCTTGGCCAGCACCTTGGCCACGGTGCGCTTCTCGGCGGCGAGGGCGGCAC GACGCTTGAGTACCTCGGCATAAGGGTTCAACTTGATCAACTTGCGCACGGTT GGTAAGGGGGTT
	Drosophila EST	several including LD45359 (AI513164)
25	Annotated Drosophila genome genomic segment	AE003763
	Annotated Drosophila genome Complete gene candidate	CG5502 RpL1 - Ribosomal protein L1
30	Human homologue of Complete gene candidate	1e-126 432359 dbj BAA04887 (D23660) ribosomal protein [Homo sapiens]
35	Putative function	structural protein of ribosome involved in protein biosynthesis
40	Confirmation by RNAi	Marked decrease in G1 and G2/M indicating fewer cycling cells

Example 27 (Category 3)

	Line ID	472/12
	Category	Mitotic defects in brain: metaphase arrest. Meiotic defects in testis: segregation defects. Abnormal spindles
5		(mitotic: High mitotic index, meiotic: Ab-08/24)
	Reversion	R?
	Map Position	96C7-9
	Rescue ID	2B6E
10	Rescue Sequence 1	
		GTCTGACGTTCTCTGAGGGCAAAAGTTTCGAGTTAGTTGAAGGTGAGGGTGCT
		CGATCACCGATTTGCGGTGAGACGAAAGAAAAGTATGCATTGTTGCGTTGTAA
		AGAGAGCCGGCGCTCGTCTTGTTTCACATTGTCGCTGAGAACGTATGTTGTGCT
		TCATCATTTCCCTTGTTGATTTCCCTTTGACGTGGCAACTTGACCATGTATGACA
15		ACTCTTTGGTGGTGCCATCTGGAAGGCAGAAATTTGATGTCAACGGTGCTCCC
		AGCCAGTCCACTCCCCAACTCACCTGCAGCTCCACTTCGATATTAACTCGCA
		ACATATTAGTGGCGTAGTTGTACCTGCCGCGGATCCCATTTCCGCTTTGAAAT
		TTCGCACTTTTCGAATATCCGTCCACATTCGATTTGAGAACATCTTCGAAACGTT
		CAGCGGTGACCCAATCGGGTATTTTGCCAGCCGCCATTGTAGATAATCGGGAT
20		AAGTATTTTGAAATCGAGCAGAAAACACATATACGTCCAGTGTGACGGTCTTG
		CGTAGACTGATGAAAGCCGAGTATTAGACTCTACACATCTGTGGAGCTTTTAA
		ATTCGTAGTGCGCGGCCGATTTCTCTCGATCTTCTCTCAAAGCTCCGCTAAT
	Annotated <i>Drosophila</i> genome genomic segment	AE003751
25	Annotated <i>Drosophila</i> genome Complete gene candidate	CG10618 - novel
	Human homologue of Complete gene candidate	none
	Putative function	no homologies which indicate function
30	Confirmation by RNAi	Only wild type profiles observed

Example 28 (Category 3)

	Line ID	571/15
	Category	Mitotic defects in brain: metaphase arrest (overcondensation, few anaphases, some polyploids)
5	Reversion	NR
	Map Position	93D
	Rescue ID	2A8E
10	Rescue Sequence	GGCGGCGCTACATTTGTTGTTGTCGCTGCTGCTCACAGCTCCACCACCATTGTC ACAGTTATATTACCTCGCTCAAGTCGCCCCCTCTCCCTCTCGCCCACTCGCTGTG TCAATCGAATTAACGAATGCTCTTCGGCGAATAATTGGGTTTAGATACTTT TCCAGCAGACAAAGTTGTATTTTTTGCACCTTCTTATTGATATTAGGCAAAACGC 15 ATCGGCCGAATCACACGCACACAAAGCACACACGCGAGCAGCGGTTTTTCAA TCTGCAGTACACCAACAACACACACTATTTCTAATGCCTGTTCTTATCCCTC TGATATTTCCAATGAATCGCTGGGCAATTGGCGATTCTGAACCGATTTTCACTT GGCTCTTTGTTTTATTTAATTTTCACCGAAACGCTCTCACACGCAGAGACGCTT TTGCTCGTTTCGCTGATGCTTCTGCTGCAATACACACCACCTACGAAACGAGCC 20 AAGGGAAATTGTATCTATGGGCTGTGTATCTGTTTCTACGCGGCACGCGCTGC ACGTCCGCTCGCTTCGGGTTTTTCGAGAGAGAATATACTTTTTTCGATACGGTA CGGTAAACGAATTCCGCGGAATTAATTCCTTGAAGACGAAAGGGCCTCGTGATA CGCCTATTTTATAGGGTAATGCATGATAATAATGGGTTCTTAGACGTCA
25	<i>Drosophila</i> EST	LP07504 (AI294185), LP06548 (AI293427)
	Annotated <i>Drosophila</i> genome genomic segment	AE003734
	Annotated <i>Drosophila</i> genome Complete gene candidate	CG15802 – novel homology to Doom, a product of the <i>Drosophila</i> mod(mdg4) gene, induces apoptosis and binds to baculovirus inhibitor-of- apoptosis proteins
30		
35	Human homologue of Complete gene candidate	none
	Putative function	inducer of apoptosis
	Confirmation by RNAi	Only wild type profiles observed

Example 29 (Category 3)

Line ID	736/15
Category	Mitotic defects in brain: prometaphase arrest (overcondensation, fewer anaphases, metaphase with bipolar
5	spindle)
Reversion	NR
Map Position	73C
Rescue ID	H5E
10	Rescue Sequence
	CTAATGAGTAAGGAAAACCAATCAGCCTTGCTAATCGCTTGGCAGTATTGGCT TCTATGCAGGGGGGCGTGTCCCGCGCCCTTGAAGCTCAAATTTTTCGAAGGG CACAGGTCGTCCCTCCTCCTCCGCGTGGGTGGCGTTCGGCCGAACGAACCGG CGCCTACTTTGCGTCCGGCTAGCGAGGATCTCTGGGTGCCACCCACGGCTGG 15 GTGTTGCGATCTGCCCATTGATAATCCATGCGTGAGAAAGCTTTAGAGAATC TGCCAGATTATTACTCCCCGCATACTCAGAAAAATGTATCCTTCAGATATG TTTATGTTTATGAAGTGAAAAAGTCCTTTGAAATACTACAAAAAGTGAGGAT CTGACCAATGATTTGATTTCTATAGAAATATACTATAAACTATAAACTAC
20	Genomic hit, Accession No. CSC:AC014181
	Annotated <i>Drosophila</i> genome genomic segment AE003526
	Annotated <i>Drosophila</i> genome Complete gene candidate CG3971 baldspot - with homology to membrane glycoprotein
25	
	Human homologue of Complete gene candidate CG3791-9e-08 4680391emb CAB41293.1 (AL034374) dJ483K16.1 (novel protein) [Homo 30 sapiens]
	Putative function membrane protein, function unknown
35	
	Confirmation by RNAi Slight reduction of G1 and G2/M peaks indicating fewer cycling cells

Example 30 (Category 3)

	Line ID Category	82/24 Mitotic defects in brain: metaphase arrest (condensation, no polyploidy, no anaphases, metaphase with bipolar spindle)
5	Reversion Map Position	NR 100D
10	Rescue ID	2E3E
	Rescue Sequence	GGTCAAGCCCCGATGGCGTCCAGCGCGGGCTCGTCGGCAAGATCATCGAGCGC TTCGAGCAGAAGGGCTTCAAGCTGGTCGCCCTGAAGTTCACCTGGGTAAAGCGG ATAATTGAATTAGGAAGAAATCAATAGATATACATACGTGGAAACGGGTTGC 15 CCCACGCGGGGTTGCTATCGGACCTAACCTCAAAGGCTGGGTGCAGGCGTCAT CGCGGAATGACATGTGTTTAGAGGTCAGAACTGCAATTAAGTATAACGAACC GTTTTGTAACCAGGCCTCCAAGGAGCTGCTGGAGAAGCACTACGCTGATCTGT CCGCCCCGCCCTTCTTCCCCGGAAGTCTGTAAGTACATGAAGTCCGGCCCCGTG GTGCCCATGGTGTGGGAGGGTCTGAATGTGGTCAAGACCGGTCGCCAGATGCT 20 CGGCGCCACCAACCCCGCCGACTCGCTGCCCGGCACCATCCGCGGTGACTTCT GCATTGAGGTCGGACGCAACATCATCCACGGCTCCGATGCCGTCGAGTCTGCC GAGAAGGAGATCGCCTGTGGTTCAACGAAAAGGAGCTGGTCACCTGGACCCC GG
25	Genomic hit, Accession No.	CSC:AC012727
	Associated ORF	Genscan ORF1 predicted sequences >16:43:49 GENSCAN_predicted_peptide_7 172_aa MKLLMLGTLAFFSVISATMAANKERTFIMVKPDGVQRGLVGKIIERFEQKGFKL 30 ALKFTWASKELLEKHYADLSARPPFGLVNYMNSGPVPMVWEGLVVKTGRQ MLGATNPADSLPGTIRGDFCIQVGRNIIHGSDAVESAKEIALWFNEKELVTWTPA AKDWIYE
	>16:43:49 GENSCAN_predicted_CDS_7 519_bp	atgaagctcctgatgctcggcacaatttggcattctttctgtaatctcggcgacaatggcggctaacaaggagaggactttcatcat 35 ggtcaagcccgatggcgtccagcgcgggctcgtcggcaagatcatcgagcgcttcgagcagaagggttcaagctggtcgccc tgaagttcacctgggctccaaggagctgctggagaagcactacgctgatctgtccgccccttctccccggactcgtgaa ctacatgaactccggccccgtggtgccatggtgtggagggtctgaatgtggtcaagaccggtcgccagatgctcgcgccac caaccccgccgactcgtcgccggcaccatccgcggtgacttctgattcaggtcgagcgaacatcatccacgggtccgatgc 40 cgtcgagctgtccgagaaggagatcgccctgtggttaacgaaaaggagctggtcacctggaccccgccgccaaggactgg atctacgaatag
	Drosophila Gene Hit	rescue sequence and TBLA; abnormal wing disc (awd) (X13107)
	Human Homologue	BLASTX with awd and TBLASTN with ORF1; tumor metastasis inhibitor nm23-H2 (A49798) non-metastatic cells 2, protein (NM23B) (P22392) and nucleoside diphosphate kinase B.
45		

- Drosophila* EST** several including LP05977 (AI257573 similar by TBLASTX to X92956 B.taurus mRNA for nucleoside diphosphate kinase (NBR-A)
- 5 **Annotated *Drosophila* genome genomic segment** AE003779
Annotated *Drosophila* genome Complete gene candidate CG2210 - awd abnormal wing discs nucleoside diphosphate kinase
- 10 **Human homologue of Complete gene candidate** gi4505409
1A5C3F84D7AD272C
[ref]NP_002503.1| non-metastatic cells 2, protein (NM23B) expressed in [Homo sapiens] (1.90E-61)
- 15
- Putative function** human nucleoside diphosphate kinase, transcriptional regulation of c-myc expression.a candidate suppressor of tumor metastasis
- 20 **Confirmation by RNAi** Only wild type profiles observed

CATEGORY 4: ANAPHASE DEFECT**Example 31 (Category 4)**

	Line ID	1132/8
5	Category	Mitotic defects in brain: anaphase defects (overcondensation, high polyploidy, some lagging chromosomes)
	Reversion	?
	Map Position	86F3-6
10	Rescue ID	2C3E
	Rescue Sequence	
	GGCCGGAGGTACCATTTTGGTAGGACCGTTTTTCGGGCCAACGAAAATACCAC AAGACGGCAGCGATAATAGTGTTTTTGGCTTCAAATGTAGTATGGCTACGCAA CTCACATATGGTTAAGAACTTCGCTGTTTATTTGGTGGTTAACTAGCTAAATA 15 CAATAAGAGTGGCAACGCCGTCACGTTTTCTACATGTATTTACTTGGCGTAGT GCGCCAAGCTTATAAACCACAGTTGGGCGGTTCTTTTGAATTGTTAATTTACA CCCCACTATGAACTTATTAGCCTTCTTTATTTATTTATATTTTATTTTATTTT AGAATACGTTTACTCAAGGTTTCGCAGCTTGTCAATCAGTATTCGCAAATATCA ATAATAAAAGGCATCAATTTTCCAATCAGCAGTTGAAAAGAACTCCCCTCGAC 20 ATTTGAACAAAATGCATTTTGGGTGATTATAATTTATTAGAATTTTATTGAC TTAAGGTAAATATAAATAAAATATTATTCAAGTACAAAGGTATATATACTCAT TAATANTATTTGGATTCAAGGAAAATATATTTCAAAATGGCGGGGGTTAATA AAACAATTTTCAAATTAAGG	
25	Genomic hit, Accession No. AC007805	
	<i>Drosophila</i> EST	several ESTs including LP09688 (AI295922)
	Annotated <i>Drosophila</i> genome genomic segment	AE003693
30	Annotated <i>Drosophila</i> genome Complete gene candidate CG6929 - Lk6 kinase	
	Human homologue of Complete gene candidate	
	gi4505191 DB39E49EC0BED990 ref NP_003675.1 MAP 35 kinase interacting kinase 1 [Homo sapiens] (6.20E-113) and gi9994197 551A82FA3D09FD58 ref NP_060042.1 G protein- 40 coupled receptor kinase 7 [Homo sapiens] (1.70E-106)	
	Putative function	Protein kinase associated with microtubules

Confirmation by RNAi
cells

Complete loss of G1 and G2/M indicating fewer cycling

Line ID 483/19
Category Meiotic defects in testis: segregation defects
Reversion ?
Map Position 86F

5 **Rescue ID** H2S
Rescue Sequence 1
CTCCGGCCACACGGATGAATTCGTCGTCATTCGTCGGAATCATTCGAACTTTG
AAAATGGATCGGTAGCTGGGAAGGAACTTAAAGCGAAATACGCAAAGAAA
10 ACGGCTTTTGTCCGCTATTCAGCGATTTTTTTTGTGTTGTAATCAGCAGAGGAA
ATTTTAACGACCAACTCCACCGCCACACCAGCCATCTCCAGCAGCCCCGGAAA
ATAAAATAGAACTAAATTAACGCCACCATCACTACAACAACCATCTCACCAAC
AACTACAAGAGCAACAACCACAGCAACAGCACTACTGCACCAAGCCCACAAA
GAAGAGGTGAAACGCAATAATCGA=CAATACCCGAAGAAAAAACAACAAAA
15 ATATCGCAGATAACCGAAAAAAGCGGTGCAATAGATAAAACCCCATTTTTTGCT
TGAGCTTTTTTCGCCTGTGTGATGAGAGAAATCAGCAGCAGCCATCGATTACA
ACAACAACAGCAGCCACACCAACGACGACTCACCACCAAACGAAGAATAATA
ACCAGCGGANAGCGATAGATA

20 **Genomic hit, Accession No.** CSC:AC018284
Drosophila EST several including GH28825 (AI517767), LP04213

Other results same as 1132/8

Example 32 (Category 4)

5	Line ID	1422/14
	Category	Male and female sterile, small wings, meiotic defects in testis: segregation defects, elongation defect
	Reversion	NR
	Map Position	90B4-8
10	Rescue ID	2F1E
	Rescue Sequence	GGCCAGCTGCTCAAACATTCTGCAGCTATTTGGCCGCCAGCGAGTAGAACGAT ATTGCCAAATATTTTATAATAGTAACCAATACGTTACCAGTATGACCGCGCCG ATAACGATAGAAAATACCACACGGTCTAAAAGTAAATACCATTGGGGTATTC 15 CCTAATCTTTTGAATTATTTACCGTTAGGTTTCGGTCGTTTTTTTTTGTTCAGCTG TTCTTTGTATGAAACGGATTAGTAATTTTATTTGTTGTTTTGTGCATTTTTGCA TATTAAGCCTTGAAACATGCCTTAAATCGTTAAAATAGATTATAAGAGGGA TGGACTGTTTGTAAAACCAATTGGAAAATTTGTAATCGCTGGTAATAACTAT CGAGATAAGCTTAATTATCGCTGTTTTCTTTGTATCTAGTTATAAATAATAATA 20 ATAAACTGGTAATTAACAAAAGTAAAAGTTACTTAACTTATACAAAAATAT TTAGTTATTGNATTCAATAATAAGATGGTAATAATAGATGGTAAGATAGTAAT ATTTAATAATTGAATTCATCACACATGCTGGTGCACGTTCCACAACTTACAA TCAAACGAAA
25	Annotated <i>Drosophila</i> genome genomic segment	AE003718
	Annotated <i>Drosophila</i> genome Complete gene candidate	CG7623 - novel with homology to UDP-galactose transporter.
30	Human homologue of Complete gene candidate	2136348 UDP-galactose transporter related isozyme 3 - human >gi1669564 dbj BAA13527 (1e-36)
35	Putative function	sugar modification protein
	Confirmation by RNAi	Slightly reduced G2/M

Example 33 (Category 4)

	Line ID	1479/10
	Category	Mitotic defects in brain: anaphase defects (overcondensation, anaphase bridge, metaphase with swollen chromosomes and bipolar spindle)
5	Reversion	NR
	Map Position	69F3-7
	Rescue ID	2D6E
10	Rescue Sequence 1	
		CCACGGGCAAATGTGGTCCGGAGGTCCACGACAACGTGCCGCTGACCATATC CCAGATTGAGCGCGCAACTCAGGATCCGGAGAACGAGAATGTGTTTCATCACA GACGACGTGCATCCGATTCACTTCTGCACCTGCATCATCTACGCCTTTGTAAC GGCAATGGAACGCACAACGAGTCGTTTCATGAAGTTCATGATCGATGATGGCA 15 CCGGCTCCCTGGAGGCCAGCATCACCAAAAAACCTTCAATGGACGCGTGATC AGCAGCCTGTACAGTGAAGCCAGTTCGCTGGCCTCGTCCGAGGCCTACAAGA GCATTGCCGTGAGCATGATGCGGCTGCTGCAGGTCTCCATGGAGTACATTGAT CCCACGCGCATCTCGAGGGGCCACAGCCTATTCCTGCGCGGTCTCCGAATAG GTTCCGCGGCAAGATGGGTCTGGACGCTTTTCAGTTCTTCATAGACAGCGGCC 20 GATCGCGGAATATGGAAATTGGCTTCGTGGACTACCTAACCGACTGGCAACG AAGGCATAAAACAATGCAAAATAC
	Rescue ID	2D6P
	Rescue Sequence 2	
25		GCCCGTGGACTTTTCACTCTGTTGATTCTTGCGTATCACGAAGTTATCCAGCTG GCTTTCTATGTCTCGAAACTCTGATTAATAATCCATTCTATTTGCTTAGTCTGC GATTTCAAAGGGGATTTCTTTATTGCAGTGCATTTTGCATTAGCGCCAAAAAA AAAAAAGTTGTGAGCATGGGCGTAGACTTCGTATTTTCTTACAAATAATATTA ATTAAAATTAATTTTGTGAGCAATTTTACACAATTGTATTATAAGTTAAAACC 30 AGGGTCACATTAATTTGCAGAACCGCGCAATATTTCTTTTAAACCCCTTACA AATTTTCAGTTGTTTTGACTACGCCCCGCTAATTTTACTTATTAAATTCAAA GTCTAAAAACATTGTCACCAGATAATACGAGTATACTATATGGACAAACGT AAAATCGTTAATAGAATATATATTCAACCATTATTTCAACCACCGAGAGAAA TTCATTTGCACAAAACGCCAGGTTGGCAGCACCATCATTGCGCACAGCAAGTG 35 GGCAAACTCGTTGTATCGCTTG
	Genomic hit, Accession No.	AC007328
	Associated ORF	
40		Genscan ORF1 predicted sequences >17:42:01 GENSCAN_predicted_peptide_2 1507_aa MKLAPTVKLNNGYEMPILGLGTYNLKKSRCEAAVCHALEMGYRHIDTAYLYRNE GIIGKVLAKLIGDQKLKREQVFLVTKLWDIYHEPKMVKYACDMQLKLLGVDDYID LYLMHSPVGVDIYSDLDLMPHENGQLRINDVDYVDTYRSMEQLVHLGLVRSLG LSNFNANQLKRLENCQIKPANLQIECHPELVQVPLIELCKFHNTVVAYSPLGRSQ 45 TCNPLPDYYTDSKLLALAAKYGKTPAQIILRYLSKDNEDGEAAVKHAIDVGYRHID TAYFYQNEAEVGKAIRDKIAEGVVKREDIFLVTKLWNIFHDPERVEGICRKQLSNF GLDYIDL YLMHMPVGYKYVDDNTLLPKNEDDVLQLSDVDYLD TYKAMEKLVKL

GLRIEQLAGLSHLSTHSDGMQFRIRMFLLTFRQGGPSHNNMQQQQRRGGGSGTDF
YNQQRDRRDSGRQMDNNYSNNYNNNNNNNNQNRNGGGNGMQQQQRRGGNGGSGG
GGGNGGGNNPAWNMHRGNQNSNNMMNMRNRGMGSRGPMRPNQVHLLVHT
AIDGLLNPGFHILQGYRPSANNQNKPRNKIKFEGDFDFEQANNKFEELRSQLAKI
KVAEDGAPKPNATAATATATNEQVGEKVEGVHTLNGETDKKDDSGNETGAG
EHEPEEDDVAVCYDKTKSFFDNISCEAAQDRSKNKKNDWRQERKLTETFGVSS
TRRGSAHQNLNVFQAVTADATNTTTIMATAALTRDMEERQATTGTIIAWVGGGG
NFRNRSNNRNNGGGRGNGMPNITNGNTAAALKAANNAAGHGSNATDSSAPNA
TTATTKSTSLLEPQTTQVAAVSLPVLLPSIGWLFIVMDGPPDIPRSADIAILFVSFEQ
SVLFLKFHKRYNEFAHLLCAMMSFEDIESQLDNFVIRKNQQSEKSTGKCGPEVHD
NVPLTISQIERATQDPENENVFITDDVPHIFCTCIYAFVTGNNGTHNESFMKFMID
DGTGSLEASITKKPFNGRVISSLYSEASSLASSEAYKSIAVSMMRLLQVSMEYIDPT
RISRGHSLFLRGRPNRFRGKMGVCTNATAPSVSSINRILRNRAAERAAAEFARAAS
YGYAHPHPHPYTSFPTWPAHHPLWGAVPLATPPGGGPAGAGGALQPGGSGSSY
GSDGNMSSNPSSNSNTTHSNGHNTNSGSGCGDSSAGSGRLSLPALSPDSGSRDS
RSPDADANRMIDIEGEDSESQSDQPKFRNRRTTFSPEQLDELEKEFDKSHYPCVN
TREKLAARTALSEARVQVWFSNRRAKWRRHQRVNLIKQRDSPSTSSSPTPLVNPV
VSPVSPVPVPVAVPESGQQKQPYPYSTSNMCNTSSSSSNSQPCNTINPGSKMSSK
TSSVSSNQHMEEPAAA VATASPTASAPLSMGGENSAFRALPMTLPMPMTLPTASA
AAFALSFAHQYIAKTLLGSPPRSQPPTTNQHKPEPNREFLNEACSSAASVQNSTTP
ATTADTPAKSAMCVHCEKKGGAMEWM

>17:42:01|GENSCAN predicted CDS 2|4524 bp

atgaagctcgctccgactgttaagctaaacaatggctacgagatgccattctggcgctaggaaacctacaattaaagaagctcgcg
25 tgtgaggctgcccgtgtgccacgccctgaaatgggtatcgccatagacaccgcatatctgtacaggaatgaagcattatag
gcaaggttttagctaaactattggcgaccagaacctgaaacgcgaacaggtgtttctgtgcacaaagctgtgggacatataccac
gaaccaagatggtgaaatacgctgtgatatgcaattaaagctactggcggtgactatatagatctatatctgatgcattcgccg
gtggcggtggactacatctctgatgaagatctgatccccacgagaatggccagctgaggaccaacgatgtggactatgtggac
acctacagaagtatggagcaactgtgcatctggcgctggtgcgcagcttgggattgtccaaacttaatgccaatcagctgaagag
30 attactggaacctgccaaatcaagccggcaaacctacaataagaatgtcatccggaattgtgcaagtgccattaatgagctctg
taaattcacataatcaccgtggtgctattcggcactggggcggtcccaacctgcaatccgctgccggattactacactgattcc
aaactactggcggttgccagcgaatacggcgaagacaccagctcaaatcatcttaagatactgtcgaagacaacgaaggcgaa
gccgctgtgaaacatgcgattgatgtggctatctgcataatagatacgccctatttaccaaaacgaggccgaagtgggcaagg
cgattcgggacaagatcgagaaggtgtgtgaagcgagaggatataatttggctactaagcttggaaacatttccacgatccag
35 agcgctgtgaggcgatttgcgcaagcagttaagcaatttggcgttgactatatcgatctgtatctgatgcataatgccagtgggcta
caaatatgtagatgacaacaccctgctgcccaaaaatgaggacgatgtgcaccaactgagcgatgtcgactatctggatacgtaca
aagccatggaaaaagctgtgtaaaactggccctgctatcgaacaactgtgacctgagtcatttcaactcattcagatggcatgc
agtctcgatagcggatgtttctaactccaacgtggcggaaccagccacaacaatatgcagcagcagcgaacgaggcgcg
gcagtggaacggaacttataaccagcagcgggatcgtcgggactccggacgtcaaatggacaacaactatagcaacaactaca
40 acaacaataataataatcagcgcaatcgtcgcgcgccggaacggaatgcaacagcagcagcaggaggaacggcgcgagc
ggcgcgccgggtggaacggaggtggaacaacccggcctggaacatgcatcgcggcaaccagaactgaacaacatgatg
aacatgcgcaaccggcgcatgggatccgcggccccatgcgaccaatcaggtacacctgctggtgactcacactgctatagat
ggtttattaaacctggctttcacatttgcagggtctatctccgcagctggccaataatcagaacaagccgcggaacaagatcaa
gttcgaggggcgacttcgatttcgagcaggcacaacaagaattcgaggaaactgcgtcccaactggccaagctcaaggtggccga
45 ggatggtgcaccaagccagccaccaatgcaacggcgccactgcaactgcaaccaatgagcaggtgggtgagaaggttgaa
ggcgttcacactgaattggcgagaccgacaagaaggatgattctggaacgagaccggcgctggagagcacgagcctgagg
aggatgatgtgtgtgtctacgacaagaccaaatgctcttcgacaacatctcgtgcgaggtgccaggaatcgagcaagaa
caagaagaacgattggcgccaggagcgcaagtgaacacggagaccttcgaggtgtctccacacgacgtggcaggtgtgctc

atcaactgaatgtattccaagcagttaccgcgacgcaaccaataactacaacaataatggcaacggcggcattaactcgggatatg
 gaggagcgccaggctacaacaggaacaattatcgatgggtggcggcggcgggaaactccgaacaggagcaacaatcgc
 aacaacggcggcgggtcgtggcggaaacggaatgccaaacatcaccaatggcaacacggctgctgcgtgaaggcggccaac
 aatgctgctggccacggatccaatgccacggactccagtgaccaaagccacaaccgacgacaaaagtcgacgtccctcttg
 5 ccagagcagacgcaacaggtggcggcagttcgttcccgtgtgttaccatcgattggttgcttttatcgtatggatggaccac
 cagacattccaagatcggcagatattgcgattctctcgttagtttgaaacaaagtgacttttccttaatttcacaagcgatacaacg
 agtttgcctcactgctgtgcgcaatgatgagttcgaggacatagaagccagctggataactcgtgatacgcaagaatcaacag
 agtgaagagtcacgggcaaatgtgtccggagggtccacgacaacgtgcccgtgaccatatccagattgagcgcgaactca
 ggatccggagaacgagaatgtgtcatcacagacgacgtgcatccgattcacttctgcacctgcatcatctacgctttgtaactgg
 10 caatggaacgcacaacgagtcgttcatgaagttcatgatcgatggcaccggctccctggaggccagcatcaccaaaaaacc
 cttaatggacgcgtgatcagcagcctgtacagtgaagccagttcgtggcctcgtcggaggcctacaagagcattgccgtgagc
 atgatcggtgctgtcaggtctccatggagtacattgatccacgcgcatctcgaaggccacagcctattcctgcgcggctgtc
 cgaataggttccgcggaagatgggtgtctgcaccaatgccactgctccttcggtagcagcatcaatcgatattcgtaatcga
 gcggcggaaaggcagctgcggaattgtctggcgcgagttacggctatgccatccatccacacatccgcatccgtacacc
 15 agtttcccacttggccggcgcatcatccgtgtggggagccgtgcccctggccacgccacctggtggcgccctgtgtagcc
 ggtggtgactgcagccggcgcgagtgccagcagctatggcagtgatggcaacatgagctcaaatcccaatagcagcaaca
 gcaacaccaccacagcaatggccacaatacaacagcgcgagtggaatgggggtagtagtgcgggaagtggagcctctc
 cctgccggcactttcggcgattccggaagtagggacagccgctcccagacgagatgccaatcggaatgatagatatcgaagg
 cgaggacagcagtgctgcaggacagtgaccagccgaagtccggcgcaatcgaccaccttcagtcggagcagctggatgag
 20 ctggagaaggagttcgacaagtcgactatccctgctgaatacccgcgagaactggccgccggagcagctgagcgagg
 ccagggtgcaggttgggtttccaacagacgagcgaatggcgcgccaccagcggtcaacttgatcaagcagcgcgactcg
 ccctcgacatcgagctcaccacgcggttggtcaatccgggtggtcagtcgggtcagtcgaatccagttccagttcagttgagtt
 ccagaatctggccaacagaagcagccatattcgtacagcaccagcaacatgtgcaacaccagcagcagcagcaacagtc
 aaccgtgcaacaccatcaatcccggcagcaaatgagcagcaaaaccagcagcgtcagcagcaaccagcacatggagagc
 25 cagcagcggcggtggccactgcctcaccacagcagtcagctcattatcaatggcggtgagaacagtgcatcttgcgctctgcc
 catgaccttgcgatgcccagaccttgcacagcagcagcggcgcccttcgcgctcagcttcgcccgccagttacatagccaa
 gagcgttctcgttctccagatcccagatcccagccaccaaccaccaaccagcataagcccagccaaatcgcgagttctcaat
 gaagcctgcagctccgagcatctgtccagaattcgacaacgccgggcaacaaccgcagatactcctacagccaaatcagcaatg
 30 tgcgtgactgcgagaaaaaggaggggccatggagtggatgtga

Drosophila Gene Hit BLASTN with rescue sequence 2: Histone acetyltransferase GCN5
 (AF029776) very small match at end, TBLASTN with ORF1:
 middle domain histone acetyltransferase GCN5 (AF029776).
 Genomic matches histone acetyltransferase

35 **Annotated Drosophila genome genomic segment** AE003541
Annotated Drosophila genome Complete gene candidate CG4107 -Pcaf /GCN5 histone
 acetyl transferase
 transcriptional activator
 40 **Human homologue of Complete gene candidate** gi6382076
 72F516F8BD10CD0C
 [ref]NP_003875.2] p300/CBP-
 associated factor [Homo
 sapiens] (1.20E-197)

Putative function Transcriptional activator

Confirmation in RNAi Only wild type profiles observed

Example 34 (Category 4)

	Line ID	184/5
	Category	Mitotic defects in brain: Anaphase defects.
5		(overcondensation, aneuploidy, some lagging chromosomes and
		breaks)
	Reversion	R
	Map Position	71B
10	Rescue ID	C4E
	Rescue Sequence	CTCGAGCAGATGTGGGACGAGCTGAGCGGAGCGCACAAACTGCCAAGTAAGT GGAGCATGTGGATGAAAGGAGTTCACAGACAGTGTGCAACCAAAAAAAAAA AAAAAAGTTAAAAAGTTAATTTTAATAGTGTAATAAATATGAATTAAATTAA 15 ATTTTATGTAAACAGTATTAGCTTTACATGAGATTACCAAATTGTGAGTGTCT GTGTTTGTGTTGCTTTTAAAAACTTTAAAAGCACATAAAGAAATATATTTTAAA TTTAATTAATAAGTTTCGTAAAAAGTAAAAGGTAGCTAAATTAATAAGTTTCCT ATTCAAATCAGATTTGGCGAACAAAGAGCCAAGTTGGCAACACTGACAATGA CTCCAAGCGCGAACAAAGCGATTTCTATCGTTATCCCACTCTCTCTCCAGAG 20 ATCGTTCTCAAGGCCAAATGGAAGGGACTTCGAGACAATTTCCGTGTGGAGTC AAAAGGATCCGCGCGCCGAATAACGG
	Genomic hit, Accession No. CSC:AC019852	
25	Associated ORF	Genscan ORF1 predicted sequences >22:43:26[GENSCAN_predicted_peptide_2 1003_aa MAPKKSTIVLNVEQFIHDIERPFIWNRNFHCNKAFLQMWDELSGAHKLKPKIVL KAKWKGLRDNFRVEYKRIPRADNGDFMVDPATFESKWLHYYALLFLTDMRHR LPKNEQDQSFYFSQSEDCEKTVVEPDLTNGLRRLQDSDEDYDEEEMEADGEAS 30 EATMEETMPTPPAAHQMNQVSTTPLATGALRAQEEAHQHALIKAGLLRAQLMEL EKEAEDLSRKPPPPQMTSPVAPSLQVLVEPPAAHCSPPPMVTTTSAQVQQPGSA AVLAPATTSASSVSSNGAPMGGKRSVSPPLYNKAAHPLATLAAAHLAADRND EDFGPTSAVGGNGDHLSTQHSYANGLIPALKLRPRLSEDSNFNGSSTMDTLPVP EDDDYHYLLSLHPYMKQLTAAQKLRIKTIQKLIFKELYKEDLEESNLDREVYVL 35 DDGAEVDLDLGNRYERFLDVTLRDNNITGKIYKLVIEKERTGEYLGKTVQVVP ITDAIQEWVERVAQTPVQGSSKPQVCIVELGGTIGDIEGMPFVEAFRQFQFRVKRE NFCLAHVSLVPLPKATGEPKTKPTQSSVRELRGCGLSPDLIVCRSEKPIGLEVKEKI SNFCHVGPDPQVICIHDLSIYHVPLLMEQNGVIEYLNRLQLNIDMSKRTKCLQQ WRDLARRTETVRREVCIAVVGKYTKFTDSYASVVKALQHAALAVNRKLELVFIE 40 SCLLEETLHSEPSKYHKEWQKLCDSHGILVPGGFGSRGMEGKIRACQWARENQ KPLLGLICGLQAAVIEFARNKLGKLDANTTEIDPNTANALVIDMPEHHTGQLGGT MRLGKRITVFSGPSVIRQLYGNPKSVQERHRHRYEVNPKYVHLLLEEQGMRFVG TDVDKTRMEIIELSGHPYFVATQYHPEYLSRPLKPSPPFLGLILASVDRNLNQYIQRG CRLSPRQLSDASSDEEDSVVGLAGATKSLSSLKIPITPTNGISKSCNGSISTSDSEGA 45 CGGVDPNTNGHK

>22:43:26|GENSCAN_predicted_CDS_2|3012_bp
 atggcgccaaaaagtccaccattgtgctcaatgtggagcagttattcacgacatcgaggagcgccggccatctggaaccgca
 atttccactgcaacaaggccttcctcgagcagatgtgggacgagctgagcggagcgacaaaactgccaaagatcgtgctcaagg
 ccaaatggaaggacttcgagacaatttccgtgtggagtacaaaaggataccgcggcgataacgggtgattttatggtggtacc
 5 ggccacctttgagtcgaagtggctgcactactatgcattgtgttttaactgatcacatgcgtcatcgtttgccaaagaacgaacagg
 atcagtcattttacttcagccagcaaaagcaggactgtgaaaagacagtggtggagccggattaacaaacgggtctaatacgtcgt
 ctgcaggacagcgacgaggattacgacgaggaggaaatggaggcgagcggagaggctagcgaagccaccatggaggaaac
 gatgccacgccaccggctgcgcatcaaatgaatcaagtttagcaccacaccactggccaccggagcttgcgagcccaagaag
 aggcacatcagcacgctttaattaaggcaggattactccgcgtcagttgatggagctggaaaaggaggcggaggacttgagca
 10 gaaagccacctccgccacagcaaatgacatctccagtggcacccctcactacaagtctagtggaaaccaccagccgcacactgtt
 ctccaccgccaatggtgaccaccacatcgcacaagtacaacacgggctcagcagctgttctggcgccggcaacgaccaca
 tccgctgcatctgtatcctgaatggagcgccaatggcgggcaagagatctgtcgcaccgcctctatacaacaaagcacacc
 atccgctggccactctggcagcagcacatctgcggccaagaccgaaatgaggatttcggaccacacctctgctgtaggaggaa
 acggagatcacctgagcttactcaacactcctacgccaatggactgataccgcccttaagctgaagcgcccgctctctccga
 15 ggatagcaattttaatggttcctcgacaatggacactccgctcgtaccagaggacgatgactaccactactgtcagcctacatcc
 gtacatgaagcagctgaccgcagcccagaagctgcgcatacgcaccaagatacaaaaagctcatctcaaggaaactctacaaga
 agatcttgaggagtccaacctagatcgcgaggttacgttttgacgatggcgccgagggtggatctggatctgggaaactatgaac
 ggttttggatgttaccctgcatcgggacaacaacataaccaccggaaaaattacaagttggtcattgagaaggagcgactggc
 20 gagtacttgggcaaaacgggtcaagttgtccacacatcactgatgccattcaggaatgggtggagcgctggccagacacccc
 gttcagggatcttcaaagccacaggtgtgcatcgtggaattgggagggaacgattggtgacatcgaaggcatgcccttcgtagagg
 cttccgtcagtttcagttccgcgtaaagagagagaacttctgttggccatgtgtcgtggttccgttgccaaaggctaccggag
 aacccaagaccgaagccacacaaaagttcgtcagagaactgagaggatgtgacctgagttccgatttgattgtctgccgatcggg
 gaaacccattggactggaggtcaaggagaagatcagcaactttgtcatgtggggccggatcaggtgatgatccacgatttga
 25 actccattatcatgttccgctgctgatggagcagaatggtgttattgaatacctaataatgagcgctacagcttaatatcgacatgagc
 aagaggaccaaatgcttcagcaatggcgagatttggcgctgaacggagaccgttcgctgaagtttgcacgcgctcgtg
 ggaaagtacaccaagttcacggattcgtacgctccgtagttaaagccctgcaacatgcgccttgagcagtgaaatcgcaactgg
 aactggctttatcgaatcgtgctgctgagggaggaaacttgcattctgagccgagcaagtaccacaaggagtgagcagaagct
 atgcgatagccatggcatcctagtcctcggtgattcgggtcgaagcgcggtcattgaattgcacgaaataaacttggctcaaggat
 30 gcaaacaccacagaatacgatccgaacacagctaataccttggctcagatgataccagagcatcacacgggtcaattggcgccg
 actatgcgcttggcgaagcgaataactgttttctctgatggctcagtgatcattcgcaggttgatggcaatccgaaaagcgtgcagg
 agcgtcatcggcatcgttacgaggttaatcccaatacgtgcatcgtggaagagcaaggcatgcgatttggggaccgacgt
 cgacaaaactaggtggaatcattgagtcagcggtcatccctacttggccaccaataatcatccagagtacttgcggcc
 35 tctgaagccgtcgctccttctcctggcctgatcctggcctcagtgatcattgaaccaataatattcagcgcggttgcggcctgtcg
 ccccgccagctatccgacgcatcctcgataggaggacagtggttgggcttggccggagcaacaaaatcgctgagctccttg
 aaaattccattacaccacaaaatggaatatcaaaaagttgcaatggtagcataagcacttccgacagcgaagggtgctcgagg
 gcgttgatcctcaatggccataagtaa

Human Homologue TBLASTN with ORF1: CTP synthase (CTPS) (NM_001905.1)
 40 *Drosophila* EST LD27370 (AA941993)

Annotated *Drosophila* genome genomic segment AE003532
 Annotated *Drosophila* genome Complete gene candidate CG6854 - novel protein,
 possible CTP synthase?

45 Human homologue of Complete gene candidate gi4503133
 C33BD849A0044697
 |ref|NP_001896.1| CTP

synthase; cytidine 5-prime
triphosphate synthetase
[Homo sapiens] (8.40E-217)

5

Putative function

Enzyme important in the biosynthesis of phospholipids and nucleic acids, and plays a key role in cell growth, development, and

10

tumorigenesis. The region of the human gene is the location of breakpoints involved in several tumor types

Confirmation by RNAi

Loss of G1 and G2/M peaks indicating fewer cycling cells

Example 35 (Category 4)

- 5 **Line ID** 225/27
 Category Meiotic defects in testis: segregation defects
 Reversion NR
 Map Position 90D
- 10 **Rescue ID** 2D2P
 Rescue Sequence 1
- Rescue ID** 2D2E
- 15 **Rescue Sequence 2**
 GCCTGAACCTTAAACGCTGCCTTCGGCTCTCGCTCGGCACTCGCTCGGCTGCG
 ACGTCGACTGCGACGCTGGCAGCGACAACAACGATTGGCCTCTCTCATTCACT
 TACCTCCTCTCTCTCTCTCGCACTCTCTCTTAGCGGTGAGAGAGTGTTTTCTC
 ACATTTGTTTTGCTTTTTCGGTTTCGCCAATGGCCCCCAAACGAAAAGAGCG
 20 CGCAAGAGCTAGCTCCACAGTGGATCCTAAGAGAACGGTCCCTGTGGACTCC
 ATCTAGCTAAGAGAAACGCACCTAGTTAGTTTCTATTTTTGGTTGTTAAGTAC
 TGCTAGCTGCCTGCCAGTTGAGTGTCCGTCCAAAACGGTGGTGGAAATGGGG
 GTGACCACTTCAAACATGAAAGCGAAATGTCCTGAGACCCTACAAAACTAG
 AAATACGCGGGTGCACCTGAGAGAAATTTTTTATTTCAAGTAAATTGGCAGAGG
 25 CTACATTTTGAATGTTTACAATGAAAATTGCTGGGGAAGCTAGTGAACAACCA
 TTTCCGCATAATTACACTATCTAAGCTTTTATTTTATAGCCACATGATATATGC
 ATGCA
- 30 **Genomic hit, Accession No. AC008361**
- Associated ORF**
 Genscan ORF1 predicted sequences >20:36:39|GENSCAN_predicted_peptide_2|515_aa
 MSSTIRLQTSSCQCCKLYKYERHPNKPQLQPTIPNYPCEILHIDIFALEKRLYLSCI
 35 DKFSKFAKL FHLQSKASVHLRETLVEALHYFTAPKVLVSDNERGLLCPTVLNLYR
 SLDIDLYYAPTQKSEVNGQVERFHSTFLEIYRCLKDELPTFKPVELVHIAVDRYNT
 SVHSVTNRKPADVFFDRSSRVNYQGLTDFRRQTLEDIKGLIEYKQIRGNMARNKN
 RDEPKSYGPGDEVFVANKQIKTEKARFRCEKVQEDNKKNRNGKAAGGKGKTR
 RVARGAQIYQNWAI CRNLF LSLACCRVCKVCDIVVEFRKGTNAVNVQIREAI
 40 SHV FHKEDIVIDVQESKEWCIWTDQVQSPLPELENLWHELWIGPSHAYLIDQIVD
 LFENLLEKYNVQVVDVVRFNFLHRALVVVIISGIIIIIIIMIGVSGGQRTNAFSSHRS
 QRSAIGGDPQQKDSAVQQVQARSSDAFCQIPHRSPRFPGRS QLIPKPNREILRNASA
 TKNLLFRIRSQ
- 45 >20:36:39|GENSCAN_predicted_CDS_2|1548_bp
 atgtccagtacgatccgtctgcaaacttcctcatgtcagttgtgcaaactctacaagtacgagagacaccctaacaaccaaacctta

caacctacgccaatcctaactacccatgtgaatacttcacatcgacattttgcgctcgaaaaagggttacctaagtgattgac
 aaatttagcaagtttgccaaactttccatctgcagtcaaaagcatctgtgcatttgcgagaaacttggaggccctacattacttc
 accgcccctaaggtcttggttcggataacgagcgagggttggtatgcccacagtgctcaactatctcggctctagatacgtatc
 gtattatgctccaaccagaagagcgaaagtaaatggtaagtcgagagattccactctacgttctagaaatttatcgttgccataaa
 5 gatgagctccctaccttcaaaccgttgagctggtacacatagcagtggaacgctacaacacttccgttccactcggtaacgaatcg
 aaaaccagcagacgttttttgaccgctcgtcaagggttaactatcagggtctgacagatttccggcggcagactttagaggacat
 caagggttaattgagtataagcaaattagaggtaatatggctcggataaaaaataggagcagccaaagtcctatggcgggga
 gatgaagttttgtgcaaataagcaaataaaaaaaaggaaaaagcgaggttcagatgcgaaaaggtacaggaagacaacaag
 aaaaatcgcaacggaaaagcggcgggtggaaggggaaaactcgagagtagcccgaggctcagatttatcaaaactggg
 10 caatctgccgaatctgttctgttctgtctctgcctgctgccgagtggttaagtggtgatatagtcgtgaattcagaaaaggaa
 ccaacgcgctcgtgaacgtgcagatccgtgaagctatcagccatgtgttcataaagaagacatagtcagatgtccaggagtc
 aaggaaatgggtgatttggaccgatgatcaggtgcagtcgctctgccagaacttgagaatctgtggcatgaactgtggataggccc
 tagccatgctacctgatcagatcagattgtcgtatcttgcgaaatctgctcgaaaaatataatgtgcaggtgtcgtatgtcgtt
 caatttcctcatcgcgctctcgtagtcgtgatcattcgggtatcatcatcattatcatcatgatcgcggttagcgccgcca
 15 aagaacaaatgccttttcacaccaccgatctcagcgatcagcgatcgccggcgaccctcaacaaaaagattcagcggtgcaaca
 ggtgcaggcacgatcttcggatgccttttgccagatacccaccgatctccagggtccaggcgccagccaactattccgaagc
 caatcgagaattctcgaacgcgagtgccacaaaaattattgttcgaattcgagccagtga

***Drosophila* Gene Hit** BLASTN with rescue sequence: couch potato (Z14974).
 20 **Human Homologue** BLASTX with couch potato: RBP-MS/type 2 (RNA binding motif family)(D84108)

25 **Annotated *Drosophila* genome genomic segment** AE003720
Annotated *Drosophila* genome Complete gene candidate CG18434 -couch potato RNA binding protein
 30 **Human homologue of Complete gene candidate** 2224621 dbj|BAA20798| (AB002338) KIAA0340 [Homo sapiens] (2e-19) and Ensembl predicted peptide Gene:ENSG00000070877 Clone:AC009710
 35 Contig:AC009710.00004 (predicted unknown protein)

Putative function Possible RNA binding protein

Example 36 (Category 4)

Line ID 238/37
Category Meiotic defects in testis: segregation defects, multi-stage defects
 5 **Reversion** ?
Map Position 70D

Rescue ID I7E
 10 **Rescue Sequence**
 GTTCAAACGCACTTTTAAGGTGGCCTATCGGCCCATCAGGAGCAACTTTGTTC
 TGCTGCCGGATCAGTACTACGGCGTCGTTTCGACCTATGTAAGTGTCTAAAGG
 TCTTCGCTCCATTAGATTAGATACGCCAAAGATTAATCCGGTCAACCATTCT
 GATTAGGACACGGGCTGCCTGAGCTTGACGTACAATGGTCGGACGCACTACG
 15 CCTCCTGGGCGCCACAAAAGGGCGGCGGCATTAAAGACACCGAGATTGG
 GATCAATGCCAGAGCGGCCAAGGAGATCGGTAAGCCATTACTTAACGGCCGG
 ATGTGCATCGGTTGCCAATGTGCCGTAATATTGGACTCCGGCCATCTGCCCCG
 TACCTCGTACGCTAGCAGCACCCACTTACCCTTTCTTGCCGTAGGTCTGCACGA
 GAATGATCTGGTCAAGTGTGCGCTCATCGCTGACGTTCTCAACCTGCGCAGCG
 20 TCCACGTTACCCCGTCTCGTCCAAGGACTGGGAGATCATAGTGAGTGACGGT
 TTCGCCTGCTTGGCGGCGTGG

Genomic hit, Accession No. CSC:AC017664

25 **Associated ORF**
 Genscan ORF1 predicted sequences >15:26:30|GENSCAN_predicted_peptide_1|1819_aa
 EMVQAKDPPSHYLSKLRTYLDPKASRSHRLYLFYFLCQKRKMVGESTSTQVLRD
 LEISLRTNHIEWVKEFLDDTNQGLDALVDYLSFRLQMMRHEQRLQGVLCASEERL
 NLNNGGDGGEIVMGNSSSVSPGGGGLLSHGNSTGHGLANGTLDNRQQHTMSYG
 30 FLRPTIADALDSPSLKRRSRHIAKLNMGAAATDDIHVSIMCLRAIMNNKYGFNMVIQ
 HREAINCIALSLIHKSLRTKALVLELLAAICLVKGGHEILGSFDNFKDVCQEKRRF
 QTLMEYFMNFEAFNIDFMVACMQFMNIVVHSVEDMNYRVHLQYEFTALGLDKY
 LERIRLTESEELKVQISAYLDNVFDVAALMEDSETKTSALERVQELEDQLEREIDR
 NSEFLYKYAELESESLTKTEREQLAMIRQKLEBELTVMQRMLOHNEQELKKRDT
 35 LLHTKNMELQTLRSRLPRSASSGDGSLANGGLMAGSTSGAASLTLP PPPPPMPASP
 TASSAAPPPPPPPAPPAPPPPGFSPGSGSLASTAPSPPHAPPMLSSFQPPPPPPVA
 GFMPAPDGAMTIKRKVPTKYKLPTLNWIALKPNQVRGTIFNELDDEKIFKQIDFNE
 FEERFKIGIGGALRNGSNGTEVDGSLQSSKRFRPDNVSLLEHTRLRNIAISRRLG
 MPIDDVIAAIHSLDLKKLSLENVELLQKMVPTDAEVKSYKEYIIERKDQQLLTEED
 40 KFMLQLSRVERISSKLAIMNYMGNFVDSVHLISPQVQSIAGASTSLKQSRKFKAVL
 EIVLAFGNYLNSNKRGPAYGFKLQSLDTLIDTKSTDKRSSLLHYIVATIRAKFPELL
 NFESELYGTDKAASVALENVVADVQELEKGMDLVRKEAELRVKGAQTHILRDFL
 NNSDKLKKIKSDLRHAQEAFCVEYFGDSSRNADAAFFALIVRFTRAFKQHD
 QENEQRLRLEKAAALAASKKENDQVLMRNKVNQKKQQA VINELKSKAHSVRE
 45 KLLQQDEVYNGALEDILLGLKSEPYRRADAVRRSQRRRIDNNRLSRTLEEMDCL
 HENDLVKCALIADVNLRSVHVTPVSSKDWEIHELSTEKISGSVLEQTRIVNSTQILI

VWINKSMQVALTVDRCLKPHMNYGRIDHNTELVVAPNLKGLTNGTSNGVIEENT
 KLSRSKTTAQVKDELTEKLTPHTHSSTVSNVKNTIQRNKRQDHMERLKKDLRRES
 SRSFEFRVIRGLWREQAQESDVFNKGHLPEFFDLDFYCMHTAADKDYVVRVR
 TVEDDIEDDLPETIHPSIELNANLMKLLGIKELERVVLRPKTTVVNFVEKIELFANK
 5 KTHYKIMENAFKRFVIERTQHKPMLFNQEEVVRLEDDLLVTVGILPEHFRYCVVD
 AQFLKESKIYAADLVRPVGEIKEETPPTSPLSVQDLIQLPEYDKIVDQVVQELRMN
 LCLSADNSVMRQCNVLLAGASGTGKTVLVERILDQLSRKPDYCHFEFFHGSRSKG
 RKTESIQKDLRNIFTSCLQHAPAIVVLENLDVLAHAAGEQSSQDGEYYNRMADTV
 YQLIVQYTTNNAIAVIATVNELQTLNKRLLSSPRGRHVFTVARLPNLERADREIILR
 10 ELCSHINVAKDLDLVKFSNLTEGYRKCDLVQFVERAIFYAYRISKQPLLTNDQLI
 ESLEHTNSYCLQIQSNQRTGNDADANEMRVEELPGLESVVGVEEVLWMPSTRY
 PTIFNASPLRNQAGVLLYGPPGTGKTYLVSQLATSWNLRIISVKGPELLAKYIGQSE
 ENVRNLFNRARSARPCVLFDEFDSLAPKRGHDSTGVTDRV

15 >15:26:30|GENSCAN_predicted_CDS_1|5457_bp|
 gaaatggtgcaggcaaggatccgccctcacattctgagtaaactgcgcacatatctggacccaaggcatcaaggagtcac
 ggctttatctcttacttcttctgtcagaaacggaaatggtcggcgagtcacgtccacccaggctcgcgcgatctggagatctc
 gctgcgcacgaaccacatcgagtggtgaaggagttcctggatgacacgaaccagggtcggacgccctggctgactatctcag
 ctccgactgcagatgatgcgacacgagcagcgcttcagggtgtctgtgtgcctcggaggagcgtctgaatctcacaacggc
 20 ggcgatggcggtgagatagtgtggaaacagtagttctgttagtcctggtggaggtggtggttactatcacatggaacagtac
 gggacatggtctggcaatggcacacttgactcaggcagcagcacacaatgtcctatggattcctacgacctaccattgccgat
 gctctgtagtagtctagttgaagcgaaggtcacgacatattgccaaattaacatgggtgccgcacggacgacatccatgtgtc
 catatgtgcctgcgagctatcatgaacaataagtatgggttaacatggttatccagcatcgcgaggccatcaactgcattgcctg
 agtcttatccacaatcgtgaggacgaaagccctggtcctggagctgctggcagccatctgtctgtaaggaggagacacgaa
 25 atcatttgggtcgttgataatttaaggatgtgtgccaggagaagcgcgtccaacgcctatggagtagtcttatgaactcga
 ggcccttaacatagatttatggtgcctgcagtcagttcatgaacatggtgtccactcgttgaggagacatgaactacagggtgcac
 ttacagtacgagtttacagccctggccttgataagtatctggagcgaattcgattgacagaatcggaggaactgaaggtgcagat
 atcagcctatttgacaacgtctttgatgtgtgccttgatggaggattccgagacaaaacttcagccctggaacgagtcacaaga
 gcttgaggatcaactgagcgagaataagatcgaactcagagttcctctataagtatcggaattagagtcggagagcttaacgct
 30 gaaaacggaacgcgagcagctggctatgattcggcagaagctggaggaggaacttacagtatgcagcgaatgttcgagcaca
 acgagcaggagctgaagaaacgggacacactgctgcacacaagaacatggagctgcagacgcttcgcgttcctgccacga
 tccgctccagcggcgatggttctctggcgaatgtggcctcatggtggtccacatcggggcgagcctcttaacattgccacc
 acctccgcccgaatgccgcctcgtactgcaagttcagctgctcaccacacctccgcccagcaccaccggctccacc
 accaccgcccgttcagtcgctggcagtcggagcggcagcctagcctgcacagcggccatcggcccacatgccccggcc
 35 atgctaagctcttccaaccgccaccgctccagtgccggctttatgcccgctccgatggcgccatgacctcaaacgcaagg
 tggccactaaatacaagttgcccacctgaactggatagcactaaagcctaatacaggtacgtgtgataatattcaacgagctggtg
 acgaaaagatcttcaagcaaatgacttcaatgagttgaggagcgttcaagatcgggattggcgggtgcttgcgcaatgtagc
 aatggaaccgaggtcgatgggtgctgcagtcacgaacgcttcaaggagcccgacaatgtctcgtctggtgagcacacgag
 40 gttaaagaacattgcaatctccgctgcaagctgggtatgccattgatgtatcgcggccattcatagctggacctgaagaa
 actttccctggagaacgtcgagctgtgcaaaaaatggtgccacggatcccgaggtcaaatcctacaaggaatatatcatcgag
 cgcaaggaccaacagctactaccgaagaagacaagttatgtcgcagttgtcgcgtgtggagcgtatctcgtccaagctagcca
 ttatgaactatatggcaatttgcgacagcgttcatctcattagtcgcaagtgcaatcgatagcaggagcgtcgaactcctaaaa
 caatctcgaattcaaggcgggtttggaattgtcctggttcggcaactatctcaacgacaacaaacggggaccagcctatgg
 45 cttaagctgaatcgctggacacgtgatcgatacaaaatccacagacaagcgatcgtcactgcttactatattgtggccaccat
 acgggccaatttcgggagctgctgaacttcgagagcgagctgtatggaacagacaaggctgcatcggtggcactagagaatgt
 ggtggccgatgttcaggagctgaaaaggcgatggtctggtgcgaaggaggccgagctgcgagtgaaagggtgccagacg
 catatcctgctgacttctgaacaacagcgaggacaagctgaagaagatcaagagcgatctgcggcatgcacaggaagcgctc
 aaggagtgctgtgagtagtcttggcgactcctgcggaatgcagatcggtgcttcttgcgttgatcgcttcacgagagcg

ttaagcaacacgatcaggagaacgagcagcgtcttcgcctggaaaaggccgctgcgctggccgctccaagaaagagaacga
 tcaggtgcttatgcgcaacaaggtaaccagaagaagcaacagggaagctgtcataaacgagctgaagagcaaggcgactcgg
 tgcgcgagaaaaagctgctgcagcaggacgaggtgtacaacggagccctggaggacatcctgctcggcctgaagagcgagcc
 gtacaggcggggcggtgctgtgcggcggtcgcagcgcggaggtcgcacaataatcgttatcgcgcacccctggaggaaatgg
 5 attgtctgcacgagaatgatctgtgcaagtgtgcgctcatcgtgacgttctcaacctgcgcagcgtccacgttaccctcgtctgt
 ccaaggactgggagatcatagaacttagcactgaaaagatatcgggcagtgctggaacaaactcgcatagtgaattcaacgca
 gatccttattgttgattaataagtcgatcaagttgcgctgacagtggtcgtgaagccgcacatgaactacgggagaataga
 tcacaatacggaaactcgtgtggcgcccaatctgtacaagggtctgaccaatggaactcgaatggtgttatagaggaaaacaaa
 aactctccagaagtaaaaccactgccaggtcaaggatgagctgactgaaaagttaacaccgttgacccattcctccacggtgtcc
 10 aatgtgaaaaatactattcagcgtaacaagcgtcaggatcacatggagcgtcttaaaaaggacttgcgcgcgaaagctcgcgta
 gcttcgaatttcgtgtcattcagggtctatggcgggagcaggccaggagtcggatgtgtgtgaacggaaagcatctgcctgag
 ttctttgatctagatctattctattgcacaccgcagccgacaggattactatgtgagagtcgcgcacagtagaagacgatattg
 aggacgatctaccagaaaccattcatcctcgcgactgaactaaatgccaatcttatgaagttgctgggtattaaaggaaatggaacgag
 tggttctaagacctaaaactaccgtagtttaactttgtagaaaaaattgagctatttgcacaagaagacgcactacaaaatcatgga
 15 gaacgcatttaagcgattgtgatagagagaactcagcacaaagccgatgctctcaaccaggaggaggtgtgacggctggaggga
 cgatttactgggtactgttggaattttaccagaacacttcgttattgcgtgggtggacgcgcagtttctgaaggagtcgaagatctacg
 cagcagatctggtgcgtccggtggcgagatttataaggaggagacgcctccgacatccactaagtggtcaggatctcatcca
 gtaccggagtagcagataagattgtggatcaggtagttcaggaattggaatgaatctatgcctcagtgctgacaattcgtcatgct
 cagtgcaatgtcctactcgtggtgctcgggaacgggttaaacagttctgtgagagcgatttggaccagctgtcacgcaagcc
 20 ggattattgtcacttcgagttctccacggatcgcgaaagcgaaggccgagacggagtcacatacaaaaagatcttcgaacatttt
 taccagctgcctgcagcatgcccccgccattgtgtgtagaaaacttgatgtactggcccacgctgctgagagcagtcacgtc
 aggatggagagtactacaatcgcagtcgggatactgtgtatcagttgattgtcagtagtataccaccaacaacgctattgcagtaacg
 ccaccgtcaacgagttgcagaccctcaataagcgattgagctaccaagggggaagacatgtctccagactgttgcctcgtctgccc
 aatttgaacgagcagatcgagagataattcttcgagagctgtgcagccataatgtggccaaggacctggatcttgaagtct
 25 ccaacctcagcggagggtaccggaaatgtgatctgttcagttcgtggagcgtgcaatattttatgcttatcgcataagcaagacc
 agcctctctgaccaatgatcagcttattgagtcctggagcacacaaactcgtactgcctgcagggcattcagagcaatcaaaga
 actggcaatgatccgatccaatgaaatgcgcgtcaggaggttgcctggcctggagtcagttgtgggagttctggaggaggtcc
 ttatgtggccatcaaggtatccaacatttttaacgcctctccactgcgcaaccaggccggagtagtactctatatggccaccaggaa
 caggtaaaacctatctgtctctcagttggccacatcgtggaacctgcgcacatcttcctgaagggtcctgagttgctgcctcaata
 30 tattgttcaaaagcaggagaaatgttcgaaacctgtcaatcgagctgcagtgcccaccatgtgtgctttcttcgacgagtttgac
 agcttggcgccgaaacgtggtcacgattccacgggggtcaccgatcagtg

Drosophila Gene Hit recue sequence and TBLastn with ORF1: mRNA for l(3)70Da (AJ243811)

35 **Human Homologue** BLASTX with l(3)70Da: peroxisome biogenesis factor 1 (AF026086)

Drosophila EST LD43687 (AJ512050)

40 **Annotated Drosophila genome genomic segment** AE003536

Annotated Drosophila genome Complete gene candidate CG6760 mRNA for l(3)70Da
 - novel protein with
 homology to endoplasmic
 45 reticulum ATPases

Human homologue of Complete gene candidate 4505725

ref|NP_000457.1|pPEX1|
peroxisome biogenesis factor
1 >gi|2655141 (AF026086)
(8e-80)

5

- | | | |
|----|-----------------------------|---|
| 10 | Putative function | Putative member of the AAA protein family (ATPases associated with diverse cellular activities) including homologies to transitional endoplasmic reticulum atpases, and an E.coli membrane-bound AAA-type metalloprotease which degrades degrades sigma32, an alternative sigma factor for heat shock promoters |
| 15 | Confirmation by RNAi | Slight loss of G1, increase in G2/M indicating arrest in G2/M |

	Line ID	238/44
	Category	Meiotic defects in testis: segregation defects, multi-stage defects (P1-02/18)
	Reversion	R
5	Map Position	70D
	Rescue ID	F8E
	Rescue Sequence	
10	GTTCAAACGCACTTTTAAGGTGGCCTATCGGCCCATCAGGAGCAACTTTGTTC TGCTGCCGGATCAGTACTACGGCGTCGTTTCGACCTATGTAAGTGTCTAAAGG TCTTCGCTCCATTCAGATTAGATACGCCAAAGATTAATCCGGTCAACCATTCT GATTAGGACACGGGCTGCCTGAGCTTGACAGTACAATGGTCGGACGCACTACG CCTCCTGGGCGCCACAAAAGGGCGGCGGCGGCATTAAAGACACCGAGATTGG GATCAATGCCAGAGCGGCCAAGGAGATCGGTAAGCCATTACTTAACGGCCGG 15 ATGTGCATCGGTTGCCAATGTGCCGTAATATTGGACTCCGGCCATTTGCCCGG TACCTCGTACGCTAGCAGCACCCACTTACCCTTTCTTGCCGTATGTCTGCACGA GAATGATCTGGTCAAAGTGTGCGCT	
20	Other results same as for line 238/37	
	Line ID	428/5
	Category	Meiotic defects in testis: cytokinesis defects, segregation defects (seg-01/01)
25	Reversion	?
	Map Position	70A
	Rescue ID	G4E
	Rescue Sequence	
30	GTTCAAACGCACTTTTAAGGTGGCCTATCGGCCCATCAGGGAGCAACTTTGTT CTGCTGCCGGATCAGTACTACGGCGTCGTTTCGACCTATGTAAGTGTCTAAAG GTCTTCGCTCCATTCAGATTAGATACGCCAAAGATTAATCCGGTCAACCATTCT TGATTAGGACACGGGCTGCCTGAGCTTGACAGTACAATGGTCGGACGCACTACG CCTCCTGGGCGCCACAAAAGGGCGGCGGCGGCATTAAAGACACCGAGATTGG 35 GATCAATGCCAGAGCGGCCAAGGAGATCGGTAAGCCATTACTTAACGGCCGG ATGTGCATCGGTTGCCAATGTGCCGTAATATTGGACTCCGGCCATCTGCCCGG TACCTCGTACCTAGCAGCACCCACTTACCCTTTCTTGCCGTAGGTCTGCACGAA AATGATCTGGTCAAAGTGTGCGCTCATCGCTGACATTCTCAACCTGCGCA	
40	Other results same as for line 238/37	

	Line ID	848/7
	Category	Mitotic defects in brain: cytokinesis defect. Meiotic defects in testis: cytokinesis defect. Multi-stage defects Polyploidy, no overcondensation
5		PI-01/10
	Reversion	R
	Map Position	70D1-2
	Rescue ID	G1E
10	Rescue Sequence 1	GGCCACCTTAAAAGTGCGTTTGAACATTCTCGTCGTGGGCGTGTGCGAATTTA GTACGCTCCTTCCTGGTTTAAATCATTTTCGCACTAAACTTCTGCTCTCAGCGG AATTTACTTTTGCTTTATTAGAGATGGGAGCTCGCGCATCAGCTGAGCCGATA CTTGCGCAACAGGTGATACAGCTGATTAGAGATGGCCCTTTTCAACTGTTCCC 15 AGCAGTGACCGCTGCCATAACCGTTTTTCAAATTTACGTGAGAACAGACATAA AATAAATATTACAGCTCGTAGTAAATGTTATTCTATATTTAAAAGGAAATTGT AATAGTTAAAACCTTGCAATGAATCAGTTACGTTCAAAAAAGGAAACACACTTT AGTTTTTGGCTAGTTTATTGGGTTAATAATTTTTATTTAAAATAGTTCGAGTG TTCAATATAGTCATGTAAATGTGTACAGAAAGATCCGGCATTTGATATTTAAT 20 ATATCGATTTCCCTTCACTTTCGCTCCTCGTATACCATGCTGGGGTCTTATCAA ATTTATT
	Rescue ID	G1P
25	Rescue Sequence 2	AAGGTGGCCTATCGGCCCATCAGGAAGCAACTTTGTTCTGCTGCCGGATCAGT ACTACGGCGTCGTTTCGACCTATGTAAGTGTCTAAAGGTCTTCGCTCCATTCAA ATTAGATACGCCAAAGATTAATCCGGTCAACCATTCTGATTAGGACACGGGCT GCCTGAGCTTGACGTACAATGGTCGGACGCACTACGCCTCCTGGGCGCCACAA AAGGGCGGCGGCGGCATTAAAGACACCGAGATTGGGATCAATGCCACAGCGG 30 CCAAGGAGATCGGTAAGCCATTACTTAACGGCCGGATGTGCATCGGTTGCCAA TGTGCCGTAATATTGGACTCCGGCCATCTGCCCCGTACCTCGTACGCTAGCAG CACCCACTTACCCTTTCTTGCCGTAGGTCTGCACGAAAAATGATCTGGTCAAG TGTGCGCCTCATCGCTGACGTTCTCAACCTGCACAGCGTCCACGTTACCCCGT CTCGTCCAA
35	Other results same as for line 238/37	

Example 37 (Category 4)

Line ID 252/40
Category Meiotic defects in testis: segregation defects, abnormal spindles.
5 (Ab-03/30)
Reversion R
Map Position 84E

Rescue ID A4B
10 **Rescue Sequence 1**
TACATGACTCTGCGATTTGACAAAAACAAAATTGAGTTTTGTCAAGAAAATCA
ACTATTTTTCTGTGTTTAAAAAACCGAAGCCAACAAATCCGACCAAAATGCCT
GCCGAAAACCTGGAGGAGCAGGGTCTGGAGAAGAACCCGAACCTGGAGCTGG
CCCAGACGAAGTTCCTGCTTACCCTGGCGGAATACAAGCAGGATGCGGCATTG
15 AAGGCGAAGCTTCTGGAGGCGATTTCGCACGGAGAATATGGCCCCGTGGGTAC
GAGCACATCCTGCTCCGGAACCTCGGCTTGGACCCGTTAGACAAGGATCTTGCC
TGGCGCCGAATTGAAGGAAAAACAATCGCGTTTAAGTTGGGAGCCA

Rescue ID A4E
20 **Rescue Sequence 2**
GTCATGTACTACCAAGTGTGACCCCAAAGTTATCGATAAATTATACCGCATATT
TTAACATTGCCAAAAATACCAGAGCGATGTCCATCAAGATAGCGACGAAATT
AGAACAGTGCAATTGCCAATTGGGAATTTGTATTTTAATTTATTTTTAAATTCT
GAAAGTAATTTTAATTTAAAAAAAACCTGAGAGCTGTCTAGAAAAGAACTTAT
25 GTTTCATGATAACTTTGTCTGAAGAATTAAGAAATATTTAGTTGTAAAATAATT
GTNTGAATCTATTTTTTCCAATAACACGACTTATATTTTTTTTTTAAATATTC
CGAGCTAAATCCCAAGAAAGTTAAACTCCAATCTTGGGATTTTGAAGTGCCCC
AGAAACTCCAAATTAAACACTTCCTTTTTAAATAATTGTTAAGACCCGTATCA
CTTATGGTTATATACTGACCTCGAAAGGGCCACACTAAGGGGGGAGTTTGAAA
30 ATTGATTTTCTGATAAAAATTTTCGCTTGGAAAGCTACAGCATCGTCCACTGTC
CATGTTTATATATCCTTATATTTGCCTATAAATATAT

Genomic hit, Accession No. AC006494

35 **Associated ORF**
Genscan: ORF1 predicted sequences >23:00:28|GENSCAN_predicted_peptide_2|389_aa
MPAENLEEQGLEKNPNLELAQTKFLLTAEYKQDAALKAKLLEAIRTENMAPWY
EHICSELGWTVDKDLLARMKENNRVEVEQLDAAIEDAEKNLGEMEVREANLKKS
EYLCRIGDKAAAETAFRKTYEKTIVSLGHRLDIVFHLIRLGLFYLDHDLITRNIDKA
40 KYLIEEGDWDRNRNLKVYQGVYSVAVRDFKAAATFFLDTVSTFTSYELMDYPT
FVRYTVYVAMIALPRNELRDKVIKSGEIQEVLHGLPDVKQFLSLYNQYENFYV
HLAGVEKQLRLDYLIHPHYRYVREMRLGYTQLLESYRSLTLQYMAESFGVTVE
YIDQELARFIAAGRLHAKVDRVGGIVETNRPDNKNWQYQATIKQGDLLLNRIQKL
SRVINI
45 >23:00:28|GENSCAN_predicted_CDS_2|1170_bp

atgcctgccgaaaacttgaggagcagggtctggagaagaacccgaacctggagctggcccagacgaagttcctgcttaccc
 ggccggaatacaagcaggatgcggcattgaaggcgaagcttctggaggcgattcgcacggagaatatggcccgtgtgtacgag
 cacatctgctcggaaactcggctggaccgtagacaaggatctgctggcgcgaatgaaggagaacaaccgcgtagagggtggagc
 agctagatgcggcaatcaggatgcggagaagaatctgggcgagatggaagtgcgcgaggcgaatcctaagaagtcagagta
 5 cttgtgcccatcggcgacaaggctgccgagagactgcctccgcaagacctacgagaagaccgtttccctgggtcaccgcct
 ggacatcgtgttccatctgatccgcttgggactgtttaccttgaccacgatctcatcactcgcaacatcgacaaggccaagtatctg
 atcgagggaaggcggcgattgggaccgacgcaaccggtgaaggtctaccagggtgttactcgggtggcggtgacttcaag
 gcggcgccacgttctcctggacaccgtaagcaccttcacctcatacgaactgatggactacccaccttcgtgcttacaccgtt
 10 tacgtggccatgattgccctgccgcaatgagctgcgcgacaaagtatcaagggtccgaaatccaggagggtgctccatggc
 ctgcccgacgtgaacagttcctgtttcctgtacaactgccaatatgagaacttctacgtacacctggccggcgtagagaagcaa
 ttgcgcttgactacctcattcatcccaactaccgtactacgtgcgcgagatgcgcattctgggtacacccagttgctggagtcg
 tatcgtccctcacctgcagtatatggccgagtcgttcggcgtaacagtggaaacattgaccaggagctggcacgcttcacgc
 cgccggacggctcatgccaaggtgagtcggttggcggcattgtggagaccaatcgccctgacaacaagaactggcagttacc
 15 aggcgaccatcaagcaggcgatctgctgctcaaccgatccagaagttgagccgctgataaacatctaa

Drosophila Gene Hit BLASTN with rescue sequence 1 and TBLASTN with ORF1: 26S proteasome regulatory complex subunit p42A (AF145308).

Human Homologue BLASTX with EST and TBLASTN with ORF1: Hypothetical protein KIAA0107 (D14663).

20 **Drosophila EST** several including GH17651 (AI387197)

Annotated Drosophila genome genomic segment AE003739

25 **Annotated Drosophila genome Complete gene candidate** CG5378 - Rpn7 19S proteasome regulatory particle, non-ATPase protein, subunit S10aHuman Homologue

30 **Human homologue of Complete gene candidate** gi7661914
8843E6684AE91ACD
[ref]NP_055629.1| KIAA0107
gene product [Homo sapiens]
(3.40E-149)

35 **Putative function** component of the 19S proteasome regulatory particle

Confirmation by RNAi Marked decrease in G1 and G2/M indicating fewer cycling cells

40

Example 38 (Category 4)

	Line ID	277/7
	Category	Mitotic defects in brain: anaphase defects (weak, higher condensation, some polyploidy, fewer anaphases, polyploids with monopolar spindles)
5	Reversion	?
	Map Position	71B
	Rescue ID	B8E
10	Rescue Sequence	AGTCGGCGCATGCGGAGAGAGAATCGAAAGAGAAAGAGAAGCAAAGAGAGC GACATACAGCAAAAACAATTCAAAAAGAACTGGTGAAGAATACGAAAATAAG ATAATTTTTTAAGGAAGTCGCGCTTTGATCCGTATCCGTTTTAGCGTCCAAGAT TTATATCTTAAATCGGACCTATATTTTGAGGTACAGTGAAGCTTTGATGCGCCA 15 GTCTTATATGAGTTAAAGTTTTAACGATTGAAAGACACCCCTGAGCTGCTCAT TATATTTCAATATTTATAAACAATCTTATATCAGAGCTTGAGAGACTTGCAATGC GCCACAAAATTCCAATTCCAATTCCAATTCGGAATAATTCACAATAATCTC AATTAACATACGTATTTTATGTTTCGTAATTTTTTAAAATTCCCAGATTCCCCAC AATTGCCATAATAATCTCGATTATGTTATTATACTCTGAGAAGTAGGAGTGTG 20 TGCAAAGACCACAAACAAATCATTAGGGGCGT
	Annotated <i>Drosophila</i> genome genomic segment	AE003584
	Annotated <i>Drosophila</i> genome Complete gene candidate	CG15383 – novel
25	Human homologue of Complete gene candidate	none
	Putative function	No homologies to indicate function
30	Confirmation by RNAi	Slightly increased G1 decreased G2/M indicating arrst in G1

Example 39 (Category 4)

	Line ID	284/4
5	Category	Mitotic defects in brain: anaphase defects (overcondensation, polyploidy (with overcondensation), few anaphases, metaphase with bipolar spindle)
	Meiotic	
	Reversion	NR
10	Map Position	89B
	Rescue ID	2C6E
	Rescue Sequence	GTCTACCACTAGCTCTTTGTCTTCGCCTTCTAGTCTCTCTCATCTTGGCAGCCC GTTCTAGTGCGCGTATTTTTAGTCGCAACACATTGCCCAATTCGCCAGCCGCTA 15 TTTGTGTCGTCCATTTGTTTCATTCATCGGGCTCTTTTCCGATTTCAGTGGGTGG CATTAAACAATAATCCCTGCGTTCGCTGTCCACGTCCACATTACGATACGTTTA GTGCACGGAAAGAAATAAGCGTGTGGTTTCATAATATTAGCTATTGAAAAAA GTTCTTAAATTTAAGCCTCACTCGATTCTGATGCATGAAATATTATTGGATTGT AAATGAGCGTCATGTTTTGGTATACAAATCTCAAAGTAATTTAAAAATTCTCA 20 TCTTACCGTACCTTGAACCACTACCAATCATCTCAGTACAGCATTTTACGCGAA TTCTCACTGTGCACTACAATGCCAGGCGGTACAAGCACCTGTATTTATTTATG GTCCGCTGCCGTAATCGACTGCAGTCGCCGCTTCCCTCTCTCTTTTGCTACCAA CAACTTGGGGTAGGGCACCTGAACTAGTTTCAAACGGCGGCGGTTCGGCCTTTT CAGCTTTTTCGCATTTGCCATTTTCCCGCGG
25	Annotated <i>Drosophila</i> genome genomic segment	AE003711
	Annotated <i>Drosophila</i> genome Complete gene candidate	CG4275 - mor transcription factor involved in chromatin remodelling
30	Human homologue of Complete gene candidate	CG4275- 4507081 [ref NP_003066.1 pSMARCC 2 SWI/SNF related, matrix associated, actin dependent 35 regulator of chromatin, subfamily c, member 2(aa)
	Putative function	Transcription factor, regulator of chromatin
40	Confirmation by RNAi	Decrease in G1 and G2/M and increase in polyploidy

Example 40 (Category 4)

Line ID 407/8
Category Meiotic defects in testis: cytokinesis defects
Reversion ?
Map Position 64B1-2

Rescue ID A9E
Rescue Sequence
 10 GACTCACCCCTTTCACGCATTTTCATTGGAACGTTTGTTCGTTTATGCACACGC
 GTGTTGACACTTTTCATGAAACGCAGTGCGTGAAAAGTGCATCGCATAAACGC
 AATAAATGTTTGATGGATGCGTTCTGATGGCTTGAAGTCGCCTATTTGGCCGA
 TTTTCGCACGTCCACTCCCGACGGCAACAGAGTCCTGACTGAATCCCGGAGCG
 GAAGGAGTGTGGATAGCCAGGACTGCCAAAGGACACTGCGCACTTTTACTTTT
 15 TCGAAAGCGAAAGCGAAAGTGGTGGGGCCCAGGCCAAAACAANCCCTTGAGT
 TGAAATTGGAAAAAAACCGGGACAGGGATGGGAGCCCAGCTCCAACAAACG
 GTTCCGGATTCCCTTGGGAAAGCCACGCCCTGCGCCTGGAAAAGGAATGCCCTC
 CACCTCATTTGTCCTCCGTTTTGCGCTATCTCTCCCCCAAATTTCCGTTAAATG
 AAAACAACCTTTGGGTTTTTGGTTTTTAACAATTTCTCCCCATTTGGTTTTNGGG
 20 TTTCCCTTTCATTTTTGGAATTGGTTTTAATTAAAT

Genomic hit, Accession No. AC005814 64A6-64B6

Associated ORF
 25 Genscan ORF1 predicted sequences >22:57:22|GENSCAN_predicted_peptide_2|524_aa
 MGRRKDKPRVPEQDARICRAICLCQLTMVLSCVSIVYLSVAIYSPSLKAFKSGFEL
 DPVMCQTVDQRMPNNCPWASCGEWCLTKTSGFCPQIHSIVRRNGTDIQLNNCTR
 VTNTSCAMIDLSRLNKFNCNNGTACNNIRGVFNCSNGHCKNMSEFFLCHHKADG
 LTVNSQKDN TKLNGFFECHGVHCTKIKKPFSCDRYCSKITTNTVNTLIMHEDNLIA
 30 ADCENAVAFNQARGSEHGVRIEPPFEWKEDDGNLLTNCATVTRSDNRITATDCI
 NGTLLHEDTLPAPFMNFTQFWAIYENSTRSVDPEQRYLPNQANLTIYSWKKLFINL
 EGCVNTLRGECKDFVARYGNDGDNNTAQSR YQCYYNKDSNVEFVVARYDL DK
 VYRELLVSLIVPIVLFVISSISLCITKSVKVGDDAKMRCVCAGDDSDNDGPFPGPL
 ANKQQDQMYD TDDDVVDLEHQAVDQGELSDHGLPLDNQELIGSTKSLIPSPVGE
 35 SGTSDQIFDQDQEKATTCDVPEKPLVIL

>22:57:22|GENSCAN_predicted_CDS_2|1575_bp
 atggggcggcgcaaggacaaaccgcggtgattcccgaacaggatgcgcgcatctgtcgcgccatctgcctgtgccagctgac
 catggtgtgtcctgcgtgtccatcgtctacctaagcgtggccatctactcgccctccctaaaggccttcaagtccggttcgagct
 40 ggatcccgatgtgccagacgggtgatgccagatgcccaacaactccccctggcatcctgcggcgagtggtgcctgacca
 agaccagtggttttggccccagatccactcaatagtgctgcgaacggcaccgatccagctgaacaactgcaccagagtcac
 caacacatcgtgcgccatgattgacctgagtcggctgaacaagtcaattgcaacaacggcaccgcctgcaacaatatcagaggc
 gtcttcaactgctcaatggacactgcaagaatatgtcggagtctcttctgtgcaccacaaagccgatggacttacggtcaattcgc
 agaaggataacaccaagctgaatggattcttcgagtgacacgggtgactgcaccaagatcaagaagcccttcagctgcgatcg
 45 ctactgttccaagataacaactaccaatgtgaacacccttattatgcacaggagataatctattgccgccgattgtgagaacgcagtg
 gctttcaaccaagcccaggatccgacacgggtgtcgtatcgaacccttgagttttgaaagaggatgatggcaacctgctga

ccaactgcgccacagtcacaagagagtcggacaatcgcactactgccacggactgcataaatggaaccctcctggaacatgaca
 ccttgcccgtcccttcacgaacttcacccagtttgggcatctatgagaacagcaccaggctcgggtggatcccagcagagggtac
 ctgccaaccaggccaacctgacctctacagctggaagaaactgttcacacacctggagggtcgtgtaacacactgcgtggg
 gagtgcaggactttgtggctcgtatggcaacgatggcgataacaacaccgccagtcacgtaccagtgtactataacaagg
 5 actcgaatgtggagtttgggtgcacgctacgattggacaagggttacaggaggcttctagtctcgtgattgtgccattgtgctc
 ttgtgatctcatctatatcgttatgtatcatcaccaaatccgtcaaggtgggtgacgatgccaagatgcgctgtttgtgccggcga
 tgattcagataatgatggccccttggcccaggactagcaaacaagcagcaggatcagatgtacgatacagacgacgatgtagt
 gacctggagcaccaagcgggtggatggtaagaactatcgaccacggacttccgctggacaaccaagagctaatacggtagcac
 caagtcgttgataccaatcagtcctcggagaatccggaactagtgtacaatcttgaccaggatcaggagaaagcaactacgt
 10 gcgatgtcccagaaaccactagtcatactataa

(corresponds to CG15003)

- 15 Annotated *Drosophila* genome genomic segment AE003480
- 15 Annotated *Drosophila* genome Complete gene candidate CG15003- novel unknown
- Human homologue of Complete gene candidate none
- 20 Putative function No homologies to suggest function
- Confirmation by RNAi Only wild type profiles observed

Example 41 (Category 4)

Line ID 422/28
Category Meiotic defects in testis: segregation defects, multipolar spindles
 5 (Mul-02/22)
Reversion NR
Map Position 68E

Rescue ID 2I4E
 10 **Rescue Sequence**
 TCGTGGACCCTCAAAGNAACGGATTTCTCCAGTTTCTTCAAAGGGTTAATAAA
 CTTTTCGCACGTTTCGCATTTTTATGCTCAATCCGGTTACAAAATGCTGATAAA
 ACCACTTGAACACTACACGTTTCCGTAAGGCTTTCTTCTTATCTGACC
 TCTGGAATTCCGCGGAATTAATTCTTGAAGACGAAAGGGCCTCGTGATACGCC
 15 TATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCA
 CTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATT
 CAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATAT
 TGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCTTT
 TTTGCGGCATTTTGCTTCCTGTTTTGCTCACCCAGAAACGCTGGTGAAAGTA
 20 AAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTACATCGAACTGGATCT
 CAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAA

Genomic hit, Accession No. CSC:AC014962

25 **Annotated *Drosophila* genome genomic segment** AE003543
Annotated *Drosophila* genome Complete gene candidate CG5684 (putative
 transcription factor, human
 homolog
 30 **Human homologue of Complete gene candidate** 1e-100 4758946
 ref|NP_004770.1|pPOP2|
 POP2 (yeast homolog)
 >gi|4106061|gb|AAD02685|
 35 (AF053318) CCR4-associated
 regulator of polymerase II
 transcription

40

Putative function Transcription factor

Example 42 (Category 4)

	Line ID	422/5
	Category	Meiotic defects in testis: segregation defects, abnormal spindles
5		(Ab-04/26)
	Reversion	?
	Map Position	82D
	Rescue ID	B9E
10	Rescue Sequence 1	ATTGGCTCTTGATGGACTACAACGCTACCAAAATGGGGCTTGAGTTGAATTAC CTGTTGGAAGACACAATGCCACCCACGATCAACAATTCGGCGGTAAACAGTG CCGCCGAAAAGCGACCCAGCGGCAAACGGGAGCGCAAGTAAGTGAACAGAT CCCTAAACAGACCCAGATACTCAGACTGATGTGTACCTTGCAGATCCGAGATC 15 ATTTGCCGCGTGAAGTATGGAAACAACCTGCCGGATATAACCATTTGATCTGAA GTTTCTGCAGTACCCCTTCGACAGCCACCGCTTCGTGCAGTACAACCCAACGT CGCTAGAGCGTAACTTCAAGTATGACGTGCTGACGGAACACGATTTGGGTGTC ACGGTGGGACCTGATTAACCGGGAGCTCTATCAGGCCGACTCCATGACGCTGC TGGACCCGCCGATGAAAACTGCTGGAGGAGGAGACTCTGACGCCACAGAC 20 TCTGTGCGTTCGCGCCAGCATTTCGAGGACGGTGTCATGGTTGCGCAAATCCGA GT
	Rescue ID	B9B
	Rescue Sequence 2	GGCCAAATCTAGAAATCCTCAAATCTGCGCTTGGCAGTGTGACCGTACTTGAC 25 CGGTACGATAATACCTCCGGTAAAAAAATACTATATTTCCGGGGGACTCAAA TGCAACATCCTCATCGTATATAACACAACATCTATTTGAATTTTCATTTCACAA CTAATATTATGGATAATGCTTTATTATCATTTTTCCAAGTTAGCGATAAATCACC CCACAAGCTGAAAAATCAACGTTTAAAAACGATTGATATTTTTTTTAATACTTT 30 TTGGTTTTACTATTTGAATTTTGTATACTTTTAGATTTTACTATTTTAATTTTTC GTTTCTTCTAGCTGACTAACGGGTAAAAAAGGATCCGTGACCTGCAGATCT CTAGAAGCTTGCGTTGCTGGCGTTTTTTCCATAGGCTCCGCCCCCTGACGAGC ATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATA AAGATACCAGGCGTTTTCCCCCTGGAAGCTCCCTCCGTGCGCTCTCCTGTTCCG 35 ACCTGCCGCTTACCGGATACCTGTCCGCCTTCT
	Genomic hit, Accession No. AC008189	
	Associated ORF	
	Genscan ORF1 predicted sequences >15:53:24 GENSCAN_predicted_peptide_3 211_aa 40 MRNANESSGKPKSKFVSNEFHAFSTICSADSPAVSREKLKIDLAARKIPSASAPK GDSPLERFSRDLFTYLRVCRWGRFSAALFTAELLIVGGIVSSNRTSESSETGNPLA NEPDPLYMKLVDPMVAGESPKRMIKDQKDVGLKSTSSSEELRKLPKTRGRQKRFI RNPNYVKANEFYDKMLSSSEYVSKRYKDLPPHPGFGADQPPA	
45	>15:53:24 GENSCAN_predicted_CDS_3 636_bp atgcgcaacgcaaatgaatcgagcggttaaaccataatgtaagcaacgaattccacgcattgtttcaacaattgttcaa	

146

ttgccgattccccggctgtctctcgagaaaaattgaaatcgatttagctgctcggaaaataccttcggcatcagccccaaaggg
 gattctccactcgagcgcttttcgcgggatctgttcaacttacttgcgctccgttgcgctggggtcgcttttcggcggcactgtttacc
 gccgaattgtgatcgtgggtggcattgtgtctccaacagacgtcagagtcttctgaaactggaaaccacttgcaaacgagccc
 gatccattatatgaaactggatcccatgtagcaggagaatcacctaaaaggatgattaaggatcagaaagatgtaggcctt
 5 aaatcaactagcagtagcgaagagctccgaaaattgccaaaacgcgaggtcgacagaagagattcattcggaatccaaactat
 gtgaaagctaacgaattctatgataagatgttaagcagtgaaacgtaagtaagcggtataaggatcttccgccgcctcatccggga
 ttggagcgggatcaaccgccagcatga

Corresponds to CG2503

10

Annotated *Drosophila* genome genomic segment AE003605
Annotated *Drosophila* genome Complete gene candidate CG2503 - novel possibly
 RNA binding

15

Human homologue of Complete gene candidate 3287674 AC005239
 (AC005239)
 F23149_1(aa)

Putative function Possible RNA binding protein

20

Confirmation by RNAi Almost no G1 and broadened G2/M indicating arrest in
 G2/M

Example 43 (Category 4)

	Line ID	423/14
	Category	Meiotic defects in testis: cytokinesis defects, abnormal spindles (Ab-16/13)
5	Reversion	R
	Map Position	67B1-10
	Rescue ID	E9E
10	Rescue Sequence	GTTTGGCGTAAAAGCTTCGGCTGTGTTTGGTGCCCAAATTTTCCACTGCTTCT CTTTTGTGTATCTCTTATATCTTGTGCTTTTTTGTGTGTATGTTTTCTCGTTTC TTTTTGCACACGCGCTTCGCGTTGCGGGCCAGCTGTTTTGTTTGATAAGTGTT TACGGTTTGTGTGTGCCAGCGGGTTTTCTTAGTCGAACTGCTCGCGATGACTG 15 ATTTTTCACAAGTGACTCAAAAACAGTCGATCGCCCTTTTAAGAAAACCCGCT CAACGCACACAAAAGCGGTTTCTCTCTTTTTGTCGTTCTCTCTTTTCACACTGA CCACACGGAACGAAAAAATGATTACCGACCACACGGAAAGAAAAATTTATGT CCAGACGAACTATTTTTGTCCAAGTAGCTGATTTGCATAACAATTTAAGCCA CAAGAACTAGATTAAAAATTTTACATTTAAATACATTATCAAATCCGAAATAT 20 CAATAATTGTAATTTATCCTTACAAAATGTTA
	Genomic hit, Accession No.	CSC:AC020214
	<i>Drosophila</i> EST	several including LP12306 (AI297868)
25	Annotated <i>Drosophila</i> genome genomic segment	AE003552
	Annotated <i>Drosophila</i> genome Complete gene candidate	CG3967 - novel
	Human homologue of Complete gene candidate	none
30	Putative function	No homologies to indicate function
	Confirmation by RNAi	Only wild type profiles observed

Example 44 (Category 4)

Line ID	427/5
Category	Mitotic defects in brain: anaphase defects. Meiotic defects in testis: segregation defects, abnormal spindles (mitotic : Overcondensation, lagging chromosomes/less aligned metaphase with bipolar spindles, Meiotic: Ab-06/20)
5	
Reversion	?
Map Position	67B1-5
10	Rescue ID H4E
Rescue Sequence	GTACAGCCTGAAGTGATCGTTGTTGTTTGAATCGGTGCTATCGGCGGTTGCGC TTTGTGGGCATCTTTATCCAATTTGCTATGCGCGCTTGCTCTTAAATTTTGAAC TGTATTCCAAGGGTTGCTTTGGCGGCTATCGATAGTATCGGCATGGTTACATT 15 TAGTTTTATAACAAGAATTTTACAGGTATTTTGATTATCTGAGCTTAGTTTTAA GCAANAATATTATTGTTAAAAATTTAAAAAGTAAACAAGCTATTTTAAACAAGC ATTTAAACAAATAGTATTAATAATATAAAAATATATCGATATGTGTTGCAAAT GTTCGTTCCCTTAGTATTCTCTCATATTTATTTCAAATAAACTGTATAAAATAT CTGAAAAAGCGAACATATTTATTTAATTTTCATCGCAGATATCGATATCACAGC 20 GCTGCTATCGATGGTGTGTCTGTCTGCAGTGCCTATCGCTTACCCTGCCATCGCT AACAAAAA

Genomic hit, Accession No. CSC:AC020120

25	Associated ORF Genscan: ORF2 predicted sequences >22:06:07 GENSCAN_predicted_peptide_7 464_aa MPSEQHTNIKVA VRVPYNVRELEQKQRSIIKVMDRSALLFDPDEEDDEFFQGA KQPYRDITKRMNKKLTMEFDRVFDIDNSNQDLFEECTAPLVDAVLNGYNCSVFV YGATGAGKTFTMLGSEAHPLTYLTMQDLFDKIQAQSDVRKFDVGVSYLEVYNE 30 HVMNLLTKSGPLKLREDNNGVVVSGLCLTPIYSAEELLRMLMLGNSHRTQHPTD ANAESSRSHAFQVHIRITERKTDTRTKVTKLSMIDLAGSERAASKGIGVRFKEGAS INKSLALGNCINKLADGLKHIPYRDSNLTRILKDSLGGNCRTLMVANVSMSSLTY EDTYNTLKYASRAKKIRTTLKQNVLKSMPTEFYVKKIDEVVAENERLKERNKA LEAKATQLERAGNSGFDPLELKTWYSKIDAVYAAARQLQEHVLGMRSKIKNINY 35 RQTLKKELEEFRKLMCVDQRVCQESF
----	--

>22:06:07|GENSCAN_predicted_CDS_7|1395_bp

40	atgccttcggaacagcatcacgaatataaaagtggcggctcgctacggccgtataatgtccgtgaattggagcaaaacagcgga gtattatcaaggtcatgatcggtcgccactgctgttcgatcccgacgaggaggacgatgagttcttcttcaggcgccaagcaac cgtaccgcgacatcaccaagcggatgaacaaaagtggaccatggaattcgacagggtattcgatatagacaattccaaccagga tctgttcgaggagtgacgcggcggcgtggtgcacgcgggtgtaaatggatacaactgctcgggtattgtataggagccactggcg ccggaaaaacattcacatgctgggcagcgagggtcatccgggtctgacctatctaccatgaagatctcttcgataagatccaa gcgcagagcgacgtgcgaagttcgatgtgggggtatcctatctagaggtgtacaacgaacatgtgatgaatctgtaactaaatc gggccctttaaacttcgcgaggacaacaatggcgtggtggtcagtggtcttctgtcacgccatctacagtcggcggagctgc 45 taagaatgctgatgctgggcaactctcatgcactcagacccccacagatgccaatgcagagagttccaggtcacatgccatcttc caggtgcacattagatcacggagcgcaagaccgacacaaaaaacgggtcaactatccatgatcgtgctggcggcagtgga gagggcgccagtcagaaaggcattggagtgcgattcaaggaaggcgccagcatcaacaaaagtctcttagcttgggaaattg
----	--

149

5 cataaacaagctagccgacggcttaaagcacatcccgtaccgagctcgaacctgacacgcacatcctgaaggactcgttgggcgg
aaattgtgcacattgatggggccaatgtctcgatgagctcactgacctatgaagatacctacaacacccttaagtacgctagccg
agctaagaagatacgcacgactctgaaacagaatgtcctcaagtccaagatgccaaccgagttctatgtgaagaagatcgacgag
gtggtagccgagaacgagcgactcaaagagcgcaacaaggcgctggaggccaaggccactcagttggagcgcgccggcaat
10 agtggattcgatccgctggagcttaagacgtggtacagcaagatagacgctgtatatgcggccgccgagcttcaggagcac
gtccttggtatgcgtagcaagatcaagaacatcaactaccggcagacactgaaaaagaactggaggagttcaggaagctgatgt
gtgtcgaccagcgagtggtgccaggagagtttttaa

Drosophila Gene Hit TBLASTN with ORF2: kinesin like protein 67a (U89264)
10 **Human Homologue** TBLASTN with ORF2: kinesin family member protein KIF3A
(AF041853)
Drosophila EST GH22018 (AJ402731)

Annotated Drosophila genome genomic segment AE003552
15 **Annotated Drosophila genome Complete gene candidate** CG10923 Klp67a -
motor protein

Human homologue of Complete gene candidate 2e-58 4758646 kinesin family
20 protein 3B
>gi|3913958|sp|O15066|KF3B
_HUMAN KINESIN-LIKE
PROTEIN KIF3B and also
predicted peptide
ENSP00000166696
25 Gene:ENSG00000073652
Clone:AC015936
Contig:AC015936.00023
6.70E-91 (predicted kinesin?:
ENST00000166696)

30

Putative function motor protein involved in cytoskeleton organization and
biogenesis

35

Confirmation by RNAi Almost no G1 and broadened G2/M indicating arrest in
G2/M

Example 45 (Category 4)

	Line ID	442/3
	Category	Meiotic defects in testis: segregation defects.
5	Reversion	?
	Map Position	70D4-7
	Rescue ID	H7E
	Rescue Sequence	
10	CGCAAGACTGTCTTCGATAGCAGAAGCGTTATTTTCGGAACATATCGTTTATCG	
	AAACTACAGTTGCTCAATACTGAACTGTCCAGCTTCGAGTAGCTGTGGCTCAA	
	ACCATTTGTTGTCATCGATAAGCAATTGCAATTTTATTTGTTTGCTTAAAAAATT	
	AAAATATAAACTACGAGGATCAAATATACATACATATTTCCCAATATGTTAGCG	
	AAAAAACATTTCTGCTCAAAAAAAGATGTTTAAATACAATGTAAGCTGTTCTA	
15	TGCATTGAACAAATTAACACATTGAGAGGTCGCTCTTATAAGTGCACATTTCA	
	ATTTAAATATATTTTAATATATTCAAATATAGTATAGCAGTATAGCATTCAAAT	
	GTAAGTGTGGTTGGACTATCGCTGTAGTCCAAGAACTGCAGATAGTGTCATC	
	GCTAGCTTTGAAGCATCTCAAAGGAAAAAGGGCGATAATTCTGATTA	
20	Genomic hit, Accession No. CSC:AC017664	
	<i>Drosophila</i> EST	CK02287 (AA141680)
	Annotated <i>Drosophila</i> genome genomic segment	AE003536
25	Annotated <i>Drosophila</i> genome Complete gene candidate CG6650 - novel transacylase like	
	Human homologue of Complete gene candidate	none
30	Putative function	Transacylase
	Confirmation by RNAi	Marked increase in G1 indicating arrest in G1
35		

	Line ID	473/22
	Category	Meiotic defects in testis: no division (no meiosis)
	Reversion	R
5	Map Position	70A1-5
	Rescue ID	2B7E
	Rescue Sequence 1	
	CGCAAGACTGTCCTTCGATAGCAGAAGGCGTTATTTTCGGAACATATCGTTTTAT 10 CGAAACTACAGTTGCTCAATACTGAACTGTCCAGCTTCGAGTAGCTGTGGCTC AAACCATTGTTGTCATCGATAAGCAATTGCAATTTTATTTGTTTGCTTAAAAAA TTAAAATATAAACTACGAGGATCAAATATACATACATATCCCAATATGTTAG CGAAAAAACATTTCTGCTCAAAAAAAGATGTTTAAATACAATGTAAGCTGTTT TATGCATTGAACAAATTAACACATTGAGAGGTCGCTCTTATAAGTGCACATTT 15 CAATTTAAATATATTTTAATATATTCAAATATAGTATAGCAGTATAGCATTCAA ATGTAAGTGTGGTTGGACTATCGCTGTAGTCCAAGAACTGCAGATAGTGTCA TCGCTAGCTTTGAAGCATCTCAAAGGAAAAAGGGCGATAATTCTGATAAGAA AGTTGGCGTAGCCGGAAGGCGGATTGTACATACAAAATAGTTTGGAAAGCC CAAACGTAG	
20	Genomic hit, Accession No. CSC:AC017664 Drosophila EST LD47104 (AI515336), SD03663 (AI532240)	
	For other results see line 442/3	
25		
	Line ID	670/6
	Category	Meiotic defects in testis: segregation defects, abnormal spindles (Ab-12/48)
30	Reversion	?
	Map Position	70C
	Rescue ID	H7E
	Rescue Sequence	
35	CGCAAGACTGTCCTTCGATAGCAGAAGGCGTTATTTTCGGAACATATCGTTTATCG AAACTACAGTTGCTCAATACTGAACTGTCCAGCTTCGAGTAGCTGTGGCTCAA ACCATTTGTTGTCATCGATAAGCAATTGCAATTTTATTTGTTTGCTTAAAAAAT AAAATATAAACTACGAGGATCAAATATACATACATATCCCAATATGTTAGCG AAAAAACATTTCTGCTCAAAAAAAGATGTTTAAATACAATGTAAGCTGTTCTA 40 TGCATTGAACAAATTAACACATTGAGAGGTCGCTCTTATAAGTGCACATTTCA ATTTAAATATATTTTAATATATTCAAATATAGTATAGCAGTATAGCATTCAAAT GTAAGTGTGGTTGGACTATCGCTGTAGTCCAAGAACTGCAGATAGTGTATC GCTAGCTTTGAAGCATCTCAAAGGAAAAAGGGCGATAATTCTGATTA	
45	Genomic hit, Accession No. CSC:AC017664 Drosophila EST CK02287 (AA141680)	
	For other results see line 442/3	

Example 46 (Category 4)

5	Line ID Category	460/20 Meiotic defects in testis: segregation defects, multipolar spindles (mitotic: High polyploids, no diploids, higher mitotic index Meiotic: Mul-02/59)
	Reversion Map Position	NR 78A1-4
10	Rescue ID	2B8E
15	Rescue Sequence	AGCTGGTCCAATTGGAACGTTAGCTGCTCCAATGGGAGCAGCTGGCGCTCTC TCTTCGATCGCGCTCGCTCTCATCTCTCTTTAGCTTGTGCCACAGTAGCTG CCGAAGGCAATTTTCATGTGCTCGTGTGTCGACCCCCACTCAGCCCACTTCTG ATCGGAATCGGGGATTTCGGAATCGTGTAAAGGCAGCCTTTGAAGGTCCCTTTTC CAGGTGGCGGCCGTATCCTTAAAGTAAACATAGTTCAACTGACTTGGCAGCGC TCCAAATGCGGTGACTTCTTGGCTATGTCATATATACCCCCACTCCCCTCCTGA CTACCCTGCCACGCCCCACCGCCCCACCGTCGGCGACGACAATTCCATTAAAAAG TTGTACGTTGTCACTTTGCGTTAACTTATCTGTGGAGCATGTTGTGCGATCGCA TTTTTATTGTGCGCCATTGTCTCTCGCTCTCTCCATCGCTCTTTCGCTGGCTTCC CTACCCTGCCACACAGGGAAGCCTACACACTCTTAAATCATGCACTTGGAAAC AAAAAGTGCAAGCATTAACCTTTATTTAAACATTCAAGAGCCGCTTCTCTATT TACCATTGAAAATTTAATTTAAAATAGAAGAGGCCTTTTCAGAATAATATAAT ACCTTTAAG
25	Genomic hit, Accession No.	CSC:AC020460
30	Annotated <i>Drosophila</i> genome genomic segment Annotated <i>Drosophila</i> genome Complete gene candidate	AE003592 CG10588 - novel gene with homology to proteases
35	Human homologue of Complete gene candidate	2e-74 4505453 ref NP_002516.1 pNRD1 nardilysin (N-arginine dibasic convertase) >gi 2462488 emb CAA6369
40	Putative function	Novel protease
	Confirmation by RNAi	Marked increase in G1 indicating arrest in G1

Example 47 (Category 4)

Line ID 477/16
Category Meiotic defects in testis: segregation defect.
5 **Reversion** NR?
Map Position 90C5-10

Rescue ID C3E
Rescue Sequence 1
10 CTGTGGACGGTCGTCAATGCGTGAATATTCTTCTATGTGTAAGTGGTGTGCGT
GTATGTAGATTTCTGGTTAAGAAAAGCCCCAAAAACCAAAGCGCCCCGCAAA
ATATATATTGAGTCTTCTTGGCCCAACAACAAATCTGCCGCCGGACTTTCGCC
GGAGGGCGAGTGAAAAATTCAGTTTCTCTCTCTCGACGATGCACTTTGGAGG
CTGTGTGAGTGTGTGTGCGAGTGAGTGCCTGTGTGTATACATATGCAAATGAT
15 TGGATGTGCAATCCTTGCATCATCATCTTCATAAACACTTGCGCAAAAAC
CGCAGGAAAACGCAAGCAGCCGAACAAAAAAGAGAGCCTCTCAAGACAAC
GGCAGCGGCCAAAAGTGAACGCGCAACAAACGCGGCCAAGCAGGCGCGGCA
ATTATTTATAAATCTTAAGCCGTTAGCCCCCTCTCTCTCCCACTCACGAAAAG
AAAATAAGTTAAACCAATTGGTGAAGATGATGCCCC

20 **Rescue ID** C3P
Rescue Sequence 2
GTCCACAGACTGGCTATATATACTAAAAACGAACTCGCGTGAGAAGACAGGG
ACAGGGCAGCAAACTCGGTATACGAACGGAACGAAATGAAACGATTCAAGTA
25 GTAGTGTATGCAAGTCTTGTCTGTCTGCGCCTGGCGTTCTTTTCTTCTTTTT
TCGATGGTTTTTCGCCAGGCTGGGCGCTGCCAAAACGCTGATACGGCGGCCAC
AATCACACGCGGCTAATCGCCAGTTGGGCCCTGCACAGGCTGCACATACTTT
CACTATTAATGCGCTGTATTTCACTTATTTTTCGAACAAATTCGCAGCATGACG
AAGAAGCGAGCCTGTACAAGATTAGAGCGGGTAGCACGCACGATAGTATCGA
30 TACGTACGAGTATTTGGCACTGCGATACATTATCGGTGCTCGTTTCGATAGCCC
CCGATAGCTCTAGCACGAAATTTTATCGCTTATCCATATTTTATACTATTTTT
ATTTATTGGACTTCAATGAATATTTAATTTACGTCTGGGTGCGTTTTTAAATAT
ATATGGTAATCAATAGCTGGCGAATTAGCGATATTTGAGTGTGACGCAAAAAT
GAGTTGCATCGATATCGATTTCTCGCTACTCTGGGACGCCATCTTTATTGCGG

35 **Genomic hit, Accession No.** AC007810

Associated ORF
Genscan ORF1 predicted sequences >17:48:58|GENSCAN_predicted_peptide_2|349_aa
40 MSRILFILLLLIVTQLSELQAAAFSVRQNRFDVDPDLQTPAPLATSTESSKKPEKAT
SGLLKKCLPCSDGIRCVPQIQCPAHVRMESHEKPQICDLPAGKFGYCCETGQNHT
APKPETSPKERRSGFPTILSPAVLDEARNFEHLMHGVAQIPVRRGFDPFAHGLVF
HSTAKDDLHNFAISNSAIEQVMTTQLFGKKEQVPVEDFITNNVPIKFTETPLAHC
QPPPVCNIRSVMYRSMGTCNNPEPQRSWLGAAGQPMERMLPPAYEDVPSASPA
45 AICSYYIGLASRLAPVSVVNCCTFAWQLDWTTGMASGECVCVECMPAEWRLGQC
PLLHEASSEMRSLLAKS

>17:48:58|GENSCAN_predicted_CDS_2|1050_bp
 atgagtcgcattttattttgttgctacttattgtgacgcaactgagcgcgagttgcaggcggcagcattttctgtgcgcaaaatcgtt
 ttgatgaagttcctgatttgcagactcctgcacctctggccacttcactgaatcttctaagaaacccgaaaaagctaccagtggtct
 5 gctgaaaaaatgccttccctgcagcgcgatggataagatgcgtgccccaaatccagtgcccggccacgttcgcatggaaagccat
 gaaaagcccccatttgcgatctcccggctggaaaattcggctactgtcgcgagactggacagaatcacactgctcccaagccg
 gagacctctcccaaggagcgtcgatccggatttccaccattctgtcaccgcagtttggatgagggcgcgtcgcaatttcgagca
 ctgatgcagtgagttgcgcagattccgtgcgcggtggcttccagatttggccatggcctggtttccactcgacggccaaggat
 gaccttcacaacttcgcatatcgaacagtggcattgaacaagtgtgaccaccagttgttgggaagaaggagcaggtgcccg
 10 tagaagatttcacccaacaatgtgccatcaagttcactgagactccgctggcacaccattgccaaccgccccagtttgcggc
 aatattcggctgtttatcgagcatggacggcacttgcaataatccagaaccacagagatctctgtggggtgctgctgtgcaaccg
 atggagcgcagtgctccccccgctatgaagatgttccgtcagcttctcctgctgctatatgtagtatatctatggcatcgcatctcg
 tctggcgcctgtttctgtgtcaattgttgacatttgcattggcaattggattggaccactggaatggcgagcggggagtggtgtgtgt
 gtggaatgtatccggcggagtggcgttgggccaatgcccggttctcatgagggcgtcgagtgaaatgagccgctcttggtcta
 15 aaagctag

Drosophila Gene Hit rescue sequence: eyelid/osa (AF053091)

Human Homologue BLASTX with eyelid: KIAA1235 protein (AB033061) Brain
 protein 120 (AB001895)

20 **Drosophila EST** several including LD04852 (AA201670), LD24466

Annotated Drosophila genome genomic segment AE003718

Annotated Drosophila genome Complete gene candidate CG7467 - osa DNA binding
 putatively involved in DNA
 25 packaging

Human homologue of Complete gene candidate CG7467 - 7e-25 2588991
 dbj|BAA23269| (AB001895)
 B120 [Homo sapiens] and
 30 O14497 SWI/SNF-
 RELATED, MATRIX-
 ASSOCIATED, ACTIN-
 DEPENDENT REGULATOR
 OF
 35 CHROMATIN SUBFAMILY
 F MEMBER 1 3e-67

40 **Putative function** transcriptional regulator

Confirmation by RNAi Only wild type profiles observed

Example 48 (Category 4)

- Line ID** 496/4
Category Meiotic defects in testis: segregation defects, abnormal spindles
 5 **Reversion** NR
Map Position 65E4-7
- Rescue ID** 2C1E
 10 **Rescue Sequence**
 GCACGATCGCTCTCTCTTGGCTCTCTCTATCACTCTCTGGACTCTCTCTCAGCA
 CCTTTGCTACCGTTTCGCAGAACAGGTGTATCGGTTTTCAAGGCAACTGTGATT
 TTTTAACCAACATTCTATATCGAAAACCTTGTAGAGGTCGGAATTTTTCTTGAG
 CGCCTAAAAGTGTGCAGTGAAATCATTTAATCCACTTCCGGTTGCAAAACAGG
 15 AATCACACATATGAAGTGATTAAAAATCATAGAAGGTTTGACACCTTCAAATA
 ATAAGAAAACAAAAATTTGTAACTGTGATAATTTATTTAATTGAAATCTTAA
 TTTAATGGCCTACAAATCTGTTGAATATCCGTTGAATACACTTTTCCAGGGTGT
 GTCCTAGTCGGCTCCTCTTTGTTACCCAGTTTGCTGGTCTTCTTAGCCGCACA
 CCAGTTTATCGCTGTTTTGCCTTTGCGCTTTTCATTATATAACAAAAACAATG
 20 TTATTGTTATTGCGGTGGCTGTAGATGTAAATGTAAATGTAGATGTAGAGGCT
 GCTTCTTGGG
- Genomic hit, Accession No.** CSC:AC018039
- 25 **Associated ORF**
 Genscan ORF1 predicted sequences >19:35:36|GENSCAN_predicted_peptide_6|190_aa
 MVSEQFNAAAEKVSLTKRPSDDEFLLQLYALFKQASVGDNDTAKPGLLDLKGKA
 KWEAWNKKQKGSSEAAQQEYITFVEGLVAKYDNGMHKQEPNTCQARNATFR
 KSSECSLDQNTYTSSVTVIPAFHEGPKNSTASWPRIYRCYQRNQQAANCKWANTN
 30 SVCCKPHGKQSRRIIFAEFLAGHTVQILG
- >19:35:36|GENSCAN_predicted_CDS_6|573_bp
 atggtttccgagcaattcaacgccgccgagaagggtgaagagcctgaccaagcgtcccagtgatgacgagttcctgcagctg
 tacgccctgttcaagcaggccagcgttggtgacaacgacaccgccaagcgggtctcctggacctgaagggaaggccaagtg
 35 ggaggcctggaacaagcagaagggaagagcagcaggccgccagcaggagtacatcacctttgtggaggcctgtggc
 caagtatgacaatggaatgcacaacaagaacaaacacttgccaagcacgcaatgcgactcggtttcgaaaagctcggaatg
 ctgctggatcagaatactatcggtcagtgtagcgggtatactgcatccacgaagggtccaaagaactcgacggcaagttggc
 caagaatttaccggtgctatcagcggaaccaacaagcggccaactgcaagtgggcaaacacaaatagcgttcgagggaaccc
 cagggaaaacagagccgccgaatctttcgagaattttcgccggccatacgggtgcagattcttggttaa
 40
- Drosophila Gene Hit** rescue sequence: melt (S144114) P element insertion site
 (AF174669), TBLASTN with ORF1: diazepam binding inhibitor
 (DBI) (U04823) and melted (AF205831)
- 45 **Annotated Drosophila genome genomic segment** AE003560
Annotated Drosophila genome Complete gene candidate CG8624 melt - putative signal

156

		transduction protein
		CG8631 msl-3 - acyl-CoA-
		binding
		protein/diazepam binding
5	Human homologue of Complete gene candidate	inhibitor
		CG8624- predicted gene
		ENSP00000065899
		Gene:ENSG00000055889
		Clone:AC015904
10		Contig:AC015904.00014
		1.70E-15 (unknown predicted
		gene 1: ENST00000065899
		and AK022666 Homo sapiens
		cDNA FLJ12604 fis 2e-29
15		
		CG8631- gi5803104
		0C85AE40FDF874CD
		[ref]NP_006791.1 male-
20		specific lethal-3 (Drosophila)-
		like 1 [Homo sapiens] (1.70E-
		36) and Ensembl predicted
		peptide ENSP0000006617
		Gene:ENSG0000005302
		Clone:AC004554
25		Contig:AC004554.00001
		8.70E-19 (unknown predicted
		gene 1: ENST0000006617
30	Putative function	
		CG8624: putative signal transduction protein
		CG8631:acyl-CoA-binding protein/diazepam binding
		inhibitor
35	Confirmation by RNAi	
		CG8624: reduced G1 and G2/M Indicating fewer cycling
		cells, CG8631: Increased G1 to G2/M ratio indicating arrest
		in G1

Example 49 (Category 4)

	Line ID	523/19
5	Category	Female sterile. Meiotic defects in testis: cytokinesis defects, segregation defects (Mitotic: Less condensed chromosomes, nuclear bridges, Meiotic: Seg-01/02
	Reversion	R
	Map Position	75C1-4
10	Rescue ID	2B4E
	Rescue Sequence	
	ACTGAGAGCATATTTGTGCACCAGAGGGCTGCATAACAACATTCTCTTTGTCC	
	ATTCGTTATACTTCGTATTCAGAATACATGTCATTTCAGTTGGTCCCGTTCTTTT	
	GCGTTCACCTTCGTATATATTCGGCGATCGAAATGAACTAACTGAATGTGTTCA	
15	AAGAATGAATGAAGCCAATGAATTTTCAATAGTAATTCAGAGTGCTTAAAATT	
	CTTCATGTTGTCATTGAGTAAAATGAGTTCGGACAGCGCGAAGGTAAGTCGAA	
	GTTTGTGTTTTATTATGTTTTATTTGTATTATTATGTACACTAGTCGGCATACTTT	
	TGCGTGCGTCTTATACGTGTGCGTCTTATTTAACAATATTGTAAAATAAAATAT	
	ATAAATTATTTGTTATATGCGTAGGGGCCTTTATTTTGTGTATTGATAGTCTTTT	
20	GTCATAGATATCATTATTCTGACAAGATTTGAACTTTTCAAGTTATTGCCTCTC	
	GTTATTCAATTCCTAGCTGGTCTTACGTTACGCGATATTTCTTAAATATCCTA	
	AAATCGCACAAAACAGTCACGCCCACACTTTTGAAAAACGTGGTAATATTTTT	
	CATACTTGCAATTAAGTCTGG	
25	Genomic hit, Accession No. AC007691	
	Annotated <i>Drosophila</i> genome genomic segment	AE003520
	Annotated <i>Drosophila</i> genome Complete gene candidate	CG4306 – novel
30	Human homologue of Complete gene candidate	4e-25 3242764 (AC005154) similar to protein U28928 (PID:g861306) [Homo sapiens]
35	Putative function	No homologies to indicate function
	Confirmation by RNAi	Only wild type profile observed

Example 50 (Category 4)

	Line ID	666/19
5	Category	Mitotic defects in brain: anaphase defects (weak, overcondensation, aneuploidy, lagging chromosomes, metaphase with bipolar spindle)
	Reversion	NR
	Map Position	64E1-5
10	Rescue ID	I9E
	Rescue Sequence	CCCTCGTCTACGTCGAAATTCTGGATGCTTCTCGGATTTAGGGTTGTATCTCGA AAACGTTTGACTGCGAATGTCAATATCGATATGCTAACCGATAGCTGTCGATG TTTTAAACACAGTGCAGTGTGTTTAAATCGCTCCCCATTTATATATATTTGTGC 15 NTGCTTTTGGCGGTNNTTTTCTTTATATGCTTCTTATGCTTTTACGATTATTATT AGCGCTTATTTGATTGCAAATGCCAAGGAAAGCGTGACTGTGATGGCGAAATG CGGAAAGTACTCCTTAAATCTCATATATCGCATAAACTATCGGTTCTGGAAT GTTTCGTGTAAGTCTGCGAAGATAGAGATCGATCTATTTTGAGGATACATTTG TTAATATTATAAGGGATTCTTCTACAGGGGTCAGATTGCTTAAAAACACACAG 20 AANAATAAACAAAATATTTCTTTGAAATATTGAAATATTTGAAATANAAAAAA CGTATTGACGAGGTAAGCATATTGAAAAAGATAGGAAGGTGATGGAGAAAGT GCATTATATTGGTCAACAAAGAGCTTATAATCAAAAGATCAATAGATATAAA TATCTTTATATGATATAAAATATAATACATATAATATAATATCATATACAATG GATAAATTGCAAGTGGCAAAATGAATTCGCGGAATTAATTCTGAANCGAAA 25 GGCCT

Genomic hit, Accession No. CSC:AC014815

Associated ORF

30	Genscan ORF1 predicted sequences >17:46:43 GENSCAN_predicted_peptide_1 334_aa MGKDFYKILGLERKASDDEIKKAYRKLALKYHPDKNKSPQAEERFKEIAEAYEVL SDKKKRDIIFDNYGEDGLKGGQPGPDGGGQPGAYTYQFHGDPRAFQAQFFGSSDP FGAFFTGGDNMFSGGQGGNTNEIFWNIGGDDMF AFNAQAPSRKRQQDPPIEHDLF VSLEEVDKGCICKMKISRMATGSNGPYKEEKVLRITVKPGWKAGTKITFPQEGDS 35 APNKT PADIVFIIRDKPHSLFKREGIDLKYTAQISLKQALCGALVSVPTLQGSRIQV NPNHEIHKPTTTRRINGLGLPVPKEPSRRGDLIVSFDIKFPDTLAPSLQNQLSELLPN
----	---

>17:46:43|GENSCAN_predicted_CDS_1|1005_bp

40	atgggcaaagacttctacaagattctgggctcgagcgcaaggccagcgacgatgagatcaagaaggcctaccgcaaactggc actcaataaccatcccagacaagaacaagagcccacaggcggaggagcgcttcaaggagatcgccgaggcggtacgaggtgctg tcggacaaaagaagcgcgacatcttcgacaattacggtaggagtgattgaaggcgaggacagccgggaccagatggcgggc gtcagccgggagcggtacattaccagttccacggcgatccgaggcgccacattgccagttcttggatcgctggatccgtttggc gcgttcttaccggcgcgataacatgttttagtgcggtcaggcgggcaataccaacgagatcttctggaacattggcgggcgacg atatgtttgctttaatgccaggcaccagtcgcaagcgccagcaggatccgccatcgagcatgatctgtctgtcgctggag 45 gaagtggacaaggatgcatcaagaagatgaaatctcacgcatggccaccggaagcaatggccgtacaaggaggagaag gtgctgaggatcacagtgaagccgggtggaaggccggtaccaagattaccttccccaagagggtgattcggcgccaacaa
----	--

159

gacgccagctgacatcgtcttcattcgcgacaaaccgcattcgtgttcaaacgcgaggggaatcgatctaaagtatacagccc
 agatcagctctgaagcaggccttgtgcggagcactggtagtgcccacgctgcagggcagcaggatacaggtgaatccgaacc
 acgagatcatcaagcccaccacaacgcgccggatcaacggactgggtctgccggtgcccaaggagccatcgaggcgcggcg
 atctgacgtctccttcgacattaagttcccgcacactggcaccagctctgcagaatcagctgtccgagctgtgcccaactag

5

Drosophila Gene Hit rescue sequence: fasciclin I (FasI) (M32311) TBLASTN with
 ORF1: DnaJ homolog (DROJ1) (U34904)

Human Homologue TBLASTN with ORF1: DnaJ-like heat shock protein 40 (HLJ1)
 (U40992.2)

10

Annotated Drosophila genome genomic segment AE003565

Annotated Drosophila genome Complete gene candidate CG10578 - DnaJ-1 a
 chaperone putatively involved
 in protein folding. Stimulates
 activity of HSP70

15

Human homologue of Complete gene candidate 8e-94 1706473 P25685
 DNJ1_HUMAN DNAJ
 PROTEIN HOMOLOG 1
 (HDJ-1) (HEAT SHOCK
 PROTEIN 40) (HSP40)

20

Putative function Chaperone involved in protein folding

25

Confirmation by RNAi Almost no G1 peak, increased G2/M indicating G2/M arrest

Example 51 (Category 4)

Line ID 714/11
Category Meiotic defects in testis: cytokinesis defects, abnormal spindles
 5 (Ab-01/04)
Reversion ?
Map Position 66A10-15

Rescue ID 2A4E
 10 **Rescue Sequence**
 AACCAGAACGAACTCCAATGCAGTTTCATTTTGTCTAGTTTAATCATTAAACA
 AAGAACTGCGCAACCGATCGCAACTAGCTCGTGGACTCTTGTTCTCCCAATAA
 TTGGTATGTTTTCCATTTTTCGTTAACATGGAAAATGTGTGAAAAGCTTTTTCC
 CCTCCAAAAGAAGCGTACTGAACTAAGCTTTCGGTGGTAGTAATAGTAGTC
 15 GTTATATCTTATTTTCTTATTTACGTGCAGCTGCAATCATTGGCTGCGTCACTT
 TGGCGTCAGCTATAAACTGGTGGATCAACTCGGCGGCCTCCAAAAGCTGCGCA
 TCTGCTCCAGACACTTTAGCCAACGCCAGGAGATGGCCAAAACCCGCATCAA
 GATGACGCCGCTGCGCAAGTCCTCGTCTCCAAGGGCATTGTGCTACCCATTA
 ATGCCGCTGGAGGGTCGGTCATTGCAGGCGCCTTAGCACGAGGAGGAGGTGC
 20 A

Genomic hit, Accession No. AC012390

Associated ORF

25 Genscan ORF1 predicted sequences >19:47:45|GENSCAN_predicted_peptide_2/711_aa
 MRSHQAVGNLLLADEALPAVQSASVYVWMAEQPLSPGQSYDIKIADSPSVSS
 KSITDNGADVQWFAFEHSQYYQGVQMFLSALERIDSEFLITLIKRCYPYHVDLSLVQ
 LSEVCKMTEDFSLASELLERALLLLESSLHINFSLTSGNCRDLYRRQENRSFYIVLF
 KHAQYLEERACSRTAFEISKLLLSLPDTPDLAMILPNQPDQCTGNMTQLQQAGK
 30 IRKRSEKQFPIGTEPRGTDALRFTLQTLASAGRDITWNIKRLQGSRTVGAAGQYLI
 DKKTAVQYKITIAHLKDPNIDQLFDSSGDGKADLHGSTPDWGCQAMMADAISR
 YKEGNPVFYITWTPYVWSNELKPGKDVVWLQVPFSALPGDKNADTKLPNAGGI
 EGLIADEEVQVLDALCDAPCVGVSHSCRLLDGNRRGNNELRLFIPGKSQFGVADG
 CADKQSVMEYHAAKTGHTKFSESEEEKKALTEEEKKAQLALIEEKLKQKRIREE
 35 REKIEALQREKNRIKSGKDMTEAKRRMEELEMKKIVEQRKREKDEEKAARDRVK
 AQIEADKAARKAREQKELGNAEPAPSVSSTTVSSPPAGVKSPPRDYTETRIQGASA
 ILAAAAPYYQPPAVPQDVQPDRPIGYGAFGVVCGSHISGWHCSAGHYEDGNENFE
 CLKTFSTSDRIGCEWRWAAATVLAATCISPNGRCGHYKRVRRRIKTNITTT

 40 >19:47:45|GENSCAN_predicted_CDS_2/2136_bp
 atgagatcgcatcaagccgttgcaatctgctgctggcggcagacgaagcgttacggcggtgcagagcgcgtcggtgatgtg
 gtatggatggcggaacagccgtttctccagggcagagtacgacatcaaaattgccgactctccatcggtgctctccaagtctatc
 acagataatggagcggacgttcaatggttgctttgagcatagccaatactaccaggagtgacgacaaatgttcttctgctctcg
 agcgcattgactcggaatttctgatcacattatcaaacgctgcccctatcatgctgactccttggttcaactcagcgaagtatgcaa
 45 gatgaccgaagacttttcttggtcctcgaactgcttgagcgcgcccttctcttctggaatcgtcgtgcacatcaactcagtttga
 cgtcgggcaactgccgactggactaccggagacaggaaaccgatccttctacatcgtgctgttcaagcacgcgcagtacctgg

aggaacgagcttgagccgcaccgccttcgagatctcaaactgctcctgagcttcagccagacacagatccttggccatgatt
 ctaccaaatacggcgatcaatgtaccggcaatatgacgcagctgcagcaggcgggcaaatccgtaagcgctcagaaaaagca
 gttccgactgggtactgaaccgcgggtactgacggttgcttcacccctgcagacactggcgctgctgggtcgcgacatcacct
 ggaatafaaagcgtctgcaagggtccggtgtaccggcgccggccaggggttacctcatcgataagaaaaccgcgctccagtacaa
 5 aatcaccatcatcgctcatctgaaagatccgaatatcgaccaactgttcgattcaagcggcgacggaaaagcggtattacacggta
 gtaccccgactggggctgccaagctatgatggcgacgccatcagtcgtacaaagagggaacccgggtgtttattacacctg
 gacccgactgggtgagtaacgaactgaagccgggcaaatgctgctgtggtgcaggtgccgttccgactgcccggcgga
 taaaaacgccgataccaaactgccgaatgccggtggcatgaaggcctcatcgccgatgaagaagtcaggctcctcatgacct
 10 ttgtgatgcggcgtgtgtgtgtgtctccactgctggactccttgatggcaatcgccgagggaataatgaactgcggtctttatt
 cccggcaaatccagtttgagtagctgatggatgtgcagacaagcagagtggtatggagtaccatcgcccaaacccggtcac
 accaaattctccgaatcgaggaggaaaagaaggcgctcaccgaggaggagaagaaggccagctggccctcatcgaggag
 aagctcaagcagaaacgcacgaacgcgaggagcgcgagaaaatcgaagccctgcagcgggaaaagaatcgcatcaagtcc
 ggcaaggacatgaccgaggccaagcgcgcatggaggagtggtgagatgaagaagatcgttgagcagcgcaagcgcgaaaa
 ggacgaggagaaggcggccgcgcatgggtaaaggctcaattgaggcgacaaggcagcacgcaaggctagagaacaaa
 15 aggaattgggcaacgcagagccagctccatccgtgagctccaccacagtttcgtcaccaccggcggtgtgaaatctccggcg
 gagactacaccgaaacccgcatccaggcgccagcgcaatcttgccgcagcggtccctactatcaaccgcccgtgttccc
 caggatgttcagccgcatgctcctatcggtatggagcattcgagttgtctcggttccacatcagcggtgcatgttctgcg
 gggcattatgaagatgtaataaaaatttcgagtgccctcaagacatttcgacttctgaccgattggctgcgaatggagatggcg
 20 gcagcaactgttcttccgcaacctgcattagcccgaacggcgttgcgggcattataaacgcgtacgtcgtgcattaaaacaaa
 cataacaactacgtga

Drosophila Gene Hit rescue sequence and BLASTX with EST: BIP1 (Y14998),
 BLASTX with genomic sequence matches BIP.
Human Homologue BLASTX with BIP1: alanine:glyoxylate aminotransferase
 25 (X53414) ?
Drosophila EST GM04749 (AA695904), GM13608 (AA803601)

Annotated Drosophila genome genomic segment AE003556
 30 **Annotated Drosophila genome Complete gene candidate** CG7574 - bip1 unknown
 function

CG13681 – unknown

Human homologue of Complete gene candidate none
 35

Putative function no homologies to indicate functions, Drosophila Bip1 interacts with
 transcriptional activator Bric-a-brac which is required for ovariole
 formation

40 **Confirmation by RNAi** Both show reduction in G1 and G2/M indicating fewer
 cycling cells

Example 52 (Category 4)

	Line ID	763/4
	Category	Meiotic defects in testis: segregation defects (overcondensation, fewer anaphases)
5	Reversion	R
	Map Position	90F
	Rescue ID	2F5E-1
10	Rescue Sequence	CGGCAATGTCTGCGCCCCCAATCTGAAC TTGCCTCGCCCTCTCCGCCCCCTGATC TCATCTCCTCTTCAAACCCCTGCTCCCCTTTTCTGCACACATTAACGTCAGCCT TTAAGTGTGCTTTTCTCAGGTGCTGCCCCCTGCGCCACCATCCCCCGCTCCATG CTCTTTCCATCTTGCCTCTCTGCGTTCTATCTACATTTTTTTTCGAGGTCGCGCG CTGCTTTTTCCGTTGATGTTCTGTTCTCGTCAATGTCGCAATATGCGCAAAAGGC AGACAAAAAAAATGAGTGGAAAAAGTACATACATACCGGTGATTGATGGG CGGTGGGTGGCGGTGGTGTAGGNGTGGTTTG
	Genomic hit, Accession No.	AC006495
20	Associated ORF	Genscan ORF1 predicted sequences >22:47:02 GENSCAN_predicted_peptide_3 283_aa MTERENNVYKAKLAEQAERYDEMVEAMKKVASMDVELTVEERNLLSVAYKNVI GARRASWRIITSIEQKEENKGAEKLEMIKTYRGQVEKELRDICSDILNVLEKHLIP CATSGESKVFYKMKGDYHRYLAEFATGSDRKDAEENSLIAYKAASDIAMNDLP PTHPIRLGLALNFSVFYIEILNSPDRACRLAKAAFDDAIAELDTLSEESYKDSTLIM QLLRDNLTLWTSDMQAEEIPIPKLPDRQSKTTLIFSPRSQVNPILHKNNTIIGRVIC SVFA
30	>22:47:02 GENSCAN_predicted_CDS_3 852_bp	atgactgagcgcgagaacaatgtgtacaaggcaaaagctggccgaacaggccgagcgctacgacgaaatggaggccatga agaaggtcgctccatggacgtagagctgaccgtcgaggagcgaaatctgctgtcgggtggcgtaagaatgtgattggagcac gccgtgcctcgtggcgcatcatcacctcgatcgaaacagaaggaggagaacaagggggccgaggagaaattggagatgatcaa aacctaccgcggacaggtggagaaggagctgcgcgacatctgctcgatatactgaacgtgctcgagaagcatctcattccatg cgccacatccggcgaaagcaagtaattactataagatgaaggcgactaccatcgctacctggccgaattcgccaccggctcc gaccgcaaggatgcggcagagaactcgctgattgcctacaaggcgccagcgatattgcatgaacgatctgccaccaacaca ccccatccgtttggccttgccattgaactctcgggtgttactatgagattctcaactcgccggaccgcgcttgccgcttgccgaaa gccgcttgcgatgatccattgccgagttggatactgagcgaagagagctacaaagactcgacactcatgcagctgctgc gcgacaacctcacattatggacgtccgatatgcaggcagaagagattccgattccaaaactcccgacagacagtccaaaacca cattgatttttagccccgaagtcaagtaaaccacaagattctccacaagaacaacaccatcatcgccagagttatctgtagcgtgtt tgcgtga
	Drosophila Gene Hit	rescue sequence: 14-3-3 epsilon isoform gene (U84898) TBLASTN with ORF1: 14-3-3 .
45	Human Homologue	TBLASTN with ORF1 and BLASTX with 14-3-3: epsilon isoform 14-3-3 protein (U43430.1)

	Annotated <i>Drosophila</i> genome genomic segment	AE003721
	Annotated <i>Drosophila</i> genome Complete gene candidate	CG8045 complex gene
5		appears to encode 3 things : Transcript: CT24102 unknown Transcript CT24072: transcription factor RNA polymerase II transcription factor ,
10		Transcript: CT24092: diacylglycerol- activated/phospholipid dependent protein kinase C inhibitor /14-3-3 protein epsilon (suppressor of ras)
15		
	Human homologue of Complete gene candidate	CT24092: e-119 NP_006752.1 tyrosine 3- monooxygenase/tryptophan 5- monooxygenase activation protein, epsilon polypeptide; 14-3-3 epsilon [Homo sapiens
20		
25	Putative function	transcription factor, or 14-3-3 proteins which associate with cdc25 phosphatases
	Confirmation by RNAi	CT24102: wild type profile only, CT24072: Loss of G1 peak CT24092: Increase of G1 peak

Example 53 (Category 4)

	Line ID	951/8
5	Category	Mitotic defects in brain: (some overcondensation, anaphase bridge, metaphase with swollen chromosome and bipolar spindle)
	Reversion	NR
	Map Position	73D
10	Rescue ID	2E8S
	Rescue Sequence	
	GTATAACAAGATCCCGAGACACCGGTCAGTTGGTGCTACACGCTCTTGGAGA	
	GCGCTGTGTTTGTTCGGTTCAGCGATTAGCGATAGTTTTGTTTCGAGCCGGTTGT	
	GTAACTTGGCTAGCTTCGGGTTTATTGTGACACTTTCCCCAAATCGATCGTTT	
15	GCGAAGCGTGCATAGCGGAACATACATACATAGATAACCAGCGTGTCTGGGT	
	GTTTCATGAAAAAGAGTGCGTGATATGGGATTCGATATGGCAACACGCTTTATG	
	GATATACTAAAGCTGACCTTTAAGTGAGTTTTCCCAGTCAGTGTCCGCTTCTTG	
	CTCTTGCGGAGCGTTAAACGGTTTTCTGTGTTTTGAGGTCTCGCGTCTTGGTTT	
	TGCAACAGCTTCTGCCCAGCATGCACACATACGTGTGCACTGGGAAAATAGTG	
20	TTGCAGAAAGTGCTTGATTATAAAATATTACAAAAAATGTGATGAAACACTTTT	
	TATTTTCTTCAAAAAATCAAGAATAAATTAACACTATCCTGCTCTTAAACAT	
	GGAGATTAATTCAATTTTAATTAATAAATAATTTTTTTTACAATTTATGATTTA	
	TGAATTTATGCACTCCTTGAAACTATTAAAGACTCAACAGTGA	
25	Genomic hit, Accession No. CSC:AC015272	
	Associated ORF	
	Genscan ORF1 predicted sequences	
	>23:03:05 GENSCAN_predicted_peptide_1 602_aaMGFDMATRFMDILKLTFKPFKTN	
30	YTEEKYFNDKLRSSKNIERRYILDVGFGRPTAVTYNPIWVISFKYEQRLSTAIYSV	
	IKTKSGPVRGVKRNTIWGGSYFSFEKIPFAKPPVGDRLFKAPEAVEPWDQELDCTS	
	PADKPLQTHMFFRKYAGSEDCLYLN VYVKDLQPDKLRPVMVWYGGGYQVGEA	
	SRGLDVVIVTVAYRLGALGFLSLDDPQLNVPGNAGLKDQIMALRWVQQNIEAFG	
	GDSNNITLFGESAGGASTHFLALSPQTEGLIHKAIVMSGSVLCPWTQPPRNNWAY	
35	RLAQKLGYTGDNDKKAIFEFLRMSGGEIVKATATVLSNDEKHHRILFAFGPVVE	
	PYTTEHTVVAKQPHELMQNSWSHRIPMMFGGTSFEGLLFYPEVSRRPATLDEVGN	
	CKNLLPSDLGLNLDPKLRENYGLQLKKA YFGDEPCNQANMMKFLELCYREFW	
	HPIYRAALNRVRQSSAPTYLYRFDHDSKLCNAIRIVLCGHQMRGVCHGDDLCYIF	
	HSMLSHQSAPDSPEHKVITGMVDVWTSFAAHGDPNCESIKSLKFAPIENVTNFKC	
40	LNIGDQFEVMALPELQKIEPVWNSFYAPNKL	
	>23:03:05 GENSCAN_predicted_CDS_1 1809_bp	
	atgggattcgcgatggcaacacgctttatggatatactaaagctgacctttaagccatttaaagcaactacactgaagaaaagtatt	
	caatgacaactcagatcttcgaaaaatattgaaaggcggtatcttgatgttgcttcgcggacccacagcagtcacgtacaat	
45	ccaatctgggtaataagcttaagtagcagcagcgcaaatgtcaacagcaatatattccgtcataaagacgaaatcaggtcctgtg	
	cggggagtggaagagaacacaatctggggagggaagctacttcagtttcgagaagatacccttcgaaagcctccggtgggagat	

ctgcgcttcaaggccccggaagcagtgaggccatgggacaggaattggattgcacttcgccggcagacaagccccttcagaca
 cacatgttttcagaaaatacgcgggctcagaggactgcctctacttaaatgtgtatgtcaaagatctgcagccggataaactgcgtc
 ccgtgatggtttggatctacggaggaggctatcaagttggcgaagcttctcaggattggatgtggtcatagtcaccgttgcttatcg
 actgggtgccttgggcttctcagcctggatgatcccaactaacgttcccggaatgcagggtctcaaggatcaaatcatggccc
 5 tgcgatgggtgcaaaaaacatcgaagcattcggcggtgattccaacaatattacactcttggcgaaagtgcggcgaggcctc
 gaccacttccttgactaagtcctccaaactgaaggtcttatccaaaagctatcgttatgtcgggcagtggtttgtcccctggagc
 caaccaccgagaaataattgggcttataggctggccaaaattgggatacaccgggtgacaataaggacaaggcgatctttgagt
 ttctgcgatcaatgagtgccggggagattgtcaaggccaccgcaacagttctcagcaacgatgaaaagcatcatcggtatccttttc
 gccttcggacctgtcgtagaacctatactaccgagcacactgtggtcgtaaacaaccgatgaactgatgcagaatagctgga
 10 gtcacaggatacccatgatgtttggaggcacgagcttcgagggtgctattctatccagagggttcaaggcgccagcaaccctc
 gatgaggtgggtaactgcaagaatctgctaccgagcgtctcgttcttaacctagatccaaactcgtgagaactacggcttgca
 actgaagaaggcgtatttcggcgacgaaccctgtaaccaggcaaacatgatgaagttctcagcgtatgctcatatcgagagtctg
 gcaccctatatacagggcagctttgaaccgtgtccggcaatccagcgcaccacgtatctgtatcgattcgatcacgattccaaact
 gtgcaacgccattaggattgtactttgcggccatcagatgcgaggtgtttgtcatggtgacgatctgtgctatatttccacagcatgtt
 15 gtcgcatcaatccgctcccgaattctccggaacacaaggtataaccggaatggtcgacgtttggacgagtttcgagcccacgga
 gatcccaactgcgaaagtataaaatcactcaagtttgacccatcgaaaacgtaaccaacttaagtgtctcaatattggggatcagt
 ttgaagtcagtgccgcttcagaattgcagaaaatcgaacctgtgtggaatagtttctacgccccaaacaaactgtag

***Drosophila* Gene Hit** TBLASTN with ORF1: alpha esterase (aE10) gene (U51054)
 20 **Human Homologue** TBLASTN with ORF1 and BLASTX with U51054: bile salt-
 dependent lipase (S79774)

Annotated *Drosophila* genome genomic segment AE003671
Annotated *Drosophila* genome Complete gene candidate CG1131 - alpha esterase 10
 25 **Human homologue of Complete gene candidate** 4e-48 4557239
 ref|NP_000656.1|pACHE|
 acetylcholinesterase (YT
 blood group) precursor
 30 >gi|113037|s

Putative function alpha esterase
 35 **Confirmation by RNAi** Only wild type profiles observed

CATEGORY 5: SMALL IMAGINAL DISCS (BLOCK TO PROLIFERATION)**Example 54 (Category 5)**

	Line ID	113/20
5	Category	2nd chromosome, small imaginal discs
	Reversion	R
	Map Position	50D/E
	Rescue ID	EcoR1
10	Rescue Sequence 1	
	CTGAGGCNCTTTGCCAATATGTGTATATTGGGCGGGGNACATGCGTNAATCGG	
	TTAAAGCCGCTACTTACATTCTGTTCTTTGCATCTCCCCATCCACAGCTATAA	
	AGCAAGATGAGCTACGCCGCTGATGTGCTGAACTCGGCCCATTTGGGAGCTCC	
	ATGGTGGTGGCGACGCCGAGTTGCGTCGTCCATTTCGATCCCACGGNCCATGAT	
15	TTGGATGCATCCTTCCGCCTTACACGCTTCGCANATCTAAAGGGGCGCGGCTG	
	CAAAGTGCCCGCAAGGAAGTNGCTCCCCACCT	
	Rescue ID	BamH1
	Rescue Sequence 2	
20	CCACCTGGTACCACAGCGCTCANACGTGTATGTACACGGATTTTCTGCCGCGT	
	GTGTGTAGCGCGGCCCGTGATTGGCTGCAGTCGCGATGGCGGCTAAAACGGG	
	CGAAGTCAGTATTTCTCCCTGTCGACGANGCGAGCAACGTGAACAATGCCAC	
	TCATTTCAATTGCAAAATGCCAAAAAGTGC GCGCTTTGAATTGGCCATTTGGT	
	TCGTTGCGTTTCGTTTGTCTTTGGTACTTACGTTTGCTTGTGCGATTGTACAAA	
25	GATAATTGTAGAGTAACGTTAGCAAATTATATTTATTTTGC GCGCTGGTTTTTGC	
	TTTTCCAACGANCAGATGTCACAACAGGGTTGTATTANCGTGTGCGGCTGAT	
	TCGATATTTGGGATGCCGATTGTCTGAAGCGANGGTTCAACGGGGCTGCCAAC	
	TCCCCGAAAATCTATCNATGGTATTGTGCGCCAAGGGTAAAATAAATAAAAA	
	TATGTTAAAACCGCGGAATAAATGGGGGAACCGAAGTGGAACCTGTGGTTCA	
30	CAGTGCTCTGACTTTTCGGGAGCAGTTAATATAGTTGGCATTAAATTCAATTAGA	
	GCTCCAAAGTGCTGGTCACAAAGAACGCACAAGAACGGGCCATGAAAAACCT	
	GTTGCGCCAGCAGAACGAAAAGTAAAAATTAGAAGAAACCAT	
	Genomic hit, Accession No. CSC:AC017131	
35	Drosophila Gene Hit	rescue sequence: selenophosphate synthetase (ptuf1) (U91994)
	Human Homologue	BLASTX with U91994: SELENIDE, WATER DIKINASE 1 (SELENOPHOSPHATE SYNTHETASE 1) (SELENIUM DONOR PROTEIN 1) (P49903)
	Drosophila EST	LD46437 (AI514756 similar by BLASTN to U91994
40		selenophosphate synthetase (ptuf1) gene)

Annotated *Drosophila* genome Complete gene candidate CG8553 selD selenophosphate
synthetase

Human homologue of Complete gene candidate

1711372 P49903

SELD_HUMAN

SELENIDE, WATER

DIKINASE

(SELENOPHOSPHATE

SYNTHETASE (1e-159)

5

10

Putative function selenophosphate synthetase

Confirmation by RNAi Only wild type profiles were observed

Example 55 (Category 5)

	Line ID	121/1
5	Category	2nd chromosome, small imaginal discs
	Reversion	NR
	Map Position	60B
	Rescue ID	BamH1
10	Rescue Sequence	
		TCCTGTGCACTCATATTGATTTGCCTTGTCAAGTGGCTAAAGAAATATTAAATG TTTGTTATTTCTGTTGCTAGCGCTCCGACAGTCTGGCAGCACTGCTCGCTGTCG ATAGTTCAACTGAGTTGCTGTTTCATCGAACAGAGCTGCCAACTCTATTTTGT AGCTGGCCAGCCAGGATTGCCAGAGTAAGGCCCTCAAATCAGCTGTTTTGTGT 15 TTTGATTTTATTTTGAAAGTCCTAGTTTAAAATTATGCTTTCTCCGACAGATCA GCACAAATAATACTAATAAAGCTCACAATGCTAAGGTTGTGCCTTCCAACCTCG AGCTGGATATGTGCGTAAGTAAGGACTTTACGTCTATAAACTTGTTATGTAA AGTAAATGTTTGCCTATTGCGCAATTTCTCCAACGAAAAACCCAGAAAACCNA AACCCCTTNAAANTTTGGAATATNCCCAATGAATGCAGCACCCGTGAAATCC 20 GTAATGCCTTTGTCCAGCTCTCCAAATTGGTAAGTAACTCCAAGATCCAAAGG AGCCTCCTAAACCCTGCCCTTTCCACAGTACCACCCAGATGTTAAGAGCAATG CTGCGTGTCCGGAGCGCACAGCCCGATTTGTTTCAGATCTCCGAGGCGTACAAG AACCTGATAAAGCCGGAACGGAAGGAAAAA
25	Genomic hit, Accession No.	CSC:AC020499
	<i>Drosophila</i> Gene Hit	rescue sequence: DnaJ60 gene for dnaJ-like protein (Y11900)
	Annotated <i>Drosophila</i> genome genomic segment	AE003463
30	Annotated <i>Drosophila</i> genome Complete gene candidate	CG12240 – DnaJ60 CG13570 – spaghetti ser/thr phosphatase
	Human homologue of Complete gene candidate	CG12240- 4827026 ref NP_005138.1 pTID1 tumorous imaginal discs (<i>Drosophila</i>) homolog >gi 3372677 (AF061749) 7e- 08
35		
40		CG1116- 2495728 HYPOTHETICAL PROTEIN KIAA0258(aa)
45	Putative function	CG12240 : Chaperone involved in protein folding CG13570 : serine/threonine phosphatase

Confirmation by RNAi

CG12240: Marked reduction in G1 and G2/M peaks
indicating fewer cycling cells
CG13570: Marked increase in G1 peak

Example 56 (Category 5)

Line ID 127/2
Category 2nd chromosome, small imaginal discs
5 **Reversion** NR
Map Position 57F

Rescue ID EcoR1
Rescue Sequence 1

10 GCCGGTGGGCCCACACTTGTNCGCCCGCGCATCGGCTGTCTGTGGGAGTGCGA
NCGAGTCAGATAGTAGATCCGATGCGCTCTCCAGATACTTTTTGAACACTGAA
GAAAACGCGCAGTTGTGGGTGAATTCAGCATCATCAGATTGAATCACACACA
ATCCTAGTCGCCTCACGCGAAGAGAACTATGTCATGATCAGATATCGGTGTAT
GCATTCTATATTATGTACTTCGAAATATGTAATTTATTAAGTTTTCGCTATACT
15 TTTCAATTCAAATTGGCAAAAACCAATTCAAAGGTTTTCAATATTTTCGAAAAG
CATTTTAGGCTTTCTATGTAACGTATGTTTTTCAAACAAAATATTAGTTTTTGA
AACTTTATTATCGGATAAACAAATGTAAGCCAAATNACAACGTTNTATGATAC
TCCCAAAGATCCGCNCTNTTAAAGTGGCCTAAAAATAGCTGACGCATTAANCC
ATAGGCGCTTCGCTTCTCAAGATAAAACCTGGCGTGCTCAACTCAAGAAACAA
20 ATATGTGGTTATATACATATATACATATATGGGGCATATAACCGATGTGTGAC
GTGACATTGGCTCGTTCTATTACATACTTAAACACTAAATGCAAACCTATCA
AAAACCNACTACACTAAGCGAAAAACGGCAGANATAGTTAAGGAAAGTGGTC
CA

25 **Rescue ID** BamH1
Rescue Sequence 2

CTTCTTTTCTCAAAAACGTCGCTCGNGTCCCNCAATCGTTTTACAACTTCGC
TCGGAACGACGTGTGCGCGCTCTGAAAGGAAAAAGTGAAAAAGTGTGTGAC
AAAGTGCAAATAAGCCACAACGCGCATGTGAGAAATCAAATTTAATTGAGAA
30 GCATCAAAAATTGTATACATATCGAGCGTATCCACATCGCTGTATGTGTGAGT
GTGCCAGTGCTAGTGTGGTTTTCCCTTTTCGCCGTGGAAAATATGAAAACCTGA
ATGAAAAACTGAATCGCAGTCAGCCAGAGCCGAATTGGAAAAGAGTAACTCG
CATTGGGGACACGAAGAGGTGTCTCGAAAAAGGTAAAATCTTTTACACAGAA
ACGACGCCAGAAAGCGATTAGCGATTTNTGACTATGTGTGAGTGTGTAATTC
35 GGTCTACGGCTGTGTGTCTGCATTTTATTTAACNTTTTGTTCCTCCNGTTNGNTC
CACNGTAAAAATAGCTAAAAAAAAGGGCAAGTACTCTTGGCGCGCTCTCCC
TCTCTTTTGTGTCGTGACTGCGACGTCACCGTTCACGTAGAATCGTTTTCA
AGTGGCGTTTCTTTCTTTCTTTTAATGTGCTGCTTCTTGCTTCTGCCTCTTCTTC
TTGCCTTTGGCTATCTGCTTTGTTTTGAAATACGTCCATGTTATTCCAGTGTCTG
40 TGCCAAATGTGTGCGANATGATCTCTACTT

Genomic hit, Accession No. AC009732

Associated ORF

45 Genscan ORF1 predicted sequence
>/tmp/aaaaafria|GENSCAN_predicted_peptide_2|456_aa

- MQTKGPITDADCIRGMACRALAGLARS DRVVRQIVSKLPLFASGQLQTLMRDPILQ
 EKRAEHVIFQKYALELLERVSGKTKPLNNPLDPSLSNMHKANVIAQTRIQYNKQQ
 LYQLIFEHLESNGLSQTAQMLQREVGLPLQPTTTRSFHQSPFDYKSLPSGSSSLSRN
 RLRSRMQDVNAAIMGNGDLNRSFGEDSSPAGAGGSNAGDGVSIPIFSSSLNTTQTP
 5 IKIRRTDRSSVSRSIQKQAMEPGGMSVGLAEDGQLHPKRITLNTTVTEYLTNQHSL
 CNNPVTTCPQFDLYEPHKCPDPKPSRLSSNYNLTSRHARTQAGFNTSRFDRRYV
 HTHFSPWRSIRSADYEDLEFTCCDLAGKYITVGTQQGDGRVFNMDGVEQFFSNC
 HNFSDAIAKANRAGDLVITSSFWRTPTSILWSIADDEFKLKLRLPDVITYCEFSQTV
 QDRLLGTQNEVY
- 10 >/tmp/aaaaafrla|GENSCAN_predicted_CDS_2|1371_bp
 atgcagaccaaaggacccattacggatgaggactgtatcgtggaatggcctgtagggccttggcgggacttgctcgtccgac
 gggtcaggcagatgctcagcaagctccactcttggcagcggacaactccagacgctgatcgggatccatactccaggaga
 agcgcgcggaacatgtaatcttcaaaagtacgattggagttgctagaacgagtgctgggtaagacgaaaccgctaaataatcc
 15 ttggatccatcgctgtccaatgcacaaggccaatgtaatgccagacacgcatccagtataacaagcagcagctgtatcagc
 ttatctcgagcacctggaaagcaacggtctctcccagacagccaaatgctgcaacgggaggtgggtcttccgctacagactcc
 cactacgcgcagtttcatcaatcaccttgcactacaaaagtcttccagtggtagtagctcgtctctagaatcgtctcgaagc
 cgcatgcaagatgtgaacgcagcgataatgggcaatggagactaaacagaagtttggtaggactcctcggcggcaggagcc
 ggtgtagcaatgcgggagatggagtcagcataccaaatttagctcccttaacacaacgcagacgcccataaaataaggagg
 20 acggatagaagttcagttagccgctctatccagaagcaggcaatggagcctggtggcatgctagttggtcttccgaagatggtca
 actgcatcccaaggagatcacccataataccatcgtaacggaatactcaccaaccagcactcgtgtgcaataatccggtgaca
 acctgcccgcagtttgattgtacgagccgcacaagtgtccagatccgaagcccagccgattgctaagctgaactacaacctga
 ctatgctggcatgctgaacccaagccggatttaataccagtcgcttggaccgtcgtatgtgcacacgcacttttaccatggcgta
 gcattcgatcgccgactacgaggacctagagttcacctgttgcgattggcgggtaatacatcattgtgggcacgcagcaggg
 25 cgacggagcagtggtcaacatgaacgatggcgtggagcagttcttccaactgtcacaactttagcgttgatgctattaaggcta
 agagccggagacttggtcatcacatctagcttctggcgacacccaccagcattctatggtctattcgggacgatgagttcaagcta
 aagttgcgacttccgatgtcacgtactgtgagtcagtcacaacggtgcaggatcgttggggcaccagaatgaggtatactaa
- corresponds to CG10082
- 30 **Drosophila EST** several including SD04293 (AI532704)
- Annotated *Drosophila* genome genomic segment AE003454
 Annotated *Drosophila* genome Complete gene candidate CG10082 – novel protein with
 35 homology to enhancer Pi uptake
- Human homologue of Complete gene candidate 1665793 dbj|BAA13393|
 (D87452) Similar to
 40 *S.cerevisiae* YD9335.03c
 protein (S54640) [Homo
 sapiens] (2e-43)
- 45 **Putative function** Putative phosphatase or enhancer of Pi uptake protein
- Confirmation by RNAi** Reduced G1 and G2/M peaks indicating fewer cycling cells

Example 57 (Category 5)

Line ID 131/8
Category 2nd chromosome, small imaginal discs
5 Reversion R
Map Position 60A

Rescue ID BamH1
Rescue Sequence 1

10 CACGATTGCNGGCCCATCGAAGTGTGGGTCTATCGATACTCGTGGGTAAATAA
ACAAGTTCTGAACTGCGATTTGCGGGGTTTGAGGGGTCAATTGTCCCCTGTGT
TGGAATGTGTTCTAAATCTACACAAACACTCCCTAAGCTTATCCTAAACTTAT
AAATATTGGTTGCTATTTAAACCCCATTTACG GTTATCCAGCACGCCCTGA
ACTGTGACCCACATCCCCGATTTTAGTGACTAGTTTTATACTTATCGTGGTTGG
15 CATTTGGTACACTACACTTTCTTATTACCTAGATCGCCGACTCCGCGCACGGT
CGCGCTCCCGTTCGCTCCCGATCTCGGCTGCGACTGCGGTGCGGATCCCGTT
CCCGGTGCGGCGACCGGCGCCTCCANATCCGGATCCCTAANCGGCANCNGT
CNTGGTGGCAATCNNGGAATGTTCCGGGGNCCNCTACCNCAGTGNAATCAC
TGGTACGTCCCACCGCNAAACTCCGCCANTGCGGTTGCCGGAACGGGTGGC
20 ANTCCAATGGGTGCTGCAGAAGGTACCATCACAGCAATCGCTCACGGANC
CCGAAGACTGCCTCTGCCGCCGGCTGGGCCACTCATACAGCTACACGGTGC
GAAATACTACATTGATCACAATGCGCATACCACGCACTGGAATCATCCGTTGG
GAACGC

25 **Rescue ID** EcoR1
Rescue Sequence 2

AATTGATTTCCGGACATATAAACAGAATCCAGAACTCATCCGGCAGCAGGCTC
AGTCAGGCCAGTAAATCCGAAAAGAGAGTAACCAGCAGGAAAAGAGAATCC
ACGTAAATACAGAGAAAATGGCTCTACGCGTCCAATTCGAGAACAACGACGA
30 CATCGGCGTATTCACTAAACTAACCAACACATACTGCCTGGTGGCCATCGGTG
GATCCGAGACCTTCTACAGCGCCTTCGAGGCGGAGCTGGGCGACACCATCCCG
GTGGTGCATGCGAATGTGGGCGGCTGCCGGATCATCGGCCGCTCACCGTGGG
CAACCGCAACGGCCTGCTGGTGCCCAACTCCACCACCGACGAAGAGCTGCAA
CACCTGCGTTACANCCTGCCANAACCCCGGAAANATTTATCGTGTGGAAGAAC
35 GCCTGTCCGCGCTGGGCAACGTTATCGCCTGCAATGATTATGTGGCCCTGGTG
CACCCGGATCTGGACAAGGAGACCGAGGAGATCATCGCGGACGTGCTCAAAG
TANANGTCTTCCGCCAGACCATTGCCGACAACACTACTGGTGGGCTCTTACGCC
GTGCTGAGCAACAGGGGGGCATGGTGCATCCCAAGACNAGCATTACAGGAAC
AGGACAACGTGTCGTCCCTGCTGCAGGTTCC

40

Genomic hit, Accession No. CSC:AC020517

Associated ORF
Genscan ORF1 predicted sequences >22:13:05|GENSCAN_predicted_peptide_4|357_aa
45 MALRVQFENDDIGVFTKLNTYCLVAIGGSETFYSAFEAELGDTIPVVHANVGG
CRIIGRLTVGNRNGLLVPNSTTDEELQHLRNSLPDAVKIYRVEERLSALGNVIACN

DYVALVHPDLDKETEEHADV LKVEVFRQTIADNSLVGSYAVLSNQGGMVHPKTS
 IQDQDELSSLLQVPLVAGTVNRGSEVLAAGMVVNDWLSFVGMNTTATEISVIESV
 FKL NQAQPATVTTKLRAALIEDISR SRVAGGGGGGGGGSSGNSSSGPSTSRRTT
 RNNAAATAADRPKINEADLEGKSPEEVEMLKTMGFCTFDTTKNRKVEGNDVGEV
 5 HVILKRKYRQYMNRKGGFNRLDFVA

>22:13:05|GENSCAN_predicted_CDS_4|1074_bp

atggctctacgcgtccaattcgagaacaacgacgacatcggcgcttctactaaactaaccaacacatactgcctgggtggccatcgg
 tggatccgagaccttctacagcgcttcgaggcggagctggcgacaccatcccgggtggtgcatgcgaatgtggcggtggtcc
 10 ggatcatcgccgcctcaccgtgggcaaccgcaacggcctgctggtgccaactccaccaccgacgaggagctgcaaacct
 gcgtaacagcctgcagacgccgtgaagattatcgtgtggaggagcgctgtccgcgctgggcaacgttatcgctgcaatgat
 tatgtggccctgggtcaccggatctggacaaggagaccgaggagatcatcgcgacgtgctcaaagtagaggctctccgccag
 accattgccgacaactcactggtgggctcttacgccgtgctgagcaaccaggcgccatggtgcatcccaagacgagcattcag
 gaccaggacgaactgtcgtccctgctgaggttccctcgtggccggaacagtgaaccggggcagcgaagtactcgcgcgcg
 15 gcatggtcgtcaacgactggtctccttcgtggcatgaaccaccagccacagagatcctgtagcagagcgttctcaagctt
 aaccaggcacagcccgcacagtgacgaccaagctgcgtgcggccctcatcgaggacatatcgcggtcgagggtcgccgga
 ggaggaggaggaggaggcgccggcggaagcagcgccggaacagcagctccggaccatcgacgtcgcgaaggacgacg
 aggaacaatcgggcgccacagctccgaccggcccaagatcaacgaggcggacctgagggttaaatcgccggaagaggt
 cgagatgctgaagacaatgggattctgcacgttcgacaccaccaagaacagggaaggtcgagggaacgatgtcgagagaagtgc
 20 atgtaatcctcaagcgaaagtaccgccagtcacatgaatcgcaagggtggcttcaaccggccgctcgatttcgtggcatag

Drosophila Gene Hit rescue sequence and TBLASTN with ORF1: b(2)gcn
 (EUKARYOTIC TRANSLATION INITIATION FACTOR 6
)(X97641)

25 **Human Homologue** BLASTX with X97641: integrin beta 4 binding protein (HUMAN
 EUKARYOTIC TRANSLATION INITIATION FACTOR 6)
 (NP_002203.1)

Drosophila EST GH08760 (AI109537 similar by BLASTN to X97641
 "D.melanogaster b(2)gcn gene.")

30

Annotated Drosophila genome genomic segment

AE003462

Annotated Drosophila genome Complete gene candidate

CG17611 – bcgn benign
 gonadal neoplasia homology
 to Eif6 translation factor

35

Human homologue of Complete gene candidate

6016331 EUKARYOTIC
 TRANSLATION
 INITIATION FACTOR 6
 (EIF-6)(aa) and 4504771
 [ref|NP_002203.1|pITGB4BP|
 integrin beta 4 binding
 protein(aa)

40

45 **Putative function** eukaryotic translation initiation factor 6 (eif-6)(aa)

Confirmation by RNAi

Slightly reduced G1 and increased G2/M indicating block in
 G2/M

Example 58 (Category 5)

	Line ID	135/25
	Category	2nd chromosome, small imaginal discs
5	Reversion	NR
	Map Position	24A
	Rescue ID	EcoR1
	Rescue Sequence	
10	ATAACATGGGCNCTGGTTTTTAAGTNAAGCTCTANTNATTGGCCCCCATTCTTA	
	NNCTCTCTCGCTCTCTTCTCGCTCTTTCGCCTGCTCTCTCGCCTGATTATTCTGC	
	TTGGTCGGCTGATGGTTTTTNGTTTTNATCTGGTGTATTTTCTGCGTAGTTTATG	
	ACAAACCGGCTGGTTCCTTGTTGTTATTGCCGTATTCTAATATATTCCCCTATTG	
15	TTCTTATTTTTGTTGCAGCCTGCACACCTCGGAGGTTCTAGATGATAAGGGGTG	
	TAGCGATGGTGGGGGGCTGTCTTGANGGGCTTCTCGCCTTGAGCTCTTGTTTAT	
	CTTTGGTCATTTGTTATTGTTTAATGCACGGCAATATTATTGGTAAACAAGTTA	
	GCCAACAGCACTAAACGCCAATCGCATTCTTTTCTAAAAACCAAGTCTATTGT	
	CGATCTTGCTAGGGAAATGATGATGACTCAGGTGCAATTGGGATCTTATCTAT	
	GGCTGTCTGGGAATCAAGAAGTGTTCCCGCAGAATTCGTGAANTACTGCCGCT	
20	CTCTCCATGGGGCCATTATTTGCACTCGTTTTNCGCGAAATACCATNAATTAGC	
	ATAAAGACACGTCGCCGGCAATCGTGACGTAGGCTATNAATGCCTTCTATGCA	
	TGTGCNAACTCGCGGAAGCATAGCAATTTGAAGGAACAATATTTTCANTGCAG	
	GTTTTAATGGGCTAAAAAA	
25	Genomic hit, Accession No. CSC:AC014199	
	Associated ORF	
	Genscan ORF1 predicted sequences >20:54:54 GENSCAN_predicted_peptide_3 117_aa	
30	MSASPTARQAITQVMPMITRKVVISDPQMPEVYSSTPGGTLYSTTPGGTKLIYER	
	AFMKNLRGSPLSQTPPSNVPSCLLRGTPRTPFRKCVVPTELKQTKSLKIEDQEQQ	
	QLDL	
	>20:54:54 GENSCAN_predicted_CDS_3 354_bp	
35	atgtccgcttcaccaccgcccgtcaagccatcaccagggttatgccatgatcaccaggaagggtgtcatctcggatccgatcca	
	gatgcccggaggtgtactcctcgacgcccggcggaacctctactccaccactcctggaggcaccaaacttatctacgagcgggc	
	tttcatgaagaatctcgtggctccccattgagccaaactccgctccaacgtgccagttgcttgctgaggggaactccgcgta	
	ctccctccgcaagtgctgcccgtccccacggaactgatcaagcagaccaagtcgctgaagattgaggaccaggaacagttcc	
	aactggatctgtag	
40	Drosophila Gene Hit TBLASTN with ORF1: BcDNA.HL08053 mRNA (AF132557)	
	Human Homologue TBLASTN with ORF1 and BLASTX with AF132557: eukaryotic	
	translation initiation factor 4E binding protein 2 (EIF4EBP2)	
	(L36056)	
45	Annotated Drosophila genome genomic segment AE003579	

	Annotated <i>Drosophila</i> genome Complete gene candidate	CG8846 - phas1 translation initiation factor 4E binding protein 2
5	Human homologue of Complete gene candidate	CG8846 - 4758260 ref NP_004087.1 pEIF4EBP2 eukaryotic translation initiation factor 4E binding protein 2 (4e-16)
10		
	Putative function	EIF4E translation factor binding protein
15	Confirmation by RNAi	Slight reduction in G1 and G2/M indicating fewer cycling cells

Example 59 (Category 5)

	Line ID	141/12
	Category	2nd chromosome, small imaginal discs
5	Reversion	R
	Map Position	21A/B
	Rescue ID	BamH1
	Rescue Sequence	
10	GGCTCTTTTCCAAANAGGCAGTTTCTTGNCCCATTTCTTGGATTGCTTTGTAGT GAACTNAATCGTTTTGTTGGTTCCTCTGTCGTCCAGTCTTGTGAAAATTTCTGTG ATAATAATGCCTGGATAAATANTTAAGCATTGGAACGGGGGAAAAAGGG CTAAGTTGTGTGAAGGAAACAATTGAAGTGACCCTTTGTNTATAAACATTCCA CGACGTGTTTCGAAAACAAACAAAGATATGCGGAAACAAAGTGTTAATAAAAA	
15	GAGCNAAAAATAGAGAGAGAGTGTGCGGATAAGCGGTTGAGCGAGATAGAG AAAATTGTTGATTAAAATGTGTGTCNAAATAAAACATCAAGCCGCTTGAACGA ACAGTCAGTTAGTTGCTTCTGATAATAACCATGGGAAGCGGCNCGTGTGCTTC GCTCCTCGTTACTTATAAAATATTTAAACGTTTGCATTCTTCNTATTTCCGAAT TTTTGCNCCCCTGAANCAACTTNGTTAAACTGCAAATAGCAATGCAAACAAAC	
20	GAATAGAAACTGAAATCGACAACNACATGTGAAATTCACAAATCAAATCGCA ATTGTCATCCCAAAGATATAGAACAAGCTATAGGGAAGATANAGAATGTAAG TGCCAAACTAAAATAAACAAACAAGAATAACATTTCCACAGGTGTTTTGCATT TCAAATGCATATTTCCGTGGCGGNTACAAATCTTTTCAAACCG	
25	Genomic hit, Accession No. CSC:AC017815	
	Associated ORF	
	Genscan ORF1 Predicted sequences >17:48:30 GENSCAN_predicted_peptide_2 554_aa MSNKKMFNRTTSVSPGQLHYHYHTDFYYSMPDLHKTRKMHGVKRVLVFCLMIVIL	
30	PAILIMPLHLRKTTFADVIYPMASDIIERAGISSIFCSKHTLRMNSNFNAFQLRNK PELATNRKHRLKKSMTLPDDTLEYWGFLLKGAKVRVKFCSTRYDGSRLIIHGHR ELNLCGLTDHNKNKLGANYAKGHEQVQVFFEDNVEITEEKGNQDVLMEHENHG GEDLTEDIPQPQVNIPVKQNNSIQPKLIRKKLKGTTIHHGEHDMHAITDLQGSHTT EHLNHHDHSSNSPAHHHNSTAHHREHSSNTNEETSРНHIRNEDEDPDQNSSKTH	
35	YSAESPPIRERLKRHNRAHRNQKRQDLYDTLYKRSKRENVYDRKTIHGGNAIN FTETDESNSVSSFETGLFQCFNGMILLQEFFRPKNECSNPIMDTSPNKSSMVVHN VIEDGYYYYIFYSDNDHVQNEIHAIFDIYKPTYQYSNMSESQSCLNTTNCFTFNISFL SDEIVVVEVPTRDIEHEEDDITNLISTCHPRSEIYAIFPITVLVLILCCSFL	
40	>17:48:30 GENSCAN_predicted_CDS_2 1665_bp atgtccaacaaaagatgttcaacaggactacgtcagtaagtcctggacagttgcattattatcacacggatttctattactcaatgcc ggatttgcataaaacccgcaaatgcacggcgtgaaaagggtgctggtttctgctgatgattgtgatactgccggccattcttacc attatgccgctgcatttgcgaaagacggtgttgcgacgtcatctatcccatggcggagtcggatattgagattcgggcagga atctcgtgatcttttgcgaaacacacactgcgtatgaactccaattcaacgcttttcaactacgtaataagccggaattgcgac	
45	gaatcgcgaagcacattaggtgaagaagtcgatgacattgccggatgatacgttgaatactggggcttctctgctgaaagggtgc caagggtgcgagtgaaattctgctccgctacgatggatcccgcatcctgatcatccatgggtcacaggagcttaattcttgcggtct	

gaccgatcacaataagaataagttgggcgccaattatgccaaaggtcacgaacaggtgcaggtgttcttgaagacaatgtggag
 atcacggagagaagggaaccaggatgtgctaattggagcacgagaaccacggcggagaggatttgactgaggatattccaca
 gccgcaggtgaacatacctgtcaagcaaaacaattctatacagcctaagttaattagggaaaaactgaaaaagggcacattcatc
 atggcgaacatgatatgcatgctataacagatttgcaggtacacaccatacggaaacacatattgaatcaccatgatcacagctcta
 5 attctccagcacatcatcacaatagtactgccatcatcgggagcacagttcgaatatcacaacgaagaaactagtcgtaatcaca
 tacgaaatgaagatgaagatccagatcagaattcaagtaagaccattatagtgcggaaagtccgcctcaccgggaacgtctcaa
 aagacacaatagggtagcccataggaatcagaagagacaggatcttacgatacgtttataaaagatcaaagaggggagaatgtc
 tacgatagaaagacgatccatggaggaaatgctataaattttacggaaacggacgagtcgaattcgggtgtccagctttgagacagg
 actatttcagtgtttcaatggaatgatcctgctgcaggagttcttcaggccaaaaaatgaatgctcaaatccgcacataatggacact
 10 cgcccaacaagagttccatgggtggtgcacaacgtcatcgaggatgggtactactattatattctacagcgacaatgatcacgttc
 aaaacgagatccacgcatattcgatatttacaagccgagtcagtcactcaaacatgagcgagtcacaaagctgtctgaatacc
 acaaattgcacattcaacatcagtttcttccgatgagattgtggtggagggtccaacacgggatggtatcgagcacgagga
 ggacgatataaccaatctgatctccacctgtcatccgcagcgagatatacgccatctttccattacgggtgctggtgctgaccttt
 gctgctccttctgtag
 15

corresponds to CG9524

	Annotated <i>Drosophila</i> genome genomic segment	AE003623
20	Annotated <i>Drosophila</i> genome Complete gene candidate	CG9524 - novel His-rich protein
	Human homologue of Complete gene candidate	none
	Putative function	No homologies which indicate function
25	Confirmation by RNAi	Reduced G1 and G2/M peaks indicating fewer cycling cells

Example 60 (Category 5)

	Line ID	146/2
	Category	2nd chromosome, small imaginal discs
5	Reversion	NR
	Map Position	26B
	Rescue ID	EcoR1
	Rescue Sequence	
10	TTTNATCCAAACTGAGANACTNTTGGCCCCAAAACTGAAAACTCGGACTCGGG	
	CGCGTAAGGGAGTCGGTCNTCGGGAGTCGGTCGTCTTTGTTGATCTTGAGAC	
	TGAAATTCCAATTGTTGATTTATCTCTCGGCTGCTGCGCCGCGGCTGCGCTGCT	
	GCAGCGCAGTCCCACTCCGATTTGACCAGCGACCAAGTTTATAAACTTTGAG	
	CCAAAATGCAGCGGCGCACAGTTGTTACCAAAACGTTGCACGCGTCGTGGCCC	
15	TCATCAAAAACAAAAAAAAAATATAAGCGAAAATGAAAACGAAATTCGGTTA	
	ACGTCAACAGAAGCTGACAAAAGGCAGAAAAGACCGAAACAAGTTGCAGGG	
	CCAGAGTAAGCCAAGTTAAATGCGAAAGAGAAGCAAGAGNCAAGAAGAAAN	
	AATGGGCACTACATACATATATTATAGCCAGCTAATCTGTTGTGCAGTGCGTT	
	TTATCAGCCNNCGAAAAGAAAACGAAAACGAAAAGTCGGTCCAAGTTCGGAC	
20	TCAAAATCCAAACAGAAGAGACTCCATNCCATCAGAGACACGCGGATCTCAT	
	CTCGGTAAATGTCTCAATAAAAAGTAATCTTAACTGCCGCCGGAATGTTGGAAA	
	AAGTGAAAATTGAAGCGCTTAACGTGTTTCGAAATACGATACATGAGAAAGTCC	
	CAAAAAAAAAA	
25	Genomic hit, Accession No. CSC:AC019865	
	<i>Drosophila</i> EST	GH19286 (AI388389)
	Annotated <i>Drosophila</i> genome genomic segment	AE003481
30	Annotated <i>Drosophila</i> genome Complete gene candidate	CG11353 - novel with weak homology to sugar acetylase? CG7525 - tie receptor protein tyrosine kinase.
35	Human homologue of Complete gene candidate	CG7525- 4e-23 4557869 ref NP_000450.1 pTEK TEK tyrosine kinase, endothelial >gi 464868 sp Q02763 TIE2_
40	Putative function	Sugar acetylase and receptor tyrosine kinase
	Confirmation by RNAi	Both gave a reduction in G1 and increase in G2/M peaks indicating arrest in G2/M

Example 61 (Category 5)

	Line ID	155/13
	Category	2nd chromosome, small imaginal discs
5	Reversion	R
	Map Position	21B
	Rescue ID	BamH1
	Rescue Sequence 1	
10		GNTTTAGTCCNCTTTTGANAGGGNCTTGGNGNCTTAAANAANNAAAAAAGGG
		GNCCCGGCNCCCAGCAAANAGNNTAAAACTTGAATGGTTTAATTCGAAAATC
		TTTLAGAAATGTCGCCTAATACCTTATCGGTATAGAGTTCACCTCGTCTCCTAA
		TCCATATTTTAAGATATCAATATCTATTAACAATTTTATCGTATGATTAGAAA
		TTCGCATTGTTTTATTATTTGACCTTTGGGCTTTACATCGACAGCTACTCTCTA
15		TCCAGACAGGAGACTGGGAGAGAGAGCACGATGCTGTCTGAAAGCATGAATG
		ATGGATGCTGTGCCTATGTGCGATATGCACGTTGCCTGAGCTAAAACGAAACG
		AGATTATTAATCTATCCGCAAGATTGAGATGCTGATTCCACATGAGTGAGCGA
		GTCCGTGAGTGGATATTGCTCTCTCCGAAATGCATGCATGAGTGAGCAGGGGG
		GCTTCAATCGCNCTNTCGATNTGCGACAGNGACATNTTTTATCTTCGACNAT
20		GCNCTCNCTCCCTCCCACAGAAATCTTGCCTNGNTCTCCGANNTNGGGNTNG
		ANGGCNCTCTTCTCTNTCCTTAAATTGGGANTTNNCTTTTTTCNAANAAGGGN
		NAGA
	Rescue ID	EcoR1
25	Rescue Sequence 2	
		AATCNTTTTNTCCATTNGGCGNCTTNCTCAAAACATATTCACATTTGGNCCCAA
		CGGCGTANGACTTNATCTCACGATTGTTTGGTTTCCTACTCTCCCGCGCTCCCT
		CTCTTCTGAGTCTCTTTCTGGCTGATTCGCATTTCGATTTTAGCCGCTGCCATCG
		CCGTTGTTTTGCCTACCTATGTGTGTGTGTGAGGAGTGTGTCTTGATTTTCAGT
30		CCGCAATGCGCTCCGCTCATTATTTGTTTGANCGCCGCGGTGTAAAGTTGTAA
		AAAGTCCAAGTGCTCGTGAAACTCGATGCAAGACGGGGAAAACGAAACGCG
		ATAAATCGTGAGAAAAGAGAGTGCCTAAAGGAAGAGGGAGTGATAATCAN
		ACGAAATGGAATAATGTNTTGCAGAGGCNACAACAACAAATGCAAATAGTTG
		TCATTGAGGCGCAATGAATGATAATTAGTGCTTANTTGAAATCATAATCNTGA
35		AGAAAGCGTAAAGCTCGATTNTGGCAATNTATTCTTGATTACCANTGAGTCTG
		TGATATTGCCGTGTGTNCCGAAAATGGANGTTATNAAACCCATGGACTTCAGC
		ACCTTCTCCGCGTTCTGCGAACATCTTAACAAATCTCCACAAAATTGCAGCAA
		CAACTGCANCGACGGTACCGCCAACTATAANCAATGGAAAANGCATTATTG
		GAGGTAANAGCNAAAAATACCAATNTTCCAATGCGAAATTGCNAGCNTGG
40		
	Genomic hit, Accession No.	AC004274
	Annotated <i>Drosophila</i> genome genomic segment	AE003590
	Annotated <i>Drosophila</i> genome Complete gene candidate	CG13693 - novel
45	Human homologue of Complete gene candidate	6e-05 4507659 translocated

180

promoter region (to activated
MET oncogene)
>gi|1730009|sp|P12270|TPR_
HUMAN POOR MATCH

5

Putative function No homologies to indicate function

Confirmation by RNAi Only wild type profiles observed

Example 62 (Category 5)

Line ID 162/24
Category 2nd chromosome, small imaginal discs
Reversion R
Map Position 55C

Rescue ID EcoR1
Rescue Sequence 1

10 TTTTNTTTCANGGNTCTTTGCNCATAAAANACACGNGCCCTCNTGTCCATTTCAC
ATTTTACTTGGAGTCGGTAACGTTGAGTTCCGCGTCCGTGCGTTCTGCCTTCCA
ATACAAAGTCTGGTGTGAATCTACCAAGCATTCCAGTGNGAAAATCAACTCAC
ATTGCTCGGTGATCCNTGCGGCGGTATNATCGCACCCGGAATTGCATAAGTTG
CGGNGAGCGGAAAGAGAGTGCACGGATTTCNGTTATCNAAGGGCCGGCANC
15 NGTGGGGCGGCGACGGNAGAGCACGCAGAANAANAATANANTGNNGTGGCG
AATTNAAAAATANNATNAAAGAAAATTCGGGCCGCTAATTTTTCTTCAAATTT
GTGTGCGGTGCGCGAAAAACAACGTGTTTTTCNATGGTTGATAATACACACGG
ACGGNNCACTCGCGCTCACCCACATAGTCACNAAAGTCGGCGACGTGACGA
CCCNACNCTCACATANGGACNTTTAATCCCGTNCATNCGTGTAGCGTNCNTA
20 TTAAACCNTNTCTGTCCATCGGAACGCNCGCNTTCTCGCCTTCNTTCTNCTTTA
CTTTAATTTCTATTTNNAAGGGGNAGNCCNATCTTTTTNCCNTNCNNTGCCNT
TTAANNTCATCCACANCTCNCNTTNTCCTCCNCCTTNTNTTCTTTTCTC
TTNCTTNTGNCCTTGCCTCGTTCTTTCTCTTCNTCTCCTTNCCTTCTCCTCCTT
TTTCTCCTTCCCCC

25 **Rescue ID** BamH1
Rescue Sequence 2

AAGNCNCCTTGGCCGNNTTNAACGGNAANTAANCCGGGNCCNCGGGNCNCGA
TAATCAGGTCNANCCTTGTGCCTACCACCACCAAATTGAAAAAGAGCNAAGA
30 TTCTCTAAGGCAAAAACTCCCCAATCTGTGGAATTTCCGGAAGCGAGAGCAC
ATTCAAAGCTACCAGTTATCAGCGAGCAGCATGTCTAAGCTCAGGAACCTGTT
GCCACAATCTTTGGCGGGAAGGAGGCACAGAATCCGACACCCGTCGAGGGA
CGCCTGGAATAGGACGCAGCTCCCGTGGACGACAACGAACCNGATTACTACT
ACTGCGGAGCCATGGCGCTGCCCTCCACCGCTGGCACGCCCACAGCCTCCTCG
35 GATCTGACCGAATCCGTGCTGCGCGAGCTCAGCGACCCAACTACAATTCAAT
GGATGTGGTGCTTTCCNNCTNTTTTCCGGGCACTCTCAGTAACGTCCAGACAA
ACAACACCATGAACGTTACNCGCGCCAGCAACAGGTGGTCATGAACTTCTCG
AATGCCAATAATCTGCACTTCGGCTCCGTCTTCAACTTCAACCAAACTTGAG
CGCCTGCNGCTCNCGAANGGGTTTACCNGTTCGCANAAGAATCGGTGCGCTC
40 TCCANACNGT

Genomic hit, Accession No. CSC:AC012981

Associated ORF

45 Genscan ORFs: ORF2 predicted sequences
>18:26:17|GENSCAN_predicted_peptide_7|1320_aa

MEETNNATTIEQQPIALINGQEQVANEQQPSSPTSVATPTSTTSGGTGNATPAFSY
 DDLFPALPANTS AQSSQSGASGTLARVTSSQKTHIVHVPCKERKSTESEKFGESES
 KRICQQITKETGAQIEIASRQVTVPREHFRVILGKGGQRLREIERVTATRINIPSQSD
 ESEFITIAGTKEGIAQAEQIRQLSAEQYKKSSDRITVPKVYHPFIVGPYSENLNKLQ
 5 EETGARINVPPQQVQKDEIVISGEKDAVAAAKAKVEATYKDMKKCSTVSVEVAK
 PKHRYVIGPKGSTIAEILQLTGVSVEMPNDSPSETITLRGPQVALGNALTVVYQK
 SNSVKSVEINAAHWIHKYVFGRKGANMKQLEEDCPNVNVNCLDKIKLEGDPEN
 VDRAYAYLSEIKNYEENFTFEVMTVNPSYYKHIIKAGANVNRLKDELKVNINIE
 EREGQNNIRIEGPKGVRAQLELQEKIDKLENEKSKDVIIDRRLHRSIIGAKGEKI
 10 REVKDRYRQVTTITPTQENTDIVKL RGPKEVDKCHKDLLKLVEIQESSHIEVPI
 FKQFHKFVIGKGGANIKKIRDETQTKIDLPAEGDTNEVIVITGKKENVLEAKERIQK
 IQNELSDIVTEEVQIPPKYNSIIGTGKLISSIMEECGGVSIKFPNSDSKSDKVITRG
 PKDDVEKAKVQLELANERQLASFTA EVRAKQHHKFLIGKNGASIRKIRDATGA
 RIIFPSNEDTDKEVITIIGKEESVKKAREQLEAIKECDEVTEGEVSVDPKHHKHFA
 15 KRGFILHRISEECGGVMISFPRVGINSDKVTIKGAKDCIEAARQRIEIVADLEAQT
 IEVVIPQRHRTIMGARGFKVQVTFEFDVQIKFPDRDATEPVEGLTNGGSGENG
 GENEGQEGEQEVEKEAEQEPVRQCDVIRITGRIEKCEAAKQALLDLPIEEELSVPF
 DLHRTIIGPRGANVRQFMSKHDVHVELPPSELKSDVIKVCCTPARVAEAREALVK
 MIEDYEADRADRELRSFVLQVDVDTFEHSLIGRHGAVINKLRADHDVVISLPKRD
 20 EPNDRIISITGYQANAEAARDAILEIVGDPETLHREVIEIDKRIHPHLIGQRRRTIRKII
 EDNKVNKFSADDDNPNISIFISGKIEDVENVKELLFGMAEDYERDYLNDVAIAPPTI
 GAFLTGFWRRCRRCQRRIRHQRRTVGEAKAGQKPDCAQHSVAGGLPALRCWRG
 SGGLHAYHLRVGPQKLSASGRVSRSPAVAAILQVGVRRGSELEMDQELEQKLELE
 LELDYRAMSGRAAAVVRTSL

25

>18:26:17|GENSCAN_predicted_CDS_7|3963_bp

atggaggaaactaacaacgaactaccatcgagcagcagccatcgctctcattaatggccaagagcaggtggccaacgagca
 gcaaccatcctcgccaacttcagtgccacgcccactagtagcaggcggaactggcaatgccacaccgccttagctac
 gacgacctgttccggccctgccggccaacttcggtcaatcgcaatcgagcgttccggttcgacttagctcgtgtgacgag
 30 ttcccaaaaaactcatattgtgcatgttccctgcaaggagcgcaagtcacaggagtcggagaagtttggcgaaggcgagtcgaag
 cgtatttgcagcagatcaccaaggagaccggagcccagatcgagattgccagtcggcaggtgaccgttcctcgggagcacttc
 cgcgtcatcctcggaagggtggccaacggctgcgcgaatcgagcgtgttactgcgacgcgcatcaacatcccagccagag
 cgtatgagagcgagttatcacgattgccggaaccaaggagggtattgccaggccgagcagagatccgtcagctgcagccg
 agcagtacaagaagtcacgaccgcatcacgggtgccaaagtaccatcccttcacgtgggcccctacagcgagaacctaaa
 35 taagctgcaggaggagaccggcgtaggatcaacgtgccggcgcagcaggttcagaaggacgagatcgatcctcgggcgag
 aaggacgcggctgcagcggcaaggccaaggtggaggccattacaaggatatgaaaagaagtctctaccgtcagtggtga
 gtagctaagcccaagcaccgatattgcttggtccgaagggtccaccatcgccgagattctgcagttgaccggtgtgtctgtag
 agatgcctcccaatgactccccctcgagacgatcatttgcgtgggcccgaagtggcttgggaaatgccctaaccgttcttac
 caaaagtcactcgggtcaagtctgtggagatcaatcgggcacattggtatccacaagtatgttctggtcgcaagggggccaaca
 40 tgaagcagctggaggaggactgccccaacgtgaacgtgaattgcctggaagacaagatcaagctggaggagatcccgagaa
 cgttgacagggtctgtagcctactgtccgaatcatcaaaactacgaggagaacttcacattcaggtgatgacgttaaccttc
 gtactacaagcacatcatcgtaaggctggagccaacgtaaatgcctgaaggatgaactgaaggtaacattaacatgaagag
 cgcgaggggccagaacaacatcgtatcgagggtcccaaggaggagtagggcagggcagcttgaattacaagaaaaatcg
 acaaaactggaaaacgaaaaatgaaggatgtgatcgcaccgccgtctccatcgttctattatcgagctaaaggcgagaagatt
 45 cgcgagggtgaaggaccgtaccgcccaggttacaatcacgatacctacgccccaggagaataccgatattgtgaagctgcggg
 acccaaggaggtgtggacaagtgcacaaggatctgctaagctgtgaaggagattcaggaatcgtgcacattatcgagggtg
 cccatctttaagcagttccacaagttctattggcaaggcgccgctaacaatcaaaaagatccgcgatgagaccagactaaaat
 tgatctgcctcggagggtgacaccaacgaagtgtatcaccggcaagaaggagaacgtgctcgaggcgaaggaaacgta

tccaaaagattcaaacgagctttccgacattgtaccgaggaggtgcaaatcccgcccaagtactacaactcaatcatcggcact
 ggccggcaaacatcatctcctcgatcatggaggaatgcggtggtttctatcaagttcccaacagcgactccaagagcgataaggt
 cactattcgcggtcccaaggacgatgtggagaaggctaagggtcagctattggagctggccaacgaacggcagctggcttctt
 accgccgaggtgcgcgccaagcagcaacaccacaagttcctgatcggcaagaatggcgcttctatccgtaagattcgcgatgcc
 5 actggtgcccgcattatcttccctcaaacgaggacactgacaagggaagtatcaccatcattggcaaggagaagcgtaaaga
 agggcccgtagcagctggaggcgatcatcaaggagtgacgaagtaaccgaaggtagggttctgtcgatcccaagcaccac
 aagcacttcgtggccaagcgtggttcatctgcaccgcatttcggaggagtgccggcgctgatgatctcttccccgtgcgg
 catcaactccgataaggtagcgaaggggtccaaggactgcattgaagcggcccgccagcgcatcgaggagatcgtcgccg
 atctggaagcgcagaccaccatcgaggtggtgattccacagcgatcatcgaccatcatggcgccacgtggttaaggttca
 10 acaagtacctttgagttcgatgtgcagatcaagttccctgatcgtgatccaccgaaccgctcagggtctgaccaacggaggc
 agcggagagaatggaggcgagaatgaaggccaggaggagagcaggaaagtagagaagggaagccgaacaggagccgggtc
 gtcagtgccgatgttatccgaatcacgggcagaattgagaagtgccaggccgcaaacaggctctgcttgatcttaccatcgag
 gaggagttgctggtgccttccacctcatcgatcatcgaccgcggtgccaatgtcgtcagttatgtccaagcagcat
 gtgcacgtagagctgccacctagtgagcttaagtcggatgtgatcaaggctcgcgtacgcccgtcgcgtcgccgaggccgc
 15 gaagcgcgtggtgaaaatgattgaggattacgaggtgataggccgatcgtgagctgcgtccttcttccaggtggacgtaga
 tacggaattccattcgaagtcattggtcgtcatggcgctgtgattaacaagctgcgtgccgatcacgacgtcatcttctgcct
 aagcgggatgaacccaatgaccgcatcatctctatcaccggctaccaggccaatcgaggagcagcccgcatgccatcctaga
 gattgtggcgaccccgagacactcatcgaggttatcgagatgataaacgcaccccccacctcattggccaacgcgga
 cgcaccattcgcaagatcatcgaggataataaggtaacatcaagttctcagctgatgatgacaacccaattcgtcttcatcagt
 20 ggcaagatagaggacgttgagaacgtcaaggagttgcttctcgcatggctgaggactacgagcgtgactacttgataacgtg
 gcgatagcgcgccaacgattggtgccttccctaactgggttctggatccgatgccgcaggtgccagcgagaacggattcgtc
 aaagacgcaccgtgggagaagcaaaagcaggccaaaacctgactgcgccaacactcagtcgcaggaggacttccgcact
 tcgctgctggcggggctcgggtggcctccacgcctatcacctcgtgtggggcccaaaaactaagtcacggccgagtgct
 ccgatccagcagtagcagcaataactacaagtcgggtgcgcccgggagtcggagctggagatggaccaggagctggagca
 25 gaagctggaactggaactgaattggattatcgggcaatgagcggcagagcagcggcagtcgtcggacatctctttag

Drosophila Gene Hit BLASTN with rescue sequence 1: dodeca-satellite protein 1 (DDP-1) (AJ238847). TBLASTN with ORF2:dodeca-satellite protein 1 (DDP-1) (AJ238847).

30 **Drosophila EST** GH20785 (AI389573), LP07358 (AI294065)

Annotated Drosophila genome genomic segment AE003799

35 **Annotated Drosophila genome Complete gene candidate** CG5170 - Dpi dodecasatellite DNA binding protein
 CG5576 - Bg5 involved in cytoskeleton organization and biogenesis which is putatively a component of the plasma membrane

40 **Human homologue of Complete gene candidate** CG5170- 4885409
 ref|NP_005327.1|pHDLBP| high density lipoprotein binding protein
 45 >gi|2498434|sp|Q00341|HB

5

CG5576- 2e-07 4506539
ref[NP_003795.1|pRIP|
UNKNOWN >gi|3426027
(U50062) RIP protein kinase
[Homo sapiens]

10

Putative function CG5170: DNA binding protein (homology with Scp160p, a new
yeast protein associated with the nuclear membrane and the
endoplasmic reticulum, is necessary for maintenance of exact
ploidy)
CG5576: death domain containing protein, possibly involved in
signal transduction

15

20

Confirmation by RNAi CG5170: Reduced G1 and G2/M peaks indicating fewer
cycling cells and more polyploidy
CG5576: Loss of G1 peak

Example 63 (Category 5)

Line ID 40/2
Category 2nd chromosome, small imaginal discs
Reversion NR
5 **Map Position** 39B

Rescue ID BamH1

Rescue Sequence 1

TTTTGCCTCCGCTTTTAAATTAATAAAAAATGTNTGTTTNGCCCTGGAGCTCTCG
10 GTCTGTTAGCGAGCGTTGCCACCTTTCTGCGAGCTGTTGCTGCACACTGCCACT
TTACGAACACAGCTCTGATAGCGGGACAAAATACGTCAAGGCAGCGACGGTG
GGTTACTAGTGAATTTGGAACGGTGGTCTTAAGACGTAAGTGGTCTTTTATATTT
TCATTATTTTTTAAATTGTCGCTCATTTACCAATAAACCTTTTTACTTTTTCTCG
ATAGTCCGAAGTCAGATCAAATAGGAAGTTTCACAAAAAATTTTCATCCAGAG
15 AAAATACGCCGACGCTATTCGAGTTTTTTGTATTGTTAACCAGGAAAGAATA
GTTTCGAATTCGTTTCGCACCTTTATCGATAGTAGATTGCTATTATGGAGCCCACTA
GTAAATTAATTAATTAATCCAGACTGATAAAAGCGATCAACTTTTGTTAATGGGT
TTAANTCTATAATAATNCTTAGTCCAAATTGTNTCAAAGTAGTCGATAATTTAT
AATAACAGTTTTAGATGACCTCTAGGAAATAACTAATTACCCACATNCTTCAA
20 GAAAGTGTTTNCATTTGTNCTATAATTAATAACAGTTGTATTAATTATGTTG
TNATTGTNACTCATAATACAAATTAACAATATAAACACACATAAATAAGAG
AATTGGAATATTTTGTCTCAGATTAGATTNCCAC

Rescue ID EcoR1

25 **Rescue Sequence 2**

AACGGGGGGCTTCCGCGNCNCCAAAACGCAATNTACCGTTCATGCTGTGAAG
CGAAAAAGAGTGGTAGCGCTACCNTGGCATATGTAGTTAAATCCGTGAAAT
AAGTGAATAAGAATATATGTATGTACTTAATTCGAAAACCTTTTCGCCGTCAG
CACAACGGGTGAACGAGAGAGCGGAAGTGGAGTTTTTTGTGGCGGGTCGTCT
30 CGCTCGCACCCGCAAANGTCGTCCGTGGCTGCGTGTATGGGTGTGTGGAAAAA
GCGTCGAGGTGAATGTGGATTTCTAACCACACCAGCATTGCAAAGACATTGAT
TGATATTTAAAGCTGCAGCAGCGAACAAGCAAATCCTAATTTCCGGCAAAGTT
TAAGAATAACGAGTGACTGGGGCGCGCGCAATAAGATAAAATTGAAGGTTAT
CTGTGTGCGTGTGAGTGACCGTNTACCAAGTGTGTGTGTGCGANCGTCCATTGT
35 AAACAAAAACAAGTGTGTGAGCGGAGAGAGAAAGGGAAAGAGAGAAAG
AGCGAACAGACTGGCGAGAGAAAAAAGAGATGCCACAAANAAAGCAGCGCA
CAAAGGAAAGCTGAAAATTTTANTAAATCTGAAAAGTGAAGAAAACCACAA
GAACCCGCAGTCNTGTAAATAAAACCCAGANTCCAAGAAACNTTAAAGAA
GCAGTGCAAACAACTGGTGCTNTGAATGCGGTTTATTTTGAATAAAAAATGCA
40 ATTCGGTCCGATGGAA

Genomic hit, Accession No. CSC:AC014744

45 **Drosophila EST** several including LD46342 (AI544109 BLASTN similar to mRNA
L07550)

Annotated *Drosophila* genome genomic segment AE003669
Annotated *Drosophila* genome Complete gene candidate CG8678 - novel with ankyrin
homology

5
Human homologue of Complete gene candidate CG8678 -gi7661580
B69CEC399B56F35C
|ref|NP_056425.1|DKFZP434J
10 154 protein [Homo sapiens]
(2.20E-85)

Putative function Novel protein with ankyrin domains, unknown function

Confirmation by RNAi Reduced G1 and G2/M indicating fewer cycling cells
15

Example 64 (Category 5)

	Line ID	55/12
	Category	2nd chromosome, small imaginal discs
5	Reversion	NR
	Map Position	49C
	Rescue ID	BamH1
	Rescue Sequence	
10	TCTCATGNTCAGGGGGCCTTTACNATGTCAAAGAGCAAATTGTCCACAGGGCA GCAACCGCAAGTGAGAGACGGGTGGAAAACCTGGGCGGCATGACCATGAATGA AAGCCGCGACCGGCAAACGTGGCCCGCCCAAAAGCGAGCATTTTCACATTTT AACTGTCTGGACATTTTGAAGTTACACCAAGGCAATGATACCAGTAAAAAAG AAGAAACAATCATTTTTGAATAGATTAATCACCTGATTAATGTTGGTTGTATGT	
15	TGATTGTAGGTGTTTTAATATACAATGTCTCTATTACTGCTTTCCTTTATTCAA AGCCATGTGTAAGTGTAAGTTCTCGATTTTCGGCTAGATTTTGAAGTTCTGCCAT TATCAATTAAGTCCAGTTCCTCTATAAATTGGTAATAAAATAGCTCTTTACA GCCAAGTATATGTGCAATTTTGAAGATTAAANGTCCAAATGTTGTGAACCTT TCCTGGCCCTGAATTTAAAAAACCATTAAATTGGTCCCATTTGACATTAAATG	
20	TTCTATGTACATTAATATGACTTTTTGTGGATGGTTTTATAAACAAGCATTACT ATATTCTAAAAATCAAGGATAAAGGACNAGCTTTACAGGAGGTAACATTCCTA TTGTACGGCTTTATTTTCTTATACCCATAAGAGCATACCACTAGGATCCGTCGA CCTGCAGATCTCTAAAAACTTGCCTTTGCTGGCGTTTTCCATAA	
25	Genomic hit, Accession No. AC007085	
	Associated ORF	
	Genscan ORF1 predicted sequences >21:54:11 GENSCAN_predicted_peptide_3 108_aa MGLVTAAFKLKRKDIQDRYQHDINRICHTRSTAHTAYAHFAEHLRRSPRQRFVN	
30	GKGAALVLLLVSARQFSGSTGAYKLGNRVVGKVEGEQEQYKLQDRTHFCGN	
	>21:54:11 GENSCAN_predicted_CDS_3 327_bp	
	atggggctggttaaccgccctcaagctgaagcgcaaggatatccaggacagatatcagcatgatattaaccgcatctgccaca	
	cacgtagcacggcacacacggcgatgctcattttcgggagcatctgttgacgaagtcacgtcaacggttgtcaacggcaa	
35	aggtgctgcgctgtgctcatcctcctcgtttctgctgctgcagaattttctgctgcagaggtgctacaaactgggtaataagagttg	
	gaaaagtagaagggaacagcaggaatacaaaactacaagacagaacaacacattttgtggcaattaa	
	Corresponds to CG8732	
40	Annotated <i>Drosophila</i> genome genomic segment	AE003836
	Annotated <i>Drosophila</i> genome Complete gene candidate	CG8732 - l(2)44Dea
		homology to fatty-acid-
		Coenzyme A ligase, long-
		chain previously described
45		spindle/chromosome

abnormalities in neuroblast
squashes

5 **Human homologue of Complete gene candidate** 1e-171 4758330
ref|NP_004448.1|pFACL3|
fatty-acid-Coenzyme A ligase,
long-chain 3
10 >gi|4165018|dbj|BAA371 and
LCFD_HUMAN LONG-
CHAIN-FATTY-ACID--COA
LIGASE 4 1e-157

Putative function Fatty acid CoA ligase

15 **Confirmation by RNAi** Only wild type profiles observed

Example 65 (Category 5)

Line ID 6/7
Category 2nd chromosome, small imaginal discs
5 **Reversion** NR
Map Position 28E

Rescue ID BamH1
Rescue Sequence 1

10 TATNAATAATCATAGGGCTCTTGCTCTTACGTGTAAGGCCTGCCCTCTNCCA
GTCTATATACAAAGAAAAACACACACACTGGCACACTGGTGTTTCGCATATG
CCAAAGCCGAGTTAATTTCACTTTGTTTAACTATCGTTTGGTGTTTTGCATTT
TTTAACCGCGCAAACGGTATTTGCGCGTTTTGCGCCTCTTACTTTGCGATTTAT
TGCACCGCTTGGCTGTGTTTTGCAATTTCTATCTTGATTTTCATTGGTATTCACG
15 CGTAATGTAATTCCTTAGCAGCGTGACCGCGCCGATAACGATAAAAAATACCAC
GGGACCAAAAATAAATACCATATGATACCACTTCAGGGAAAAGAAATCCTAT
TTAATACCACTCACTTTAAAAATAAGTTTTTAAAAATATATATNTTTATTTAAA
AAAAGGTGTATTTATAATCAAATACTCGGTACTTNTTAATTACTCCAAGAANA
ATTAATTTGAAAAAAAGGGGTTCCATTATAAAATATATATTAACCGCTTACAC
20 ATAATCCCCAAACAAAACAGCGATTGGGATTTAAAAGGTTCTAAGTCCATCAT
TATAAAAGATCATTTCCGAAAAACAAAAGAAATAGATTCAAAATTAGGCGAC
ATCAGCCCGCTGATAANGATCATAAAATACAGAAGCTNATTCAGCGAATCA
GAAANTCCTACTCGCCACTATCCGAAAACNTNGAAAAAAAATGG

25 **Rescue ID** EcoR1
Rescue Sequence 2

TGAAAGGTAGCAACAACGTTTCCTTGGAAGGCTGTAAATAGTAAACAAAA
TTGTCAAGTTAACGAGCCAAAGTTATTAATAAGGTTTCGAGTACGTTGGCATC
GGCTGCCCAGGCAGCAAAANAAAAACAAAGACGCAGTTCAAGATCAGCTGGAC
30 ACTTAGAAGANTTTAAGAATTGAAGCACATTNNAAGAAGANAAACAAGAAC
CCCACAAAAACCCGCGTGCGTTTGTATGTGTGTGTGCCATCAAATTTCCCGC
ACTGGGTGAATGTGCNTGCGTGTGTNTGTGTTCATTTAATTTTCTACCAATAA
TCGCCTTCCAAGAAGTGAATACCAGCCGATCCACCGCTAAATCGAAAAAAGTT
TNACTCTGGGTAAANTCACTGTTTACGGCTTTTGTGCTATAATTACCTTTCCCG
35 TAAGCNGTGGGAANCTAAAANCCAAAACNTNAGAATCCGAATTCCG

Genomic hit, Accession No. CSC:AC017934

Associated ORF

40 Genscan partial ORF1 predicted sequences
>22:35:21|GENSCAN_predicted_peptide_4|128_aa
MG TNSGATAGINNKPVGGATGAGVLVGGGVGGANSSIGGVLSNSLGGGGSGGLS
ISGLNAGGQNANVGGMGNVGGDDGGNGMVGGGVNNQQATTTPQYTIPGILHFIQ
HEWSRFELERSQWDVDRAELQ

45 >22:35:21|GENSCAN_predicted_CDS_4|384_bp

atgggcaccaattcgggagccaccgctggcataaacaacaagccggtggcgggtgcaacaggagccggcgctcctttagggcg
 gcgggtgtggcggtgccaattcctcgatcggcgggtgtcctgtcgaacagcctggcggtggcggcagcgcggtctgagcatc
 agcggcctcaacgctggtggacagaacccaatgtgggcggaatgggcaacgttggcggcgacgacggcggaacgggatg
 gtggcgggcggtgtaaataaccagcaggccacaacgccccatacacaataccgggcatcttgacttcatccagcacgagtg
 5 tcgcgcttcgagctggagcgatcacagtgggacgtggacagggccgaattgcag

Human Homologue TBLASTN with ORF1: very weak homology with striatin,
 calmodulin-binding protein (STRN) (NM_003162.1)

Drosophila EST several including LD42534 (AI516610), LD03224

Annotated Drosophila genome genomic segment AE003619

Annotated Drosophila genome Complete gene candidate CG7392 – novel WD40 family
 member

Human homologue of Complete gene candidate CG7392- SG2N_HUMAN
 CELL-CYCLE NUCLEAR
 AUTOANTIGEN SG2NA
 (S/G2 ... 622 e-178 A cell-
 cycle nuclear autoantigen
 containing WD-40 motifs
 expressed mainly in S
 and G2 phase cells

Putative function WD40 protein a novel nuclear protein mainly expressed in S and
 G2 phase cells that was characterized using autoantibodies from a
 cancer patient

Confirmation by RNAi Reduction of G1peak , more polyploidy

Line ID 103/1

Category 2nd chromosome, small imaginal discs

Reversion R

Map Position 57B

Rescue ID BamH1

Rescue Sequence 1

GATTTCAAAATTAGGCGACATCAGCCCGCTGATAAAGAATCATAAAAAATACT
 GAGGCTTATTTAGCGAGTCAGAGACTCCTACTCGCCAACATATCGAAAACATA
 GNGAAGATATAGTCGCCAACCGATCTGCCTTCTATAGTGTTGCTTATTGTTGTC
 CCCTAATCAAATTAATAAAAAATCTGCATTAGGCTGCTTCGCCGCCAGCAACA
 AATGTTTTACACCTACTGTACTTTTCGCAGAACAGAGATCCAAATGCAGGATC
 GTTTCATGACTGTACATTTATTCGGATTAGACATTAAATTACACCCTACAGCT
 ATACATACTAACAGTGAACACGGCAAATGCTTAGCTAGCATTGGGCCACTTTC
 GTTGACTGCGAATAAAAAATGATTGGCCGATGCCTTTAGCAGATTCTTTTGAT
 CGAATTACTCGGATGGCTTGTGTGTCCACCTTTACAAGAACTCCTCGCACCA

ATCGTTGAGACAGTTGTAGCAATCGGATGCTTGGTTGGAGCTGGCGTGGCACA
CCTTCTTCATCCAGTCCTTGGACAGNTTCTTGGNCCTTTTCAGNANCAGGATCT
GGTCCCAAACGGNGGAAGGCCTAAAACGAATGGNAATTGATCGGTAGCCCTT
GACTGGCATTGGTAATTTGCGCACATGGGNGTCATCGGATTTACACACGCACC
5 ATATCGAATCAGCGTCCTTAAGCGTCAACCGAGGGTTTCCCAATTCCGGCCA
GTTCCGTCACCGACTTGGTTGCCATTGG

Rescue ID EcoR1**Rescue Sequence 2**

10 ATCAAAGCGNCTGGGCCCGTGCATCGCCNCAGCGTTCGTCTTAATTAATTAGT
GATTGCAAGCGGGTGCAATTATGCACAAAATTACGGACTAATACAACCTGCC
GCTTCGCGCTCTCTCCATCTCCCTTCCAAATAGTCGTTTGCTCTTCGCACACAA
AAGTGTAACCCCTGTGAAAGGTAGCAACAACGTTTCCTTGGAAAAAGCTGTA
AATAGTAAACAAAATTGTCAAGTTAACGAGCCAAAGTTATTAAATAAGGTTTCG
15 AGTACGTTGGCATCGGCTGCCCAGGCAGCAAAGAAAAACAAAGACGCAGTTC
AAGATTACGCTGGACACTTAGAAGAGTTTAAGAATTGAAGCACATAAAAAAG
AAGAGAAACAAGAACCCACCAAAAACCCCGCCGTGCGTTTGTATGTGTGTG
TGCCATTCAAATTTCCCTGCACTGGGTGAGTGTGCGTGCGTGTGTGTGTGTC
AGTTTAATTTTCTACCAATAATCGCCTTTCCAAGACGTGATTACCAGCCGATC
20 CACCGCTTAAAATTGATAAACGTTTAACTCTTGCGTTACATCAGCTGTTTAC
GGCTTTTTGTGCTATAAGTTACGCTTTTCCCGTAAGCCGTTGGCAACACTAGAA
CGCAAAAGAGCATAAAGAATCGCGAGTACCGTANAGAGGAAGAGAGGAAGA
GAGAGAGATAGAGAGTGTGAGCGTGTGAGTGAGCGGGGAATGTGGGGGCGGT
TCCGGTGCGAAAAAACGTAGTAGTAGTACATNNAGAGAGTGCGAACGAGAGG
25 GAGGCAGCCAGCGAGTGTCTGCGACTGCTCCCCCTTTACCCTCGTCGCTTTT
CTATTCGGAAAATTCAATGACCTCATTTGTTTCATGTGCCGAACTTTGCTTTTC
TTTCCCAACCTAAAAACGCAAAAAAAAAAAAAACNCCAAACAGGATATACGTNG
GAACANTGANCAAAACNANTTCGANAAAACCAACAACNANGGACCGTGCCCTG
GGGCNCCTGAAAGGCAAACAGCTGGCNCNCAATCCGGAAAAGGATCNGGAA
30 NAACAGGATCNGCGGGCNCAAGGATCNCCGGAACAGGCAAAGGAAACNCCC
GGCNACNGCACAAGCCNCTGAAAAGCAACNTGAACCAATGGGCACCANTTC
CGGGANCCACCGCTGGCATTAAA

Genomic hit, Accession No. CSC:AC017934

35

rest of results as for line 6/7

Example 66 (Category 5)

Line ID 65/24
Category 2nd chromosome, small imaginal discs
5 Reversion NR
Map Position 48A

Rescue ID BamH1
Rescue Sequence
10 TACGATTTTTGCANTGCNCCATTTCGTGGCACCCGATTGTATATATATTTTTT
ATATAACCCACGGATTGCCAACTTTCATTGCCCTTTCACACTCTTATTCGCCAT
TTATGAACTCTTCTTTGACGATTGGAACGGTTCCTTTTCGCTATTTTCGACTGC
ACCCGCGCTCTTTTCGCTTCGCTCTCCTCCCTCTCTACACACCGCTCTTTATCCT
TAATTGCTTTTTCTATTTAGCGGAATTGATCGTTCCTCAACTTGGTCGCCATTGC
15 AGCTCCACAGGCGAAAAAATCGGTGGAAATGCCAATACAGGTGCACGGCGAG
TGCCGATAAGCTGGAAAAATCGGGAAAACGCACGCCTACACATTTCATTGCCAG
CATCGGCTTTGCCTTTTCGCTGTCGAGATTAGCATATTTCCACTTTTGGTTCGC
GCACAACACTANCTAAATTATTGNTTATTTTTTTCCCAACTGTGAGGTGAAAC
TGTGAAACAAAACCACTGTGGGCGGGTCAGTGTGACCCTCTCGCGGTGGGTG
20 AAAATCCTAGTGAGCTTCGTTGTTAGGGCTGTATGACACGAAAGCAAGTTGAA
AAGAACTTTTTTAAAATTATATTGGTTAATTGAGCAGAACTAAACTATATN
AAAATATTTAAGAATNCAGATTAGTGATGTATTTAATATAATAATAGTAAGAT
GTTC

25 Rescue ID EcoR1
Rescue Sequence 2
CTTNTTGTATAGANATAGGCTTCTTTTAAAAAANAAGCAGCANCAGGGG
CCNGAAGTGCGTGNNTGTGAACGCTGATTGCTTGCAAGTGTGTTCTGTGTG
TGTGATTGTGTGCTCCGANCAAGTGAAATCAATAATTTGCAGCCACAAGCA
30 ATTAATAAAAACTGCAATAATGTCAAAAAATCTAATTGAGGCAACAAATTAN
CAAAGCCATNAAAGCAGGCTGCACTGCGAGAAAATTGTGCCTTTCCACAGAT
CTTCTGCTGCAAAGCNAAAGAANGTAAGCAAGTCGGCCANTTTATTNCATTCT
TCTCATCTCTCTTCTTCGCGAATTGGCGCNTANCACTTACAATAATTNATATNA
CTTCTTAAATTTCAAANTCCCTTTCNTGAACGGANCTTTTAACGGAAAAACAAA
35 GCGGGTAAACTAACTTAACTAACTAATTANAANTGTANGTATAAATGAACC
GAACTCGCTTTAGATATNATGCGTTTCACTAACANATTANAACAAACTTTGAA
GCTGTANTGTCAGGTGTTATTNCGTTCACCANATGTAGACTGNCCGNNAATT
TNACCTTTCCCATANTCTGTTCTTAANTGTNTTGTTTTTTCCCAATNNTTTGATC
ATNCNTTGGTNAATNANCTNAACGGCCCCAAAGTNAATGAATTCCANTCACGTC
40 CACTGGCTCTGGTTCNATANTTAATNGGCTGTTTCTTACTTCCCTTAACCCTAA
CATCTNTTAATCACCTGTGCCATNTGTTTGTGTGTGTGTGAACGAATGAGAAA
AAAAA

Annotated *Drosophila* genome Complete gene candidate CG9005 - novel putative cell adhesion

5 **Human homologue of Complete gene candidate** CG9005- Ensembl predicted gene
ENSP00000006008
Gene:ENSG00000005238
Clone:AC004472
Contig:AC004472.00001 6.00E-38
10 (KIAA1539 protein AB040972) and
AK022837 Homo sapiens cDNA
FLJ12775 4e-33

15 **Putative function** Putative cell adhesion protein

Confirmation by RNAi Reduced G2/M peak

Example 67 (Category 5)

	Line ID	74/3
	Category	2nd chromosome, small imaginal discs
5	Reversion	NR
	Map Position	47A
	Rescue ID	EcoR1
	Rescue Sequence	
10	GCACAGAATGGCNCCTTCACGACAAAAGATCTNCNAATTAGGATGATGCAGA	
	AGGAGGACACGCTTTTCATTATCTGGTTGCCACCTAATTTAAGTTCCACATCAA	
	GGGAAGAAGGAAAATACGTTCCAACGGACGTCAAATTTACTAACTACACTACTT	
	GAAAAGCCTGTCTATAAAAAACACGATAACGTTTTTGTCTAATCTCAAGACAATG	
	TTAAATATAATTGGAGAAAAGTATTGAATATGAATATCACAAAAATTGTTTAGG	
15	GTCTCTACGTGGTAAATAGTATTTGGCATAGACAGTGAGATGTGAGTCGTACG	
	TACTAATTAATAAAAGTTGTTCAARAGAACCTCATATACTGTAAGTGACAACGA	
	ACGAAGCTGACAACCTCTGCTTGACATATTTGGCGGAGTTGAAAATATCATC	
	GCATTGGTATTGTTTTGTINTCCACCNTGGGGCGAGATTTTGTGTTGCTTTAC	
	TTTGCTTGTTTTTTCNCCACAAANCGAACCATAATGTTTCGAAATGGTAAAATTA	
20	CCGTGCCAACAAGCTCTCTCTCTCCCCACTCCGAACTCTCTCATCTCTCCTTG	
	CAATTGTTTAAAGGTGTGCAAGGAAATGAAAAATGTCCCGGCTGTGTTNCCATG	
	CATTCCCCTTCAAAGCCAATTATNTTTGTGCCTCTCCAACNTTTTTGATCGGN	
	TGATTTTTTTGGCTCCCCNTANTCCCCCCCCCTTTCNCCCATTCCGGGTTANAT	
	TATTNTNCCAATTTTCCTATTTTACGGTCCCN GTTCCCTGGAAATANTTCCTNC	
25	AATCNCCGCTCCATNTCNCCATNTTTGACAGATTTTC	
	Annotated <i>Drosophila</i> genome genomic segment	AE003829
	Annotated <i>Drosophila</i> genome Complete gene candidate	CG12052 lola -a specific RNA
30		polymerase II transcription
		factor involved in axon
		guidance
	Human homologue of Complete gene candidate	1e-09 3789797 (AF059569)
		actin binding protein
35		MAYVEN [Homo sapiens]
	Putative function	lola-like specific RNA polymerase II transcription factor
	Confirmation by RNAi	Almost no G1 peak and increase in G2/M peak indicating
40		arrest in G2/M

Example 68 (Category 5)

Line ID 79/7
Category 2nd chromosome, small imaginal discs
Reversion R
Map Position 55B

Rescue ID BamH1
Rescue Sequence 1

10 GTCTCATGCACCCTGGCCCTNAGCTGCATAAGTGTAAGTGTGTGNCTGTGTGC
 GAGTGTGGGTAGGCGGCGGCAACTATCTCGCTTGCTCTTGCGTCCGGGGTTAT
 CGGTAGCTTCTTCTAGGCTGAGTGCATTTTCGTTGAATCGTGGATGTTGAAAGTT
 GTCTAATTTCCGAACATTGATTTTTCCCTTCCCGTCAAGAACTGCATTGT
 TGCTTCTTGAAGACCAGTTTTGGTAACATCAGGAGAATGGAAAGGAGCGAGT
 15 GAGTCGGTGAGTAAGTGAGTGAGCGATGCGAGCGACAAAATCAACAACAACA
 ACAACAACGGTCAAAACGAGTTCCAACGAAAGTTGCAACACTCTCAACAATT
 TGAGCAGCTCCGTTTGTGTTATTGCATTACTCAATCGGGAAGACTCTACACTC
 GACGGAATAGTGTGCTCGTCTGAAATTTATCNATTTCCATTCTTCCTTTGTTT
 TTGGGCCAAACAATGGCNTCGGCAANC GTTCGTGGAAAACCGCAGGAACCAC
 20 CAAAATGCCTGGCGTCACATTAACCGAGCCGCCTTTGTTTATGCAAATATTATT
 GTAATATTTGGTNAAAATTAAGTCGCGCTTCNCGTTACTTTTTATTTCATATAC
 ACGCAGCAGCAGCAGCAGCAGCAGTCACGTCACGCACACATACAATCGCCGTN
 CACATACACTTGTCTTTTTNCCACACACTTTCCTAATCAT

Rescue ID EcoR1
Rescue Sequence 2

25 NGNGTCTCATGCACCCTGGCCCTNAGCTGCATAAGTGTAAGTGTGTGNCTGT
 GTGCGAGTGTGGGTAGGCGGCGGCAACTATCTCGCTTGCTCTTGCGTCCGGGG
 TTATCGGTAGCTTCTTCTAGGCTGAGTGCATTTTCGTTGAATCGTGGATGTTGAA
 30 AGTTGTCTAATTTCCGAACATTGATTTTTCCCTTCCCGTCAAGAACTGCA
 TTGTTGCTTCTTGAAGACCAGTTTTGGTAACATCAGGAGAATGGAAAGGAGCG
 AGTGAGTCGGTGAGTAAGTGAGTGAGCGATGCGAGCGACAAAATCAACAACA
 ACAACAACAACGGTTCAAAACGAGTTCCAACGAAAGTTGCAACACTCTCAAC
 AATTTGAGCAGCTCCGTTTGTGTTATTGCATTACTCAATCGGGAAGAACTCTA
 35 CACTCGACGGAATAGTGTGCTCGTCTGAAATTTATCNATTTCCATTCTTCCTT
 TGTTTTTGGGCCAAACAATGGCNTCGGCAANC GTTCGTGGAAAACCGCAGGA
 ACCACCAAAATGCCTGGCGTCACATTAACCGAGCCGCCTTTGTTTATGCAAAT
 ATTATTGTAATATTTGGTNAAAATTAAGTCGCGCTTCNCGTTACTTTTTATTTC
 ATATACACGCAGCAGCAGCAGCAGCAGTCACGTCACGCACACATACAATCGCC
 40 GTNCACATACACTTGTCTTTTTNCCACACACTTTCCTAATCATNNTA

Genomic hit, Accession No. AC004296

Associated ORF

45 Genscan: ORF2 predicted sequences >15:31:31|GENSCAN_predicted_peptide_3|109_aa
 MVTSEFRHLRDEKSFTDVTLACEGQTCKAHKMLVLSACSPYFKALLEENPSKHPHIII

KDVSYIHLQAILEFMYAGEVNVVSQEQLP AFLKTADRLKVKGLAETPSSIKREG

>15:31:31|GENSCAN_predicted_CDS_3|330_bp

atggtgacctggtccgtcacctgcgcgacgagaagagcttcacagatgtaacactcgctgcgagggccaaacctgcaaagcc
 5 cacaaaatggtgcttccgcttcagtcctactttaagcgctactggaggagaacccatcgaagcatccgatcattatcctgaaa
 gatgtctcctacattcacctacaggctatactggagtcacgtacgccggtgaggtgaacggtgccaggaacaattgccagcatt
 ctaagaccgccgatcgccitcaaagtgaaggcctcgagagacaccagtcgataaagcggaagggtga

10 **Drosophila Gene Hit** TBLASTN with ORF2: several zinc finger proteins including
 Broad-Complex mRNA for BRcore-Z2 protein (X54665)
Human Homologue TBLASTN with ORF2: kelch (*Drosophila*)-like 2 (Mayven actin
 binding protein) (KLHL2) (AF059569)

15 **Annotated *Drosophila* genome genomic segment** AE003800
Annotated *Drosophila* genome Complete gene candidate CG5738- lola, lola-like
 putative kelch-like putative
 specific RNA polymerase II
 transcription factor known to
 affect disc morphology

20 or could be CG10914 - novel
 unknown

25 **Human homologue of Complete gene candidate** CG5738- 9e-09 3789797
 (AF059569) actin binding
 protein MAYVEN [Homo
 sapiens]

30 CG10914- predicted gene
 ENSP00000051207
 Gene:ENSG00000047313
 Clone:AC068261
 Contig:AC068261.00019
 4.00E-49 (potential cell
 35 division GTP binding protein
 1: ENST00000051207

Putative function CG5738: lola like specific RNA polymersae II transcription factor,
 CG10914: Possible GTP binding protein

40 **Confirmation by RNAi** Both show marked reduction in G1 to G2/M ratio

Example 69 (Category 5)

	Line ID	80/2, 81/8
	Category	2nd chromosome, small imaginal discs
5	Reversion	R
	Map Position	57D/E
	Rescue ID	BamH1
	Rescue Sequence 1	
10	CANTTTCAGAGGCCATAGNCCTTCACAAAATTCNCCATCTCTGCCCCGGCATCC	
	GTGCTTGAAAATGGTGCCAATGCGTCGTGGAGAATCTGCTGCACTCGATGGTC	
	TGCAAAATTGCACATTTATTAGATTTAATAAAATTTTCAACTGTCCGCGANCAC	
	GTTTGCTCGTGTTGAATTCGAGTACAAAATTAGTGCGACTGTTGGATTGCATT	
	GAAATGCCAAAAATCGGTGTGACCATTTTGAAGTCCCCACAGGCTCATGACTT	
15	TCGCGGTTACCAAATCCAAATAACGCAAGCTGGTCACGCTGTCAAACATCGG	
	TGACGGAATGGTGACGACACAAACAATTTGCTTAAAAACTTTCTTGCGGCCGT	
	AAAAATGCGCAAGCAGCCTGGCAGCGCAACGCACGTACACGTAATTGGAACA	
	AATGTTTGCTGAACCACAACCGCCCACTAAATGTTANCCGCCAAGTCTTTTCC	
	CCCGCCGCCGCCGTCNTCNCNCNCCGGATTATTTGGTTTACAATTTGCTTAC	
20	ACAAGTGCAATCGTCGATAGCGCTTCATTTTGGAGTAACAAGTAATATTTTGC	
	GCCGTACTGCTGTTGCGCGTATCAGACAGAAGGTTGGTATCAGTTCGACGCAG	
	CTTGTGACGGTATTGCATACGCGGCGAAACGCCACGTGAAAACGGATCGCA	
	GTTCTCGAAAACTCNGGATAAAAA	
25	Rescue ID	EcoR1
	Rescue Sequence 2	
	TGGGGTCTCANGCCCCGACGGCCATATTTTAACACAAGATTCNNCANCTCTGC	
	AGGGCATCCGTGCTTGAAAATGGTGCCAATGCGTCGTGGAGAATCTGCTGCAC	
	TCGATGGTCTGCAAAATTGCACATTTATTAGATTTAATAAAATTTTCAACTGTC	
30	CGCGAGCACGTTTGCTCGGTGTTGAATTCGAGTACAAAATTAGTGCGACTGT	
	TGGATTGCATTGAAATGCCAAAAATCGGTGTGACCATTTTGAAGTCCCCACAG	
	GCTCATGACTTTTTCGCGGTTACCAAATCCAAATAACGCAAGCTGGTCACGCTG	
	TCAAACATCGGTGACGGAATGGTGACGACACAAACAATTTGCTTAAAAACTTT	
	CTTGCGGCCGTAAAAATGCGCAAGCAGCCTGGCAGCGCAACGCACGTACACG	
35	TAATTGGAACAAATGTTTGCTGAACCACAACCGCCCACTAAATGTTAGCGCCA	
	ACTNCTTTTCCCCGCCGCCGCCGGTTCGTCNTCNCNCCGGATTATTTGTTTACA	
	ATTTGCTTACACAAGTGCAATCGTCGATAGCGCTTCATTTTGGAGTAACAAGT	
	AGTATTTTGCGCCGTACTGCTGTTGCGCGTATCANACAGAAGGTTGGTATCAG	
	TTCGACGCAGCTTGTGACGGTATGCATACGCGGGGAAACGCCACGTGAAAAC	
40	GGATCGCAGTNCTCGAAACTCNGGATAAAAAGAAAAAGTAGGCTGAATG	

Genomic hit, Accession No. AC007175

Associated ORF

- 45 Genscan: ORF2 predicted sequences >16:09:09|GENSCAN_predicted_peptide_3|2497_aa
MNEGNSAGGGHEGLSPAPPAVPDRVTPHSTEISVAPANSTSTTVRAAGSVGAALP

ATRHHQHIAATQVKGIASSSSKQKQLASAPLPVPLSPLPQQQQQTAEATAAAAAAP
 AHSNVSVSSSTIEASVLPPQAKRQRLDDNEDRTSAASIVGPAESSNIVSSLLPASVA
 SSSEVGGLSSTALQDLNALKKRILQKQLILRNLERHLENVSEYFYLQNGGSM
 DYPAWRKKTPTPQFISYSNANRIDQLIHEDKPSTSAAAAAQNQKYTTQQTDSVE
 5 SSLVSGIGTGATKGAPLDGNISNSTVKTNQSQVPSKIGSFTESTPAATESNSSTTV
 GTATSGAATSTSATSASGNVLAVEAEIKIPAVGATPVAISTKLPAAVVQLTQQG
 GTPLPCNTSAGSTALRRPQGQNNASSGSAAASGGGGSLTPTPLYTGNGPAALGG
 SGGTLPGTPTSGSLLSPALGGGSGTPNSAAQEFSEKAKQEVYVMQRISLQREGL
 WTERRLPKLQEPSRPAHWDYLLLEEMVWLAADFAQERKWKKNAKKCAKMOV
 10 QKYFQDKATAAQRAEKAQELQLKRVASFIAREVKSFWNSVEKLVEYKHQTKIEE
 KRKQALDQHLQFIVDQTEKFSQQLVEGMNKSVAADTPSLNSSRLTSPKRESDDDFR
 PESGSEDDEETIAKAEDAADVKEEVTALAKESEMDFFDNDLPPGYLENRDKL
 MKEEQSSAIKTETPDDSDSEFEAKEASDDDDENTISKQEEAEQIDHKKEIDELEA
 DNDLSVEQLLAKYKSEQPPSPKRRKLAPRDELDSDDDSTAVDSTEESEDAATED
 15 EEDLSTVKTDTDMEEQDEQEDGLKSLMADADATSGAAGSGSTAGASGNKDDML
 NDAAALAESLQPKGNTLSSTNVVTPVPFLKHSREYQHIGLDWLVTMNERKLN
 GILADEMGLGKTIQTIALLAHLACAKGNWGPPLIVVPSSVMLNWEMEFKKWCPG
 FKILTYYGSKERKLKRVGWTKPNAFHVCSYKLVVQDQQSFRKKWKYLILD
 EAQNIKNFQSQRWQLLLNFSTERRLLLTGTPLQNDLMELWSLMHFLMPYVFSSHR
 20 EFKEWFSNPMGTGMEGNMEYNETLITRLHKVIRPFLRLKKEVEKQMPKKYEHV
 ITCRLSNRQRYLYEDFMSRAKTRETLQTNLLSVINVLMLRKCNCNHPNMFEARP
 TISPFQMDGITFHTPRLVCDIMEYDPFTQINLETNLNLLLHLEQMTAYVSHKSRL
 APPRKLIEDIDTAPLPAPRCPNGKYRFHVRSAELAQRILNAVKGASPAMRLE
 GSKIMPMRNLLPSGRVLKRVASINPVNMLKPVVINSVTTTTSSSTTASSPTGAL
 25 SVLSNSKLLGARSQINAPTPAKVAKTMQDGKPFYLTATNSGAAGARLTLSKT
 TASASTTTSRTTVASTTSGQQLIRDPVKDLATHVKSTVQKQSIANGKTEPEEETE
 AEDPYKVQELIQMRKEQRLAALKRMAMINRRRTDATPIYGEDCREAIQRCMQAT
 RSLKRSTWQTRGYANCCTAMAHNRGWSLNHLLKSFEERCADLKPVFANFVIYVP
 SVCAPRIRRYVQNLSSTHWQHEQRIENTVDQALRPKLALLHPIISEMTTKFPDRLI
 30 QYDCGKLQTMDRLLRQLKVNGHRVLFTQMTKMLDVLEAFNLNYHGHYLRDGS
 TRVEQRQILMERFNGDKRIFCFILSTRSGGVGINLTGADTVIFYDSWNPMDAQA
 QDRCHRIGQTRDVHIYRLVSERTIEVNILKKANQKRMLSDMAIEGGNFITTYFKSS
 TIKDLFTMEQSEQDESSQEKSENKDRIVATTTLSSTPSTVVETEKQSLRAFEHALA
 AAEDQDVQATKTAKAEVAADLAEFDENIPIATEDPNAEGGPQVELSKADLEMQ
 35 NLVKQLSPIERYAMRFVEETGAAWTAEQLRAAEAELEAQKREWEANRLAAMHK
 EEELLKQETEAEMLTYSRKDSSNQVNTKTDSSNSNKRRLVRENRRNSAQKLSRSV
 SSHSTGSNNKNSKSATTRGNSQNSLNQTVPVGSGISRVRNTGAGVSSSSRGKSNST
 KSTGKGTDAAAPQVRRQTRLHSLGAVNMAARTPTTRKTTRTALAASAAASTLED
 ASLIVEERPKRQSANIAMSKMMKTPFKQNVPSNISIKTTPPKRGRRDSVAAAATRS
 40 KLLERRATIAAPLKHMDDESDQDEEEQEEQEESEEDTEGEEANATVDDDEEGEEEL
 ASLDEETIQTGSQTNDDEDDDEEEVGEEGMVIDIDTEDSEADVKSSTYGTAAADGK
 PEEABSLDGWDAHDQVQDTTMTSSTYYNVSESDTDEHHDSCAEAKEPPQNSDK
 SDESEAVGHTPRTRSRGTVKINLWTLDVSPVANALNKSSANRSLKKAPRTESTPK
 ESQSEPRRKITQPKLPKKEETNNKSNSNIGTLHRWISKSPRVMLRSTPVTAAASSS
 45 AAVSGVSGGNASSSGTAR

>16:09:09|GENSCAN_predicted_CDS_3|7494_bp

atgaatgaaggaattcagcaggagggggcatgaaggctcagccggccctctgctgtgccagaccgcgtaactccaca

ttcaacggaaatttcagttgcccccgaattctacaagcacaaacagtacgagcagcaggatcagtaggagcagccttgccggcc
acccgccatcaccaacatatagcgacccaagtgaagggaatgccagcagcagcagcaaacacagaagcaactggccagtg
cgcagctgcctgtgccgtgtgcccttgccgcaacaacacagcaaacggcagaggcaacggcagcagcagcagcacccg
cccactccaacgtatccgtttctccagcacaatagaagcctctgttttgccggccgagggccaagcgtcagcgtttggacgacaac
5 gaggacaggacgagtgccgcccagtcattgttgaccagcggagagcagcaacattgtaagctccctgctaccagcgtcggtggc
ctccagcagcggagtgccgggctttctctacggccctgcaggacttgatgccctcaagaagcgcatactccagcagaattg
cagatcttgcgtaatcttaagaaaggcatcttgaattgttccgaatactttacctacaaaacggcggcagtatgatggactacc
ccgctgtggcgcaagaagacaccaaccccgagttcatcagctacagcaatgcgaatcgtatagatcagctgatacacgaagata
agccaagcacatcagcagcagcagctgcggcacagaatcagaatataccaccaacagacagactctgtggagtctcacta
10 gtacgtggcatcggtactggagcgcacaaaaggagcgccattggatggcaatatcagaatagtactgtgaaacgaatacgc
tctcaagttccaagcaagattggcagcttcacagaatcaacgcccgcagcaacagaaaagcaactcaagtaccacagttccagg
acagctacaaagtgccgcccgaaccagcacatcagctacttcggccgaggctagtgtgaatgtcttggcagtggaagcagaatc
aaaatcccagctgtttgagccacaccagtgccatttccaccaagcttcccgctgcgctgtccagctaacgcaacaaggtggca
cccccttattgcccgtcaatacatccgcccgggtccacggcgcttcgtcgtcccaaggtcagaacaatgcctcaagcggatccgc
15 cgcggcatctggaggcggaggaagcctcacaccacaccgctctacactggcaatggcccggccgctctgggcccgttagcggga
ggactcacgctggcactccaacttctggcagctgtgtcagccctgccttggcggtgtgctccgggaacgccaacagtgccggcg
caggagttctctttaaggccaagcaagaggtgtatgtgatgcagcgtatatacgaactacagagagaggattatgactgagc
ggcgccgtcccaagctgcaggagcccagccgcccgaaggcgcattgggactatcttctcagaggagatgtcttggcgtggcggca
gattttgcacaggaacgcgaagtggagaaaaacgcggccaagaagtgtgccaagatggtgcagaagtatttccaggacaaggc
20 caccgctgccagcggcggaaaaaggcccaagagctgcagctaaagcgtgtcgtcttattgacgcgaggtgaagagctt
ttggctgaatgttgagaagctgtgcgagtacaagcaccaaaataagatcagggaaaaacgcaagcaggctttagaccaacac
cagctttattgtagaccagacagaaaagttctcacagcaattggtagagggaatgaacaagagtgtgcccgatacccccagctta
attctagccgtctaacatcgcggaacgggagtcgatgatgacttccgctgagctgtgttcagaagatgatgaggagactatc
gccaaggccgaagaagatgcagccgatgtgaaagaggaggtgacggcgctagctaaggaaatctgaaatggactttgatgactt
25 cttaatgatctaccacctggctatctggaataatcgtgataagcttatgaaagaggagcagagctcggcgataaagaccgaacgc
ctgatgacagcgatgatagtgaagtcgagcgaagggaagccagcgacgatgacgaaaataccatcagcaagcaggaagaagc
cgagcaggagatagaccacaaaaaggagatcgatgaactggaggcagacaatgatctctcagttggagcagttgttggcgaaat
acaagctgaacaacctcttagtccaagcgacgaaagttagcgccgctgatctgagctggactctgatgatattcgacggc
agttgattccaccgaagaagcgaagatgcggccaccgaggatgaagaagatctctactgttaaaactgatacggatatggag
30 gaacaggatgaacaggaggacggtcttaagagtctaattggcgagcgtgatgaacaagtggctgtctggcagcgggaagcac
ggctggggcaagcggcaacaggatgatgtgtaacgacgctgcccgcctggcgagagcctccagcccaagggttaatacc
ttgtctcaaccaatgtggttactctgtgcccttctgctaagcactccttgcgtgagtagaccagcacatcgggctcgattggctggt
cacaatgaatgagcgaagttaaacggcatcttgccgacgagatgggtctgggcaagaccatccagaccattgcgtattggc
ccacctgcctgcgcaaggggcaactggggacctatctcattgtggtgcttctgtctgatgctcaattgggaaatggagttcaa
35 gaagtgggtgcccggctttaaaatactacactctacggctcccagaaggagcgcgaagctaaaacgcgtagggttggaacagcc
aaatgcgttccatgtgtgatcagctcctacaagctgggtggtgcaagatcaacaagcttccggcgcaaaaagtggaaatgatctat
cctggatgaagcgcagaacattaaagaactttagtcccagcgtggcagttgacttaactttccacagagaggcgctgtgtat
actggaacccactacagaacgatctgatggagctgtgtccctgatgcacttccctatgccatgtgttctatcgcaccgcgagt
ttaaggaatggttctgaacccaatgactggcatgattgagggcaacatggagtacaacgagactttaatactgctgcacaagg
40 tgattcgtccgttctacttcgacgctcaaaaaggaggtggaaaaacagatgcccaagaagtiacgagcatgtataacgtgtc
ctgtcgaatcgccagcgtattatagaggacttcatgacggcgccaaaactcgtgagactctgcaaacgggaaactgttgag
cgtgataaatgtactgatgcagttgcgaaaagtgtgcaatcatccgaacatgtttgaagcgcgtcctcatgatctgccatttcaaat
gacggaattacattccacactccgcgactcgtcgcataataatggaatatgatccgttcacgcaataaatctagagacgttaac
cttctgtgttgcatttggagcaaacatgaccgctcagctcgcacaaaatcccgcctgctcggcccgcccgcaagctgatcgag
45 gataatcgatacggctccattgccagctccccgtgtccaatggcaataacggcttccataatccaggttcgtagcgtgaactggcg
cagcgcatcaaatgaatgctgtgaaggtaggagcaagtcagccatgcgggtggagggttcaagattatgcaatgcgcaatt
gctaccaagtggaagagtgctgaaaagggtcagtgcttcgatcaacccgtgaataatggcttgaaccagtggtgatcaatagtgt
ggtgacaacaacatcatcagccacagcatcttctactggagctttaagcgtgctgagcaactccaagttgctgggtgcac

gttcacaaattaatgctccaacgcccgttaaagtagcgaaaacgatgcaagacggaaaaccattttctacctcacaccggcgac
gaattcaggagcagcaggagcgcgtcttaccctgacaagcaaaaccacagcctcggcggtccacgacgacctccagaacaaca
gttacagcatcaactacttctgtgcagcaactaataaggatccattgtcaagatttggccactcatgtaaaaagcacagtacaa
aagcaaaagcattgccaatgggaagacggagcccagggaagaaactgaagcagaggatccctacaaagtagcaggagctgattc
5 agatgcgcaaggagcagcgaattggcagcgcctaaacgtatggcaatgataaatctcgcggacggatgccactcccatafacg
gcgaagattgtcgcgaggtatatacagcgtgcatgcaggcgacccgatccctaaagcgatcaacctggcagacgcgtggatag
gccaaactgtgcactgcatggcgcatcggaacgggttgctcctaaaccacttgctgaagagcttcgaggaaaggtgcgtgac
taaagccagtggttgcacacttggatctacgttcttctgttggcgccccggatccgtctgtatgtacaaaatctctacgacgc
actggcagcacgaacaaaggattgaaaacattgtgcatcaggccctgcggcctaagctggcggtgctgcatccaatcatttcgga
10 aatgaccactaagtcccagatccgcgtctcatccaatacagactgtggcaagttgagaccatggatcgttgcacgacgtaaa
ggtaaccgggcatcgtgtactgataatcactcagatgaccaagatgttggatgtttggaagcttttcaactaccacggcatatttat
ctgcgttttagatggcttactcgggtggaacagcggcagatcctgatggagcgggttaatggagataaacgaatcttctgctc
ctctccacgcggctgtggtgagtggtgcatcaattgacgggtgccgatactgtgatctttacgactccgactggaacccacaaatg
gatgcgcaggcccaagatcgttgcacgtattggtcaaacgcgagatgtacatactaccgtcttgcctccgaagaacacataga
15 ggtaacattcttaagaaggcaaaccaaaagcgaatgctgagcgacatggccatcgagggtggcaatttacaactacgtacttta
agagttccaccataaaggatctctttacaatggagcagagcgcgagcaggacgagtcgagccaagagaagtcggaaaacaaggat
agaattgttgcataacaacgcttcagatacgccttcgacgggttggtgagacggagaagcagtcactgcgtgattgacacgc
gttggctgcggccgaggacgagcaggatgtcaggccacgaaaacggcctaagccgaagtggcagctgactctgcccaggttc
gacgagaacattctattgcaacagaagatccaaatgcggaaggaggtcctcaagtggaaactcagcaaggccgactgtggagatg
20 cagaacttggttaaacagctctcaccgatagagcgatatgccatgcgtttgtggaagaaactggagcagcatggacggcgga
caattgcgagccgcggaagcggagctggaggccagaaacgcgagtgaggagccaatcgttggcgccatgcacaagga
ggaggagctgttgaagcaagaaacgggaagcggaggagatgcttacctacagtcgcaaggattcgagtaatcaggtaatacaca
aacagattccaattccaataagcgacgactggtagggaaaatcgcaaaactcagctcagaagctgagcaggagtgttagcag
ccatagcaccggtagcaacaacaagaacagtaaatcggaacgacccgtggaatagccagaacagcctcaatcagactgtac
25 cagtgggtcaggaataagcagggtgaatagaacggggcggggtcagtagcagtagccaggcaaaagtaacagcacga
agtcaacgggggaagggaacagacgcccgcaccgcaagttcggcgagaccggtctccactcttggcgagcagtaaatggc
cagcgcccgaacaccgcccactagaaagacaacacgtacagctctggtctgcatctgcagctgcatctacttttagaggatgcctctt
tgatcgtcggaggagcgtcccaaaagacagtcggccaacatagctatgagcaagatgatgaagacgcccctcaaacagaatgttc
catccaacatcagatataaagacaactcctcctaaaggggcggaagagacagtggtgagctgccacacgcagtaaaactgc
30 tggaaagaagagctacaattgctgctcctttaaaccatatggatgatgaaagtaccaggatgaaggagcagggaagagcagg
agtctgaagaagataccgagggcgagggaagcaaatgccacagtagacgacgacgaggagggggaggaggaggttggcgtca
cttgacgaagagaccatacaaacggatcgcaacaatgatgaagaagacgatgacgaggaagaagttggtgaagaggga
tggtgatattgatactgaagattcagaggcagatgtcaaatccagctccacctatgtacagcggcagatggtgaagcccgaagaa
gccgaaagcttgatggctgggatgcacacgaccaggtgcaggacaccacaatgactagctccactactacaatgtcagcga
35 ggaatcagacacggatgagcatcacgatagcaaggcggaggctaaagagccgcgcaaaattccgataagagcgacgagag
cgaggctgttgacacacaccacgtacaaggctgcgcggcacagtaaatcaatctgtggaccctggacgtgagtcctcgtagc
aaacgcattgaataaaagcagcgccaataggagcctcaaaaagcaccgaagactgagtcacgccaaggaggtcagagc
gagccaaggcgaaagattactcagccaagctgccgaagaaagaaactaacaacaatcacaagcaatatggcacctta
caccgctgatatcgaagtcccccgagtaatgttcgatccacacctgttacggcagcgagcgctagctcatcagcagcagctca
40 gtggtgttctgggaggaatgcctcctcagcggaaacagccaggtga

Drosophila Gene Hit TBLASTN with ORF2: brahma protein (M85049) and imitation-SWI protein (ISWI) (L27127) and chromodomain-helicase-DNA-binding (CHD-1)

45 **Human Homologue** BLASTX with EST TBLASTN with ORF2: Snf2-related CBP activator protein (SRCAP) (AF143946) and SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (SMARCA4) (NM_003072.1)

	<i>Drosophila</i> EST	several including SD07794 (AI534784), LD34465 (AA990657)
	Annotated <i>Drosophila</i> genome genomic segment	AE003453
5	Annotated <i>Drosophila</i> genome Complete gene candidate	CG9696 – domino an enzyme involved in DNA repair homology to snf2 family helicases
10	Human homologue of Complete gene candidate	CG9696- gi4557447 416409C913D6A935 ref NP_001261.1 chromodomain helicase DNA binding protein 1 [Homo sapiens] (1.90E-85
15	Putative function	snf2 helicase family member protein that contains a chromodomain, which occurs in proteins that are implicated in chromatin compaction, and an SNF2/SWI2-like helicase domain, which occurs in proteins 20 that are believed to activate transcription by counteracting the repressive effects of chromatin structure
25	Confirmation by RNAi	Loss of G1, peak, increase in G2M indicating arrest in G2/M

Example 70 (Category 5)

Line ID 99/31
Category 2nd chromosome, small imaginal discs
5 **Reversion** NR
Map Position 53E

Rescue ID EcoR1

Rescue Sequence 1

10 AAGGCCCGACCAGAAACGAAATTTTCGGCGCGTNTTTTAAAATGCGCGGTAA
ATTCACTTTGATTTTGTCTCTCTCGTTCTTCACACACACAGTTAGTTAGA
TTGTGTGTTTCGCTGGCTTTGCCTTTTAATTTTATTTACCTGCATCCGATTTCG
GTATTTGAAACAGCCGTTGAGTCTCCTTTGGCTTTTTATCAGCGACGTCATCA
GTGGCGGCAGAAAGCAGAAGCGTCGACAGCGGCGGGGATTTCGGCTGCATCTT
15 TGGAGCCCCCTTCCGGCTGTGCCCCACGGCTTTCGCCACCCCGCAGTAACC
GATGCATTTTCCACATCGCTTACCTTATCGGCGGCATTTTCTTTGGCTGCCGTT
TCTGCCGCTTTGTAGCATCCTTTTCGTGCGGCGANGGCATGGAAAGATACAA
ATCAGAATTGGATTACACTTGCTAATTTTTTGGCGGNCAATACAATGGTTCGG
TGCGCCTATTCTTTTAATCGAATCGCAATTGAGTGTNAATTAAGTCTCCGCA
20 ATGCAATTTGTGTATCTGTCTCCTCCCCGANCGAACAACGATNGAAAAAGGAA
CCAGAAATAAAANAGGNAATGAAAAACACATTGCAATCTATAAGGCCACAC
ACACACATATCATCCCGTCTACCANTCCATCGGATTCGANCCACANAANCCAT
NTTATACCNCAACGAACGNGGAAAAAACNATATCNGNAATTACCCCCGAA
AATTGTTGCCNCTTTTACCCAAATATTTACAACCNCCGTTCAATCACTCCTGGA
25 ACATTCCNGGCTTTCCCAATTTTCNCCTTTACTACAATTTCAATGGTTTCTTTT
CCTCAC

Rescue ID BamH1

Rescue Sequence 2

30 CCTNAAATGTNGCGCTGGGNCCTAAANCGTCNCTCCTTGTGTCTCTCTTGTTTA
CCGCGCTATGCTGATGTTGGCATGTGGTTCGATCCCCCTCCGTGTCGATGTTA
CAAAACCATNATTAGAGTTTGATGATTGAGTTCTCTTAACCTTTCCTCCTCCT
CCTTCCTTGGCTTTTGTTCATGCTAAATCCTTTAAATGGGGTTCTGCGTAGTTT
AATGCCGAGGTACAGCAAACTTCAATATTCATGTTCCCTTGCCTCCCAAAC
35 GAAATTAGCATTGGACGTCCCAAGGTTGAAGACATTTNATTATTTAACATCT
TTTTNATTTTATTACATTTGAACTCTTACAAGTAATAATAATTACAATTAATAT
TATAGCTGCAGCGGACAAAAAGGAGAAATCCCCCTCGCCGTAATAAAGAAT
CCAACAATAAGGATGCTNAAAANGAAGAAAACCCNAAAAAGGAGAAGAAAA
ATCGGAANAAGGNGATGAGCCNGAAGATGAGGNGATGAGAAAGCTAGCGA
40 TGAAGAGAGCGAGAAGAAGAAANCGANATGAGATGCAGAGGACAGATAAAG
GATGCCACNGATGAATCCAAGCCAAAATCGGGAGCCGATAAGCCCAAGAAAC
TGAGCCCAAGGCCAAGAATGGCAAGGTGGNT

Genomic hit, Accession No. CSC:AC020063

45

Associated ORF

Genscan ORF1 predicted sequences >16:48:25|GENSCAN_predicted_peptide_1|722_aa
MPSPEHKDANKAAETAAKENAADKVSVDENASVTAGVAKAVGAQPERGSKDA
AESPAAVDASASAATDDVADKKAKGDSTAVSNTESDAAAADKKEKSPSPVIKKS
NNKDAKKEDNSEKDEENSEDGDEPEDEADEKASDEESEKKKPKLDAEDKIKDAT
5 DESKPKSGADKPKKPEPKAKNGKVAKBEDDDEEDEDDEDAEDDDGDENDGLDK
NNEVAEDDENVVALAIEDRINENINKTRVDGLQTLHAICFGAQGKNNVVKKNLRS
FAGFEFAKDSA EYNKKLEAIKKVDNKGRLSICEILTLDRKGSKNETVLRVLKFLM
EPDESLCLEQGDEEEEDAEDEDLDEDEEDPPSEEDKKRKSGKSSGGAGRGSARN
STGRPRRATAGKKMSA YVDFSSSDSEQKVA VPKRRRNDDSESGSDYNPSANS
10 SDGGRGGGAGAAGRKVPSRGGGRGPARKSRRRNSDSEEEEESEVSDADSDVPKR
KRGSVGKRGRPAAPASAGRGRGRGAASRKRKSDSSEDEEVSEDEEEEDVSDFA
SDQSEVCKFNLISSIWCFIKYMPIFQEERPKSKKKPITPAKNSKANNSKPKAGKADS
RSKKSKKESSEEDDDVDDKDESEDEDEPLTKKGKQAFPTDEQIRGYVKEILDKANL
EETMKTVCVKQVYAKYPDFDLTDKKDFIKATVKADGVQDLGSPELIPRGRTT VT
15 IWLICCCNNQIFGET

[illegible]

45 **Human Homologue** TBLASTN with ORF1: poor homology with DEK gene
(D6S231E) (NM_003472.1)
Drosophila EST several including LD33301 (AA979048)

	Annotated <i>Drosophila</i> genome genomic segment	AE003805
	Annotated <i>Drosophila</i> genome Complete gene candidate	CG5935 - EG:EG0003.6 - novel with weak homology to DEK oncogene
5		CG8648 - EG:EG0003.3 - novel XPG/ flap endonuclease-like, DNA repair?
10	Human homologue of Complete gene candidate	CG5935- 1e-17 4503249 ref NP_003463.1 pD6S231E DEK gene >gi 544150 sp P35659 DEK_H UMAN DEK PROTEIN >gi 284375
15		CG8648- 4758356 ref NP_004102.1 pFEN1 flap structure-specific endonuclease 1;
20		MATURATION FACTOR 1 (MF1); DNase IV; RAD2_HUMAN(aa)
25	Putative function	CG5935: function unknown but putative DNA-binding protein predicted to be involved in chromosomal organisation. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA
30		CG8648: Novel XPG/ flap endonuclease-like, DNA repair protein
	Confirmation by RNAi	Both show slight reduction of G1 peak

REFERENCES

- Deak, P., Omar, M.M., Saunders, R.D.C., Pal, M., Komonyi, O., Szidonya, J., Maroy, P., Zhang, Y., Ashburner, M., Benos, P., Savakis, C., Siden-Kiamos, I., Louis, C., Bolshakov, V.N., Kafatos, F.C., Madueno, E., Modolell, J., Glover, D.M. (1997)
- 5 Correlating physical and cytogenetic maps in chromosomal region 86E-87F of *Drosophila melanogaster*. Genetics 147:1697-1722.
- Torok, T., Tick, G., Alvarado, M., Kiss, I. (1993) P-lacW insertional mutagenesis on the second chromosome of *Drosophila melanogaster*: isolation of lethals with different overgrowth phenotypes. Genetics 135(1):71-80
- 10 Saunders, R.D.C., Glover, D.M., Ashburner, M., Siden-Kiamos, I., Louis, C., Monastirioti, M., Savakis, C., Kafatos, F.C.(1989) PCR amplification of DNA microdissected from a single polytene chromosome band: a comparison with conventional microcloning. Nucleic Acids Res. 17:9027-9037
- Lefevre, G. (1976) A photographic representation and interpretation of the
- 15 polytene chromosomes of *Drosophila melanogaster* salivary glands. In: The Genetics and Biology of *Drosophila*, Eds Ashburner,M. and Novitski,E. Academic Press.
- Jowett, T. (1986) Preparation of nucleic acids. In "*Drosophila*: A Practical Approach." Ed Roberts,D.B. IRL Press Oxford.
- Pirrotta, V. (1986) Cloning *Drosophila* genes. In: . In "*Drosophila*: A Practical
- 20 Approach." Ed Roberts,D.B. IRL Press Oxford.
- Altschul, S.F. and Lipman, D. J. (1990) Protein database searches for multiple alignments. Proc. Natl. Acad. Sci. USA 87: 5509-5513

Burge, C. and Karlin, S. (1997) Prediction of complete gene structures in human genomic DNA. J. Mol. Biol. 268, 78-94.

Each of the applications and patents mentioned above, and each document cited or referenced in each of the foregoing applications and patents, including during the prosecution of each of the foregoing applications and patents ("application cited documents") and any manufacturer's instructions or catalogues for any products cited or mentioned in each of the foregoing applications and patents and in any of the application cited documents, are hereby incorporated herein by reference. Furthermore, all documents cited in this text, and all documents cited or referenced in documents cited in this text, and any manufacturer's instructions or catalogues for any products cited or mentioned in this text, are hereby incorporated herein by reference.

Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

CLAIMS

1. A polynucleotide selected from:
 - (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 1 to 70 or the complement thereof.
 - 5 (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 1 to 70, or a fragment thereof.
 - (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 1 to 70 or a fragment thereof.
 - 10 (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).
2. A polynucleotide selected from:
 - (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 1 to 14 or the complement thereof.
 - 15 (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 1 to 14, or a fragment thereof.
 - (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 1 to 14 or a fragment thereof.
 - 20 (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).
3. A polynucleotide selected from:

- (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 15 to 19 or the complement thereof.
- (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 15 to 19, or a fragment thereof.
- 5 (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 15 to 19 or a fragment thereof.
- (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).
- 10 4. A polynucleotide selected from:
 - (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 20 to 30 or the complement thereof.
 - (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 20 to 30, or a fragment thereof.
 - 15 (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 20 to 30 or a fragment thereof.
 - (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).
- 20 5. A polynucleotide selected from:
 - (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 31 to 53 or the complement thereof.
 - (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 31 to 53, or a fragment thereof.

- (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in 31 to 53 or a fragment thereof.
- (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).
- 5
6. A polynucleotide selected from:
- (a) polynucleotides comprising any one of the nucleotide sequences set out in 54 to 70 or the complement thereof.
- (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in 54 to 70, or a fragment thereof.
- 10
- (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in 54 to 70 or a fragment thereof.
- (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).
- 15
7. A polynucleotide probe which comprises a fragment of at least 15 nucleotides of a polynucleotide according to any of Claims 1 to 6.
8. A polypeptide which comprises any one of the amino acid sequences set out in Examples 1 to 70 or in any of Examples 1 to 14, Examples 15 to 19, Examples 20 to 30, Examples 31 to 53 and Examples 54 to 70, or a homologue, variant, derivative or fragment thereof.
- 20
9. A polynucleotide encoding a polypeptide according to Claim 8.
10. A vector comprising a polynucleotide according to any of Claims 1 to 7 and 9.

11. An expression vector comprising a polynucleotide according to any of Claims 1 to 7 and 9 operably linked to a regulatory sequence capable of directing expression of said polynucleotide in a host cell.
12. An antibody capable of binding a polypeptide according to Claim 8.
- 5 13. A method for detecting the presence or absence of a polynucleotide according to any of Claims 1 to 7 and 9 in a biological sample which comprises:
- (a) bringing the biological sample containing DNA or RNA into contact with a probe according to Claim 9 under hybridising conditions; and
 - (b) detecting any duplex formed between the probe and nucleic acid in the
10 sample.
14. A method for detecting a polypeptide according to Claim 8 present in a biological sample which comprises:
- (a) providing an antibody according to Claim 12;
 - (b) incubating a biological sample with said antibody under conditions which
15 allow for the formation of an antibody-antigen complex; and
 - (c) determining whether antibody-antigen complex comprising said antibody is formed.
15. A polynucleotide according to according to any of Claims 1 to 7 and 9 for use in therapy.
- 20 16. A polypeptide according to Claim 8 for use in therapy.
17. An antibody according to Claim 12 for use in therapy.

18. A method of treating a tumour or a patient suffering from a proliferative disease comprising administering to a patient in need of treatment an effective amount of a polynucleotide according to any of Claims 1 to 7 and 9.
19. A method of treating a tumour or a patient suffering from a proliferative disease,
5 comprising administering to a patient in need of treatment an effective amount of a polypeptide according to Claim 8.
20. A method of treating a tumour or a patient suffering from a proliferative disease, comprising administering to a patient in need of treatment an effective amount of an antibody according to Claim 12 to a patient.
- 10 21. Use of a polypeptide according to Claim 8 in a method of identifying a substance capable of affecting the function of the corresponding gene.
22. Use of a polypeptide according to Claim 8 in an assay for identifying a substance capable of inhibiting the cell division cycle.
23. Use as claimed in Claim 22, in which the substance is capable of inhibiting mitosis
15 and/or meiosis.
24. A method for identifying a substance capable of binding to a polypeptide according to Claim 8, which method comprises incubating the polypeptide with a candidate substance under suitable conditions and determining whether the substance binds to the polypeptide.
- 20 25. A method for identifying a substance capable of modulating the function of a polypeptide according to Claim 8 or a polypeptide encoded by a polynucleotide according to any of Claims 1 to 7 and 9, the method comprising the steps of: incubating the polypeptide with a candidate substance and determining whether activity of the polypeptide is thereby modulated.

26. A substance identified by a method or assay according to any of Claims 21 to 25.
27. Use of a substance according to Claim 26 in a method of inhibiting the function of a polypeptide.
28. Use of a substance according to Claim 26 in a method of regulating a cell division
5 cycle function.